CN1444652A - 哺乳动物受体蛋白;相关试剂和方法 - Google Patents
哺乳动物受体蛋白;相关试剂和方法 Download PDFInfo
- Publication number
- CN1444652A CN1444652A CN01813327A CN01813327A CN1444652A CN 1444652 A CN1444652 A CN 1444652A CN 01813327 A CN01813327 A CN 01813327A CN 01813327 A CN01813327 A CN 01813327A CN 1444652 A CN1444652 A CN 1444652A
- Authority
- CN
- China
- Prior art keywords
- leu
- pro
- ser
- ala
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 115
- 102000005962 receptors Human genes 0.000 title abstract description 59
- 108020003175 receptors Proteins 0.000 title abstract description 59
- 239000012634 fragment Substances 0.000 claims abstract description 102
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 64
- 241000288906 Primates Species 0.000 claims abstract description 63
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 60
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 210000004027 cell Anatomy 0.000 claims description 157
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 124
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 229920001184 polypeptide Polymers 0.000 claims description 74
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 74
- 238000012360 testing method Methods 0.000 claims description 66
- 239000002773 nucleotide Substances 0.000 claims description 59
- 125000003729 nucleotide group Chemical group 0.000 claims description 59
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 239000000523 sample Substances 0.000 claims description 53
- 230000027455 binding Effects 0.000 claims description 51
- 102000003675 cytokine receptors Human genes 0.000 claims description 51
- 108010057085 cytokine receptors Proteins 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 37
- 230000008859 change Effects 0.000 claims description 28
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 230000004927 fusion Effects 0.000 claims description 26
- 239000002299 complementary DNA Substances 0.000 claims description 25
- 230000008521 reorganization Effects 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 238000009396 hybridization Methods 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 17
- 239000005557 antagonist Substances 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 16
- 239000000556 agonist Substances 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 12
- 230000013595 glycosylation Effects 0.000 claims description 11
- 238000006206 glycosylation reaction Methods 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 239000007790 solid phase Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 239000012266 salt solution Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 230000008034 disappearance Effects 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 5
- 210000000664 rectum Anatomy 0.000 claims description 5
- 230000010076 replication Effects 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000035800 maturation Effects 0.000 claims description 3
- 210000003928 nasal cavity Anatomy 0.000 claims description 3
- 239000002985 plastic film Substances 0.000 claims description 3
- 229920006255 plastic film Polymers 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 230000002303 anti-venom Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000036978 cell physiology Effects 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 238000000163 radioactive labelling Methods 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 824
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 517
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 413
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 356
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 326
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 324
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 297
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 275
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 227
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 181
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 157
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 139
- 230000004913 activation Effects 0.000 description 90
- 210000001744 T-lymphocyte Anatomy 0.000 description 60
- 241000282326 Felis catus Species 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 52
- 239000000370 acceptor Substances 0.000 description 50
- 210000004072 lung Anatomy 0.000 description 45
- 108020004414 DNA Proteins 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 37
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 30
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 30
- 210000001616 monocyte Anatomy 0.000 description 30
- 241000283984 Rodentia Species 0.000 description 28
- 102220023258 rs387907548 Human genes 0.000 description 28
- 210000001161 mammalian embryo Anatomy 0.000 description 27
- 108020004635 Complementary DNA Proteins 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 238000010804 cDNA synthesis Methods 0.000 description 24
- 230000036039 immunity Effects 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 238000013519 translation Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 239000003446 ligand Substances 0.000 description 20
- 102220023257 rs387907546 Human genes 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 18
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 18
- 238000012216 screening Methods 0.000 description 18
- 241000894007 species Species 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 17
- 230000002163 immunogen Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 108090000978 Interleukin-4 Proteins 0.000 description 16
- 210000001072 colon Anatomy 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- -1 be called lymphokine Proteins 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 102220369445 c.668T>C Human genes 0.000 description 13
- 210000004988 splenocyte Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 11
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 102220023256 rs387907547 Human genes 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 241000244203 Caenorhabditis elegans Species 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 230000010287 polarization Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 102220369446 c.1274G>A Human genes 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000010369 molecular cloning Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 102220004457 rs11567847 Human genes 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 101000988288 Dictyostelium discoideum Protein hssA Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000000586 desensitisation Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 206010010356 Congenital anomaly Diseases 0.000 description 5
- 241000206602 Eukaryota Species 0.000 description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 5
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 102220369447 c.1352G>A Human genes 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000002741 palatine tonsil Anatomy 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 231100000167 toxic agent Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 208000001204 Hashimoto Disease Diseases 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 3
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 3
- NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- SYTFJIQPBRJSOK-NKIYYHGXSA-N Gln-Thr-His Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 SYTFJIQPBRJSOK-NKIYYHGXSA-N 0.000 description 3
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 3
- 102000039989 IL-17 family Human genes 0.000 description 3
- 108091069193 IL-17 family Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 3
- KVOFSTUWVSQMDK-KKUMJFAQSA-N Leu-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 KVOFSTUWVSQMDK-KKUMJFAQSA-N 0.000 description 3
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 3
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- DLYOEFGPYTZVSP-AEJSXWLSSA-N Val-Cys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N DLYOEFGPYTZVSP-AEJSXWLSSA-N 0.000 description 3
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000008614 cellular interaction Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 108010025306 histidylleucine Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 210000001986 peyer's patch Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000009991 scouring Methods 0.000 description 3
- 108010026333 seryl-proline Proteins 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 108010013043 Acetylesterase Proteins 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- AAWLEICNDUHIJM-MBLNEYKQSA-N Ala-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C)N)O AAWLEICNDUHIJM-MBLNEYKQSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000004554 Interleukin-17 Receptors Human genes 0.000 description 2
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 2
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- PZSCUPVOJGKHEP-CIUDSAMLSA-N Pro-Gln-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PZSCUPVOJGKHEP-CIUDSAMLSA-N 0.000 description 2
- ZMLRZBWCXPQADC-TUAOUCFPSA-N Pro-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 ZMLRZBWCXPQADC-TUAOUCFPSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical group C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- PWPJLBWYRTVYQS-PMVMPFDFSA-N Trp-Phe-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PWPJLBWYRTVYQS-PMVMPFDFSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000000409 cytokine receptor agonist Substances 0.000 description 2
- 239000000430 cytokine receptor antagonist Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000006068 polycondensation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 201000002045 Ancylostomiasis Diseases 0.000 description 1
- 208000033211 Ankylostomiasis Diseases 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- PDQBXRSOSCTGKY-ACZMJKKPSA-N Asn-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PDQBXRSOSCTGKY-ACZMJKKPSA-N 0.000 description 1
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000224495 Dictyostelium Species 0.000 description 1
- 241000168726 Dictyostelium discoideum Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 101100125854 Mus musculus Il18 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000414651 Omosita colon Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 101100497639 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYR1 gene Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010043943 Starch Phosphorylase Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- XOVDRAVPGHTYLP-JYJNAYRXSA-N Tyr-Pro-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(O)=O XOVDRAVPGHTYLP-JYJNAYRXSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- CGIHPACLZJDCBQ-UHFFFAOYSA-N acibenzolar Chemical compound SC(=O)C1=CC=CC2=C1SN=N2 CGIHPACLZJDCBQ-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- KUUVQVSHGLHAKZ-UHFFFAOYSA-N thionine Chemical compound C=1C=CC=CSC=CC=1 KUUVQVSHGLHAKZ-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
编码哺乳动物如灵长类,受体、纯化的受体蛋白及其片段的核酸。抗体,包括多克隆和单克隆抗体,也在此提供。这些组合物用于诊断和治疗用途的方法在此描述。
Description
技术领域
本发明涉及影响哺乳动物生理学包括免疫系统功能的组合物和方法。具体来说,它提供调节发育和/或免疫系统的方法。这些材料的诊断和治疗用途也在此公开。
背景技术
重组DNA技术一般是指将供体来源的遗传信息整合入随后的加工载体中,如通过引入宿主,其中转移的遗传信息在新环境中被拷贝和/或表达。通常该遗传信息以源于信使RNA(mRNA)的互补DNA(cDNA)形式存在,它编码预期的蛋白产物。载体经常是具有携带cDNA能力的质粒以供随后在宿主中复制,并且在某些情况下,实际控制该cDNA的表达并指导宿主中其编码产物的合成。见,例如,Sambrook等(1989)Molecular Cloning:A Laboratory Manual,(2nd ed.)vols.1-3,CSHPress,NY。
哺乳动物免疫应答基于一系列复杂的细胞相互作用,称为“免疫网络”,对此已有一段时间的了解。近来的研究对该网络的内部工作机制提供了新的理解。大多数免疫应答事实上是在淋巴细胞、巨噬细胞、粒细胞和其它细胞的网络样相互作用之间循环往复,对此已了解清楚,然而免疫学家现在一般持这种观点:可溶性蛋白,称为淋巴因子、细胞因子或单核因子,在控制这些细胞相互作用中起关键作用。因而,对细胞调节因子的分离、表征及其作用机制有相当的兴趣,对它们的理解将导致很多医学异常,例如免疫系统疾病的诊断和治疗的显著进步。
脊椎动物免疫系统由多种器官和几种不同的细胞类型组成。两种主要的细胞类型包括髓样细胞和淋巴样细胞。淋巴样细胞包括B细胞,其原始特征是在胎肝或成年骨髓中分化,和T细胞,其原始特征是在胸腺中分化。见,例如,Paul(ed.1998)
Fundamental Immunology(4thed.)Raven Press,San Diego。淋巴因子显然以多种方式介导细胞活动,已经表明它们支持细胞,如多能造血干细胞的增殖、生长、和/或分化,成为大量前体细胞,其中含有多样的细胞谱系,它们构成复杂的免疫系统。细胞成分间的适当和平衡的相互作用对于健康的免疫应答是必要的。当联合其它药物给予淋巴因子时,不同细胞谱系经常以不同方式应答。
对免疫应答特别重要的细胞谱系包括两类淋巴细胞:B细胞,它产生并分泌免疫球蛋白(能识别并结合外源物质以将其清除的蛋白),和不同亚类的T细胞,它们分泌淋巴因子并诱导或抑制B细胞和多种其它细胞(包括其它T细胞),从而形成免疫网络。这些淋巴细胞与多种其它类型的细胞相互作用。
由于受到一般不能在体外维持免疫系统的细胞的限制,而妨碍了更好了解并治疗多种免疫疾病的研究。免疫学家已发现,通过使用T细胞和其它细胞上清,其中包含多种生长因子,包括许多淋巴因子,可以成功培养很多这些细胞。
存在多种调节形态发生发育的生长和调节因子,并且也已知很多细胞因子的受体。在功能性受体中经常有至少两个关键性亚基。见,例如,Gonda和D’Andrea(1997)
Blood 89:355-369;Presky等(1996)Proc.Nat’1 Acad.Sci.USA93:14002-14007;Drachman和Kaushansky(1995)
Curr.Opin.Hematol.2:22-28;Theze(1994)
Eur.Cytokine Netw.5:353-368;和Lemmon和Schlessinger(1994)
Trends Biochem. Sci.19:459-463。
由上可见,很明显发现和开发新可溶性蛋白及其受体,包括淋巴因子类似物,应有助于宽范围的退行性或异常疾病的新治疗方法,它们直接或间接参与,例如,免疫系统和/或造血细胞的发育、分化或功能。具体来说,发现和了解增强或提高其它淋巴因子有益活性的淋巴因子样分子的受体将是非常有益的。然而,缺乏对免疫系统如何调节或分化的了解已经阻碍了有效调节防御机制对生物学攻击的能力。因而以异常或不适当调节相关细胞发育或生理为特征的医学状况仍然不能控制。发现和表征特异性细胞因子及其受体将有助于开发影响免疫系统、造血细胞以及其它类型细胞的宽范围退行性或其它疾病的治疗方法。本发明提供表现与细胞因子样组合物相似配体的新受体和相关化合物,及其使用方法。
发明简述
本发明涉及属于细胞因子受体的新受体,如灵长类细胞因子受体样分子结构,被称为DNAX细胞因子受体亚基(DCRS)及其生物学活性。具体来说,本发明提供多种亚基的描述,它们被称为DCRS6、DCRS7、DCRS8、DCRS9和DCRS10。这些亚基的灵长类如人,和啮齿动物如小鼠的具体实例在此提供。包括编码其自身多肽的核酸及其生产方法和使用。本发明核酸的部分特征是它们与本说明书所附克隆的互补DNA(cDNA)序列的同源性。
本发明提供选自下面的物质的组合物:足够纯的或重组的多肽,其中含有与SEQ ID NO:2,5,8,11,23或26片段一致的至少三个不同的至少含四个氨基酸的非重叠片段;足够纯的或重组的多肽,其中含有与SEQ ID NO:14片段一致的至少三个不同的至少含四个氨基酸的非重叠片段;足够纯的或重组的多肽,其中含有与SEQ ID NO:14片段一致的至少两个不同的至少含五个氨基酸的非重叠片段;天然序列DCRS8,其中含有成熟的SEQ ID NO:14;融合多肽,其中含有DCRS8序列;足够纯的或重组的多肽,其中含有与SEQ ID NO:17或20片段一致的至少三个不同的至少含四个氨基酸的非重叠片段;足够纯的或重组的多肽,其中含有与SEQ ID NO:17或20片段一致的至少两个不同的至少含五个氨基酸的非重叠片段;天然序列DCRS9,其中含有成熟的SEQ ID NO:17或20;或融合多肽,其中含有DCRS9序列。优选地,其中不同的非重叠一致性片段包括:一个至少含8个氨基酸;一个至少含4个氨基酸和另一个至少含5个氨基酸;含至少4、5或6个氨基酸的至少三个片段,或一个至少含12个氨基酸的片段。在其它实施方案中,含表1、2、3、4或5成熟序列的多肽;是DCRS8或DCRS9的非糖基化形式;来自灵长类,如人;含有至少17个氨基酸的SEQ IDNO:14或17;表现出至少4个含至少7个氨基酸的SEQ ID NO:14或17的非重叠片段;是DCRS8或DCRS9的天然等位基因变体;至少长30个氨基酸;表现出对灵长类DCRS8或DCRS9特异的至少两个非重叠表位;被糖基化;天然糖基化的分子量至少30kD;是合成多肽,连接于固相基质上;与另一个化学实体偶联;天然序列的不大于5倍取代;或是天然序列的缺失或插入变体。
本发明进一步包括一种组合物,其中含有:足够纯的DCRS8或DCRS9和另一种细胞因子受体家族成员;无菌DCRS8或DCRS9多肽;DCRS8或DCRS9多肽及载体,其中载体是:水性化合物,包括水、盐水和/或缓冲液;和/或供口、直肠、鼻、外用或注射给药的组合物。其它实施方案包括一种多肽,其中含有:表1、2、3、4或5的天然蛋白序列;检测或纯化标签,包括FLAG、His6或Ig序列;或另一种细胞因子受体蛋白的序列。试剂盒实施方案包括这些,其中含有:所述多肽,和:含该蛋白或多肽的隔室;或试剂盒中试剂使用和处理的说明书。
本发明提供结合组合物,例如,含有抗体的抗原结合位点,它特异性结合天然DCRS8或DCRS9多肽,其中:结合化合物在容器中;DCRS8或DCRS9多肽来自人;结合化合物是Fv、Fab或Fab2片段;结合化合物与另一种化学实体偶联;或抗体:由抗表3或4的成熟多肽的肽序列产生;由抗成熟的DCRS8或DCRS9产生;由抗纯化的人DCRS8或DCRS9产生;经免疫选择;是多克隆抗体;结合变性的DCRS8或DCRS9;表现对抗原的Kd至少30μM;连接到固相基质上,包括珠或塑料膜;处于无菌组合物中;或被可检测性标记,包括放射性或荧光标记。试剂盒包括这些,其中含有这种结合化合物,和:含有结合化合物的隔室;或试剂盒中试剂使用和处理的说明书。
本发明也提供生产抗原:抗体复合物的方法,其中含有:在适当条件下将灵长类DCRS8或DCRS9多肽与所述抗体接触,由此形成复合物。优选方法包括这些,其中:从其它细胞因子受体中纯化复合物;从其它抗体中纯化复合物;与含干扰素的样品接触;接触可以定量检测抗原;与含抗体的样品接触;或接触可以定量检测抗体。进一步组合物包括那些,其中含有:如上所述的无菌结合化合物,或结合化合物和载体,其中载体是:水性化合物,包括水、盐水和/或缓冲液;和/或供口、直肠、鼻、外用或注射给药的组合物。
核酸组合物包括编码所述多肽的分离或重组核酸,其中:DCRS8或DCRS9来自人;或核酸:编码表3或4的抗原性肽序列;编码表3或4的多种抗原性肽序列;表现出与编码该片段的天然cDNA至少13个核苷酸以上的一致性;是表达载体;进一步含有复制起点;来自天然来源;含有可检测标记;含有合成核苷酸序列;小于6kb,优选小于3kb;来自灵长类;含有天然全长的编码序列;是编码DCRS8或DCRS9基因的杂交探针;或是PCR引物、PCR产物、或突变引物。本发明也提供细胞或组织,其中含有这种重组核酸,例如,其中的细胞是:原核细胞,真核细胞;细菌细胞;酵母细胞;昆虫细胞;哺乳动物细胞;小鼠细胞;灵长类细胞;或人细胞。
试剂盒实施方案包括那些,其中含有所述核酸和:含该核酸的隔室;进一步含灵长类DCRS8或DCRS9的隔室;或试剂盒中试剂使用或处理说明书。
提供的其它核酸包括这些:在小于2M盐水中30℃30分钟洗涤条件下它们与SEQ ID NO:13或16的编码部分杂交;或表现出与灵长类DCRS8或DCRS9的至少约30个核苷酸链的一致性。优选地,它们将是这种核酸:洗涤条件是:45℃和/或500mM盐水;55℃和/或150mM盐水;或链长至少55或75个核苷酸。
本发明也提供调节细胞或组织培养细胞生理或发育的方法,其中含有将细胞与哺乳动物DCRS8或DCRS9的激动剂或拮抗剂接触。优选地,细胞用编码DCRS8或DCRS9和另一种细胞因子受体亚基的核酸转化。
发明详述
提纲
I.概述
II.活性
III.核酸
A.编码片段,序列,探针
B.突变,嵌合体,融合体
C.制备核酸
D.载体,细胞
IV.蛋白,肽
A.片段,序列,免疫原,抗原
B.突变蛋白
C.激动剂/拮抗剂,功能性等同物
D.制备蛋白
V.制备核酸、蛋白
A.合成
B.重组
C.天然来源
VI.抗体
A.多克隆
B.单克隆
C.片段;Kd
D.抗独特型抗体
E.杂交瘤细胞系
VII.定量DCRS的试剂盒和方法
A.ELISA
B.mRNA编码测试
C.定性/定量
D.试剂盒
VIII.治疗组合物、方法
A.组合物
B.单位剂量
C.给药
IX.筛选
X.配体I.概述
本发明提供哺乳动物,在本文中是灵长类,细胞因子受体样亚基分子的氨基酸序列和DNA序列,它们被称为DNAX细胞因子受体亚基6(DCRS6)、7(DCRS7)、8(DCRS8)、9(DCRS9)和10(DCRS10),它们都具有结构和生物学上具体定义的特性。多种编码这些分子的cDNA由灵长类,例如人,和/或啮齿动物,例如小鼠的cDNA序列文库获得。其它灵长类或其它哺乳动物也在预期范围内。
一些适用的标准方法被描述或引用,例如,Maniatis等(1982)Molecular Cloning,A Laboratory Manual,Cold Spring HarborLaboratory,Cold Spring Harbor Press;Sambrook等(1989)Molecular Cloning,A Laboratory Manual,(2nd ed.),vols.1-3,CSHPress,NY;Ausubel等,
Biology,Greene Publishing Associates,Brooklyn,NY;或Ausubel等(1987和增刊)
Current Protocols in Molecular Biology,Greene/Wiley,New York;其中每一个都在此引作参考。
灵长类如人DCRS6编码片段的核酸(SEQ ID NO:1)和相应的氨基酸序列(SEQ ID NO:2)与其反式翻译序列(SEQ ID NO:3)一起示于表1。对应的啮齿动物如小鼠序列也在此提供,例如SEQ ID NO:4-6。
与之相似,灵长类如人DCRS7编码片段的核酸(SEQ ID NO:7)和相应的氨基酸序列(SEQ ID NO:8)与其反式翻译序列(SEQ ID NO:9)一起示于表2。对应的啮齿动物如小鼠序列也在此提供,例如SEQ IDNO:10-12。灵长类如人DCRS8编码片段的核酸(SEQ ID NO:13)和相应的氨基酸序列(SEQ ID NO:14)与其反式翻译序列(SEQ ID NO:15)一起示于表3。
灵长类如人DCRS9编码片段的核酸(SEQ ID NO:16)和相应的氨基酸序列(SEQ ID NO:17)与其反式翻译序列(SEQ ID NO:18)一起示于表4。对应的啮齿动物如小鼠序列也在此提供,例如SEQ ID NO:19-21。灵长类如人DCRS10编码片段的核酸(SEQ ID NO:22)和相应的氨基酸序列(SEQ ID NO:23)与其反式翻译序列(SEQ ID NO:24)一起示于表5。对应的啮齿动物如小鼠序列也在此提供,例如SEQ ID NO:26-27。
表1:DNAX细胞因子受体亚基样实例(DCRS6)的核酸和多肽序列。灵长类如人的实例(见SEQ ID NO:1和2)。预测的信号序列已标出,但可能变化几个位置并依赖于细胞类型。gcg atg tcg ctc gtg ctg cta agc ctg gcc gcg ctg tgc agg agc gcc 48
Met Ser Leu Val Leu Leu Ser Leu Ala Ala Leu Cys Arg Ser Ala
-10 -5 -1 1gta ccc cga gag ccg acc gtt caa tgt ggc tct gaa act ggg cca tct 96Val Pro Arg Glu Pro Thr Val Gln Cys Gly Ser Glu Thr Gly Pro Ser
5 10 15cca gag tgg atg cta caa cat gat cta atc ccg gga gac ttg agg gac 144Pro Glu Trp Met Leu Gln His Asp Leu Ile Pro Gly Asp Leu Arg Asp
20 25 30ctc cga gta gaa cct gtt aca act agt gtt gca aca ggg gac tat tca 192Leu Arg Val Glu Pro Val Thr Thr Ser Val Ala Thr Gly Asp Tyr Ser
35 40 45att ttg atg aat gta agc tgg gta ctc cgg gca gat gcc agc atc cgc 240Ile Leu Met Asn Val Ser Trp Val Leu Arg Ala Asp Ala Ser Ile Arg50 55 60 65ttg ttg aag gcc acc aag att tgt gtg acg ggc aaa agc aac ttc cag 288Leu Leu Lys Ala Thr Lys Ile Cys Val Thr Gly Lys Ser Asn Phe Gln
70 75 80tcc tac agc tgt gtg agg tgc aat tac aca gag gcc ttc cag act cag 336Ser Tyr Ser Cys Val Arg Cys Asn Tyr Thr Glu Ala Phe Gln Thr Gln
85 90 95acc aga ccc tct ggt ggt aaa tgg aca ttt tcc tat atc ggc ttc cct 384Thr Arg Pro Ser Gly Gly Lys Trp Thr Phe Ser Tyr Ile Gly Phe Pro
100 105 110gta gag ctg aac aca gtc tat ttc att ggg gcc cat aat att cct aat 432Val Glu Leu Asn Thr Val Tyr Phe Ile Gly Ala His Asn Ile Pro Asn
115 120 125gca aat atg aat gaa gat ggc cct tcc atg tct gtg aat ttc acc tca 480Ala Asn Met Asn Glu Asp Gly Pro Ser Met Ser Val Asn Phe Thr Ser130 135 140 145cca ggc tgc cta gac cac ata atg aaa tat aaa aaa aag tgt gtc aag 528Pro Gly Cys Leu Asp His Ile Met Lys Tyr Lys Lys Lys Cys Val Lys
150 155 160gcc gga agc ctg tgg gat ccg aac atc act gct tgt aag aag aat gag 576Ala Gly Ser Leu Trp Asp Pro Asn Ile Thr Ala Cys Lys Lys Asn Glu
165 170 175gag aca gta gaa gtg aac ttc aca acc act ccc ctg gga aac aga tac 624Glu Thr Val Glu Val Asn Phe Thr Thr Thr Pro Leu Gly Asn Arg Tyr
180 185 190atg gct ctt atc caa cac agc act atc atc ggg ttt tct cag gtg ttt 672Met Ala Leu Ile Gln His Ser Thr Ile Ile Gly Phe Ser Gln Val Phe
195 200 205gag cca cac cag aag aaa caa acg cga gct tca gtg gtg att cca gtg 720Glu Pro His Gln Lys Lys Gln Thr Arg Ala Ser Val Val Ile Pro Val210 215 220 225act ggg gat agt gaa ggt gct acg gtg cag ctg act cca tat ttt cct 768Thr Gly Asp Ser Glu Gly Ala Thr Val Gln Leu Thr Pro Tyr Phe Pro
230 235 240act tgt ggc agc gac tgc atc cga cat aaa gga aca gtt gtg ctc tgc 816Thr Cys Gly Ser Asp Cys Ile Arg His Lys Gly Thr Val Val Leu Cys
245 250 255cca caa aca ggc gtc cct ttc cct ctg gat aac aac aaa agc aag ccg 864Pro Gln Thr Gly Val Pro Phe Pro Leu Asp Asn Asn Lys Ser Lys Pro
260 265 270gga ggc tgg ctg cct ctc ctc ctg ctg tct ctg ctg gtg gcc aca tgg 912Gly Gly Trp Leu Pro Leu Leu Leu Leu Ser Leu Leu Val Ala Thr Trp
275 280 285gtg ctg gtg gca ggg atc tat cta atg tgg agg cac gaa agg atc aag 960Val Leu Val Ala Gly Ile Tyr Leu Met Trp Arg His Glu Arg Ile Lys290 295 300 305aag act tcc ttt tct acc acc aca cta ctg ccc ccc att aag gtt ctt 1008Lys Thr Ser Phe Ser Thr Thr Thr Leu Leu Pro Pro Ile Lys Val Leu
310 315 320gtg gtt tac cca tct gaa ata tgt ttc cat cac aca att tgt tac ttc 1056Val Val Tyr Pro Ser Glu Ile Cys Phe His His Thr Ile Cys Tyr Phe
325 330 335act gaa ttt ctt caa aac cat tgc aga agt gag gtc atc ctt gaa aag 1104Thr Glu Phe Leu Gln Asn His Cys Arg Ser Glu Val Ile Leu Glu Lys
340 345 350tgg cag aaa aag aaa ata gca gag atg ggt cca gtg cag tgg ctt gcc 1152Trp Gln Lys Lys Lys Ile Ala Glu Met Gly Pro Val Gln Trp Leu Ala
355 360 365act caa aag aag gca gca gac aaa gtc gtc ttc ctt ctt tcc aat gac 1200Thr Gln Lys Lys Ala Ala Asp Lys Val Val Phe Leu Leu Ser Asn Asp370 375 380 385gtc aac agt gtg tgc gat ggt acc tgt ggc aag agc gag ggc agt ccc 1248Val Asn Ser Val Cys Asp Gly Thr Cys Gly Lys Ser Glu Gly Ser Pro
390 395 400agt gag aac tct caa gac ctc ttc ccc ctt gcc ttt aac ctt ttc tgc 1296Ser Glu Asn Ser Gln Asp Leu Phe Pro Leu Ala Phe Asn Leu Phe Cys
405 410 415agt gat cta aga agc cag att cat ctg cac aaa tac gtg gtg gtc tac 1344Ser Asp Leu Arg Ser Gln Ile His Leu His Lys Tyr Val Val Val Tyr
420 425 430ttt aga gag att gat aca aaa gac gat tac aat gct ctc agt gtc tgc 1392Phe Arg Glu Ile Asp Thr Lys Asp Asp Tyr Asn Ala Leu Ser Val Cys
435 440 445ccc aag tac cac ctc atg aag gat gcc act gct ttc tgt gca gaa ctt 1440Pro Lys Tyr His Leu Met Lys Asp Ala Thr Ala Phe Cys Ala Glu Leu450 455 460 465ctc cat gtc aag cag cag gtg tca gca gga aaa aga tca caa gcc tgc 1488Leu His Val Lys Gln Gln Val Ser Ala Gly Lys Arg Ser Gln Ala Cys
470 475 480cac gat ggc tgc tgc tcc ttg tagcccaccc atgagaagca agagacctta 1539His Asp Gly Cys Cys Ser Leu
485aaggcttcct atcccaccaa ttacagggaa aaaacgtgtg atgatcctga agcttactat 1599gcagcctaca aacagcctta gtaattaaaa cattttatac caataaaatt ttcaaatatt 1659gctaactaat gtagcattaa ctaacgattg gaaactacat ttacaacttc aaagctgttt 1719tatacataga aatcaattac agctttaatt gaaaactgta accattttga taatgcaaca 1779ataaagcatc ttcagcc 1796MSLVLLSLAALCRSAVPREPTVQCGSETGPSPEWMLQHDLIPGDLRDLRVEPVTTSVATGDYSILMNVSWVLRADASIRLLKATKICVTGKSNFQSYSCVRCNYTEAFQTQTRPSGGKWTFSYIGFPVEINTVYFIGAHNIPNANMNEDGPSMSVNFTSPGCLDHIMKYKKKCVKAGSLWDPNITACKKNEETVEVNFTTTPLGNRYMALIQHSTIIGFSQVFEPHQKKQTRASVVIPVTGDSEGATVQLTPYFPTCGSDCIRHKGTVVLCPQTGVPFPLDNNKSKPGGWLPLLLLSLLVATWVLVAGIYLMWRHERIKKTSFSTTTLLPPIKVLVVYPSEICFHHTICYFTEFLQNHCRSEVILEKWQKKKIAEMGPVQWLATQKKAADKVVFLLSNDVNSVCDGTCGKSEGSPSENSQDLFPLAFNLFCSDLRSQIHLHKYVVVYFREIDTKDDYNALSVCPKYHLMKDATAFCAELLHVKQQVSAGKRSQACHDGCCSL.灵长类如人的DCRS6的反式翻译序列(SEQ ID NO:3):atgwsnytng tnytnytnws nytngcngcn ytntgymgnw sngcngtncc nmgngarccn 60acngtncart gyggnwsnga racnggnccn wsnccngart ggatgytnca rcaygayytn 120athccnggng ayytnmgnga yytnmgngtn garccngtna cnacnwsngt ngcnacnggn 180gaytaywsna thytnatgaa ygtnwsntgg gtnytnmgng cngaygcnws nathmgnytn 240ytnaargcna cnaarathtg ygtnacnggn aarwsnaayt tycarwsnta ywsntgygtn 300mgntgyaayt ayacngargc nttycaracn caracnmgnc cnwsnggngg naartggacn 360ttywsntaya thggnttycc ngtngarytn aayacngtnt ayttyathgg ngcncayaay 420athccnaayg cnaayatgaa ygargayggn ccnwsnatgw sngtnaaytt yacnwsnccn 480ggntgyytng aycayathat gaartayaar aaraartgyg tnaargcngg nwsnytntgg 540gayccnaaya thacngcntg yaaraaraay gargaracng tngargtnaa yttyacnacn 600acnccnytng gnaaymgnta yatggcnytn athcarcayw snacnathat hggnttywsn 660cargtnttyg arccncayca raaraarcar acnmgngcnw sngtngtnat hccngtnacn 720ggngaywsng arggngcnac ngtncarytn acnccntayt tyccnacntg yggnwsngay 780tgyathmgnc ayaarggnac ngtngtnytn tgyccncara cnggngtncc nttyccnytn 840gayaayaaya arwsnaarcc nggnggntgg ytnccnytny tnytnytnws nytnytngtn 900gcnacntggg tnytngtngc nggnathtay ytnatgtggm gncaygarmg nathaaraar 960acnwsnttyw snacnacnac nytnytnccn ccnathaarg tnytngtngt ntayccnwsn 1020garathtgyt tycaycayac nathtgytay ttyacngart tyytncaraa ycaytgymgn 1080wsngargtna thytngaraa rtggcaraar aaraarathg cngaratggg nccngtncar 1140tggytngcna cncaraaraa rgcngcngay aargtngtnt tyytnytnws naaygaygtn 1200aaywsngtnt gygayggnac ntgyggnaar wsngarggnw snccnwsnga raaywsncar 1260gayytnttyc cnytngcntt yaayytntty tgywsngayy tnmgnwsnca rathcayytn 1320cayaartayg tngtngtnta yttymgngar athgayacna argaygayta yaaygcnytn 1380wsngtntgyc cnaartayca yytnatgaar gaygcnacng cnttytgygc ngarytnytn 1440caygtnaarc arcargtnws ngcnggnaar mgnwsncarg cntgycayga yggntgytgy 1500wsnytn 1506啮齿动物如小鼠的实例(见SEQ ID NO:4和5)。gat ttc agc agc cag acg cat ctg cac aaa tac ctg gag gtc tat ctt 48Asp Phe Ser Ser Gln Thr His Leu His Lys Tyr Leu Glu Val Tyr Leu1 5 10 15ggg gga gca gac ctc aaa ggc gac tat aat gcc ctg agt gtc tgc ccc 96Gly Gly Ala Asp Leu Lys Gly Asp Tyr Asn Ala Leu Ser Val Cys Pro
20 25 30caa tat cat ctc atg aag gac gcc aca gct ttc cac aca gaa ctt ctc 144Gln Tyr His Leu Met Lys Asp Ala Thr Ala Phe His Thr Glu Leu Leu
35 40 45aag gct acg cag agc atg tca gtg aag aaa cgc tca caa gcc tgc cat 192Lys Ala Thr Gln Ser Met Ser Val Lys Lys Arg Ser Gln Ala Cys His
50 55 60gat agc tgt tca ccc ttg tagtccaccc gggggaatag agactctgaa 240Asp Ser Cys Ser Pro Leu65 70gccttcctac tctcccttcc agtgacaaat gctgtgtgac gactctgaaa tgtgtgggag 300aggctgtgtg gaggtagtgc tatgtacaaa cttgctttaa aactggagtt tgcaaagtca 360acctgagcat acacgcctga ggctagtcat tggctggatt tatgaagaca acacagttac 420agacaataat gagtgggacc tacatttggg atatacccaa agctgggtaa tgattatcac 480tgagaaccac gcactctggc catgaggtaa tacggcactt ccctgtcagg ctgtctgtca 540ggttgggtct gtcttgcact gcccatgctc tatgctgcac gtagaccgtt ttgtaacatt 600ttaatctgtt aatgaataat ccgtttggga ggctctc 637DFSSQTHLHKYLEVYLGGADLKGDYNALSVCPQYHLMKDATAFHTELLKATQSMSVKKRSQACHDSCSPL.啮齿动物如小鼠的DCRS6的反式翻译序列(SEQ ID NO:6):gayttywsnw sncaracnca yytncayaar tayytngarg tntayytngg nggngcngay 60ytnaarggng aytayaaygc nytnwsngtn tgyccncart aycayytnat gaargaygcn 120acngcnttyc ayacngaryt nytnaargcn acncarwsna tgwsngtnaa raarmgnwsn 180cargcntgyc aygaywsntg ywsnccnytn 210
表2:DNAX细胞因子受体亚基样实例(DCRS7)的核酸和多肽序列。灵长类如人的实例(见SEQ ID NO:7和8)。预测的信号序列已标出,但可能变化几个位置并依赖于细胞类型。gagtcaggac tcccaggaca gagagtgcac aaactaccca gcacagcccc ctccgccccc 60tctggaggct gaagagggat tccagcccct gccacccaca gacacgggct gactggggtg 120tctgcccccc ttgggggcan ccacagggcc tcaggcctgg gtgccacctg gcactagaag 180atg cct gtg ccc tgg ttc ttg ctg tcc ttg gca ctg ggc cga agc cag 228Met Pro Val Pro Trp Phe Leu Leu Ser Leu Ala Leu Gly Arg Ser Gln-20 -15 -10 -5tgg atc ctt tct ctg gag agg ctt gtg ggg cct cag gac gct acc cac 276Trp Ile Leu Ser Leu Glu Arg Leu Val Gly Pro Gln Asp Ala Thr His
-1 1 5 10tgc tct ccg ggc ctc tcc tgc cgc ctc tgg gac agt gac ata ctc tgc 324Cys Ser Pro Gly Leu Ser Cys Arg Leu Trp Asp Ser Asp Ile Leu Cys
15 20 25ctg cct ggg gac atc gtg cct gct ccg ggc ccc gtg ctg gcg cct acg 372Leu Pro Gly Asp Ile Val Pro Ala Pro Gly Pro Val Leu Ala Pro Thr
30 35 40cac ctg cag aca gag ctg gtg ctg agg tgc cag aag gag acc gac tgt 420His Leu Gln Thr Glu Leu Val Leu Arg Cys Gln Lys Glu Thr Asp Cys45 50 55 60gac ctc tgt ctg cgt gtg gct gtc cac ttg gcc gtg cat ggg cac tgg 468Asp Leu Cys Leu Arg Val Ala Val His Leu Ala Val His Gly His Trp
65 70 75gaa gag cct gaa gat gag gaa aag ttt gga gga gca gct gac tta ggg 516Glu Glu Pro Glu Asp Glu Glu Lys Phe Gly Gly Ala Ala Asp Leu Gly
80 85 90gtg gag gag cct agg aat gcc tct ctc cag gcc caa gtc gtg ctc tcc 564Val Glu Glu Pro Arg Asn Ala Ser Leu Gln Ala Gln Val Val Leu Ser
95 100 105ttc cag gcc tac cct act gcc cgc tgc gtc ctg ctg gag gtg caa gtg 612Phe Gln Ala Tyr Pro Thr Ala Arg Cys Val Leu Leu Glu Val Gln Val
110 115 120cct gct gcc ctt gtg cag ttt ggt cag tct gtg ggc tct gtg gta tat 660Pro Ala Ala Leu Val Gln Phe Gly Gln Ser Val Gly Ser Val Val Tyr125 130 135 140gac tgc ttc gag gct gcc cta ggg agt gag gta cga atc tgg tcc tat 708Asp Cys Phe Glu Ala Ala Leu Gly Ser Glu Val Arg Ile Trp Ser Tyr
145 150 155act cag ccc agg tac gag aag gaa ctc aac cac aca cag cag ctg cct 756Thr Gln Pro Arg Tyr Glu Lys Glu Leu Asn His Thr Gln Gln Leu Pro
160 165 170gac tgc agg ggg ctc gaa gtc tgg aac agc atc ccg agc tgc tgg gcc 804Asp Cys Arg Gly Leu Glu Val Trp Asn Ser Ile Pro Ser Cys Trp Ala
175 180 185ctg ccc tgg ctc aac gtg tca gca gat ggt gac aac gtg cat ctg gtt 852Leu Pro Trp Leu Asn Val Ser Ala Asp Gly Asp Asn Val His Leu Val
190 195 200ctg aat gtc tct gag gag cag cac ttc ggc ctc tcc ctg tac tgg aat 900Leu Asn Val Ser Glu Glu Gln His Phe Gly Leu Ser Leu Tyr Trp Asn205 210 215 220cag gtc cag ggc ccc cca aaa ccc cgg tgg cac aaa aac ctg act gga 948Gln Val Gln Gly Pro Pro Lys Pro Arg Trp His Lys Asn Leu Thr Gly
225 230 235ccg cag atc att acc ttg aac cac aca gac ctg gtt ccc tgc ctc tgt 996Pro Gln Ile Ile Thr Leu Asn His Thr Asp Leu Val Pro Cys Leu Cys
240 245 250att cag gtg tgg cct ctg gaa cct gac tcc gtt agg acg aac atc tgc 1044Ile Gln Val Trp Pro Leu Glu Pro Asp Ser Val Arg Thr Asn Ile Cys
255 260 265ccc ttc agg gag gac ccc cgc gca cac cag aac ctc tgg caa gcc gcc 1092Pro Phe Arg Glu Asp Pro Arg Ala His Gln Asn Leu Trp Gln Ala Ala
270 275 280cga ctg cga ctg ctg acc ctg cag agc tgg ctg ctg gac gca ccg tgc 1140Arg Leu Arg Leu Leu Thr Leu Gln Ser Trp Leu Leu Asp Ala Pro Cys285 290 295 300tcg ctg ccc gca gaa gcg gca ctg tgc tgg cgg gct ccg ggt ggg gac 1188Ser Leu Pro Ala Glu Ala Ala Leu Cys Trp Arg Ala Pro Gly Gly Asp
305 310 315ccc tgc cag cca ctg gtc cca ccg ctt tcc tgg gag aat gtc act gtg 1236Pro Cys Gln Pro Leu Val Pro Pro Leu Ser Trp Glu Asn Val Thr Val
320 325 330gac gtg aac agc tcg gag aag ctg cag ctg cag gag tgc ttg tgg gct 1284Asp Val Asn Ser Ser Glu Lys Leu Gln Leu Gln Glu Cys Leu Trp Ala
335 340 345gac tcc ctg ggg cct ctc aaa gac gat gtg cta ctg ttg gag aca cga 1332Asp Ser Leu Gly Pro Leu Lys Asp Asp Val Leu Leu Leu Glu Thr Arg
350 355 360ggc ccc cag gac aac aga tcc ctc tgt gcc ttg gaa ccc agt ggc tgt 1380Gly Pro Gln Asp Asn Arg Ser Leu Cys Ala Leu Glu Pro Ser Gly Cys365 370 375 380act tca cta ccc agc aaa gcc tcc acg agg gca gct cgc ctt gga gag 1428Thr Ser Leu Pro Ser Lys Ala Set Thr Arg Ala Ala Arg Leu Gly Glu
385 390 395tac tta cta caa gac ctg cag tca ggc cag tgt ctg cag cta tgg gac 1476Tyr Leu Leu Gln Asp Leu Gln Ser Gly Gln Cys Leu Gln Leu Trp Asp
400 405 410gat gac ttg gga gcg cta tgg gcc tgc ccc atg gac aaa tac atc cac 1524Asp Asp Leu Gly Ala Leu Trp Ala Cys Pro Met Asp Lys Tyr Ile His
415 420 425aag cgc tgg gcc ctc gtg tgg ctg gcc tgc cta ctc ttt gcc gct gcg 1572Lys Arg Trp Ala Leu Val Trp Leu Ala Cys Leu Leu Phe Ala Ala Ala
430 435 440ctt tcc ctc atc ctc ctt ctc aaa aag gat cac gcg aaa ggg tgg ctg 1620Leu Ser Leu Ile Leu Leu Leu Lys Lys Asp His Ala Lys Gly Trp Leu445 450 455 460agg ctc ttg aaa cag gac gtc cgc tcg ggg gcg gcc gcc agg ggc cgc 1668Arg Leu Leu Lys Gln Asp Val Arg Ser Gly Ala Ala Ala Arg Gly Arg
465 470 475gcg gct ctg ctc ctc tac tca gcc gat gac tcg ggt ttc gag cgc ctg 1716Ala Ala Leu Leu Leu Tyr Ser Ala Asp Asp Ser Gly Phe Glu Arg Leu
480 485 490gtg ggc gcc ctg gcg tcg gcc ctg tgc cag ctg ccg ctg cgc gtg gcc 1764Val Gly Ala Leu Ala Ser Ala Leu Cys Gln Leu Pro Leu Arg Val Ala
495 500 505gta gac ctg tgg agc cgt cgt gaa ctg agc gcg cag ggg ccc gtg gct 1812Val Asp Leu Trp Ser Arg Arg Glu Leu Ser Ala Gln Gly Pro Val Ala
510 515 520tgg ttt cac gcg cag cgg cgc cag acc ctg cag gag ggc ggc gtg gtg 1860Trp Phe His Ala Gln Arg Arg Gln Thr Leu Gln Glu Gly Gly Val Val525 530 535 540gtc ttg ctc ttc tct ccc ggt gcg gtg gcg ctg tgc agc gag tgg cta 1908Val Leu Leu Phe Ser Pro Gly Ala Val Ala Leu Cys Ser Glu Trp Leu
545 550 555cag gat ggg gtg tcc ggg ccc ggg gcg cac ggc ccg cac gac gcc ttc 1956Gln Asp Gly Val Ser Gly Pro Gly Ala His Gly Pro His Asp Ala Phe
560 565 570cgc gcc tcg ctc agc tgc gtg ctg ccc gac ttc ttg cag ggc cgg gcg 2004Arg Ala Ser Leu Ser Cys Val Leu Pro Asp Phe Leu Gln Gly Arg Ala
575 580 585ccc ggc agc tac gtg ggg gcc tgc ttc gac agg ctg ctc cac ccg gac 2052Pro Gly Ser Tyr Val Gly Ala Cys Phe Asp Arg Leu Leu His Pro Asp
590 595 600gcc gta ccc gcc ctt ttc cgc acc gtg ccc gtc ttc aca ctg ccc tcc 2100Ala Val Pro Ala Leu Phe Arg Thr Val Pro Val Phe Thr Leu Pro Ser605 610 615 620caa ctg cca gac ttc ctg ggg gcc ctg cag cag cct cgc gcc ccg cgt 2148Gln Leu Pro Asp Phe Leu Gly Ala Leu Gln Gln Pro Arg Ala Pro Arg
625 630 635tcc ggg cgg ctc caa gag aga gcg gag caa gtg tcc cgg gcc ctt cag 2196Ser Gly Arg Leu Gln Glu Arg Ala Glu Gln Val Ser Arg Ala Leu Gln
640 645 650cca gcc ctg gat agc tac ttc cat ccc ccg ggg acn tcc gcg ccg gga 2244Pro Ala Leu Asp Ser Tyr Phe His Pro Pro Gly Xaa Ser Ala Pro Gly
655 660 665cgc ggg gtg gga cca ggg gcg gga cct ggg gcg ggg gac ggg act 2289Arg Gly Val Gly Pro Gly Ala Gly Pro Gly Ala Gly Asp Gly Thr
670 675 680taaataaagg cagacgctg 2308MPVPWFLLSLALGRSQWILSLERLVGPQDATHCSPGLSCRLWDSDILCLPGDIVPAPGPVLAPTHLQTELVLRCQKETDCDLCLRVAVHLAVHGHWEEPEDEEKFGGAADLGVEEPRNASLQAQVVLSFQAYPTARCVLLEVQVPAALVQFGQSVGSVVYDCFEAALGSEVRIWSYTQPRYEKELNHTQQLPDCRGLEVWNSIPSCWALPWLNVSADGDNVHLVLNVSEEQHFGLSLYWNQVQGPPKPRWHKNLTGPQIITLNHTDLVPCLCIQVWPLEPDSVRTNICPFREDPRAHQNLWQAARLRLLTLQSWLLDAPCSLPAEAALCWRAPGGDPCQPLVPPLSWENVTVDVNSSEKLQLQECLWADSLGPLKDDVLLLETRGPQDNRSLCALEPSGCTSLPSKASTRAARLGEYLLQDLQSGQCLQLWDDDLGALWACPMDKYIHKRWALVWLACLLFAAALSLILLLKKDHAKGWLRLLKQDVRSGAAARGRAALLLYSADDSGFERLVGALASALCQLPLRVAVDLWSRRELSAQGPVAWFHAQRRQTLQEGGVVVLLFSPGAVALCSEWLQDGVSGPGAHGPHDAFRASLSCVLPDFLQGRAPGSYVGACFDRLLHPDAVPALFRTVPVFTLPSQLPDFLGALQQPRAPRSGRLQERAEQVSRALQPALDSYFHPPGTSAPGRGVGPGAGPGAGDGT.灵长类如人的DCRS7的反式翻译序列(SEQ ID NO:9):atgccngtnc cntggttyyt nytnwsnytn gcnytnggnm gnwsncartg gathytnwsn 60ytngarmgny tngtnggncc ncargaygcn acncaytgyw snccnggnyt nwsntgymgn 120ytntgggayw sngayathyt ntgyytnccn ggngayathg tnccngcncc nggnccngtn 180ytngcnccna cncayytnca racngarytn gtnytnmgnt gycaraarga racngaytgy 240gayytntgyy tnmgngtngc ngtncayytn gcngtncayg gncaytggga rgarccngar 300gaygargara arttyggngg ngcngcngay ytnggngtng argarccnmg naaygcnwsn 360ytncargcnc argtngtnyt nwsnttycar gcntayccna cngcnmgntg ygtnytnytn 420gargtncarg tnccngcngc nytngtncar ttyggncarw sngtnggnws ngtngtntay 480gaytgyttyg argcngcnyt nggnwsngar gtnmgnatht ggwsntayac ncarccnmgn 540taygaraarg arytnaayca yacncarcar ytnccngayt gymgnggnyt ngargtntgg 600aaywsnathc cnwsntgytg ggcnytnccn tggytnaayg tnwsngcnga yggngayaay 660gtncayytng tnytnaaygt nwsngargar carcayttyg gnytnwsnyt ntaytggaay 720cargtncarg gnccnccnaa rccnmgntgg cayaaraayy tnacnggncc ncarathath 780acnytnaayc ayacngayyt ngtnccntgy ytntgyathc argtntggcc nytngarccn 840gaywsngtnm gnacnaayat htgyccntty mgngargayc cnmgngcnca ycaraayytn 900tggcargcng cnmgnytnmg nytnytnacn ytncarwsnt ggytnytnga ygcnccntgy 960wsnytnccng cngargcngc nytntgytgg mgngcnccng gnggngaycc ntgycarccn 1020ytngtnccnc cnytnwsntg ggaraaygtn acngtngayg tnaaywsnws ngaraarytn 1080carytncarg artgyytntg ggcngaywsn ytnggnccny tnaargayga ygtnytnytn 1140ytngaracnm gnggnccnca rgayaaymgn wsnytntgyg cnytngarcc nwsnggntgy 1200acnwsnytnc cnwsnaargc nwsnacnmgn gcngcnmgny tnggngarta yytnytncar 1260gayytncarw snggncartg yytncarytn tgggaygayg ayytnggngc nytntgggcn 1320tgyccnatgg ayaartayat hcayaarmgn tgggcnytng tntggytngc ntgyytnytn 1380ttygcngcng cnytnwsnyt nathytnytn ytnaaraarg aycaygcnaa rggntggytn 1440mgnytnytna arcargaygt nmgnwsnggn gcngcngcnm gnggnmgngc ngcnytnytn 1500ytntaywsng cngaygayws nggnttygar mgnytngtng gngcnytngc nwsngcnytn 1560tgycarytnc cnytnmgngt ngcngtngay ytntggwsnm gnmgngaryt nwsngcncar 1620ggnccngtng cntggttyca ygcncarmgn mgncaracny tncargargg nggngtngtn 1680gtnytnytnt tywsnccngg ngcngtngcn ytntgywsng artggytnca rgayggngtn 1740wsnggnccng gngcncaygg nccncaygay gcnttymgng cnwsnytnws ntgygtnytn 1800ccngayttyy tncarggnmg ngcnccnggn wsntaygtng gngcntgytt ygaymgnytn 1860ytncayccng aygcngtncc ngcnytntty mgnacngtnc cngtnttyac nytnccnwsn 1920carytnccng ayttyytngg ngcnytncar carccnmgng cnccnmgnws nggnmgnytn 1980cargarmgng cngarcargt nwsnmgngcn ytncarccng cnytngayws ntayttycay 2040ccnccnggna cnwsngcncc nggnmgnggn gtnggnccng gngcnggncc nggngcnggn 2100gayggnacn 2109
啮齿动物如小鼠的实例(见SEQ ID NO:10和11)。预测的信号序列已标出,但可能变化几个位置并依赖于细胞类型。ccaaatcgaa agcacgggag ctgatactgg gcctggagtc caggctcact ggagtgggga 60agcatggctg gagaggaatt ctagcccttg ctctctccca gggacacggg gctgattgtc 120agcaggggcg aggggtctgc ccccccttgg gggggcagga cggggcctca ggcctgggtg 180ctgtccggca cctggaag atg cct gtg tcc tgg ttc ctg ctg tcc ttg gca 231
Met Pro Val Ser Trp Phe Leu Leu Ser Leu Ala
-20 -15 -10ctg ggc cga aac cct gtg gtc gtc tct ctg gag aga ctg atg gag cct 279Leu Gly Arg Asn Pro Val Val Val Ser Leu Glu Arg Leu Met Glu Pro
-5 -1 1 5cag gac act gca cgc tgc tct cta ggc ctc tcc tgc cac ctc tgg gat 327Gln Asp Thr Ala Arg Cys Ser Leu Gly Leu Ser Cys His Leu Trp Asp
10 15 20ggt gac gtg ctc tgc ctg cct gga agc ctc cag tct gcc cca ggc cct 375Gly Asp Val Leu Cys Leu Pro Gly Ser Leu Gln Ser Ala Pro Gly Pro
25 30 35gtg cta gtg cct acc cgc ctg cag acg gag ctg gtg ctg agg tgt cca 423Val Leu Val Pro Thr Arg Leu Gln Thr Glu Leu Val Leu Arg Cys Pro40 45 50 55cag aag aca gat tgc gcc ctc tgt gtc cgt gtg gtg gtc cac ttg gcc 471Gln Lys Thr Asp Cys Ala Leu Cys Val Arg Val Val Val His Leu Ala
60 65 70gtg cat ggg cac tgg gca gag cct gaa gaa gct gga aag tct gat tca 519Val His Gly His Trp Ala Glu Pro Glu Glu Ala Gly Lys Ser Asp Ser
75 80 85gaa ctc cag gag tct agg aac gcc tct ctc cag gcc cag gtg gtg ctc 567Glu Leu Gln Glu Ser Arg Asn Ala Ser Leu Gln Ala Gln Val Val Leu
90 95 100tcc ttc cag gcc tac ccc atc gcc cgc tgt gcc ctg ctg gag gtc cag 615Ser Phe Gln Ala Tyr Pro Ile Ala Arg Cys Ala Leu Leu Glu Val Gln
105 110 115gtg ccc gct gac ctg gtg cag cct ggt cag tcc gtg ggt tct gcg gta 663Val Pro Ala Asp Leu Val Gln Pro Gly Gln Ser Val Gly Ser Ala Val120 125 130 135ttt gac tgt ttc gag gct agt ctt ggg gct gag gta cag atc tgg tcc 711Phe Asp Cys Phe Glu Ala Ser Leu Gly Ala Glu Val Gln Ile Trp Ser
140 145 150tac acg aag ccc agg tac cag aaa gag ctc aac ctc aca cag cag ctg 759Tyr Thr Lys Pro Arg Tyr Gln Lys Glu Leu Asn Leu Thr Gln Gln Leu
155 160 165cct gac tgc agg ggt ctt gaa gtc cgg gac agc atc cag agc tgc tgg 807Pro Asp Cys Arg Gly Leu Glu Val Arg Asp Ser Ile Gln Ser Cys Trp
170 175 180gtc ctg ccc tgg ctc aat gtg tct aca gat ggt gac aat gtc ctt ctg 855Val Leu Pro Trp Leu Asn Val Ser Thr Asp Gly Asp Asn Val Leu Leu
185 190 195aca ctg gat gtc tct gag gag cag gac ttt agc ttc tta ctg tac ctg 903Thr Leu Asp Val Ser Glu Glu Gln Asp Phe Ser Phe Leu Leu Tyr Leu200 205 210 215cgt cca gtc ccg gat gct ctc aaa tcc ttg tgg tac aaa aac ctg act 951Arg Pro Val Pro Asp Ala Leu Lys Ser Leu Trp Tyr Lys Asn Leu Thr
220 225 230gga cct cag aac att act tta aac cac aca gac ctg gtt ccc tgc ctc 999Gly Pro Gln Asn Ile Thr Leu Asn His Thr Asp Leu Val Pro Cys Leu
235 240 245tgc att cag gtg tgg tcg cta gag cca gac tct gag agg gtc gaa ttc 1047Cys Ile Gln Val Trp Ser Leu Glu Pro Asp Ser Glu Arg Val Glu Phe
250 255 260tgc ccc ttc cgg gaa gat ccc ggt gca cac agg aac ctc tgg cac ata 1095Cys Pro Phe Arg Glu Asp Pro Gly Ala His Arg Asn Leu Trp His Ile
265 270 275gcc agg ctg cgg gta ctg tcc cca ggg gta tgg cag cta gat gcg cct 1143Ala Arg Leu Arg Val Leu Ser Pro Gly Val Trp Gln Leu Asp Ala Pro280 285 290 295tgc tgt ctg ccg ggc aag gta aca ctg tgc tgg cag gca cca gac cag 1191Cys Cys Leu Pro Gly Lys Val Thr Leu Cys Trp Gln Ala Pro Asp Gln
300 305 310agt ccc tgc cag cca ctt gtg cca cca gtg ccc cag aag aac gcc act 1239Ser Pro Cys Gln Pro Leu Val Pro Pro Val Pro Gln Lys Asn Ala Thr
315 320 325gtg aat gag cca caa gat ttc cag ttg gtg gca ggc cac ccc aac ctc 1287Val Asn Glu Pro Gln Asp Phe Gln Leu Val Ala Gly His Pro Asn Leu
330 335 340tgt gtc cag gtg agc acc tgg gag aag gtt cag ctg caa gcg tgc ttg 1335Cys Val Gln Val Ser Thr Trp Glu Lys Val Gln Leu Gln Ala Cys Leu
345 350 355tgg gct gac tcc ttg ggg ccc ttc aag gat gat atg ctg tta gtg gag 1383Trp Ala Asp Ser Leu Gly Pro Phe Lys Asp Asp Met Leu Leu Val Glu360 365 370 375atg aaa acc ggc ctc aac aac aca tca gtc tgt gcc ttg gaa ccc agt 1431Met Lys Thr Gly Leu Asn Asn Thr Ser Val Cys Ala Leu Glu Pro Ser
380 385 390ggc tgt aca cca ctg ccc agc atg gcc tcc acg aga gct gct cgc ctg 1479Gly Cys Thr Pro Leu Pro Ser Met Ala Ser Thr Arg Ala Ala Arg Leu
395 400 405gga gag gag ttg ctg caa gac ttc cga tca cac cag tgt atg cag ctg 1527Gly Glu Glu Leu Leu Gln Asp Phe Arg Ser His Gln Cys Met Gln Leu
410 415 420tgg aac gat gac aac atg gga tcg cta tgg gcc tgc ccc atg gac aag 1575Trp Asn Asp Asp Asn Met Gly Ser Leu Trp Ala Cys Pro Met Asp Lys
425 430 435tac atc cac agg cgc tgg gtc cta gta tgg ctg gcc tgc cta ctc ttg 1623Tyr Ile His Arg Arg Trp Val Leu Val Trp Leu Ala Cys Leu Leu Leu440 445 450 455gct gcg gcg ctt ttc ttc ttc ctc ctt cta aaa aag gac cgc agg aaa 1671Ala Ala Ala Leu Phe Phe Phe Leu Leu Leu Lys Lys Asp Arg Arg Lys
460 465 470gcg gcc cgt ggc tcc cgc acg gcc ttg ctc ctc cac tcc gcc gac gga 1719Ala Ala Arg Gly Ser Arg Thr Ala Leu Leu Leu His Ser Ala Asp Gly
475 480 485gcg ggc tac gag cgc ctg gtg gga gca ctg gcg tcc gcg ttg agc cag 1767Ala Gly Tyr Glu Arg Leu Val Gly Ala Leu Ala Ser Ala Leu Ser Gln
490 495 500atg cca ctg cgc gtg gcc gtg gac ctg tgg agc cgc cgc gag ctg agc 1815Met Pro Leu Arg Val Ala Val Asp Leu Trp Ser Arg Arg Glu Leu Ser
505 510 515gcg cac gga gcc cta gcc tgg ttc cac cac cag cga cgc cgt atc ctg 1863Ala His Gly Ala Leu Ala Trp Phe His His Gln Arg Arg Arg Ile Leu520 525 530 535cag gag ggt ggc gtg gta atc ctt ctc ttc tcg ccc gcg gcc gtg gcg 1911Gln Glu Gly Gly Val Val Ile Leu Leu Phe Ser Pro Ala Ala Val Ala
540 545 550cag tgt cag cag tgg ctg cag ctc cag aca gtg gag ccc ggg ccg cat 1959Gln Cys Gln Gln Trp Leu Gln Leu Gln Thr Val Glu Pro Gly Pro His
555 560 565gac gcc ctc gcc gcc tgg ctc agc tgc gtg cta ccc gat ttc ctg caa 2007Asp Ala Leu Ala Ala Trp Leu Ser Cys Val Leu Pro Asp Phe Leu Gln
570 575 580ggc cgg gcg acc ggc cgc tac gtc ggg gtc tac ttc gac ggg ctg ctg 2055Gly Arg Ala Thr Gly Arg Tyr Val Gly Val Tyr Phe Asp Gly Leu Leu
585 590 595cac cca gac tct gtg ccc tcc ccg ttc cgc gtc gcc ccg ctc ttc tcc 2103His Pro Asp Ser Val Pro Ser Pro Phe Arg Val Ala Pro Leu Phe Ser600 605 610 615ctg ccc tcg cag ctg ccg gct ttc ctg gat gca ctg cag gga ggc tgc 2151Leu Pro Ser Gln Leu Pro Ala Phe Leu Asp Ala Leu Gln Gly Gly Cys
620 625 630tcc act tcc gcg ggg cga ccc gcg gac cgg gtg gaa cga gtg acc cag 2199Ser Thr Ser Ala Gly Arg Pro Ala Asp Arg Val Glu Arg Val Thr Gln
635 640 645gcg ctg cgg tcc gcc ctg gac agc tgt act tct agc tcg gaa gcc cca 2247Ala Leu Arg Ser Ala Leu Asp Ser Cys Thr Ser Ser Ser Glu Ala Pro
650 655 660ggc tgc tgc gag gaa tgg gac ctg gga ccc tgc act aca cta gaa 2292Gly Cys Cys Glu Glu Trp Asp Leu Gly Pro Cys Thr Thr Leu Glu
665 670 675taaaagccga tacagtattc ct 2314MPVSWFLLSLALGRNPVVVSLERLMEPQDTARCSLGLSCHLWDGDVLCLPGSLQSAPGPVLVPTRLQTELVLRCPQKTDCALCVRVVVHLAVHGHWAEPEEAGKSDSELQESRNASLQAQVVLSFQAYPIARCALLEVQVPADLVQPGQSVGSAVFDCFEASLGAEVQIWSYTKPRYQKELNLTQQLPDCRGLEVRDSIQSCWVLPWLNVSTDGDNVLLTLDVSEEQDFSFLLYLRPVPDALKSLWYKNLTGPQNITLNHTDLVPCLCIQVWSLEPDSERVEFCPFREDPGAHRNLWHIARLRVLSPGVWQLDAPCCLPGKVTLCWQAPDQSPCQPLVPPVPQKNATVNEPQDFQLVAGHPNLCVQVSTWEKVQLQACLWADSLGPFKDDMLLVEMKTGLNNTSVCALEPSGCTPLPSMASTRAARLGEELLQDFRSHQCMQLWNDDNMGSLWACPMDKYIHRRWVLVWLACLLLAAALFFFLLLKKDRRKAARGSRTALLLHSADGAGYERLVGALASALSQMPLRVAVDLWSRRELSAHGALAWFHHQRRRILQEGGVVILLFSPAAVAQCQQWLQLQTVEPGPHDALAAWLSCVLPDFLQGRATGRYVGVYFDGLLHPDSVPSPFRVAPLFSLPSQLPAFLDALQGGCSTSAGRPADRVERVTQALRSALDSCTSSSEAPGCCEEWDLGPCTTLE.啮齿动物如小鼠的DCRS7的反式翻译序列(SEQ ID NO:12):atgccngtnw sntggttyyt nytnwsnytn gcnytnggnm gnaayccngt ngtngtnwsn 60ytngarmgny tnatggarcc ncargayacn gcnmgntgyw snytnggnyt nwsntgycay 120ytntgggayg gngaygtnyt ntgyytnccn ggnwsnytnc arwsngcncc nggnccngtn 180ytngtnccna cnmgnytnca racngarytn gtnytnmgnt gyccncaraa racngaytgy 240gcnytntgyg tnmgngtngt ngtncayytn gcngtncayg gncaytgggc ngarccngar 300gargcnggna arwsngayws ngarytncar garwsnmgna aygcnwsnyt ncargcncar 360gtngtnytnw snttycargc ntayccnath gcnmgntgyg cnytnytnga rgtncargtn 420ccngcngayy tngtncarcc nggncarwsn gtnggnwsng cngtnttyga ytgyttygar 480gcnwsnytng gngcngargt ncarathtgg wsntayacna arccnmgnta ycaraargar 540ytnaayytna cncarcaryt nccngaytgy mgnggnytng argtnmgnga ywsnathcar 600wsntgytggg tnytnccntg gytnaaygtn wsnacngayg gngayaaygt nytnytnacn 660ytngaygtnw sngargarca rgayttywsn ttyytnytnt ayytnmgncc ngtnccngay 720gcnytnaarw snytntggta yaaraayytn acnggnccnc araayathac nytnaaycay 780acngayytng tnccntgyyt ntgyathcar gtntggwsny tngarccnga ywsngarmgn 840gtngarttyt gyccnttymg ngargayccn ggngcncaym gnaayytntg gcayathgcn 900mgnytnmgng tnytnwsncc nggngtntgg carytngayg cnccntgytg yytnccnggn 960aargtnacny tntgytggca rgcnccngay carwsnccnt gycarccnyt ngtnccnccn 1020gtnccncara araaygcnac ngtnaaygar ccncargayt tycarytngt ngcnggncay 1080ccnaayytnt gygtncargt nwsnacntgg garaargtnc arytncargc ntgyytntgg 1140gcngaywsny tnggnccntt yaargaygay atgytnytng tngaratgaa racnggnytn 1200aayaayacnw sngtntgygc nytngarccn wsnggntgya cnccnytncc nwsnatggcn 1260wsnacnmgng cngcnmgnyt nggngargar ytnytncarg ayttymgnws ncaycartgy 1320atgcarytnt ggaaygayga yaayatgggn wsnytntggg cntgyccnat ggayaartay 1380athcaymgnm gntgggtnyt ngtntggytn gcntgyytny tnytngcngc ngcnytntty 1440ttyttyytny tnytnaaraa rgaymgnmgn aargcngcnm gnggnwsnmg nacngcnytn 1500ytnytncayw sngcngaygg ngcnggntay garmgnytng tnggngcnyt ngcnwsngcn 1560ytnwsncara tgccnytnmg ngtngcngtn gayytntggw snmgnmgnga rytnwsngcn 1620cayggngcny tngcntggtt ycaycaycar mgnmgnmgna thytncarga rggnggngtn 1680gtnathytny tnttywsncc ngcngcngtn gcncartgyc arcartggyt ncarytncar 1740acngtngarc cnggnccnca ygaygcnytn gcngcntggy tnwsntgygt nytnccngay 1800ttyytncarg gnmgngcnac nggnmgntay gtnggngtnt ayttygaygg nytnytncay 1860ccngaywsng tnccnwsncc nttymgngtn gcnccnytnt tywsnytncc nwsncarytn 1920ccngcnttyy tngaygcnyt ncarggnggn tgywsnacnw sngcnggnmg nccngcngay 1980mgngtngarm gngtnacnca rgcnytnmgn wsngcnytng aywsntgyac nwsnwsnwsn 2040gargcnccng gntgytgyga rgartgggay ytnggnccnt gyacnacnyt ngar 2094
表3:DNAX细胞因子受体亚基样实例(DCRS8)的核酸和多肽序列。灵长类如人的实例(见SEQ ID NO:13和14)。预测的信号序列已标出,但可能变化几个位置并依赖于细胞类型。cccacgcntc cgggccagca gcgggcggcc ggggcgcaga gaacggcctg gctgggcgag 60cgcacggcc atg gcc ccg tgg ctg cag ctc tgc tcc gtc ttc ttt acg gtc 111
Met Ala Pro Trp Leu Gln Leu Cys Ser Val Phe Phe Thr Val
-15 -10 -5aac gcc tgc ctc aac ggc tcg cag ctg gct gtn gcc gct ggc ggg tcc 159Asn Ala Cys Leu Asn Gly Ser Gln Leu Ala Xaa Ala Ala Gly Gly Ser
-1 1 5 10ggc cgc gcg cng ggc gcc gac acc tgt agc tgg ang gga gtg ggg cca 207Gly Arg Ala Xaa Gly Ala Asp Thr Cys Ser Trp Xaa Gly Val Gly Pro15 20 25 30gcc agc aga aac agt ggg ctg tac aac atc acc ttc aaa tat gac aat 255Ala Ser Arg Asn Ser Gly Leu Tyr Asn Ile Thr Phe Lys Tyr Asp Asn
35 40 45tgt acc acc tac ttg aat cca gtg ggg aag cat gtg att gct gac gcc 303Cys Thr Thr Tyr Leu Asn Pro Val Gly Lys His Val Ile Ala Asp Ala
50 55 60cag aat atc acc atc agc cag tat gct tgc cat gac caa gtg gca gtc 351Gln Asn Ile Thr Ile Ser Gln Tyr Ala Cys His Asp Gln Val Ala Val
65 70 75acc att ctt tgg tcc cca ggg gcc ctc ggc atc gaa ttc ctg aaa gga 399Thr Ile Leu Trp Ser Pro Gly Ala Leu Gly Ile Glu Phe Leu Lys Gly
80 85 90ttt cgg gta ata ctg gag gag ctg aag tcg gag gga aga cag ngc caa 447Phe Arg Val Ile Leu Glu Glu Leu Lys Ser Glu Gly Arg Gln Xaa Gln95 100 105 110caa ctg att cta aag gat ccg aag cag ntc aac agt agc ttc aaa aga 495Gln Leu Ile Leu Lys Asp Pro Lys Gln Xaa Asn Ser Ser Phe Lys Arg
115 120 125act gga atg gaa tct caa cct ttn ctg aat atg aaa ttt gaa acg gat 543Thr Gly Met Glu Ser Gln Pro Xaa Leu Asn Met Lys Phe Glu Thr Asp
130 135 140tat ttc gta agg ttg tcc ttt tcc ttc att aaa aac gaa agc aat tac 591Tyr Phe Val Arg Leu Ser Phe Ser Phe Ile Lys Asn Glu Ser Asn Tyr
145 150 155cac cct ttc ttc ttt aga acc cga gcc tgt gac ctg ttg tta cag ccg 639His Pro Phe Phe Phe Arg Thr Arg Ala Cys Asp Leu Leu Leu Gln Pro
160 165 170gac aat cta gct tgt aaa ccc ttc tgg aag cct cgg aac ctg aac atc 687Asp Asn Leu Ala Cys Lys Pro Phe Trp Lys Pro Arg Asn Leu Asn Ile175 180 185 190agc cag cat ggc tcg gac atg cag gtg tcc ttc gac cac gca ccg cac 735Ser Gln His Gly Ser Asp Met Gln Val Ser Phe Asp His Ala Pro His
195 200 205aac ttc ggc ttc cgt ttc ttc tat ctt cac tac aag ctc aag cac gaa 783Asn Phe Gly Phe Arg Phe Phe Tyr Leu His Tyr Lys Leu Lys His Glu
210 215 220gga cct ttc aag cga aag acc tgt aag cag gag caa act aca gag atg 831Gly Pro Phe Lys Arg Lys Thr Cys Lys Gln Glu Gln Thr Thr Glu Met
225 230 235acc agc tgc ctc ctt caa aat gtt tct cca ggg gat tat ata att gag 879Thr Ser Cys Leu Leu Gln Asn Val Ser Pro Gly Asp Tyr Ile Ile Glu
240 245 250ctg gtg gat gac act aac aca aca aga aaa gtg atg cat tat gcc tta 927Leu Val Asp Asp Thr Asn Thr Thr Arg Lys Val Met His Tyr Ala Leu255 260 265 270aag cca gtg cac tcc ccg tgg gcc ggg ccc atc aga gcc gtg gcc atc 975Lys Pro Val His Ser Pro Trp Ala Gly Pro Ile Arg Ala Val Ala Ile
275 280 285aca gtg cca ctg gta gtc ata tcg gca ttc gcg acg ctc ttc act gtg 1023Thr Val Pro Leu Val Val Ile Ser Ala Phe Ala Thr Leu Phe Thr Val
290 295 300atg tgc cgc aag aag caa caa gaa aat ata tat tca cat tta gat gaa 1071Met Cys Arg Lys Lys Gln Gln Glu Asn Ile Tyr Ser His Leu Asp Glu
305 310 315gag agc tct gag tct tcc aca tac act gca gca ctc cca aga gag agg 1119Glu Ser Ser Glu Ser Ser Thr Tyr Thr Ala Ala Leu Pro Arg Glu Arg
320 325 330ctc cgg ccg cgg ccg aag gtc ttt ctc tgc tat tcc agt aaa gat ggc 1167Leu Arg Pro Arg Pro Lys Val Phe Leu Cys Tyr Ser Ser Lys Asp Gly335 340 345 350cag aat cac atg aat gtc gtc cag tgt ttc gcc tac ttc ctc cag gac 1215Gln Asn His Met Asn Val Val Gln Cys Phe Ala Tyr Phe Leu Gln Asp
355 360 365ttc tgt ggc tgt gag gtg gct ctg gac ctg tgg faa gac ttc agc ctc 1263Phe Cys Gly Cys Glu Val Ala Leu Asp Leu Trp Glu Asp Phe Ser Leu
370 375 380tgt aga gaa ggg cag aga gaa tgg gtc atc cag aag atc cac gag tcc 1311Cys Arg Glu Gly Gln Arg Glu Trp Val Ile Gln Lys Ile His Glu Ser
385 390 395cag ttc atc att gtg gtt tgt tcc aaa ggt atg aag tac ttt gtg gac 1359Gln Phe Ile Ile Val Val Cys Ser Lys Gly Met Lys Tyr Phe Val Asp
400 405 410aag aag aac tac aaa cac aaa gga ggt ggc cga ggc tcg ggg aaa gga 1407Lys Lys Asn Tyr Lys His Lys Gly Gly Gly Arg Gly Ser Gly Lys Gly415 420 425 430gag ctc ttc ctg gtg gcg gtg tca gcc att gcc gaa aag ctc cgc cag 1455Glu Leu Phe Leu Val Ala Val Ser Ala Ile Ala Glu Lys Leu Arg Gln
435 440 445gcc aag cag agt tcg tcc gcg gcg ctc agc aag ttt atc gcc gtc tac 1503Ala Lys Gln Ser Ser Ser Ala Ala Leu Ser Lys Phe Ile Ala Val Tyr
450 455 460ttt gat tat tcc tgc gag gga gac gtc ccc ggt atc cta gac ctg agt 1551Phe Asp Tyr Ser Cys Glu Gly Asp Val Pro Gly Ile Leu Asp Leu Ser
465 470 475acc aag tac aga ctc atg gac aat ctt cct cag ctc tgt tcc cac ctg 1599Thr Lys Tyr Arg Leu Met Asp Asn Leu Pro Gln Leu Cys Ser His Leu
480 485 490cac tcc cga gac cac ggc ctc cag gag ccg ggg cag cac acg cga cag 1647His Ser Arg Asp His Gly Leu Gln Glu Pro Gly Gln His Thr Arg Gln495 500 505 510ggc agc aga agg aac tac ttc cgg agc aag tca ggc cgg tcc cta tac 1695Gly Ser Arg Arg Asn Tyr Phe Arg Ser Lys Ser Gly Arg Ser Leu Tyr
515 520 525gtc gcc att tgc aac atg cac cag ttt att gac gag gag ccc gac tgg 1743Val Ala Ile Cys Asn Met His Gln Phe Ile Asp Glu Glu Pro Asp Trp
530 535 540ttc gaa aag cag ttc gtt ccc ttc cat cct cct cca ctg cgc tac cgg 1791Phe Glu Lys Gln Phe Val Pro Phe His Pro Pro Pro Leu Arg Tyr Arg
545 550 555gag cca gtc ttg gag aaa ttt gat tcg ggc ttg gtt tta aat gat gtc 1839Glu Pro Val Leu Glu Lys Phe Asp Ser Gly Leu Val Leu Asn Asp Val
560 565 570atg tgc aaa cca ggg cct gag agt gac ttc tgc cta aag gta gag gcg 1887Met Cys Lys Pro Gly Pro Glu Ser Asp Phe Cys Leu Lys Val Glu Ala575 580 585 590gct gtt ctt ggg gca acc gga cca gcc gac tcc cag cac gag agt cag 1935Ala Val Leu Gly Ala Thr Gly Pro Ala Asp Ser Gln His Glu Ser Gln
595 600 605cat ggg ggc ctg gac caa gac ggg gag gcc cgg cct gcc ctt gac ggt 1983His Gly Gly Leu Asp Gln Asp Gly Glu Ala Arg Pro Ala Leu Asp Gly
610 615 620agc gcc gcc ctg caa ccc ctg ctg cac acg gtg aaa gcc ggc agc ccc 2031Ser Ala Ala Leu Gln Pro Leu Leu His Thr Val Lys Ala Gly Ser Pro
625 630 635tcg gac atg ccg cgg gac tca ggc atc tat gac tcg tct gtg ccc tca 2079Ser Asp Met Pro Arg Asp Ser Gly Ile Tyr Asp Ser Ser Val Pro Ser
640 645 650tcc gag ctg tct ctg cca ctg atg gaa gga ctc tcg acg gac cag aca 2127Ser Glu Leu Ser Leu Pro Leu Met Glu Gly Leu Ser Thr Asp Gln Thr655 660 665 670gaa acg tct tcc ctg acg gag agc gtg tcc tcc tct tca ggc ctg ggt 2175Glu Thr Ser Ser Leu Thr Glu Ser Val Ser Ser Ser Ser Gly Leu Gly
675 680 685gag gag gaa cct cct gcc ctt cct tcc aag ctc ctc tct tct ggg tca 2223Glu Glu Glu Pro Pro Ala Leu Pro Ser Lys Leu Leu Ser Ser Gly Ser
690 695 700tgc aaa gca gat ctt ggt tgc cgc agc tac act gat gaa ctc cac gcg 2271Cys Lys Ala Asp Leu Gly Cys Arg Ser Tyr Thr Asp Glu Leu His Ala
705 710 715gtc gcc cct ttg taacaaaacg aaagagtcta agcattgcca ctttagctgc 2323Val Ala Pro Leu
720tgcctccctc tgattcccca gctcatctcc ctggttgcat cgcccacttg gagctgaggt 2383ctcatacaag gatatttgga gtgaaatgct ggccagtact tgttctccct tgccccaacc 2443ctttaccgga tatcttgaca aactctccaa ttttctaaaa tgatatggag ctctgaaagg 2503catgtccata aggtctgaca acagcttgcc aaatttggtt agtccttgga tcagagcctg 2563ttgtgggagg tagggaggaa atatgtaaag aaaaacagga agatacctgc actaatcatt 2623cagacttcat tgagctctgc aaactttgcc tgtttgctat tggctacctt gatttgaaat 2683gctttgtgaa aaaaggcact tttaacatca tagccacaga aatcaagtgc cagtctatct 2743ggaatccatg ttgtattgca gataatgttc tcatttattt ttg 2786MAPWLQLCSVFFTVNACLNGSQLAVAAGGSGRAXGADTCSWXGVGPASRNSGLYNITFKYDNCTTYLNPVGKHVIADAQNITISQYACHDQVAVTILWSPGALGIEFLKGFRVILEELKSEGRQXQQLILKDPKQXNSSFKRTGMESQPXLNMKFETDYFVRLSFSFIKNESNYHPFFFRTRACDLLLQPDNLACKPFWKPRNLNISQHGSDMQVSFDHAPHNFGFRFFYLHYKLKHEGPFKRKTCKQEQTTEMTSCLLQNVSPGDYIIELVDDTNTTRKVMHYALKPVHSPWAGPIRAVAITVPLVVISAFATLFTVMCRKKQQENIYSHLDEESSESSTYTAALPRERLRPRPKVFLCYSSKDGQNHMNVVQCFAYFLQDFCGCEVALDLWEDFSLCREGQREWVIQKIHESQFIIVVCSKGMKYFVDKKNYKHKGGGRGSGKGELFLVAVSAIAEKLRQAKQSSSAALSKFIAVYFDYSCEGDVPGILDLSTKYRLMDNLPQLCSHLHSRDHGLQEPGQHTRQGSRRNYFRSKSGRSLYVAICNMHQFIDEEPDWFEKQFVPFHPPPLRYREPVLEKFDSGLVLNDVMCKPGPESDFCLKVEAAVLGATGPADSQHESQHGGLDQDGEARPALDGSAALQPLLHTVKAGSPSDMPRDSGIYDSSVPSSELSLPLMEGLSTDQTETSSLTESVSSSSGLGEEEPPALPSKLLSSGSCKADLGCRSYTDELHAVAPL.灵长类如人的DCRS8的反式翻译序列(SEQ ID NO:15):atggcnccnt ggytncaryt ntgywsngtn ttyttyacng tnaaygcntg yytnaayggn 60wsncarytng cngtngcngc nggnggnwsn ggnmgngcnn nnggngcnga yacntgywsn 120tggnnnggng tnggnccngc nwsnmgnaay wsnggnytnt ayaayathac nttyaartay 180gayaaytgya cnacntayyt naayccngtn ggnaarcayg tnathgcnga ygcncaraay 240athacnathw sncartaygc ntgycaygay cargtngcng tnacnathyt ntggwsnccn 300ggngcnytng gnathgartt yytnaarggn ttymgngtna thytngarga rytnaarwsn 360garggnmgnc arrnncarca rytnathytn aargayccna arcarnnnaa ywsnwsntty 420aarmgnacng gnatggarws ncarccnnnn ytnaayatga arttygarac ngaytaytty 480gtnmgnytnw snttywsntt yathaaraay garwsnaayt aycayccntt yttyttymgn 540acnmgngcnt gygayytnyt nytncarccn gayaayytng cntgyaarcc nttytggaar 600ccnmgnaayy tnaayathws ncarcayggn wsngayatgc argtnwsntt ygaycaygcn 660ccncayaayt tyggnttymg nttyttytay ytncaytaya arytnaarca ygarggnccn 720ttyaarmgna aracntgyaa rcargarcar acnacngara tgacnwsntg yytnytncar 780aaygtnwsnc cnggngayta yathathgar ytngtngayg ayacnaayac nacnmgnaar 840gtnatgcayt aygcnytnaa rccngtncay wsnccntggg cnggnccnat hmgngcngtn 900gcnathacng tnccnytngt ngtnathwsn gcnttygcna cnytnttyac ngtnatgtgy 960mgnaaraarc arcargaraa yathtaywsn cayytngayg argarwsnws ngarwsnwsn 1020acntayacng cngcnytncc nmgngarmgn ytnmgnccnm gnccnaargt nttyytntgy 1080taywsnwsna argayggnca raaycayatg aaygtngtnc artgyttygc ntayttyytn 1140cargayttyt gyggntgyga rgtngcnytn gayytntggg argayttyws nytntgymgn 1200garggncarm gngartgggt nathcaraar athcaygarw sncarttyat hathgtngtn 1260tgywsnaarg gnatgaarta yttygtngay aaraaraayt ayaarcayaa rggnggnggn 1320mgnggnwsng gnaarggnga rytnttyytn gtngcngtnw sngcnathgc ngaraarytn 1380mgncargcna arcarwsnws nwsngcngcn ytnwsnaart tyathgcngt ntayttygay 1440taywsntgyg arggngaygt nccnggnath ytngayytnw snacnaarta ymgnytnatg 1500gayaayytnc cncarytntg ywsncayytn caywsnmgng aycayggnyt ncargarccn 1560ggncarcaya cnmgncargg nwsnmgnmgn aaytayttym gnwsnaarws nggnmgnwsn 1620ytntaygtng cnathtgyaa yatgcaycar ttyathgayg argarccnga ytggttygar 1680aarcarttyg tnccnttyca yccnccnccn ytnmgntaym gngarccngt nytngaraar 1740ttygaywsng gnytngtnyt naaygaygtn atgtgyaarc cnggnccnga rwsngaytty 1800tgyytnaarg tngargcngc ngtnytnggn gcnacnggnc cngcngayws ncarcaygar 1860wsncarcayg gnggnytnga ycargayggn gargcnmgnc cngcnytnga yggnwsngcn 1920gcnytncarc cnytnytnca yacngtnaar gcnggnwsnc cnwsngayat gccnmgngay 1980wsnggnatht aygaywsnws ngtnccnwsn wsngarytnw snytnccnyt natggarggn 2040ytnwsnacng aycaracnga racnwsnwsn ytnacngarw sngtnwsnws nwsnwsnggn 2100ytnggngarg argarccncc ngcnytnccn wsnaarytny tnwsnwsngg nwsntgyaar 2160gcngayytng gntgymgnws ntayacngay garytncayg cngtngcncc nytn 2214
表4:DNAX细胞因子受体亚基样实例(DCRS9)的核酸和多肽序列。灵长类如人的实例(见SEQ ID NO:16和17)。预测的信号序列已标出,但可能变化几个位置并依赖于细胞类型。atg ggg agc tcc aga ctg gca gcc ctg ctc ctg cct ctc ctc ctc ata 48Met Gly Ser Ser Arg Leu Ala Ala Leu Leu Leu Pro Leu Leu Leu Ile
-20 -15 -10gtc atc gac ctc tct gac tct gct ggg att ggc ttt cgc cac ctg ccc 96Val Ile Asp Leu Ser Asp Ser Ala Gly Ile Gly Phe Arg His Leu Pro
-5 -1 1 5cac tgg aac acc cgc tgt cct ctg gcc tcc cac acg gaa gtt ctg cct 144His Trp Asn Thr Arg Cys Pro Leu Ala Ser His Thr Glu Val Leu Pro
10 15 20 25ata tcc ctt gcc gca cct ggt ggg ccc tct tct cca caa agc ctt ggt 192Ile Ser Leu Ala Ala Pro Gly Gly Pro Ser Ser Pro Gln Ser Leu Gly
30 35 40gtg tgc gag tct ggc act gtt ccc gct gtt tgt gcc agc atc tgc tgt 240Val Cys Glu Ser Gly Thr Val Pro Ala Val Cys Ala Ser Ile Cys Cys
45 50 55cag gtg gct cag gtc ttc aac ggg gcc tct tcc acc tcc tgg tgc aga 288Gln Val Ala Gln Val Phe Asn Gly Ala Ser Ser Thr Ser Trp Cys Arg
60 65 70aat cca aaa agt ctt cca cat tca agt tct ata gga gac aca aga tgc 336Asn Pro Lys Ser Leu Pro His Ser Ser Ser Ile Gly Asp Thr Arg Cys
75 80 85cag cac ctg ctc aga gga agc tgc tgc ctc gtc gtc acc tgt ctg aga 384Gln His Leu Leu Arg Gly Ser Cys Cys Leu Val Val Thr Cys Leu Arg90 95 100 105aga gcc atc aca ttt cca tcc cct ccc cag aca tct ccc aca agg gac 432Arg Ala Ile Thr Phe Pro Ser Pro Pro Gln Thr Ser Pro Thr Arg Asp
110 115 120ttc gct cta aaa gga ccc aac ctt cgg atc cag aga cat ggg aaa gtc 480Phe Ala Leu Lys Gly Pro Asn Leu Arg Ile Gln Arg His Gly Lys Val
125 130 135ttc cca gat tgg act cac aaa ggc atg gag gtg ggc act ggg tac aac 528Phe Pro Asp Trp Thr His Lys Gly Met Glu Val Gly Thr Gly Tyr Asn
140 145 150agg aga tgg gtt cag ctg agt ggt gga ccc gag ttc tcc ttt gat ttg 576Arg Arg Trp Val Gln Leu Ser Gly Gly Pro Glu Phe Ser Phe Asp Leu
155 160 165ctg cct gag gcc cgg gct att cgg gtg acc ata tct tca ggc cct gag 624Leu Pro Glu Ala Arg Ala Ile Arg Val Thr Ile Ser Ser Gly Pro Glu170 175 180 185gtc agc gtg cgt ctt tgt cac cag tgg gca ctg gag tgt gaa gag ctg 672Val Ser Val Arg Leu Cys His Gln Trp Ala Leu Glu Cys Glu Glu Leu
190 195 200agc agt ccc tat gat gtc cag aaa att gtg tct ggg ggc cac act gta 720Ser Ser Pro Tyr Asp Val Gln Lys Ile Val Ser Gly Gly His Thr Val
205 210 215gag ctg cct tat gaa ttc ctt ctg ccc tgt ctg tgc ata gag gca tcc 768Glu Leu Pro Tyr Glu Phe Leu Leu Pro Cys Leu Cys Ile Glu Ala Ser
220 225 230tac ctg caa gag gac act gtg agg cgc aaa aaa tgt ccc ttc cag agc 816Tyr Leu Gln Glu Asp Thr Val Arg Arg Lys Lys Cys Pro Phe Gln Ser
235 240 245tgg cca gaa gcc tat ggc tcg gac ttc tgg aag tca gtg cac ttc act 864Trp Pro Glu Ala Tyr Gly Ser Asp Phe Trp Lys Ser Val His Phe Thr250 255 260 265gac tac agc cag cac act cag atg gtc atg gcc ctg aca ctc cgc tgc 912Asp Tyr Ser Gln His Thr Gln Met Val Met Ala Leu Thr Leu Arg Cys
270 275 280cca ctg aag ctg gaa gct gcc ctc tgc cag agg cac gac tgg cat acc 960Pro Leu Lys Leu Glu Ala Ala Leu Cys Gln Arg His Asp Trp His Thr
285 290 295ctt tgc aaa gac ctc ccg aat gcc acg gct cga gag tca gat ggg tgg 1008Leu Cys Lys Asp Leu Pro Asn Ala Thr Ala Arg Glu Ser Asp Gly Trp
300 305 310tat gtt ttg gag aag gtg gac ctg cac ccc cag ctc tgc ttc aag gta 1056Tyr Val Leu Glu Lys Val Asp Leu His Pro Gln Leu Cys Phe Lys Val
315 320 325caa cca tgg ttc tct ttt gga aac agc agc cat gtt gaa tgc ccc cac 1104Gln Pro Trp Phe Ser Phe Gly Asn Ser Ser His Val Glu Cys Pro His330 335 340 345cag act ggg tct ctc aca tcc tgg aat gta agc atg gat acc caa gcc 1152Gln Thr Gly Ser Leu Thr Ser Trp Asn Val Ser Met Asp Thr Gln Ala
350 355 360cag cag ctg att ctt cac ttc tcc tca aga atg cat gcc acc ttc agt 1200Gln Gln Leu Ile Leu His Phe Ser Ser Arg Met His Ala Thr Phe Ser
365 370 375gct gcc tgg agc ctc cca ggc ttg ggg cag gac act ttg gtg ccc ccc 1248Ala Ala Trp Ser Leu Pro Gly Leu Gly Gln Asp Thr Leu Val Pro Pro
380 385 390gtg tac act gtc agc cag gtg tgg cgg tca gat gtc cag ttt gcc tgg 1296Val Tyr Thr Val Ser Gln Val Trp Arg Ser Asp Val Gln Phe Ala Trp
395 400 405aag cac ctc ttg tgt cca gat gtc tct tac aga cac ctg ggg ctc ttg 1344Lys His Leu Leu Cys Pro Asp Val Ser Tyr Arg His Leu Gly Leu Leu410 415 420 425atc ctg gca ctg ctg gcc ctc ctc acc cta ctg ggt gtt gtt ctg gcc 1392Ile Leu Ala Leu Leu Ala Leu Leu Thr Leu Leu Gly Val Val Leu Ala
430 435 440ctc acc tgc cgg cgc cca cag tca ggc ccg ggc cca gcg cgg cca gtg 1440Leu Thr Cys Arg Arg Pro Gln Ser Gly Pro Gly Pro Ala Arg Pro Val
445 450 455ctc ctc ctg cac gcg gcg gac tcg gag gcg cag cgg cgc ctg gtg gga 1488Leu Leu Leu His Ala Ala Asp Ser Glu Ala Gln Arg Arg Leu Val Gly
460 465 470gcg ctg gct gaa ctg cta cgg gca gcg ctg ggc ggc ggg cgc gac gtg 1536Ala Leu Ala Glu Leu Leu Arg Ala Ala Leu Gly Gly Gly Arg Asp Val
475 480 485atc gtg gac ctg tgg gag ggg agg cac gtg gcg cgc gtg ggc ccg ctg 1584Ile Val Asp Leu Trp Glu Gly Arg His Val Ala Arg Val Gly Pro Leu490 495 500 505ccg tgg ctc tgg gcg gcg cgg acg cgc gta gcg cgg gag cag ggc act 1632Pro Trp Leu Trp Ala Ala Arg Thr Arg Val Ala Arg Glu Gln Gly Thr
510 515 520gtg ctg ctg ctg tgg agc ggc gcc gac ctt cgc ccg gtc agc ggc ccc 1680Val Leu Leu Leu Trp Ser Gly Ala Asp Leu Arg Pro Val Ser Gly Pro
525 530 535gac ccc cgc gcc gcg ccc ctg ctc gcc ctg ctc cac gct gcc ccg cgc 1728Asp Pro Arg Ala Ala Pro Leu Leu Ala Leu Leu His Ala Ala Pro Arg
540 545 550ccg ctg ctg ctg ctc gct tac ttc agt cgc ctc tgc gcc aag ggc gac 1776Pro Leu Leu Leu Leu Ala Tyr Phe Ser Arg Leu Cys Ala Lys Gly Asp
555 560 565atc ccc ccg ccg ctg cgc gcc ctg ccg cgc tac cgc ctg ctg cgc gac 1824Ile Pro Pro Pro Leu Arg Ala Leu Pro Arg Tyr Arg Leu Leu Arg Asp570 575 580 585ctg ccg cgt ctg ctg cgg gcg ctg gac gcg cgg cct ttc gca gag gcc 1872Leu Pro Arg Leu Leu Arg Ala Leu Asp Ala Arg Pro Phe Ala Glu Ala
590 595 600acc agc tgg ggc cgc ctt ggg gcg cgg cag cgc agg cag agc cgc cta 1920Thr Ser Trp Gly Arg Leu Gly Ala Arg Gln Arg Arg Gln Ser Arg Leu
605 610 615gag ctg tgc agc cgg ctc gaa cga gag gcc gcc cga ctt gca gac cta 1968Glu Leu Cys Ser Arg Leu Glu Arg Glu Ala Ala Arg Leu Ala Asp Leu
620 625 630ggt tgagcagagc tccaccgcag tcccgggtgt ctgcggccgc t 2012GlyMGSSRLAALLLPLLLIVIDLSDSAGIGFRHLPHWNTRCPLASHTEVLPISLAAPGGPSSPQSLGVCESGTVPAVCASICCQVAQVFNGASSTSWCRNPKSLPHSSSIGDTRCQHLLRGSCCLVVTCLRRAITFPSPPQTSPTRDFALKGPNLRIQRHGKVFPDWTHKGMEVGTGYNRRWVQLSGGPEFSFDLLPEARAIRVTISSGPEVSVRLCHQWALECEELSSPYDVQKIVSGGHTVELPYEFLLPCLCIEASYLQEDTVRRKKCPFQSWPEAYGSDFWKSVHFTDYSQHTQMVMALTLRCPLKLEAALCQRHDWHTLCKDLPNATARESDGWYVLEKVDLHPQLCFKVQPWFSFGNSSHVECPHQTGSLTSWNVSMDTQAQQLILHFSSRMHATFSAAWSLPGLGQDTLVPPVYTVSQVWRSDVQFAWKHLLCPDVSYRHLGLLILALLALLTLLGVVLALTCRRPQSGPGPARPVLLLHAADSEAQRRLVGALAELLRAALGGGRDVIVDLWEGRRVARVGPLPWLWAARTRVAREQGTVLLLWSGADLRPVSGPDPRAAPLLALLHAAPRPLLLLAYFSRLCAKGDIPPPLRALPRYRLLRDLPRLLRALDARPFAEATSWGRLGARQRRQSRLELCSRLEREAARLADLG.灵长类如人的DCRS9的反式翻译序列(SEQ ID NO:18):atgggnwsnw snmgnytngc ngcnytnytn ytnccnytny tnytnathgt nathgayytn 60wsngaywsng cnggnathgg nttymgncay ytnccncayt ggaayacnmg ntgyccnytn 120gcnwsncaya cngargtnyt nccnathwsn ytngcngcnc cnggnggncc nwsnwsnccn 180carwsnytng gngtntgyga rwsnggnacn gtnccngcng tntgygcnws nathtgytgy 240cargtngcnc argtnttyaa yggngcnwsn wsnacnwsnt ggtgymgnaa yccnaarwsn 300ytnccncayw snwsnwsnat hggngayacn mgntgycarc ayytnytnmg nggnwsntgy 360tgyytngtng tnacntgyyt nmgnmgngcn athacnttyc cnwsnccncc ncaracnwsn 420ccnacnmgng ayttygcnyt naarggnccn aayytnmgna thcarmgnca yggnaargtn 480ttyccngayt ggacncayaa rggnatggar gtnggnacng gntayaaymg nmgntgggtn 540carytnwsng gnggnccnga rttywsntty gayytnytnc cngargcnmg ngcnathmgn 600gtnacnathw snwsnggncc ngargtnwsn gtnmgnytnt gycaycartg ggcnytngar 660tgygargary tnwsnwsncc ntaygaygtn caraarathg tnwsnggngg ncayacngtn 720garytnccnt aygarttyyt nytnccntgy ytntgyathg argcnwsnta yytncargar 780gayacngtnm gnmgnaaraa rtgyccntty carwsntggc cngargcnta yggnwsngay 840ttytggaarw sngtncaytt yacngaytay wsncarcaya cncaratggt natggcnytn 900acnytnmgnt gyccnytnaa rytngargcn gcnytntgyc armgncayga ytggcayacn 960ytntgyaarg ayytnccnaa ygcnacngcn mgngarwsng ayggntggta ygtnytngar 1020aargtngayy tncayccnca rytntgytty aargtncarc cntggttyws nttyggnaay 1080wsnwsncayg tngartgycc ncaycaracn ggnwsnytna cnwsntggaa ygtnwsnatg 1140gayacncarg cncarcaryt nathytncay ttywsnwsnm gnatgcaygc nacnttywsn 1200gcngcntggw snytnccngg nytnggncar gayacnytng tnccnccngt ntayacngtn 1260wsncargtnt ggmgnwsnga ygtncartty gcntggaarc ayytnytntg yccngaygtn 1320wsntaymgnc ayytnggnyt nytnathytn gcnytnytng cnytnytnac nytnytnggn 1380gtngtnytng cnytnacntg ymgnmgnccn carwsnggnc cnggnccngc nmgnccngtn 1440ytnytnytnc aygcngcnga ywsngargcn carmgnmgny tngtnggngc nytngcngar 1500ytnytnmgng cngcnytngg nggnggnmgn gaygtnathg tngayytntg ggarggnmgn 1560caygtngcnm gngtnggncc nytnccntgg ytntgggcng cnmgnacnmg ngtngcnmgn 1620garcarggna cngtnytnyt nytntggwsn ggngcngayy tnmgnccngt nwsnggnccn 1680gayccnmgng cngcnccnyt nytngcnytn ytncaygcng cnccnmgncc nytnytnytn 1740ytngcntayt tywsnmgnyt ntgygcnaar ggngayathc cnccnccnyt nmgngcnytn 1800ccnmgntaym gnytnytnmg ngayytnccn mgnytnytnm gngcnytnga ygcnmgnccn 1860ttygcngarg cnacnwsntg gggnmgnytn ggngcnmgnc armgnmgnca rwsnmgnytn 1920garytntgyw snmgnytnga rmgngargcn gcnmgnytng cngayytngg n 1971
啮齿动物如小鼠的实例(见SEQ ID NO:19和20)。预测的信号序列已标出,但可能变化几个位置并依赖于细胞类型。cagctccggg ccaggccctg ctgccctctt gcagacagga aagacatggt ctctgcgccc 60tgatcctaca gaagctc atg ggg agc ccc aga ctg gca gcc ttg ctc ctg 110
Met Gly Ser Pro Arg Leu Ala Ala Leu Leu Leu
-20 -15tct ctc ccg cta ctg ctc atc ggc ctc gct gtg tct gct cgg gtt gcc 158Ser Leu Pro Leu Leu Leu Ile Gly Leu Ala Val Ser Ala Arg Val Ala
-10 -5 -1 1tgc ccc tgc ctg cgg agt tgg acc agc cac tgt ctc ctg gcc tac cgt 206Cys Pro Cys Leu Arg Ser Trp Thr Ser His Cys Leu Leu Ala Tyr Arg5 10 15 20gtg gat aaa cgt ttt gct ggc ctt cag tgg ggc tgg ttc cct ctc ttg 254Val Asp Lys Arg Phe Ala Gly Leu Gln Trp Gly Trp Phe Pro Leu Leu
25 30 35gtg agg aaa tct aaa agt cct cct aaa ttt gaa gac tat tgg agg cac 302Val Arg Lys Ser Lys Ser Pro Pro Lys Phe Glu Asp Tyr Trp Arg His
40 45 50agg aca cca gca tcc ttc cag agg aag ctg cta ggc agc cct tcc ctg 350Arg Thr Pro Ala Ser Phe Gln Arg Lys Leu Leu Gly Ser Pro Ser Leu
55 60 65tct gag gaa agc cat cga att tcc atc ccc tcc tca gcc atc tcc cac 398Ser Glu Glu Ser His Arg Ile Ser Ile Pro Ser Ser Ala Ile Ser His
70 75 80aga ggc caa cgc acc aaa agg gcc cag cct tca gct gca gaa gga aga 446Arg Gly Gln Arg Thr Lys Arg Ala Gln Pro Ser Ala Ala Glu Gly Arg85 90 95 100gaa cat ctc cct gaa gca ggg tca caa aag tgt gga gga cct gaa ttc 494Glu His Leu Pro Glu Ala Gly Ser Gln Lys Cys Gly Gly Pro Glu Phe
105 110 115tcc ttt gat ttg ctg ccc gag gtg cag gct gtt cgg gtg act att cct 542Ser Phe Asp Leu Leu Pro Glu Val Gln Ala Val Arg Val Thr Ile Pro
120 125 130gca ggc ccc aag gca cgt gtg cgc ctt tgt tat cag tgg gca ctg gaa 590Ala Gly Pro Lys Ala Arg Val Arg Leu Cys Tyr Gln Trp Ala Leu Glu
135 140 145tgt gaa gac ttg agt agc cct ttt gat acc cag aaa att gtg tct gga 638Cys Glu Asp Leu Ser Ser Pro Phe Asp Thr Gln Lys Ile Val Ser Gly
150 155 160ggg cac act gta gac ctg cct tat gaa ttc ctt ctg ccc tgc atg tgc 686Gly His Thr Val Asp Leu Pro Tyr Glu Phe Leu Leu Pro Cys Met Cys165 170 175 180ata gag gcc tcc tac ctg caa gag gac act gtg agg cgc aaa agt gtc 734Ile Glu Ala Ser Tyr Leu Gln Glu Asp Thr Val Arg Arg Lys Ser Val
185 190 195cct tcc aga gct ggc ctg aag ctt atg gct cag act tct ggc agt caa 782Pro Ser Arg Ala Gly Leu Lys Leu Met Ala Gln Thr Ser Gly Ser Gln
200 205 210tac gct tca ctg act aca gcc agc ac 808Tyr Ala Ser Leu Thr Thr Ala Ser
215 220MGSPRLAALLLSLPLLLIGLAVSARVACPCLRSWTSHCLLAYRVDKRFAGLQWGWFPLLVRKSKSPPKFEDYWRHRTPASFQRKLLGSPSLSEESHRISIPSSAISHRGQRTKRAQPSAAEGREHLPEAGSQKCGGPEFSFDLLPEVQAVRVTIPAGPKARVRLCYQWALECEDLSSPFDTQKIVSGGHTVDLPYEFLLPCMCIEASYLQEDTVRRKSVPSRAGLKLMAQTSGSQYASLTTAS啮齿动物如小鼠的DCRS9的反式翻译序列(SEQ ID NO:21):atgggnwsnc cnmgnytngc ngcnytnytn ytnwsnytnc cnytnytnyt nathggnytn 60gcngtnwsng cnmgngtngc ntgyccntgy ytnmgnwsnt ggacnwsnca ytgyytnytn 120gcntaymgng tngayaarmg nttygcnggn ytncartggg gntggttycc nytnytngtn 180mgnaarwsna arwsnccncc naarttygar gaytaytggm gncaymgnac nccngcnwsn 240ttycarmgna arytnytngg nwsnccnwsn ytnwsngarg arwsncaymg nathwsnath 300ccnwsnwsng cnathwsnca ymgnggncar mgnacnaarm gngcncarcc nwsngcngcn 360garggnmgng arcayytncc ngargcnggn wsncaraart gyggnggncc ngarttywsn 420ttygayytny tnccngargt ncargcngtn mgngtnacna thccngcngg nccnaargcn 480mgngtnmgny tntgytayca rtgggcnytn gartgygarg ayytnwsnws nccnttygay 540acncaraara thgtnwsngg nggncayacn gtngayytnc cntaygartt yytnytnccn 600tgyatgtgya thgargcnws ntayytncar gargayacng tnmgnmgnaa rwsngtnccn 660wsnmgngcng gnytnaaryt natggcncar acnwsnggnw sncartaygc nwsnytnacn 720acngcnwsn 729
表5:DNAX细胞因子受体亚基样实例(DCRS10)的核酸和多肽序列。灵长类如人的实例(见SEQ ID NO:22和23)。ttttgagcag aggcttccta ggctccgtag aaatttgcat acagcttcca cttcctgctt 60cagagcctgt tcttctactt acctgggccc ggagaaggtg gagggagacg agaagccgcc 120gagagccgac taccctccgg gcccagtctg tctgtccgtg gtggatctaa gaaactaga 179atg aac cga agc att cct gtg gag gtt gat gaa tca gaa cca tac cca 227Met Asn Arg Ser Ile Pro Val Glu Val Asp Glu Ser Glu Pro Tyr Pro1 5 10 15agt cag ttg ctg aaa cca atc cca gaa tat tcc ccg gaa gag gaa tca 275Ser Gln Leu Leu Lys Pro Ile Pro Glu Tyr Ser Pro Glu Glu Glu Ser
20 25 30gaa cca cct gct cca aat ata agg aac atg gca ccc aac agc ttg tct 323Glu Pro Pro Ala Pro Asn Ile Arg Asn Met Ala Pro Asn Ser Leu Ser
35 40 45gca ccc aca atg ctt cac aat tcc tcc gga gac ttt tct caa gct cac 371Ala Pro Thr Met Leu His Asn Ser Ser Gly Asp Phe Ser Gln Ala His
50 55 60tca acc ctg aaa ctt gca aat cac cag cgg cct gta tcc cgg cag gtc 419Ser Thr Leu Lys Leu Ala Asn His Gln Arg Pro Val Ser Arg Gln Val65 70 75 80acc tgc ctg cgc act caa gtt ctg gag gac agt gaa gac agt ttc tgc 467Thr Cys Leu Arg Thr Gln Val Leu Glu Asp Ser Glu Asp Ser Phe Cys
85 90 95agg aga cac cca ggc ctg ggc aaa gct ttc cct tct ggg tgc tct gca 515Arg Arg His Pro Gly Leu Gly Lys Ala Phe Pro Ser Gly Cys Ser Ala
100 105 110gtc agc gag cct gcg tct gag tct gtg gtt gga gcc ctc cct gca gag 563Val Ser Glu Pro Ala Ser Glu Ser Val Val Gly Ala Leu Pro Ala Glu
115 120 125cat cag ttt tca ttt atg gaa aaa cgt aat caa tgg ctg gta tct cag 611His Gln Phe Ser Phe Met Glu Lys Arg Asn Gln Trp Leu Val Ser Gln
130 135 140ctt tca gcg gct tct cct gac act ggc cat gac tca gac aaa tca gac 659Leu Ser Ala Ala Ser Pro Asp Thr Gly His Asp Ser Asp Lys Ser Asp145 150 155 160caa agt tta cct aat gcc tca gca gac tcc ttg ggc ggt agc cag gag 707Gln Ser Leu Pro Asn Ala Ser Ala Asp Ser Leu Gly Gly Ser Gln Glu
165 170 175atg gtg caa cgg ccc cag cct cac agg aac cga gca ggc ctg gat ctg 755Met Val Gln Arg Pro Gln Pro His Arg Asn Arg Ala Gly Leu Asp Leu
180 185 190cca acc ata gac acg gga tat gat tcc cag ccc cag gat gtc ctg ggc 803Pro Thr Ile Asp Thr Gly Tyr Asp Ser Gln Pro Gln Asp Val Leu Gly
195 200 205atc agg cag ctg gaa agg ccc ctg ccc ctc acc tcc gtg tgt tac ccc 851Ile Arg Gln Leu Glu Arg Pro Leu Pro Leu Thr Ser Val Cys Tyr Pro
210 215 220cag gac ctc ccc aga cct ctc agg tcc agg gag ttc cct cag ttt gaa 899Gln Asp Leu Pro Arg Pro Leu Arg Ser Arg Glu Phe Pro Gln Phe Glu225 230 235 240cct cag agg tat cca gca tgt gca cag atg ctg cct ccc aat ctt tcc 947Pro Gln Arg Tyr Pro Ala Cys Ala Gln Met Leu Pro Pro Asn Leu Ser
245 250 255cca cat gct cca tgg aac tat cat tac cat tgt cct gga agt ccc gat 995Pro His Ala Pro Trp Asn Tyr His Tyr His Cys Pro Gly Ser Pro Asp
260 265 270cac cag gtg cca tat ggc cat gac tac cct cga gca gcc tac cag caa 1043His Gln Val Pro Tyr Gly His Asp Tyr Pro Arg Ala Ala Tyr Gln Gln
275 280 285gtg atc cag ccg gct ctg cct ggg cag ccc ctg cct gga gcc agt gtg 1091Val Ile Gln Pro Ala Leu Pro Gly Gln Pro Leu Pro Gly Ala Ser Val
290 295 300aga ggc ctg cac cct gtg cag aag gtt atc ctg aat tat ccc agc ccc 1139Arg Gly Leu His Pro Val Gln Lys Val Ile Leu Asn Tyr Pro Ser Pro305 310 315 320tgg gac caa gaa gag agg ccc gca cag aga gac tgc tcc ttt ccg ggg 1187Trp Asp Gln Glu Glu Arg Pro Ala Gln Arg Asp Cys Ser Phe Pro Gly
325 330 335ctt cca agg cac cag gac cag cca cat cac cag cca ccc aat aga gct 1235Leu Pro Arg His Gln Asp Gln Pro His His Gln Pro Pro Asn Arg Ala
340 345 350ggt gct cct ggg gag tcc ttg gag tgc cct gca gag ctg aga cca cag 1283Gly Ala Pro Gly Glu Ser Leu Glu Cys Pro Ala Glu Leu Arg Pro Gln
355 360 365gtt ccc cag cct ccg tcc cca gct gct gtg cct aga ccc cct agc aac 1331Val Pro Gln Pro Pro Ser Pro Ala Ala Val Pro Arg Pro Pro Ser Asn
370 375 380cct cca gcc aga gga act cta aaa aca agc aat ttg cca gaa gaa ttg 1379Pro Pro Ala Arg Gly Thr Leu Lys Thr Ser Asn Leu Pro Glu Glu Leu385 390 395 400cgg aaa gtc ttt ate act tat tcg atg gac aca gct atg gag gtg gtg 1427Arg Lys Val Phe Ile Thr Tyr Ser Met Asp Thr Ala Met Glu Val Val
405 410 415aaa ttc gtg aac ttt ttg ttg gta aat ggc ttc caa act gca att gac 1475Lys Phe Val Asn Phe Leu Leu Val Asn Gly Phe Gln Thr Ala Ile Asp
420 425 430ata ttt gag gat aga atc cga ggc att gat atc att aaa tgg atg gag 1523Ile Phe Glu Asp Arg Ile Arg Gly Ile Asp Ile Ile Lys Trp Met Glu
435 440 445cgc tac ctt agg gat aag acc gtg atg ata atc gta gca atc agc ccc 1571Arg Tyr Leu Arg Asp Lys Thr Val Met Ile Ile Val Ala Ile Ser Pro
450 455 460aaa tac aaa cag gac gtg gaa ggc gct gag tcg cag ctg gac gag gat 1619Lys Tyr Lys Gln Asp Val Glu Gly Ala Glu Ser Gln Leu Asp Glu Asp465 470 475 480gag cat ggc tta cat act aag tac att cat cga atg atg cag att gag 1667Glu His Gly Leu His Thr Lys Tyr Ile His Arg Met Met Gln Ile Glu
485 490 495ttc ata aaa caa gga agc atg aat ttc aga ttc atc cct gtg ctc ttc 1715Phe Ile Lys Gln Gly Ser Met Asn Phe Arg Phe Ile Pro Val Leu Phe
500 505 510cca aat gct aag aag gag cat gtg ccc acc tgg ctt cag aac act cat 1763Pro Asn Ala Lys Lys Glu His Val Pro Thr Trp Leu Gln Asn Thr His
515 520 525gtc tac agc tgg ccc aag aat aaa aaa aac atc ctg ctg cgg ctg ctg 1811Val Tyr Ser Trp Pro Lys Asn Lys Lys Asn Ile Leu Leu Arg Leu Leu
530 535 540aga gag gaa gag tat gtg gct cct cca cgg ggg cct ctg ccc acc ctt 1859Arg Glu Glu Glu Tyr Val Ala Pro Pro Arg Gly Pro Leu Pro Thr Leu545 550 555 560cag gtg gtt ccc ttg tgacaccgtt catccccaga tcactgaggc caggccatgt 1914Gln Val Val Pro Leu
565ttggggcctt gttctgacag cattctggct gaggctggtc ggtagcactc ctggctggtt 1974tttttctgtt cctccccgag aggccctctg gcccccagga aacctgttgt gcagagctct 2034tccccggaga cctccacaca ccctggcttt gaagtggagt ctgtgactgc tctgcattct 2094ctgcttttaa aaaaaccatt gcaggtgcca gtgtcccata tgttcctcct gacagtttga 2154tgtgtccatt ctgggcctct cagtgcttag caagtagata atgtaaggga tgtggcagca 2214aatggaaatg actacaaaca ctctcctatc aatcacttca ggctactttt atgagttagc 2274cagatgcttg tgtatcctca gaccaaactg attcatgtac aaataataaa atgtttactc 2334ttttgtaaaa aaaaaaaaaa aaaaaaaaag aaaaaaaaaa aaa 2377MNRSIPVEVDESEPYPSQLLKPIPEYSPEEESEPPAPNIRNMAPNSLSAPTMLHNSSGDFSQAHSTLKLANHQRPVSRQVTCLRTQVLEDSEDSFCRRHPGLGKAFPSGCSAVSEPASESVVGALPAEHQFSFMEKRNQWLVSQLSAASPDTGHDSDKSDQSLPNASADSLGGSQEMVQRPQPHRNRAGLDLPTIDTGYDSQPQDVLGIRQLERPLPLTSVCYPQDLPRPLRSREFPQFEPQRYPACAQMLPPNLSPHAPWNYHYHCPGSPDHQVPYGHDYPRAAYQQVIQPALPGQPLPGASVRGLHPVQKVILNYPSPWDQEERPAQRDCSFPGLPRHQDQPHHQPPNRAGAPGESLECPAELRPQVPQPPSPAAVPRPPSNPPARGTLKTSNLPEELRKVFITYSMDTAMEVVKFVNFLLVNGFQTAIDIFEDRIRGIDIIKWMERYLRDKTVMIIVAISPKYKQDVEGAESQLDEDEHGLHTKYIHRMMQIEFIKQGSMNFRFIPVLFPNAKKEHVPTWLQNTHVYSWPKNKKNILLRLLREEEYVAPPRGPLPTLQVVPL灵长类如人的DCRS10的反式翻译序列(SEQ ID NO:24):atgaaymgnw snathccngt ngargtngay garwsngarc cntayccnws ncarytnytn 60aarccnathc cngartayws nccngargar garwsngarc cnccngcncc naayathmgn 120aayatggcnc cnaaywsnyt nwsngcnccn acnatgytnc ayaaywsnws nggngaytty 180wsncargcnc aywsnacnyt naarytngcn aaycaycarm gnccngtnws nmgncargtn 240acntgyytnm gnacncargt nytngargay wsngargayw snttytgymg nmgncayccn 300ggnytnggna argcnttycc nwsnggntgy wsngcngtnw sngarccngc nwsngarwsn 360gtngtnggng cnytnccngc ngarcaycar ttywsnttya tggaraarmg naaycartgg 420ytngtnwsnc arytnwsngc ngcnwsnccn gayacnggnc aygaywsnga yaarwsngay 480carwsnytnc cnaaygcnws ngcngaywsn ytnggnggnw sncargarat ggtncarmgn 540ccncarccnc aymgnaaymg ngcnggnytn gayytnccna cnathgayac nggntaygay 600wsncarccnc argaygtnyt nggnathmgn carytngarm guccnytncc nytnacnwsn 660gtntgytayc cncargayyt nccnmgnccn ytnmgnwsnm gngarttycc ncarttygar 720ccncarmgnt ayccngcntg ygcncaratg ytnccnccna ayytnwsncc ncaygcnccn 780tggaaytayc aytaycaytg yccnggnwsn ccngaycayc argtnccnta yggncaygay 840tayccnmgng cngcntayca rcargtnath carccngcny tnccnggnca rccnytnccn 900ggngcnwsng tnmgnggnyt ncayccngtn caraargtna thytnaayta yccnwsnccn 960tgggaycarg argarmgncc ngcncarmgn gaytgywsnt tyccnggnyt nccnmgncay 1020cargaycarc cncaycayca rccnccnaay mgngcnggng cnccnggnga rwsnytngar 1080tgyccngcng arytnmgncc ncargtnccn carccnccnw snccngcngc ngtnccnmgn 1140ccnccnwsna ayccnccngc nmgnggnacn ytnaaracnw snaayytncc ngargarytn 1200mgnaargtnt tyathacnta ywsnatggay acngcnatgg argtngtnaa rttygtnaay 1260ttyytnytng tnaayggntt ycaracngcn athgayatht tygargaymg nathmgnggn 1320athgayatha thaartggat ggarmgntay ytnmgngaya aracngtnat gathathgtn 1380gcnathwsnc cnaartayaa rcargaygtn garggngcng arwsncaryt ngaygargay 1440garcayggny tncayacnaa rtayathcay mgnatgatgc arathgartt yathaarcar 1500ggnwsnatga ayttymgntt yathccngtn ytnttyccna aygcnaaraa rgarcaygtn 1560ccnacntggy tncaraayac ncaygtntay wsntggccna araayaaraa raayathytn 1620ytnmgnytny tnmgngarga rgartaygtn gcnccnccnm gnggnccnyt nccnacnytn 1680cargtngtnc cnytn 1695啮齿动物如小鼠的实例(见SEQ ID NO:25和26)。cag gac ctc cct ggg cct ctg agg tcc agg gaa ttg cca cct cag ttt 48Gln Asp Leu Pro Gly Pro Leu Arg Ser Arg Glu Leu Pro Pro Gln Phe1 5 10 15gaa ctt gag agg tat cca atg aac gcc cag ctg ctg ccg ccc cat cct 96Glu Leu Glu Arg Tyr Pro Met Asn Ala Gln Leu Leu Pro Pro His Pro
20 25 30tcc cca cag gcc cca tgg aac tgt cag tac tac tgc ccc gga ggg ccc 144Ser Pro Gln Ala Pro Trp Asn Cys Gln Tyr Tyr Cys Pro Gly Gly Pro
35 40 45tac cac cac cag gtg cca cac ggc cat ggc tac cct cca gca gca gcc 192Tyr His His Gln Val Pro His Gly His Gly Tyr Pro Pro Ala Ala Ala
50 55 60tac cag caa gta ctc cag cct gct ctg cct ggg cag gtc ctt cct ggg 240Tyr Gln Gln Val Leu Gln Pro Ala Leu Pro Gly Gln Val Leu Pro Gly65 70 75 80gca agg gca aga ggc cca cgc cct gtg cag aag gtc atc ctg aat gac 288Ala Arg Ala Arg Gly Pro Arg Pro Val Gln Lys Val Ile Leu Asn Asp
85 90 95tcc agc ccc caa gac caa gaa gag aga cct gca cag aga gac ttc tct 336Ser Ser Pro Gln Asp Gln Glu Glu Arg Pro Ala Gln Arg Asp Phe Ser
100 105 110ttc ccg agg ctc ccg agg gac cag ctc tac cgc cca cca tct aat gga 384Phe Pro Arg Leu Pro Arg Asp Gln Leu Tyr Arg Pro Pro Ser Asn Gly
115 120 125gtg gaa gcc cct gag gag tcc ttg gac ctt cct gca gag ctg aga cca 432Val Glu Ala Pro Glu Glu Ser Leu Asp Leu Pro Ala Glu Leu Arg Pro
130 135 140cat ggt ccc cag gct cca tcc cta gct gcc gtg cct aga ccc cct agc 480His Gly Pro Gln Ala Pro Ser Leu Ala Ala Val Pro Arg Pro Pro Ser145 150 155 160aac ccc tta gcc cga gga act cta aga acc agc aat ttg cca gaa gaa 528Asn Pro Leu Ala Arg Gly Thr Leu Arg Thr Ser Asn Leu Pro Glu Glu
165 170 175tta cgg aaa gtc ttt atc act tat tct atg gac aca gcc atg gag gtg 576Leu Arg Lys Val Phe Ile Thr Tyr Ser Met Asp Thr Ala Met Glu Val
180 185 190gtg aaa ttt gtg aac ttt ctg ttg gtg aac ggc ttc caa act gcg att 624Val Lys Phe Val Asn Phe Leu Leu Val Asn Gly Phe Gln Thr Ala Ile
195 200 205gac ata ttt gag gat aga atc cgg ggt att gat atc att aaa tgg atg 672Asp Ile Phe Glu Asp Arg Ile Arg Gly Ile Asp Ile Ile Lys Trp Met
210 215 220gag cgc tat ctt cga gat aag aca gtg atg ata atc gta gca atc agc 720Glu Arg Tyr Leu Arg Asp Lys Thr Val Met Ile Ile Val Ala Ile Ser225 230 235 240ccc aaa tac aaa cag gat gtg gaa ggc gct gag tcg cag ctg gac gag 768Pro Lys Tyr Lys Gln Asp Val Glu Gly Ala Glu Ser Gln Leu Asp Glu
245 250 255gac gag cat ggc tta cat act aag tac att cat cgg atg atg cag att 816Asp Glu His Gly Leu His Thr Lys Tyr Ile His Arg Met Met Gln Ile
260 265 270gag ttc ata agt cag gga agc atg aac ttc aga ttc atc cct gtg ctc 864Glu Phe Ile Ser Gln Gly Ser Met Asn Phe Arg Phe Ile Pro Val Leu
275 280 285ttc cca aat gcc aag aag gag cat gtg ccg acc tgg ctt cag aac act 912Phe Pro Asn Ala Lys Lys Glu His Val Pro Thr Trp Leu Gln Asn Thr
290 295 300cat gtt tac agc tgg ccc aag aat aag aaa aac atc ctg ctg cgg ctg 960His Val Tyr Ser Trp Pro Lys Asn Lys Lys Asn Ile Leu Leu Arg Leu305 310 315 320ctc agg gag gaa gag tat gtg gct cct ccc cga ggc cct ctg ccc acc 1008Leu Arg Glu Glu Glu Tyr Val Ala Pro Pro Arg Gly Pro Leu Pro Thr
325 330 335ctt cag gtg gta ccc ttg tgacgatggc cactccagct cagtgccagc 1056Leu Gln Val Val Pro Leu
340ctgttctcac agcattcttc tagcggagct ggctggtggc acccaggccc tggaacacct 1116cttctacaga gtcctctgtc tcctgagtct gagttgtcct cgctgggctt ccagagcttc 1176agtgcctgga tgctgcaggt gacagaaaca aacatctatg accacaaaaa ctctcatcac 1236ttcagctact tttatgagtc ggtcagatgc tctgtgtcct tagaccagtc taaatcatgc 1296tcaaataata aaatgattat tctttgt 1323QDLPGPLRSRELPPQFELERYPMNAQLLPPHPSPQAPWNCQYYCPGGPYHHQVPHGHGYPPAAAYQQVLQPALPGQVLPGARARGPRPVQKVILNDSSPQDQEERPAQRDFSFPRLPRDQLYRPPSNGVEAPEESLDLPAELRPHGPQAPSLAAVPRPPSNPLARGTLRTSNLPEELRKVFITYSMDTAMEVVKFVNFLLVNGFQTAIDIFEDRIRGIDIIKWMERYLRDKTVMIIVAISPKYKQDVEGAESQLDEDEHGLHTKYIHRMMQIEFISQGSMNFRFIPVLFPNAKKEHVPTWLQNTHVYSWPKNKKNILLRLLREEEYVAPPRGPLPTLQVVPL.啮齿动物如小鼠的DCRS10的反式翻译序列(SEQ ID NO:27):cargayytnc cnggnccnyt nmgnwsnmgn garytnccnc cncarttyga rytngarmgn 60tayccnatga aygcncaryt nytnccnccn cayccnwsnc cncargcncc ntggaaytgy 120cartaytayt gyccnggngg nccntaycay caycargtnc cncayggnca yggntayccn 180ccngcngcng cntaycarca rgtnytncar ccngcnytnc cnggncargt nytnccnggn 240gcnmgngcnm gnggnccnmg nccngtncar aargtnathy tnaaygayws nwsnccncar 300gaycargarg armgnccngc ncarmgngay ttywsnttyc cnmgnytncc nmgngaycar 360ytntaymgnc cnccnwsnaa yggngtngar gcnccngarg arwsnytnga yytnccngcn 420garytnmgnc cncayggncc ncargcnccn wsnytngcng cngtnccnmg nccnccnwsn 480aayccnytng cnmgnggnac nytnmgnacn wsnaayytnc cngargaryt nmgnaargtn 540ttyathacnt aywsnatgga yacngcnatg gargtngtna arttygtnaa yttyytnytn 600gtnaayggnt tycaracngc nathgayath ttygargaym gnathmgngg nathgayath 660athaartgga tggarmgnta yytnmgngay aaracngtna tgathathgt ngcnathwsn 720ccnaartaya arcargaygt ngarggngcn garwsncary tngaygarga ygarcayggn 780ytncayacna artayathca ymgnatgatg carathgart tyathwsnca rggnwsnatg 840aayttymgnt tyathccngt nytnttyccn aaygcnaara argarcaygt nccnacntgg 900ytncaraaya cncaygtnta ywsntggccn aaraayaara araayathyt nytnmgnytn 960ytnmgngarg argartaygt ngcnccnccn mgnggnccny tnccnacnyt ncargtngtn 1020ccnytn 1026
表6:多种细胞因子受体亚基的细胞质部分的比对。IL-17R_Hu(SEQID NO:28)是GenBank AAB99730.1(U58917),gi|7657230;IL17R_Mu(SEQ ID NO:29)是GenBank AAC52357.1(U31993),gi|6680411;IL-17R_Ce(SEQ ID NO:30)是GenBank AAA811100.1(U39997),gi|1353171;和DCRS6_Ce(SEQ ID NO:31)是EMBCAA90543.1(Z50177),gi|7503597。特别感兴趣的是基序或特征,对应于灵长类DCRS8中339/340位R/K;348/349位D/E;H35 3-Q365、C370-S381、E389-H396、K410-D414和D485-H495的α螺旋区;对应F400-V404和F458-Y462的β片层区;431位E;442/443位E/D;458位Y/F;468-470位D/E;481位Y/F;和523位Q/R/F。DCRS7_Mu RTALLLHSADG-AGYERLVGALASALSQMP---LRVAVDLWSRRE-LSAHGALAWFHHQRDCRS7_Hu RAALLLYSADD-SGFERLVGALASALCQLP---LRVAVDLWSRRE-LSAQGPVAWFHAQRIL-17R_Hu RKVWIIYSADH-PLYVDVVLKFAQFLLTACG--TEVALDLLEEQA-ISEAGVMTWVGRQKIL-17R_Mu RKVWIVYSADH-PLYVEVVLKFAQFLITACG--TEVALDLLEEQV-ISEVGVMTWVSRQKDCRS10 RKVFITYSMD----TAMEVVKFVNFLLVNG---FQTAIDIFEDR--IRGIDIIKWMERYLDCRS10_Mu RKVFITYSMD----TAMEVVKFVNFLLVNG---FQTAIDIFEDR--IRGIDIIKWMERYLDCRS9_Hu RPVLLLHAADS-EAQPRLVGALAELLRAALGGGRDVIVDLWEGRH-VARVGPLPWLWAARDCRS8_Hu PKVFLCYSSKDGQNHMNVVQCFAYFLQDFCG--CEVALDLWEDFS-LCREGQREWVIQKIIL-17R_Ce VKVMIVYADDN-DLHTDCVKKLVENLRNCAS--CDPVFDLEKLI--TAEIVPSRWLVDQIDCRS6_Hu IKVLVVYPSEI--CFHHTICYFTEFLQNHCR--SEVILEKWQKKK-IAEMGPVQWLATQKDCRS6_Ce FKVMLVCPEVS-GRDEDFMMRIADALKKSN---NKVVCDRWFEDSKNAEENMLHWVYEQT
. : . : :. * : *.DCRS7_Mu RRILQEGGVVILLFSPAAVAQCQ---QWLQLQTVEP---GP---HDALAAWLSCVLPDFLDCRS7_Hu RQTLQEGGVVVLLFSPGAVALCS---EWLQDGVSGPGAHGP---HDAFRASLSCVLPDFLIL-17R_Hu QEMVESNSKIIVLCSRGTRAKWQALLGRGAP-VRLRCDHGKPV-GDLFTAAMNMILPDFKIL-17R_Mu QEMVESNSKIIILCSRGTQAKWKAILGWAEPAVQLRCDHWKPA-GDLFTAAMNMILPDFKDCRS10 R---DKTVMIIVAISPKYKQDVE----GAESQLDED-EHGL---HTKYIHRM-MQIEFIKDCRS10_Mu R---DKTVMIIVAISPKYKQDVE----GAESQLDED-EHGL---HTKYIHRM-MQIEFISDCRS9_Hu TRVAREQGTVLLLWSGADLRPVS----GPDP-RAAP-----------LLA----LLHAAPDCRS8_Hu H----ESQFIIVVCSKGMKYFVD---KKNYKHKGGGRGSGK---GELFLVAVSAIAEKLRIL-17R_Ce S----SLKKFIIVVSDCAEKILD----TEASETHQLVQARP--FADLFGPAMEMIIRDATDCRS6_Hu K----AADKVVFLLSNDVNSVCD----GTCGKSEGSPSENS---QDLFPLAFNLFCSDLRDCRS6_Ce K----IAEKIIVFHSAYYHPRCG---IYDVINNFFPCTDPR-----LAHIALT---PEAQ
.:. * .DCRS7_Mu QGRATGR-----YVGVYFDGLLHPDSVPSPFRVAPLFSLP-SQLPAFLDALQ--GGCSTSDCRS7_Hu QGRAPGS-----YVGACFDRLLHPDAVPALFRTVPVFTLP-SQLPDFLGALQ--QPRAPRIL-17R_Hu RPACFGT-----YVVCYFSEVSCDGDVPDLFGAAPRYPLM-DRFEEVYFRIQ--DLEMFQIL-17R_Mu RPACFGT-----YVVCYFSGICSERDVPDLFNITSRYPLM-DRFEEVYFRIQ--DLEMFEDCRS10 QGSMNFR-----FIPVLFPNAK-KEHVPTWLQNTHVYSWP-KNKKNILLRLL-REEEYVADCRS10_Mu QGSMNFR-----FIPVLFPNAK-KEHVPTWLQNTHVYSWP-KNKKNILLRLL-REEEYVADCRS9_Hu RPL---------LLLAYFSRLCAKGDIPPPLRALPRYRLL-RDLPRLLRALD--ARPFAEDCRS8_Hu QAKQSSSAALSKFIAVYFDYSC-EGDVPGILDLSTKYRLM-DNLPQLCSHLHSRDHGLQEIL-17R_Ce HNFPEAR---KKYAVVRFNYSP---HVPPNLAILNLPTFIPEQFAQLTAFLHN-VEHTERDCRS6_Hu SQIHLHK-----YVVVYFREID-TKDDYNALSVCPKYHLM-KDATAFCAELL---HVKQQDCRS6_Ce RSVPKEV----EYVLPRDQKLL--EDAFDITIADPLVIDIPIEDVAIPENVP--IHHESCDCRS7_Mu AGRPADRVER-----VT----QALRSALDSCTS-----------DCRS7_Hu SGRLQERAEQ-----VS----RALQPALDSYFHPP---------IL-17R_Hu PGRMHRVGELSGDNYLRS---PGGRQLRAALDRFRDWQVRCPDWIL-17R_Mu PGRMHHVRELTGDNYLQS---PSGRQLKEAVLRFQEWQTQCPDWDCRS10 P----PRGPL-----------PTLQVVPL---------------DCRS10_Mu P----PRGPL-----------PTLQVVPL---------------DCRS9_Hu ATSWGRLGAR-----------QRRQSRLELCSR-----------DCRS8_Hu PGQHTRQGSR-----RNYFRSKSGRSLYVAICNMHQFIDEEPDWIL-17R_Ce ANVTQNISEA------Q------IHEWNLCASRMMSFFVRNPNWDCRS6_Hu VS----AGKR------------SQACHDGCCSL-----------DCRS6_Ce DSIDSRNNSK------------THSTDSGVSSLSS-----NS--
表6表示灵长类、啮齿动物和多种其它受体已知序列的比较。多种保守残基被比对并标出。结构同源的细胞质结构域最可能通过与IL-17相似的途径,如通过NFkB传递信号。与IL-1信号传递相似,这些受体可能参与先天性免疫和/或发育。
如本文所用,名词DCRS应用于描述一种蛋白,其中分别含有表1-5所示的氨基酸序列。在很多情况下,其中的实质性片段在功能和结构上将是等价的,包括,例如,细胞外或细胞内结构域。本发明也包括提供序列的各个DCRS等位基因的蛋白变体,例如,突变蛋白或可溶性细胞外构造物。典型情况下,这种激动剂或拮抗剂将表现小于约10%的序列差异,并因而经常有1-11个取代,例如2-、3-、5-、7-及其它倍。它也涉及等位基因及其它变体,例如,所述蛋白的多态性。典型情况下,它将结合其相应的生物学配体,可能与α受体亚基以二聚体状态,以高亲和力形式,例如至少约100nM,通常优于约30nM,优选优于约10nM,更优选优于约3nM。本文中该名词也用于指该哺乳动物蛋白的相应天然存在形式,例如,等位基因,多态性变体,和代谢变体。受体复合物的优选形式将以适于配体-受体相互作用的亲和力和选择性来结合合适的配体。
本发明也包含与表1-5中氨基酸序列有实质性氨基酸序列一致性的蛋白或多肽的组合。它将包括有相对少残基取代的序列变体,例如,优选少于约3-5个。
实质性多肽“片段”或“片断”是指一段氨基酸残基,至少约8个氨基酸,一般至少10个氨基酸,更一般至少12个氨基酸,经常至少14个氨基酸,更经常至少16个氨基酸,典型至少18个氨基酸,更典型至少20个氨基酸,通常至少22个氨基酸,更通常至少24个氨基酸,优选至少26个氨基酸,更优选至少28个氨基酸,以及,在特别优选的实施方案中至少约30个氨基酸。这包括,例如,40,50,60,70,85,100,115,130,150及其它长度。不同蛋白的片段序列可以在适当长度区间内,典型地在保守基序之间互相比较。在很多情况下,片段可表现出完整亚基的功能特性,例如,跨膜受体的细胞外结构域可以保持配体结合特性,并可用于制备可溶性受体样复合体。
通过最优化残基匹配来确定氨基酸序列同源性,或序列一致性。在有些比较中,必要时可加入间隙。见,例如,Needleham等,(1970)J.Mol.Biol.48:443-453;Sankoff等,(1983)第一章,
Time Warps, String Edits,和Macromolecules:The Theory and Practice of Sequence Comparison,Addison-Wesley,Reading,MA;和来自IntelliGenetics,Mountain View,CA的软件包;和the Universityof Wisconsin,Genetics Computer Group(GCG),Madison,WI;它们各自都在此引作参考。当比较中考虑到保守性替换时这有所改变。保守性替换典型包括在下组范围内的替换:甘氨酸,丙氨酸;缬氨酸,异亮氨酸,亮氨酸;天冬氨酸,谷氨酸;天冬酰胺,谷酰胺;丝氨酸,苏氨酸;赖氨酸,精氨酸;和苯丙氨酸,酪氨酸。同源性氨基酸序列意味着包括细胞因子序列中的天然等位基因和种间变异。典型的同源蛋白或肽与氨基酸序列片段,例如表3或4中,有50-100%的同源性(如果引入间隙),到60-100%的同源性(如果包括保守性替换)。同源性至少约70%,一般至少76%,更一般至少81%,经常至少85%,更经常至少88%,典型至少90%,更典型至少92%,通常至少94%,更通常至少95%,优选至少96%,更优选至少97%,并且在特别优选的实施方案中至少98%或更高。同源性程度将随比较片断的长度变化。同源性蛋白或肽,如等位基因变体,都将具有表1-5中所述实施方案中的绝大多数生物学活性。
如此处所用,术语“生物学活性”用于,非限制性地,描述细胞因子样配体对炎症反应、先天免疫、和/或形态发育的作用。例如,这些配体介导磷酸酶或磷酸化酶活性,这些活性很容易用标准方法测量,见,例如,Hardie等编辑(1995)
The Protein Kinase FactBook,vols.I和II,Academic Press,San Diego,CA;Hanks等(1991)
Meth. Enzymol.200:38-62;Hunter等(1992)
Cell 70:375-388;Lewin(1990)Cell 61:743-752;Pines等(1991)
Cold Spring Harbor Symp.Quant. Biol.56:449-463;和Parker等(1993)
Nature 363:736-738.受体或其部分可用作磷酸标记酶以标记通用或特异性底物。亚基也可以是功能性的免疫原以引起识别抗体,或能结合抗体的抗原。
术语配体、激动剂、拮抗剂及类似的,例如,DCRS8或DCRS9,包括调节对细胞因子配体蛋白有特征性细胞反应的分子,正如具有配体-受体相互作用、更标准的结构结合竞争特性的分子,例如,当受体是天然受体或抗体时。典型地可能通过受体酪氨酸激酶途径介导细胞应答。
另外,配体分子可以是所述受体或其类似物结合的天然配体,或者是天然配体的功能性类似物。功能性类似物可以是结构修饰的配体;或者是完全不相关的分子,但具有与适当配体结合决定簇相互作用的分子外形。配体可以起激动剂或拮抗剂的作用,见,例如,Goodman等编辑,(1990)
Goodman&Gilman’s:The Pharmacological Bases of Therapeutics,Pergamon Press,New York.
合理药物设计也可建立于受体或抗体和其它效应子或配体的分子外形的结构研究之上。见例如,Herz等(1997)
J.Recept.Signal Transduct.Res.17:671-776;和Chaiken等(1996)
Trends Biotechnol.14:369-375。效应子可以是配体结合应答中介导其它功能的其它蛋白,或者是与受体正常相互作用的其它蛋白。鉴定哪些位点与特异性的其它蛋白相互作用的一种方法是物理结构鉴定,例如,X射线晶体学或二维NMR技术。这将给哪些氨基酸残基形成分子接触区提供指导。关于蛋白质结构鉴定的详细描述,见,例如,Blundell和Johnson(1976)
Protein Crystallography,Academic Press,New York,它在此引作参考。II.活性
细胞因子受体样蛋白将有很多不同的生物学活性,例如,调节细胞增殖,或在磷酸代谢中,加入或从特异性底物中去除,典型情况下该底物是蛋白。一般这将导致调节炎性功能、其它先天性免疫应答、或形态作用。亚基将可能以特异性的低亲和度结合到配体上。
DCRS8和DCRS9具有通过JAK途径传递信号的受体的特异性基序。见,例如,Ihle等(1997)
Stem Cells 15(增刊1):105-111;Silvennoinen等(1997)
APMIS 105:497-509;Levy(1997)
Cytokine Growth Factor Review 8:81-90;Winston和Hunter(1996)
Current Biol.6:668-671;Barrett(1996)
Baillieres Clin.Gastroenterol.10:1-15;和Briscoe等(1996)
Philos.Trans.R.Soc.Lond.B.Biol. Sci.351:167-171.
细胞因子受体亚基的生物学活性将与添加或从底物上去除磷酸结构有关,典型地以特异性方式,但偶尔以非特异性方式。可以通过标准方法鉴定底物、或酶测试活性条件,例如,描述于Hardie等编辑(1995)
The Protein Kinase Fact Book卷I和II,Academic Press,San Diego,CA;Hanks等(1991)
Meth.Enzymol.200:38-62;Hunter等(1992)
Cell 70:375-388;Lewin(1990)
Cell 61:743-752;Pines等(1991)
Cold Spring Harbor Symp.Quant.Biol.56:449-463;和Parker等(1993)
Nature 363:736-738。
受体亚基可以结合形成功能性复合体,例如,可用于结合配体或制备抗体。它们具有实质性的诊断用途,包括检测或定量。III.核酸
本发明涉及使用分离的核酸或其片段,例如,它们编码这些或紧密相关的蛋白或其片段,例如,来编码对应的多肽,优选具有生物活性。此外,本发明涵盖分离或重组DNA,它们编码具有特征性序列的这种蛋白或多肽的组合,例如DCRS序列。典型地在适当条件下,该核酸能与表1-5中所示的核酸序列片段杂交,但优选不与表6中所示其它受体的对应片段杂交。所述生物活性蛋白或多肽可以是全长蛋白或片段,并且典型地具有一段高度同源的氨基酸序列片段,例如,与表1-5所示之一表现出显著一致性。进一步,本发明涵盖使用分离或重组核酸或其片段,它们编码与DCRS8或DCRS9蛋白等价片段的蛋白。该分离核酸可以有在5’和3’旁侧的独立调节序列,例如,启动子,增强子,多聚A添加信号及来自天然基因的其它序列。此处也描述多种组合。
“分离”核酸是一种核酸,例如,RNA,DNA,或混合的聚合物,它们基本上是纯的,例如,分离自天然地伴随原生序列的其它组份,如来自原始物种的核糖体,聚合酶和旁侧基因组序列。该术语包括来自天然环境中的核酸序列,并包括重组或克隆的DNA分离物,它们可以与天然存在的组合物、和化学合成类似物或由异源体系生物合成的类似物相区分。基本上是纯的分子包括该分子的分离形式,完全纯或基本纯的。
一般地分离核酸在分子组成上是均一的,但在某些实施方案中,包含不均一性,优选较小的不均一性。该不均一性典型地发现于聚合物末端或对期望生物功能或活性不关键的部分。
典型地“重组”核酸根据其产生方法或其结构定义。参考其产生方法,例如,由一种工艺制造的产物,该工艺使用重组核酸技术,例如,包括人为介入核酸序列。典型地该介入涉及体外操作,尽管在某些情况下可以包括较经典的动物繁育技术。此外,它可以是一种核酸,通过产生包含两个片段融合物的序列而制成,这些片段天然状态下不连续,但是排除天然产物,例如在其天然状态中发现的天然存在的突变体。因而,例如,用非天然存在载体转化细胞产生的产物被包括在内,以及含有用任何合成寡核苷酸方法衍生序列的核酸。这种方法经常用于用编码相同或保守性氨基酸的简并密码子代替一种密码子,这典型地引入或去除限制酶序列识别位点。另外,该方法用于连接期望功能的核酸片段以产生单个遗传实体,它含有在常见天然形式中未发现的功能的组合,例如编码融合蛋白。限制酶识别位点经常是这种人工操作的靶点,但也可以设计引入其它特异性靶点,例如启动子、DNA复制位点、调节序列、控制序列、或其它有用特性。类似的概念包括重组的,例如融合的多肽。它包括二聚体重复。特别包括合成核酸,根据遗传编码简并性,它们编码与DCRS片段等价的多肽,和来自多种不同相关分子的序列的融合体,例如,来自其它细胞因子受体家族成员。
核酸中的“片段”是一段连续片断,至少约17个核苷酸,通常至少21个核苷酸,更通常至少25个核苷酸,普通至少30个核苷酸,更普通至少35个核苷酸,经常至少39个核苷酸,更经常至少45个核苷酸,典型至少50个核苷酸,更典型至少55个核苷酸,常常至少60个核苷酸,更常常至少66个核苷酸,优选至少72个核苷酸,更优选至少79个核苷酸,在特别优选的实施方案中至少85或更多个核苷酸。典型地,不同遗传学序列的片段可在适当的长度区间上互相比较,特别是如下述结构域的定义片段。
编码DCRS8或DCRS9的核酸特别可用于鉴定编码自身或紧密相关蛋白的基因、mRNA和cDNA,以及编码多态性、等位基因或其它遗传学变体的DNA,例如,来自不同个体或相近物种。用于这些筛选的优选探针是白介素的这些区域,它们在不同多态性变体之间保守,或包含缺乏特异性的核苷酸,并且优选全长或几乎全长。在其它情况下,多态性变体特异性序列更有用。
本发明进一步涵盖重组核酸分子和片段,它们具有与此处所述分离DNA一致或高度同源的核酸序列。特别地,该序列经常可操作性连接到DNA片段上,该片段控制转录、翻译和DNA复制。典型地这些附加片段有助于期望核酸片段的表达。
当互相比较时,同源或高度一致性的核酸序列,例如DCRS8序列表现出显著相似性。核酸同源性的标准是本领域常用的根据序列比较的同源性量度,或根据杂交条件。比较杂交条件在下面将更详细描述。
核酸序列比较中的基本一致性意指,在比较时片段或其互补链在最优匹配时在一定区域内是可互换的,并具有适当的核苷酸插入或缺失,这种可互换性区域是至少约60%核苷酸,一般至少66%,普通至少71%,经常至少76%,更经常至少80%,通常至少84%,更通常至少88%,典型至少91%,更典型至少93%,优选至少约95%,更优选至少约96-98%或更多,且在特别实施方案中,高达约99%或更高的核苷酸,包括,例如编码结构域的片段如下述片段。另外,在选择性杂交条件下,当片段与一条链或其互补链杂交时,存在基本一致性,该链典型地使用来自表1-5的序列。典型地,选择性杂交在以下条件下存在,在一段至少约14个核苷酸上有至少约55%同源性,更典型地至少约65%,优选至少约75%,且更优选至少约90%。见,Kanehisa(1984)
Nucl.Acids Res.12:203-213,在此引作参考。如所述,同源性比较的长度可以更长,且在某些实施方案中是一段至少约17个核苷酸,一般至少约20个核苷酸,普通至少约24个核苷酸,通常至少约28个核苷酸,典型至少约32个核苷酸,更典型至少约40个核苷酸,优选至少约50个核苷酸,且更优选至少约75到100或更多个核苷酸。这包括,例如,125,150,175,200,225,246,273,及其它长度。
杂交同源性中所称的严谨条件是指杂交反应中典型受控制的盐、温度、有机溶剂和其它参数的严谨组合条件。严谨温度条件通常包括这种温度,超过约30℃,更通常超过约37℃,典型超过约45℃,更典型超过约55℃,优选超过约65℃,更优选超过约70℃。严谨盐条件普通低于约500mM,通常低于约400mM,更通常低于约300mM,典型低于约200mM,优选低于约100mM,更优选低于约80mM,甚至降到低于约20mM。然而,参数的组合远比任何单个参数的量值更重要,见,例如,Wetmur和Davidson(1968)
J.Mol.Biol.31:349-370,它在此引作参考。
很容易通过核苷酸替换、核苷酸缺失、核苷酸插入和核苷酸区段倒置来修饰分离DNA。这些修饰产生编码该蛋白或其衍生物的新DNA序列。这些修饰序列可用于产生突变蛋白或增强突变体的表达。表达增强可涉及基因扩增,转录增加,翻译增加和其它机制。这种突变DCRS8样衍生物包括蛋白或其片段的预定或位点特异性突变,包括用遗传密码简并性的沉默突变。如此处所用,突变DCRS8包括一种多肽,它在如上述DCRS8同源性定义范围内,但其氨基酸序列不同于自然界发现的其它细胞因子受体样蛋白,而不论是通过缺失、替换或插入。特别地,“位点特异性突变DCRS8”包括具有与表3中蛋白有实质性序列一致性的蛋白,并典型地同样具有此处公开形式的绝大多数生物活性或作用。
尽管位点特异性突变位点已预先确定,突变体不必是位点特异的。哺乳动物DCRS8突变产生可通过制造基因中氨基酸插入或缺失并结合表达来实现。可产生替换、缺失、插入或许多其它组合达到最终结构。插入包括氨基或羧基端融合。如果已知结构-活性关系的一些方面,可在靶标密码子产生随机突变,然后筛选表达的哺乳动物DCRS突变体的期望活性。在已知序列的DNA上的预定位点产生替换突变的方法为本领域所熟知,例如,通过M13引物突变,也见Sambrook等(1989)和Ausubel等(1987年和增刊)。
DNA突变正常情况下不应将编码序列置于读码框之外,且优选不产生互补区,这些互补区可以杂交产生mRNA二级结构如环或发夹。
Beaucage和Carruthers(1981)Tetra.Letts.22:1859-1862中所述的氨基膦酸酯法产生合适的合成DNA片段。经常通过合成互补链并在适当条件下一起退火,或者通过用DNA聚合酶与适当的引物序列添加互补链,来得到双链片段。
聚合酶链式反应(PCR)技术经常可用于产生突变。此外,突变引物是在预定位点产生规定突变的常用方法。见,例如,Innis等编辑(1990)
PCR Protocols:A Guide to Methods and ApplicationsAcademic Press,San Diego,CA;和Dieffenbach和Dveksler编辑(1995)
PCR Primer:A Laboratory Manual Cold Spring Harbor Press,CSH,NY。
本发明的某些实施方案涉及含有所述受体或配体序列的组合物。在其它实施方案中,可以连接该序列的功能性部分以编码融合蛋白。在其它形式中,可以替换所述序列的变体。IV.蛋白,肽
如上所述,本发明包括灵长类DCRS6-10,例如,在表1-5中公开的以及上述序列。等位基因和其它变体也涵盖在内,包括,例如表位标签和功能性结构域。
本发明也提供重组蛋白,例如,用来自灵长类或啮齿类蛋白的片段产生的异源融合蛋白。异源融合蛋白是蛋白或片段的融合体,在天然状态中不以相同方式正常融合。因而,融合产物,例如DCRS8与另一种细胞因子受体的融合产物,是连续的蛋白分子,具有以典型肽连接方式融合的序列,典型地作为单个翻译产物并表现出来自每个来源多肽的特性,例如序列或抗原性。类似的概念应用于异源核酸序列上。多种指定蛋白组合成复合体也在此提供。
另外,可组合来自其它相关蛋白的功能或结构相似的结构域来产生新构造物,例如,这些其它相关蛋白可以是细胞因子受体或Toll样受体,包括变种。例如,可以在不同新融合多肽或片段之间“交换”配体结合或其它片段。见,例如,Cunningham等(1989)Science243:1330-1336;和O’Dowd等(1988)J.Biol.Chem.263:15985-15992,每个都在此引作参考。因而,表现新特异性组合的新嵌合多肽来自于受体结合特异性的功能性连接。例如,其它相关受体分子的配体结合结构域可以加入或替换成这种或相关蛋白的其它结构域。所得蛋白经常有杂交功能和特性。例如,融合蛋白可以包括靶向结构域,它可以将融合蛋白定位到特定的亚细胞细胞器。
候选融合部分和序列可选自多种序列数据库,例如,GenBank,c/oIntelli Genetics,Mountain View,CA;和BCG,University ofWisconsin Biotechnology Computing Group,Madison,WI,每种都在此引作参考。特别地,优选表1-5提供的多肽序列组合。在所述组合中可以替换蛋白的变体形式。
本发明特别提供这类突变蛋白,它们结合细胞因子样配体,和/或在信号转导中受到影响。人DCRS与细胞因子受体家族的其它成员的结构比对显示出保守特性/残基。见表6。人DCRS8序列与细胞因子受体家族其它成员的比对显示出多种结构和功能的共同特性。也见,Bazan等(1996)Nature 379:591;Lodi等(1994)Science263:1762-1766;Sayle和Milner-White(1995)TIBS 20:374-376;和Gronenberg等(1991)Protein Engineering 4:263-269。
小鼠序列或人序列的替换特别优选。反过来说,配体结合相互作用区域的保守性替换可能保留大多数信号活性;而细胞内结构域的保守性替换可能保留大多数配体结合活性。
灵长类DCRS8的“衍生物”包括氨基酸序列突变体,糖基化变体,代谢衍生物和与其它化学结构的共价或聚集性配合体。共价衍生物的制备可通过将官能团连接到DCRS8氨基酸侧链中或N-或C-端出现的基团上,例如,这可使用本领域熟知的方法。这些衍生物可包括但不限于,羧基端或含羧基侧链残基的脂肪族酯或酰胺,含羟基残基的O-酰基衍生物,和氨基端氨基酸或含氨基残基的N-酰基衍生物,例如赖氨酸或精氨酸。酰基选自烷基结构的组,包括C3到C18正烷基,由此形成烷酰基芳酰基化合物。
特别地,包括糖基化改变,例如在其合成和加工过程中,或在进一步的加工步骤中,改变多肽的糖基化模式。为此目的特别优选的方法是将多肽与来自正常提供这种加工的细胞的糖基化酶接触,例如,哺乳动物糖基化酶。去糖基化酶也包括在内。同时包括有其它轻度修饰的相同的一级氨基酸序列,包括磷酸化氨基酸残基,例如,磷酸化酪氨酸、磷酸化丝氨酸或磷酸化苏氨酸。
主要的衍生物是受体或其片段与其它多肽蛋白的共价配合体。这些衍生物可在重组培养物中合成如N-或C-端融合体,或使用本领域已知的蛋白交联试剂通过其活性侧基合成。优选的交联剂衍生位点是游离氨基、碳水化合物结构和半胱氨酸残基。
此处也提供受体与其它同源或异源蛋白的融合多肽。同源多肽可以是不同受体的融合体,得到例如对多种不同细胞因子配体表现结合特异性的杂合体蛋白,或得到可以扩展或消弱底物作用特异性的受体。同样地,可以构建异源融合体,表现衍生蛋白的特性或活性的组合。典型实例是受体多肽融合体,例如,带受体片段或结构域的荧光素酶,例如,可以是配体结合片段,由此容易鉴定期望配体的存在及其定位。见,例如,Dull等,U.S.Patent No.4,859,609,在此引作参考。其它基因融合伴侣包括谷胱甘肽-S-转移酶(GST),细菌β-半乳糖苷酶,trpE,蛋白A,β-内酰胺酶,α-淀粉酶,乙醇脱氢酶和酵母α接合因子。见,例如,Godowski等(1988)
Science241:812-816。在所述蛋白组合中标记蛋白经常被取代。
Beaucage和Carruthers(1981)
Tetra.Letts.22:1859-1862所述的氨基膦酸酯法可产生合适的合成DNA片段。经常通过合成互补链并在适当条件下一起退火,或者通过用DNA聚合酶与适当的引物序列添加互补链,来得到双链片段。
通过磷酸化、磺化、生物素化、或添加或去除其它结构,特别是那些分子外形与磷酸基相似的基团,这种多肽也可有化学修饰的氨基酸残基。在一些实施方案中,修饰是有用的标记试剂、或用作纯化靶,例如亲和配体。
融合蛋白的制造典型通过核酸重组法或多肽合成法。核酸操作和表达技术有一般性描述,例如在Sambrook等(1989)
Molecular Cloning: A Laboratory Manual(2nd ed.),Vols.1-3,Cold Spring HarborLaboratory,和Ausubel等编辑(1987和增刊)
Current Protocols in Molecular Biology,Greene/Wiley,New York,它们在此引作参考。多肽合成的技术描述于,例如,Merrifield(1963)
J.Amer.Chem.Soc.85:2149-2156;Merrifield(1986)
Science 232:341-347;和Atherton等(1989)
Solid Phase Peptide Synthesis:A Pracitical Approach,IRL Press,Oxford;都在此引作参考。也见,Dawson等(1994)Science 266:776-779关于制造较大多肽的方法。
本发明也涉及除氨基酸序列或糖基化变体以外DCRS8衍生物的用途。这些衍生物与化学结构形成共价或聚集性结合。一般将这些衍生物分为三类:(1)盐,(2)侧链或末端残基共价修饰,和(3)吸附复合体,例如与细胞膜一起。这些共价或聚集性衍生物可用作免疫原免疫试验试剂,或用于纯化方法中,如受体或其它结合分子如抗体的亲和纯化。例如,通过本领域熟知的方法,细胞因子配体可以共价固定到固相支持物如溴化氰活化的Sepharose上;或用或不用戊二醛交联吸附到聚烯烃表面上,用于细胞因子受体、抗体或其它类似分子的测试或纯化。也可用可检测基团标记配体,例如氯胺T法放射性碘标记,共价结合到稀土螯合物上,或与另一个荧光基团结合用于诊断测试。
本发明的组合,例如,包括一种DCRS8,可用作免疫原生产抗血清或特异性抗体,例如对于所述组合能识别其它细胞因子受体家族成员。复合体可用于筛选单克隆抗体或抗原结合片段,它们由多种形式含该蛋白的不纯制备物免疫接种制得。特别地,术语“抗体”也包括天然抗体的抗原结合片段,例如,Fab,Fab2,Fv等。也可用纯化的DCRS8作为试剂检测由表达水平提高而产生的抗体,或导致产生针对内源性受体的抗体的免疫学疾病。此外,DCRS8片段也可作为免疫原产生本发明的抗体,如下面所述。例如,本发明包括对表1-5中所示氨基酸序列、其片段或多种同源性肽具有结合亲和性或亲和力增加的抗体。特别地,本发明包括对推测或实际上是天然DCRS8或DCRS9蛋白外表面暴露的特异性片段具有结合亲和性或亲和力增加的抗体。也可使用蛋白组合复合体,并可由此产生其抗体制备物。
抑制配体与受体的结合可以阻断受体配体的生理应答,这可能通过竞争性抑制。因而,本发明的体外测试经常使用抗体或这些抗体的抗原结合片段,或连接到固相基质上的片段。这些测试也考虑到诊断确定配体结合区突变和修饰、或者其它突变或修饰的作用,例如,影响信号传递或酶功能的突变或修饰。
本发明也包括竞争性药物筛选试验的用途,例如,受体复合物或片段的中和抗体与测试化合物竞争与配体或其它抗体的结合。以此方式,中和抗体或片段可用于检测是否存在这种多肽,它具有与受体相同的一或多个结合位点,并也可用于占据受体上可能接合配体的结合位点。V.制造核酸和蛋白
可通过化学合成、筛选cDNA文库、或筛选由宽范围细胞系或组织样品制备的基因组文库来获得编码蛋白或其片段的DNA。用标准方法和此处提供的序列,例如表1-5中,可分离天然序列。可通过杂交方法或多种PCR方法,结合或通过检索序列数据库,例如GenBank,而鉴定其它物种的对应物。
该DNA可在广泛的宿主细胞中表达以合成全长受体或片段,反过来,例如,它们可用于产生多克隆或单克隆抗体;用于结合研究;用于构建和表达修饰的配体结合或激酶/磷酸酶结构域;以及用于结构/功能研究。用适当的表达载体转化或转染宿主细胞可表达变体或片段。与来自重组宿主的那些相比,这些分子基本上可避免蛋白或细胞污染,因此当与药物允许的载体和/或稀释剂组合使用时,在药物组合物中特别有用。该蛋白或其部分可以与其它蛋白一起表达为融合蛋白。所述蛋白、或编码它们的核酸的组合特别有意义。
表达载体典型地是自主复制的DNA或RNA构造物,其中含期望受体基因或其片段,通常可操作性连接到合适的遗传控制元件上,在合适的宿主细胞中它们可以被识别。这些控制元件在合适的宿主内能影响表达。多个基因可以协同表达,并且可以表达在一个多顺反子信使上。影响表达必需的控制元件的特定类型取决于最终所用的宿主细胞。一般来说,遗传控制元件可以包括原核启动子系统或真核启动子表达控制系统,典型地包括转录启动子、控制转录起始的可选的操纵基因、增加mRNA表达水平的转录增强子、编码合适的核糖体结合位点的序列、和终止转录和翻译的序列。表达载体通常也包含复制起始点,以使载体独立于宿主细胞复制。
本发明的载体包括那些,它们所包含的DNA编码如所述的蛋白或生物活性等价多肽的组合。DNA可以在病毒启动子控制之下并可编码选择标记。本发明进一步包括这种表达载体的用途,它们可以在原核或真核宿主中表达编码这种蛋白的真核cDNA,在此载体与宿主相容,并且真核cDNA插入载体中使含该载体的宿主表达该可疑的cDNA。通常,表达载体设计成在其宿主中稳定复制或扩增以大大增加每个细胞中期望基因的总拷贝数。并非总有必要使表达载体在宿主细胞中复制,例如,可以用不包含可被宿主细胞识别的复制起点的载体影响该蛋白或其片段的瞬时表达。也可以用通过重组使编码蛋白的部分整合到宿主DNA中去的载体。
如此处所用,载体含有质粒,病毒,噬菌体,可整合DNA片段,和其它能使DNA片段整合入宿主基因组中的媒介物。表达载体是专用载体,其中包含影响可操作性连接基因表达的遗传控制元件。质粒是最常用的载体形式,但具有相等功能、且本领域已经或正要公知的所有其它载体形式在此处也都适用。见,例如,Pouwels等(1985年和增刊)
Cloning Vectors:A Laoratory Manual,Elsevier,N.Y.,和Rodriguez等(eds.1988)
Vectors:A Survey of Molecular Cloning Vectors and Their Uses,Buttersworth,Boston,在此引作参考。
转化细胞是这些细胞,优选哺乳动物细胞,已经用重组DNA方法构建的载体将其转化或转染。转化宿主细胞通常表达期望蛋白,但对于克隆、扩增和操作DNA目的,则不需要表达此蛋白。本发明进一步包括在营养基中培养转化细胞,以允许蛋白积累。可以从培养物中、或某些情况下从培养基中回收蛋白。
对本发明目的,当它们彼此之间功能相关时,核酸序列被可操作性连接。例如,如果表达为前蛋白或参与将多肽导向细胞膜或参与该多肽分泌,则将前序列或分泌先导肽的DNA可操作性连接到多肽上。如果它控制多肽转录则将启动子操作性连接到编码序列上;如果其定位允许转录则将核糖体结合位点操作性连接到编码序列上。通常,操作性连接表示连续的并在读码框内,然而,某些遗传元件如阻遏基因不是连续连接但仍结合到启动子序列上从而控制表达。
合适的宿主细胞包括原核、低等真核、和高等真核生物。原核生物包括革兰氏阴性和革兰氏阳性生物,例如,大肠杆菌和枯草芽孢杆菌。低等真核生物包括酵母,例如,啤酒糖酵母和毕赤氏酵母,以及盘基网柄菌属的物种。高等真核生物包括从动物细胞建立的组织培养细胞系,包括非哺乳动物起源,例如,昆虫细胞和鸟,以及哺乳动物起源,例如,人,灵长类和啮齿动物。
原核宿主-载体系统包括很多不同物种的广泛的载体。如此处所用,E.coli及其载体常用于包括其它原核生物中使用的等价载体。DNA扩增的代表性载体是pBR322或许多其衍生物。可用于表达受体及其片段的载体包括但不限于这类载体,它们包含lac启动子(pUC系列);trp启动子(pBR322-trp);Ipp启动子(pIN系列);λ-pP或pR启动子(pOTS);或杂合启动子如ptac(pDR540)。见,Brosius等(1988)“Expression Vectors Employing Lambda-,trp-,lac-,and Ipp-derived Promo
ters”,in Vectors:A Survey of Molecular Cloning Vectors and Their Uses,(Rodriguez和Denhardt编辑),Buttersworth,Boston,第10章,pp.205-236,在此引作参考。
可以用含DCRS8序列的载体转化低等真核生物,例如,酵母和盘基网柄菌。就本发明目的,最常见的低等真核宿主是面包酵母、啤酒糖酵母。尽管也可用许多其它株和种,但一般经常用它代表低等真核生物。典型地酵母载体由复制起点(除非整合型),选择基因,启动子,编码受体或其片段的基因,和翻译终止、多聚腺苷酸化、和转录终止序列组成。适用的酵母表达载体包括组成型启动子如3-磷酸甘油酸激酶和多种其它糖酵解酶基因启动子或诱导型启动子如乙醇脱氢酶2启动子或金属硫堇启动子。合适的载体包括以下类型的衍生物:自主复制低拷贝数(如YRp系列),自主复制高拷贝数(如YEp系列),整合型(如YIp系列),或微小染色体(如YCp系列)。
正常情况下高等真核组织培养细胞是表达功能活性白介素或受体蛋白最优选的宿主细胞。大体上,很多高等真核组织培养细胞系可以使用,如,昆虫杆状病毒表达系统,无论其来自无脊椎动物或脊椎动物。然而,优选哺乳动物细胞。这种细胞的转化或转染和扩增已成为常规方法。使用细胞系的实例包括HeLa细胞,中国仓鼠卵巢(CHO)细胞系,幼年大鼠肾(BRK)细胞系,昆虫细胞系,鸟细胞系,和猴(COS)细胞系。这些细胞系常用的表达载体包括复制起点,启动子,翻译起始位点,RNA拼接位点(如果使用基因组DNA),多聚腺苷酸位点,和转录终止位点。这些载体也常常包含选择基因或扩增基因。合适的表达载体可以是质粒,病毒,或逆病毒,其中携带的启动子来源于例如腺病毒,SV40,细小病毒,痘苗病毒,或巨细胞病毒。合适表达载体的代表性实例包括pCDNA1;pCD,见Okayama等(1985)
Mol.Cell Biol.5:1136-1142;pMClneo PolyA,见Thomas等(1987)
Cell 51:503-512;和杆状病毒载体如pAC 373或pAC 610。
对于分泌蛋白及一些膜蛋白,开放阅读框编码的多肽通常由成熟或分泌产物及共价连在其N端的信号肽组成。在成熟型或活性多肽分泌之前切除信号肽。切点可由经验规律高度精确地预测,例如,von-Heijne(1986)
Nucleic Acids Research 14:4683-4690;和Nielson等(1997)
Protein Eng.10:1-12,并且信号肽的精确氨基酸组成经常显示不出其功能的关键性,例如,Randall等(1989)
Science243:1156-1159;和Kaiser等(1987)
Science 235:312-317。本发明的成熟蛋白很容易用标准方法鉴定。
经常希望在提供特异性或确定糖基化模式的系统中表达这些多肽。就此来说,通常的模式是表达系统天然提供的类型。然而,将多肽,如未糖基化形式,暴露于引入异源表达系统中的适当糖基化蛋白,可以改变其模式。例如,受体基因可以与一或多个编码哺乳动物或其它糖基化酶的基因共转化。以此方式,可以在原核或其它细胞中获得某些哺乳动物糖基化模式。原核形式表达通常得到未糖基化形式的蛋白。
DCRS8的来源可以是真核或原核宿主表达的重组DCRS8,如上述。来源也可以是细胞系,优选的细胞系来自人,但其它哺乳动物细胞系也包括在本发明内。
因为序列已知,可通过常规合成肽方法制备灵长类DCRS8或DCRS9、片段、或其衍生物。这包括描述于下文的方法:如,Stewart和Young(1984),
Solid Phase Peptide Synthesis,Pierce Chemical Co.,Rockford,IL;Bodanszky和Bodanszky(1984)
The Principles of Peptide Synthesis,Springer-Verlag,New York;所有这些都在此引作参考。例如,叠氮化法,酰氯法,酸酐法,混合酐法,活化酯法(例如,对-硝基苯酯,N-羟基琥珀酰亚胺酯,或氰甲酯),碳二亚胺唑法,氧化-还原法,或二环己基碳二亚胺(DCCD)/添加剂法都可使用。固相和液相合成在前述方法中都可使用。部分DCRS8或DCRS9序列可以使用相似的方法。
采用如肽合成中典型使用的上述方法适当制备DCRS8蛋白、片段、或其衍生物,一般或者通过所谓逐步法,其中将氨基酸按顺序一个一个缩聚到末端氨基酸上,或者通过将肽片段偶联到末端氨基酸上。典型情况下,偶联反应中不用的氨基必须保护起来以免在不当位置偶联。
如果使用固相合成,将C端氨基酸通过其羧基结合到不溶性载体或支持物上。只要其具有与活性羧基的结合能力,对不溶性载体不作特别限制。这种不溶性载体的实例包括卤甲基树脂,如氯甲基树脂或溴甲基树脂,羟甲基树脂,苯酚树脂,叔-烷氧羰基肼化树脂等。
通过其活化羧基和已形成肽或链的活性氨基的缩聚,按顺序结合上氨基被保护的氨基酸,由此逐步合成肽。合成完全序列后,从不溶性载体上切下该肽从而得到该肽。这种固相方法一般的描述于Merrifield等(1963)
J.Am.Chem.Soc.85:2149-2156,它在此引作参考。
可以分离所制备的蛋白及其片段并用肽分离方法从反应混合物中纯化,例如,通过抽提、沉淀、电泳、多种色谱等。根据需要的用途可以得到不同纯度的本发明受体。使用此处公开的(见下文)蛋白纯化方法,或者使用在本说明书免疫吸附亲和色谱方法中描述的抗体,可以完成纯化。该免疫吸附亲和色谱如下进行,首先将抗体连接到固相支持物上,然后将偶联的抗体与适当细胞的溶解裂解液、表达该受体的其它细胞裂解液、或作为DNA方法的(见下)结果产该蛋白的细胞的裂解液或上清液相接触。
一般来说,纯化蛋白的纯度至少约40%,普通至少约50%,通常至少约60%,典型至少约70%,更典型至少约80%,优选至少约90%,更优选至少约95%,在特别优选的实施方案中97%-99%或以上的纯度。纯度通常是重量比,但也可是摩尔比。根据需要进行不同测试。可以纯化个别蛋白然后再组合。VI.抗体
可以制备多种哺乳动物,例如,灵长类DCRS8或DCRS9蛋白及其片段的抗体,包括其天然存在形式及其重组形式,区别在于活性受体的抗体更可能识别只在天然构象中存在的表位。变性抗原检测也可用于,例如,Western分析。抗独特型抗体也包括在内,它可用作天然受体或抗体的激动剂或拮抗剂。
抗体包括结合片段和单链形式以及抗蛋白的预定片段,可通过用片段与免疫原性蛋白的配合物免疫动物制备抗体。单克隆抗体从分泌期望抗体的细胞中制备。可以筛选这些抗体结合正常或缺陷蛋白的能力,或者筛选其激动或拮抗活性。
这些单克隆抗体的结合能力通常至少KD约1mM,更通常至少约300μM,典型至少约100μM,更典型至少约30μM,优选至少约10μM,且更优选至少约3μM或更好。
包括其抗原结合片段在内,本发明的抗体具有显著的诊断和治疗价值。它们是潜在的拮抗剂,可以结合受体并抑制其与配体的结合或抑制受体表现生物反应的能力,例如作用于其底物。它们也可用作非中和性抗体并可与毒素或放射性核素偶联以结合生产性细胞或定位于白介素来源的细胞。进一步,这些抗体可与药物或其它治疗剂连接,直接连接或通过连接体间接连接。
本发明的抗体也可用于诊断用途。作为捕获或非中和性抗体,它们可以结合到受体上而不抑制配体或底物的结合。作为中和抗体,它们可用于竞争结合试验。它们也可用于配体检测或定量。它们可用作对应蛋白Western印迹分析的试剂,或用于免疫沉淀或免疫纯化。同样,可将核酸和蛋白固定到固相基质上用于亲和纯化或检测方法。基质可以是,例如,固体树脂珠或塑料膜。
蛋白片段可以与其它物质连接,特别是多肽,作为融合或共价连接的多肽用作免疫原。哺乳动物细胞因子受体及其片段可融合或共价连接到多种免疫原上,如锁眼帽贝血蓝蛋白,牛血清白蛋白,破伤风类毒素等。见(1969)
Microbiology,Hoeber Medical Division,Harper和Row;Landsteiner(1962)
Specificity of Serological Reactions,Dover Publicatiohs,New York;和Williams等(1967)
Methods in Immunology and Immunochemistry,Vol.1,Academic Press,New York;它们全都在此引作参考,其中描述了制备多克隆抗血清的方法。典型方法涉及用抗原高度免疫动物,然后在重复免疫后不久收集动物血液并分离γ-球蛋白。
在一些情况下,希望从多种哺乳动物宿主制备单克隆抗体,如小鼠,啮齿动物,灵长类,人等。这种单克隆抗体的制备方法描述可见于,例如,Stites等编辑,
Basic and Clinical Immunology(4th ed.),Lange Medical Publications Los Altos,CA,及其引用的文献;Harlow和Lane(1988)
Antibodies:A Laboratory Manual,CSH Press;Goding(1986)
Monoclonal Antibodies:Principles and Practice(2nd ed.)Academic Press,New York;特别是Kohler和Milstein(1975)Nature 256:495-497,其中讨论了一种产生单克隆抗体的方法。所有这些文献在此引作参考。简而言之,该方法包括用免疫原注射动物,然后处死动物并收集其脾细胞,将其与骨髓瘤细胞融合,从而得到杂合细胞或“杂交瘤”,它可以在体外增殖。然后筛选杂交瘤以分离单个克隆,其中每个克隆分泌针对免疫原的单种抗体。以此方式,所得单种抗体是永生化和克隆的单个B细胞的产物,该B细胞来自免疫动物,由对免疫原性物质上所识别的特异性位点的应答而产生。
其它使用方法包括将抗原性多肽于体外暴露给淋巴细胞,或者从噬菌体或类似载体中的抗体库中选择。见,例如,Huse等(1989)“Generation of a Large Combinatorial Library of theImmunoglobulin Repertior in Phage Lambda,”Science 246:1275-1281;和Ward等(1989)Nature 341:544-546,二者在此都引作参考。本发明多肽和抗体使用时可以修饰或不修饰,包括嵌合抗体或人源化抗体。经常通过共价或非共价连接提供检测信号的物质对多肽和抗体进行标记。已知广泛的标记物和连接方法,并在科学和专利文献中有广泛报道。适用的标记包括放射性核素,酶,底物,辅因子,抑制剂,荧光物质,化学发光物质,磁粒等。有关这些标记的专利包括美国专利3,817,837;3,850,752;3,939,350;3,996,345;4,277,437;4,275,149;和4,366,24l。另外,可以生产重组或嵌合免疫球蛋白,见Cabilly,美国专利4,816,567;或在转基因小鼠中制备,见Mendez等(1997)Nature Genetics 15:146-156;Abgenix;和Medarex。这些文献在此引作参考。
本发明的抗体也可用于亲和色谱以分离DCRS8蛋白或肽。可以准备抗体连接到固体支持物上的柱子,支持物如颗粒,如琼脂糖、Sephadex等,细胞裂解液流过柱子,洗柱,随后增加温和变性剂浓度,从而释放纯化蛋白。此外,该蛋白可用于纯化抗体。可以使用适当的交叉吸收或提取。
抗体也可用于筛选特定表达产物的表达文库。通常用容易通过抗体结合检测抗原存在的物质标记这种方法中使用的抗体。
抗细胞因子受体的抗体也可用于产生抗独特型抗体。这些将用于检测或诊断与该蛋白表达相关的多种免疫学状态或者表达该蛋白的细胞。它们也可用作配体的激动剂或拮抗剂,可能是天然存在配体的竞争性抑制剂或替代物。
典型地通过免疫试验检测与抗已知免疫原的抗体特异性结合或有特异性免疫反应的细胞因子受体蛋白,如由SEQ ID NO:14的氨基酸序列组成的免疫原。典型地,免疫试验中使用多克隆抗血清,如由抗,例如,SEQ ID NO:14蛋白产生的抗血清。选择与其它细胞因子受体家族成员的交叉免疫活性低的抗血清,受体优选来自相同物种,并且在用于免疫试验前通过免疫吸附去除任何这种交叉免疫活性。
为产生用于免疫试验的抗血清,要按此处所述分离蛋白,例如SEQID NO:14蛋白。例如,可以在哺乳动物细胞系中生产重组蛋白,用所选蛋白免疫适当的宿主如同系鼠如Balb/c,典型地使用标准佐剂如弗氏佐剂,和标准小鼠免疫方法(见Harlow和Lane,同上)。另外,可用来源于此处公开序列并偶联到载体蛋白上的合成肽作为免疫原。收集多克隆血清并在免疫试验中用免疫原蛋白滴定,例如,免疫原固定到固相支持物上的固相免疫试验。选择滴度大于等于104的抗血清,并检测与其它细胞因子受体家族成员间的交叉反应性,其中使用竞争性结合试验,如Harlow和Lane,同上,570-573页。优选在此鉴定中使用至少两个细胞因子受体家族成员,这些细胞因子受体家族成员可以制成重组蛋白并用此处所述的标准分子生物学和蛋白质化学方法分离。
竞争性结合模式下的免疫试验可用于交叉活性检测。例如,SEQ IDNO:14蛋白可固定到固相支持物上。加到试验中的蛋白与固定化抗原竞争与抗血清的结合。上述蛋白与固定化抗原竞争与抗血清结合的能力与其它蛋白相比较。用标准算法计算上述蛋白的百分交叉活性。选择与上列每种蛋白交叉活性小于10%的抗血清并将其合并,然后从合并抗血清中通过上述蛋白的免疫吸附除去交叉反应的抗体。
然后将免疫吸附并合并的抗血清用于如上述的竞争性结合免疫试验,将免疫原蛋白与另一种蛋白作比较(例如,SEQ ID NO:14的DCRS8样蛋白)。为进行此比较,分别在宽浓度范围内测试这两种蛋白,并检测抑制抗血清与固定化蛋白50%结合所需的每种蛋白量。如果所需第二种蛋白的量小于所选蛋白或所需蛋白的两倍,那么第二种蛋白被称为特异性结合到免疫原产生的抗体上。
可以明白,这些细胞因子受体蛋白是同源蛋白家族的成员,其中目前含有至少9个已鉴定成员,6个哺乳动物和3个蠕虫成员。对于特定基因产物,如DCRS8,该术语不仅指此处公开的氨基酸序列,也指等位基因、非等位基因、或种间变体的其它蛋白。也可明白,该术语包括非天然突变,其引入可以通过人为突变用常规重组方法如单点突变,或者通过切除编码对应蛋白的DNA的短片段,或者通过用新氨基酸替换、或加入新氨基酸。典型地这种微小改变基本上保留原始分子的免疫一致性和/或其生物活性。因而,这些改变包括与给定天然存在的DCRS8蛋白有特异性免疫活性的蛋白。可通过在适当细胞系中表达该蛋白并检测适当的作用来鉴定改变后蛋白的生物学特性,例如,通过转染淋巴细胞。所认为的微小的具体蛋白修饰将包括具有相似化学特性的氨基酸的保守性替换,如上所述此处将细胞因子受体家族看作一个整体。通过将蛋白与细胞因子受体家族蛋白进行最优化比对,并通过用此处所述的常规免疫试验来鉴定其免疫一致性,可以确定本发明蛋白的组成。VII.试剂盒和定量
本发明细胞因子受体样分子的天然存在和重组形式对试剂盒和检测方法都特别有用。例如,这些方法也将用于筛选结合活性,例如配体与这些蛋白的结合活性。近些年已经开发了几种自动化试验方法,每年可以筛选几万种化合物。见,例如,BIOMEK自动化工作站,BeckmanInstruments,Palo Alto,California,和Fodor等(1991)Science251:767-773,在此被引作参考。后者描述了测试与合成在固相支持物上的多种明确聚合物的结合特性的方法。正如本发明所提供,通过提供大量纯化的、可溶的、处于活性状态的细胞因子受体,可以大大促进筛选配体或激动剂/拮抗剂同源蛋白的适用方法的开发。
用前述配体筛选方法,纯化蛋白可以直接包被到板子上。然而,这些蛋白的非中和抗体可用作捕获抗体以将对映受体固定到固定相上,这是很有用的,例如诊断用途。
本发明也包括受体亚基、其片段、肽、及其融合产物用于检测蛋白或其配体存在的多种诊断试剂盒和方法。另外,或又及,抗这些分子的抗体也可结合到试剂盒和方法中。典型地试剂盒有一个隔室,其中包含,例如DCRS8肽或基因片段或识别一个或另一个的试剂。典型地,在包含肽的情况下,识别试剂是受体或抗体,或者在包含基因片段的情况下,通常是杂交探针。
检测样本中DCRS8浓度的优选试剂盒通常含有标记化合物,例如配体或抗体,它们已知对DCRS8有结合亲和性,作为阳性对照的DCRS8(天然存在或重组)源,以及分离游离和结合标记化合物的方法,例如,固定检测样本中DCRS8的固定相。正常情况下提供的隔室包含试剂和说明书。也提供含适当核酸或蛋白的试剂盒。
对哺乳动物DCRS8或其肽段、或受体片段有特异性的抗体,包括抗原结合片段,可用于诊断检测配体和/或其片段水平是否增加。诊断试验可以是均相反应(没有游离试剂与抗体-抗原复合体的分离步骤)或异相反应(有分离步骤)。有多种商品试验方法,如放射免疫试验(RIA),酶联免疫吸附试验(ELISA),酶免疫试验(EIA),酶倍增免疫试验方法(EMIT),底物标记荧光免疫试验(SLFIA)等。例如,通过使用可识别细胞因子受体抗体或其特定片段的标记二抗,可使用未标记抗体。这些试验在文献中也有广泛讨论。见,例如,Harlow和Lane(1988)
Antibodies:A Laboratory Manual,CSH,和Coligan编辑(1991和增刊)
Current Protocols In Immunology Greene/Wiley,New York。
抗独特型抗体有用作细胞因子受体激动剂或拮抗剂的类似用途。在适当情况下它们可用作治疗剂。
诊断试验试剂经常以试剂盒供应,以使试验灵敏度最优化。对于本发明,根据试验性质、方法、和标记物,提供标记或未标记抗体、或者标记配体。这通常一起提供其它添加剂,如缓冲液、稳定剂、产生信号必需的物质如酶底物等。试剂盒优选包含正确使用和用后物品处理的说明书。试剂盒典型有每种有用试剂的小格,还包含正确使用和用后物品处理的说明书。希望试剂以冻干粉形式提供,试剂可以在含适当浓度的水性载体中重新水化供测试用。
诊断试验的前述成分可以不经修改直接使用或以多种方式修改。例如,可以通过共价或非共价连接直接或间接提供检测信号的结构进行标记。在许多试验中,可以直接或间接标记待测化合物、细胞因子受体、或其抗体。可以直接标记的包括标记基团:放射性标记如125I,酶(美国专利3,645,090)如过氧化物酶和碱性磷酸酶,和荧光标记(美国专利3,940,475),可以检测荧光强度、波长漂移或荧光极化的改变,两个专利在此都引作参考。可能的间接标记包括一种成分的生物素化,随之将偶联的亲和素结合到一个上述标记基团上。
也有很多分离游离配体和结合配体的方法,或者分离游离待测化合物与结合化合物的方法。细胞因子受体可固定化到多种基质上并随后洗涤。适用的基质包括塑料如ELISA板、滤膜和珠子。固定受体到基质上的方法包括但不限于,用捕获抗体、化学偶联和生物素-亲和素直接粘到塑料上。该方法的最后一步涉及通过几种方法的任一种沉淀抗体/抗原复合物,包括用例如,有机溶剂如聚乙二醇或盐如硫酸铵。其它合适的分离方法包括但不限于,荧光素抗体磁粒法,见Rattle等(1984)Clin.Chem.30(9):1457-1461,和双抗磁粒分离法,描述于美国专利4,659,678,二者在此都引作参考。
连接蛋白或片段与多种标记的方法已在文献中广泛报道,在此不需详细讨论。很多方法中的连接涉及使用活化羧基,通过使用碳二亚胺或活化酯形成肽键,通过巯基与活化卤素如氯乙酰、或活化烯烃如马来酰亚胺的反应形成硫醚等。在这些应用中也将发现使用了融合蛋自。
本发明的另一个诊断方面涉及来自细胞因子受体序列的寡核苷酸或多核苷酸序列。这些序列可用作探针检测怀疑有免疫疾病的患者中对应细胞因子受体的水平。RNA和DNA核苷酸序列的制备、序列标记、和序列的优选大小在文献中已有大量描述和讨论。寡核苷酸探针正常情况下有至少约14个核苷酸,通常至少约18个核苷酸,多核苷酸探针可以有几千kb。可以使用多种标记,最常用的是放射性核素,特别是32P。然而,也可使用其它方法,如用生物素修饰的核苷酸引入到多核苷酸中,然后生物素用作亲和素或抗体的结合位点,它们可以用广泛的标记物标记,如放射性核素,荧光剂,酶等。此外,可以用识别特异性双体的抗体,包括DNA双链,RNA双链,DNA-RNA杂合双链,或DNA-蛋白质双体。随后标记抗体并在结合双体的表面进行试验,由此通过在表面形成双体可以检测是否存在结合到双体上的抗体。新RNA的探针可以在常规方法中使用,如核酸杂交、加减筛选、重组探针、杂合体释放翻译(HRT)、和杂合体固定翻译(HART)。反义核酸可用于阻断蛋白表达,也在此提供。见,例如,Isis Pharmaceuticals,Sequitur,Inc.,或Hybridon。这也包括扩增技术如聚合酶链式反应(PCR)。
本发明还包括也检测其它标记物定性或定量存在的诊断试剂盒。诊断和预后依赖于所用标记物多种指征的组合。因而,试剂盒可以检测组合标记物。见,例如,Viallet等(1989)
Progress in Growth Factor Res.1:89-97。VIII.治疗用途
本发明提供有显著治疗价值的试剂。见,例如,Levitzki(1996)Curr.Opin.Cell Biol.8:239-244。细胞因子受体(天然存在或重组)及其片段、突变受体蛋白、和抗体,与已鉴定对受体或抗体有结合亲和性的化合物一起,可用于治疗它们配体的受体表现异常表达的状况。这种异常典型表现为免疫疾病,例如先天免疫或发育。另外,本发明提供在与配体异常表达或应答异常触发向光有关的多种疾病或紊乱中的治疗价值。例如,已有提示IL-1配体参与形态发育,例如背腹极性确定,和免疫应答,特别是原始的先天免疫,见,例如,Sun等(1991)
Eur.J.Biochem.196:247-254;和Hultmark(1994)Nature367:116-117。
可以纯化重组细胞因子受体、突变蛋白、其激动剂或拮抗剂的抗体、或抗体并施用于患者。这些药剂可以与另外的活性成分一起用于治疗,例如与常规药物允许的载体或稀释剂,并伴随生理无毒的稳定剂和赋形剂。这些组合物可以是无菌的,例如过滤的,并通过冻干于剂量容器内或保存于稳定的水性制备物中以剂量形式存放。本发明也包括抗体或其结合片段(非补体结合区)的用途。
用细胞因子受体或其片段筛选配体可用于鉴定与受体有结合亲和的分子。然后可用随后的生物学测试确定是否假想的配体可提供竞争性结合,这种结合可阻断其固有的刺激活性。受体片段可用作阻断剂或拮抗剂用于阻断配体活性。同样,有固有刺激活性的化合物可活化受体,因此是激动剂,可以刺激配体活性,例如诱导信号传递。本发明进一步包括细胞因子受体的抗体用作拮抗剂的治疗用途。
有效治疗必需的试剂量取决于很多不同因素,包括给药方式、靶点、试剂生理寿命、药理寿命、患者生理状态、和给予的其它药物。因而,需要确定治疗剂量以使安全性和疗效最佳。典型地,体外使用剂量对这些药剂的原位给药量可提供有效指导。对特定疾病的治疗剂量的动物试验可提供人用剂量的进一步预测。在以下文献中提到了多种因素,例如,Gilman等编辑(1990)
Goodman和Gilman’s:The Pharmaccological Bases of Therapeutics,8thEd.,Pergamon Press;和
Remington’s Pharmaceutical Sciences,17th ed.(1990),MackPublishing Co.,Easton,Penn.;每个文献都在此引作参考。在其中及下面讨论了给药方法,例如,经口,静脉内,腹膜内,或肌内给药,透皮扩散等。药物允许的载体包括水,盐水,缓冲液及文献中描述的其它化合物,例如,在Merck Index,Merck & Co.,Rahway,NewJersey。因为在假想配体和其受体之间可能有很高的亲和性结合、或转换数,初步预计低剂量的这些药剂即有疗效。并且信号传递途径提示极低量的配体可能即有作用。因而,一般剂量范围预计小于1mM浓度,典型地小于约10μM浓度,通常小于约100nM优选小于约10pM(皮摩尔),最优选小于约1fM(飞摩尔),并与适当的载体一起使用。经常使用缓释配方、或缓释装置以连续给药。
细胞因子受体、其片段、和抗体或其片段、拮抗剂,和激动剂,可以直接施用于待治疗对象,或者根据化合物大小,可能希望在给药前将其连接到载体蛋白如卵清蛋白或血清白蛋白上。可以多种常规剂量组合施用治疗组合物。可以单独施用活性成分,然而优选以药物组合物形式提供。组合物含有如上定义的至少一种活性成分,并还含有一或多种允许的载体。考虑到与其它成分的相容性以及不伤害患者,每种载体必须既是药物允许的也是生理允许的。组合物包括适于经口腔、直肠、鼻腔、或胃肠道外(包括皮下、肌内、静脉内和皮内)给药的那些。组合物可以单位剂量形式方便地提供并可以制药领域熟知的方法制备。见,例如,Gilman等编辑(1990)
Goodman和Gilman:The Pharmacological Bases of Therapeutics,8th ed.Pergamon Press;和
Remington’s Pharmaceutical Sciences,17th ed.(1990),MackPublishing Co.,Easton,Penn.;Avis等编辑(1993)
Pharmaceutical Dosage Forms:Parenteral Medications Dekker,NY;Lieberman等编辑(1990)
Pharmaceutical Dosage Forms:Tablets Dekker,NY;和Lieberman等编辑(1990)
Pharmaceutical Dosage Forms:Disperse Systems Dekker,NY。本发明的疗法可合并其它治疗剂使用或用于结合其它治疗剂,特别是其它细胞因子受体家族成员的激动剂或拮抗剂。IX.筛选
用DCRS8或其片段进行药物筛选可鉴定与受体亚基有结合亲和性的化合物,包括相关成分的分离。随后的生物学测试可用于确定化合物是否有固有的刺激活性,并因此是阻断剂或拮抗剂,从而阻断配体活性。同样,有固有刺激活性的化合物可活化受体并因而是激动剂,从而刺激细胞因子配体的活性。本发明进一步包括受体的抗体作为细胞因子激动剂或拮抗剂的治疗用途。
与之相似,含有多种蛋白的复合体可用于筛选能识别该复合体的配体或药物。绝大多数细胞因子受体含有至少两个亚基,它们可以相同或不同。另外,跨膜受体可以结合含有细胞因子样配体的复合体,它与另一种可溶性蛋白结合,这种蛋白用作,例如另一个受体亚基。
一种药物筛选方法使用这种真核或原核宿主细胞,其中稳定转化了表达DCRS8的重组DNA分子并组合另一种细胞因子受体亚基。表达一种受体的细胞可以与其它功能性受体相分离。这种细胞可以是活性或固定形式,可用于标准抗体/抗原或配体/受体试验。也见,Parce等(1989)Science246:243-247;和Owicki等(1990)Proc.Nat’l Acad.Sci.USA87:4007-4011,其中描述了检测细胞反应的灵敏方法。竞争试验特别有用,其中细胞(假想配体的来源)与已知与该配体有结合亲和性的标记受体或抗体,如125I-抗体接触并保温,并测量试样与结合组合物的结合亲和性。然后分离标记和游离的标记结合组合物以估算配体结合度。测试化合物的结合量与结合到已知来源上的标记受体量成反比。许多方法可用于从游离配体中分离结合配体以估算配体结合度。典型地该分离步骤涉及一组程序,如粘到滤膜上随后洗涤,粘到塑料上随后洗涤,或离心细胞膜。活细胞也可用于筛选药物对细胞因子介导功能的影响,例如,第二信使水平,例如Ca2+;细胞增殖;肌醇磷酸库变化等。一些检测方法允许没有分离步骤,例如,接近距离敏感的检测系统。用荧光光度计或荧光细胞分选装置,钙敏感染料可用于检测Ca2+水平。X.配体
此处DCRS8的描述提供鉴定配体的方法,如上述。这种配体也以相当高的亲和度特异性结合对应受体。可以制备多种构造物,以允许标记受体,从而检测其配体。例如,直接标记细胞因子受体,将二次标记的标记物融合到其上,例如,FLAG或其它表位标签等,从而可以检测受体。这可以是组织学方法,用于生化纯化的亲和方法,或者标记或在表达克隆方法中选择。也可使用双杂选择系统,用可获得的细胞因子受体序列制备适当的构造物。见,例如,Fields和Song(1989)Nature 340:245-246。
大多数候选物将与IL-17家族成员结构相关。见,例如,USSN09/480,287。
参考以下实施例可以最好地理解本发明的宽广范围,它们并非试图限制本发明到具体实施方案上。
实施例I.一般方法
一些标准方法在此描述或引作参考,例如,Maniatis等(1982)Molecular Cloning,A Laboratory Manual,Cold Spring HarborLaboratory,Cold Spring Harbor Press;Sambrook等(1989)Molecular Cloning:A Laboratory Manual,(2nd ed.),1-3卷,CSH出版社,NY;或Ausubel等(1987和增刊)
Currrent Protocols in Molecular Biology,Greene/Wiley,New York。蛋白纯化方法包括这类方法,如硫酸铵沉淀、柱层析、电泳、离心、结晶等。见,例如,Ausubel等(1987和增刊);Coligan等编辑(1996和增刊),CurrentProtocols in Protein Science Greene/Wiley,New York;Deutscher(1990)“Guide to Protein Purification”in
Methods in Enzymology,182卷,和该丛书的其它卷;和有关蛋白纯化产品的制造商文献,例如,Pharmacia,Piscataway,N.J.,或Bio-Rad,Richmond,CA。结合重组技术可以融合到适当片段中,例如,FLAG序列或等价序列,可以通过蛋白酶切除序列融合起来。见,例如,Hochuli(1990)“Purification of Recombinant Proteins with Metal ChelateAbsorbent”,于Setlow编辑的
Genetic Engineering,Principle and Methods 12:87-98,Plenum出版社,N.Y.;和Crowe等(1992)QIAexpress:The High Level Expression & Protein Purification System QUIAGEN,Inc.,Chatsworth,CA。
进行计算机序列分析,例如,用可得到的软件程序,包括来自GCG(U.Wisconsin)和GenBank的程序。公共序列数据库也要使用,例如,从GenBank和其它处。
IL-10受体可用的许多方法可以用于DCRS,如所述,例如,在USSN08/110,683(IL-10受体),它在此引作参考。II.计算机分析
从基因组序列数据库中鉴定与细胞因子受体相关的人序列,例如用BLAST服务器(Altschul等(1994)
Nature Genet.6:119-129)。可用标准分析程序评价结构,例如,PHD(Ros t和Sander(1994)
Proteins19:55-72)和DSC(King和Sternberg(1996)
Protein Sci.5:2298-2310)。标准比较软件包括,例如,Altschul等(1990)
J.Mol.Biol.215:403-10;Waterman(1995)
Introduction to Computational Biology:Maps,Sequences and Genomes Chapman & Hall;Lander和Waterman编辑(1995)
Calculating the Secrets of Life: Applications of the Mathematical Sciences in Molecular Biology,National Academy Press;和Speed和Waterman编辑(1996)
Genetic Mapping and DNA Sequencing(IMA Volumes in Mathematics and ItsApplications,Vol 81)Springer Verlag,每篇文献在此引作参考。III.全长cDNA的克隆;染色体定位
来源于该序列的PCR引物用于探测人cDNA文库。序列可以来源自,例如表1-5,优选邻近序列末端的那些。克隆灵长类、啮齿动物、或其它物种DCRS8的全长cDNA,例如,通过DNA杂交筛选λgt10噬菌体。用T.aquaticus Taqplus DNA聚合酶(Stratagene)在适当条件下进行PCR反应。延长部分长度cDNA克隆是典型的路线。
准备染色体铺展。用植物血凝素刺激的培养72h的人淋巴细胞获得染色体制备物,进行原位杂交。培养的最后7小时加入5-溴脱氧尿嘧啶(60μg/ml培养基),以确保杂交后染色体显带的高质量。
PCR片段由引物的辅助而扩增,克隆进适当载体中。通过缺口平移用3H标记载体。放射性标记的探针与中期相铺展物杂交,其最终浓度200ng/ml杂交液,如下文所述,例如,Mattei等(1985)
Hum.Genet.69:327-331。
用核示踪乳液(KODAK NTB2)包被后,曝光片子。为避免显带过程中的银粒滑动,首先用缓冲吉姆萨溶液对染色体铺展物染色并对中期相拍照。然后通过荧光染料-光解-吉姆萨(FPG)法进行R显带,并在分析前对中期相重新拍照。类似的适用方法也可用于其它物种。IV.mRNA定位
人多组织(Cat#1,2)和癌细胞系印迹膜(Cat#7757-1),其中每条道包含约2μg poly(A)+RNA,它们购自Clontech(Palo Alto,CA)。探针用[α-32P]dATP进行探针标记,例如,用Amersham Rediprime随机引物标记试剂盒(RPN1633)。进行预杂交和杂交,例如在65℃在0.5M Na2HPO4、7%SDS、0.5M EDTA(pH8.0)中。进行高严谨度洗涤,例如,在65℃用2x SSC、0.1%SDS两次初步洗脱40分钟,随后用0.1x SSC、0.1%SDS洗涤20分钟。然后在-70℃在增感屏存在下将膜对X-射线胶片(Kodak)曝光。更详细研究中用选定的适当的人DCRS克隆进行cDNA文库Southern杂交以检验其在造血或其它细胞亚类中的表达。
另外,从表1-5中选择两个合适的引物,在选定的适当mRNA样品上用RT-PCR确定产生cDNA的信使的存在,例如,表达该基因的样品。
可通过cDNA文库杂交分离全长克隆,文库来自经PCR信号预选择的适当组织。可以进行Northern印迹。
编码DCRS基因的信使将通过适当方法测试,例如,PCR,免疫试验,杂交等。组织和器官cDNA制备物可以从,例如,Clontech,MountainView,CA获得。如所述,天然表达来源的鉴定是有用的。并且功能性受体亚基配对的鉴定允许预测,何种细胞表达的受体亚基的组合将导致对每种细胞因子配体的生理性反应。
关于小鼠对应物的分布,例如可进行Southern分析:用适当的限制酶消化来自初步扩增的cDNA文库的DNA(5μg),以释放插入片段,跑1%琼脂糖凝胶电泳并转移到尼龙膜(Schleicher和Schuell,Keene,NH)上。
供分离小鼠mRNA的样品包括:静息小鼠成纤维细胞L细胞系(C200);Braf:ER(Braf融合到雌激素受体上)转染细胞,对照(C201);T细胞,极化THl(Mel14 bright,来自脾的CD4+细胞,用IFN-γ和抗IL-4极化7天;T200);T细胞,极化TH2(Mel14 bright,来自脾的CD4+细胞,用IL-4和抗IFN-γ极化7天;T201);T细胞,高度极化TH1(见Openshaw等(1995)
J.Exp.Med.182:1357-1367;用抗CD-3活化2、6、16h合并;T202);T细胞,高度极化TH2(见Openshaw等(1995)
J.Exp.Med.182:1357-1367;用抗CD-3活化2、6、16h合并;T203);CD44-CD25+前T细胞,从胸腺分拣(T204);TH1 T细胞克隆D1.1,抗原最后刺激后静息3周(T205);TH1 T细胞克隆D1.1,10μg/ml ConA刺激15h(T206);TH2T细胞克隆CDC35,抗原最后刺激后静息3周(T207);TH2 T细胞克隆CDC35,10μg/ml ConA刺激15h(T208);来自脾的Mel14+幼稚T细胞,静息(T209);Mel14+T细胞,用IFN-γ/IL-12/抗IL-4极化6、12、24h成Th1合并(T210);Mel14+T细胞,用IFN-γ/IL-12/抗IL-4极化6、12、24 h成Th1合并(T210);Mel14+T细胞,用IL-4/抗IFN-γ极化6、13、24 h成Th2合并(T211);未刺激的成熟B细胞白血病细胞系A20(B200);未刺激B细胞系CH12(B201);来自脾的未刺激大B细胞(B202);来自全脾的大B细胞,LPS活化(B203);来自脾的甲泛葡胺富集的树状突细胞,静息(D200);来自骨髓的树状突细胞,静息(D201);单核细胞细胞系RAW264.7,周LPS活化4h(M200);用GM和M-CSF衍生的骨髓巨噬细胞(M201);巨噬细胞系J774,静息(M202);巨噬细胞系J774+LPS+抗IL-10在0.5、1、3、6、12h合并(M203);巨噬细胞系J774+LPS+IL-10在0.5、1、3、5、12h合并(M204);气溶胶激发的小鼠肺组织,Th2引物;气溶胶OVA激发7、14、23h合并(见Garlisi等(1995)Clinical Immunology and Immunopathology 75:75-83;X206);钩虫感染的肺组织(见Coffman等(1989)
Science 245:308-310;X200);全成年肺,正常(O200);全肺,rag-1(见Schwarz等(1993)Immunodeficiency 4;249-252;O205);IL-10 K.O.脾(见Kuhn等(1991)Cell75:263-274;X201);全成年脾,正常(O201);全脾,rag-1(O207);IL-10 K.O.派尔斑(O202);全派尔斑,正常(O210);IL-10 K.O.肠系膜淋巴结(X203);全肠系膜淋巴结,正常(O211);IL-10 K.O.结肠(X203);全结肠,正常(O212);NOD小鼠胰腺(见Makino等(1980)JikkenDobutsu 29:1-13;X205);全胸腺,rag-1(O208);全肾,rag-1(O209);全心,rag-1(O202);全脑,rag-1(O203);全睾丸,rag-1(O204);全肝,rag-1(O206);大鼠正常关节组织(O300);和大鼠关节炎关节组织(X300)。
供分离人mRNA的样品包括,例如:外周血单个核细胞(单核细胞,T细胞,NK细胞,粒细胞,B细胞),静息(T100);外周血单个核细胞,用抗CD-3活化2、6、12h合并(T101);T细胞,TH0克隆Mot 72,静息(T102);T细胞,THO克隆Mot 72,用抗CD28和抗CD3活化3、6、12h合并(T103);T细胞,TH0克隆Mot 72,用特异性肽脱敏处理2、7、12h合并(T104);T细胞,TH1克隆HY06,静息(T107);T细胞,TH1克隆HY06,用抗CD28和抗CD3活化3、6、12h合并(T108);T细胞,TH1克隆HY06,用特异性肽脱敏处理2、6、12h合并(T109);T细胞,TH2克隆HY935,静息(T110);T细胞,TH2克隆HY935,用抗CD28和抗CD3活化2、7、12h合并(T111);T细胞,CD4+CD45RO-T细胞,用抗CD28、IL-4和抗IFN-γ极化27天,极化TH2,用抗CD3和抗CD28活化4h(T116);T细胞肿瘤细胞系Jurkat和Hut78,静息(T117);T细胞克隆,合并AD130.2、Tc783.12、Tc783.13、Tc783.58、Tc782.69,静息(T118);T细胞随机γδT细胞克隆,静息(T119);脾细胞,静息(B100);脾细胞用抗CD40和IL-4活化(B101);B细胞EBV细胞系合并WT49、RSB、JY、CVIR、721.221、RM3、HSY,静息(B102);B细胞系JY,用PMA和离子霉素活化1、6h合并(B103);NK20克隆合并,静息(K100);NK20克隆合并,用PMA和离子霉素活化6h(K101);NKL克隆,来源自LGL白血病患者的外周血,IL-2处理(K106);NK细胞毒克隆640-A30-1,静息(K107);造血前体细胞系TF1,用PMA和离子霉素活化1、6h合并(C100);U937前单核细胞系,静息(M100);U937前单核细胞系,用PMA和离子霉素活化1、6h合并(M101);分离单核细胞,用LPS、IFN-γ、抗IL-10活化1、2、6、12、24h合并(M102);分离单核细胞,用LPS、IFN-γ、IL-10活化1、2、6、12、24h合并(M103);分离单核细胞,用LPS、IFN-γ、抗IL-10活化4、16h合并(M106);用LPS、IFN-γ、IL-10活化4、16h合并(M107);分离单核细胞,用LPS活化1h(M108);分离单核细胞,用LPS活化6h(M109);DC70%CD1a+,来自CD34+GM-CSF、TNFα12天,静息(D101);DC70%CD1a+,来自CD34+GM-CSF、TNFα12天,用PMA和离子霉素活化1h(D102);DC70%CD1a+,来自CD34+GM-CSF、TNFα12天,用PMA和离子霉素活化6h(D103);DC95%CD1a+,来自CD34+GM-CSF、TNFα12天FACS分选,用PMA和离子霉素活化1、6h合并(D104);DC95%CD14+,不包括CD34+GM-CSF、TNFα12天FACS分选,用PMA和离子霉素活化1、6h合并(D105);DC CD1a+CD86+,来自CD34+GM-CSF、TNFα12天FACS分选,用PMA和离子霉素活化1、6h合并(D106);DC,来自单核细胞GM-CSF、IL-45天,静息(D107);DC,来自单核细胞GM-CSF、IL-45天,静息(D108);LPS活化4、16h合并(D109);DC,来自单核细胞GM-CSF、IL-45天,TNFα活化,单核细胞supe4、16h合并(D110);平滑肌瘤L11良性肿瘤(X101);正常子宫肌层M5(O115);恶性平滑肌肉瘤GS1(X103);肺成纤维细胞肉瘤系MRC5,用PMA和离子霉素活化1、6h合并(C101);肾上皮癌细胞系CHA,用PMA和离子霉素活化1、6h合并(C102);男性胎肾28周(O100);男性胎肺28周(O101);男性胎肝28周(O102);男性胎心28周(O103);男性胎脑28周(O104);男性胚胎胆囊28周(O106);男性胚胎小肠(O107);男性胚胎脂肪组织(O108);女性胚胎卵巢25周(O109);女性胚胎子宫25周(O110);男性胚胎睾丸28周(O111);男性胎脾28周(O112);成年胎盘28周(O113);和发炎的扁桃腺,来自12岁(X100)。
TaqMan定量PCR方法表明小鼠和人的DCRS6都在T细胞上表达,包括胸腺细胞和CD4+幼稚和分化细胞(hDCRS6也表达于树状突细胞),在胃肠道组织中有表达,包括胃、肠、结肠和相关淋巴组织,例如派尔斑和肠系膜淋巴结,且在炎症性肠疾病模型中上调,例如IL-10基因敲除的小鼠。hDCRS7在静息和活化的树状突细胞、上皮细胞、和粘膜组织,包括胃肠道和生殖道中都可检测到。这些数据提示家族成员表达于粘膜组织和免疫系统细胞类型中,和/或在胃肠道、气管和生殖道发育中表达。
如此,治疗适应症包括,例如,短肠综合征,放/化疗后或酗酒后恢复,合并溃疡治疗或关节炎治疗,Th2 pregnancy skewing,胃壁/组织再生,吸收面损失疾病等。见例如,Yamada等编辑(1999)Textbook of Gastroenterology;Yamad等编辑(1999)
Textbook and Atlas of Gastroenterology;Gore和Levine(2000)
Textbook of Gastrointestinal Radiology;和(1987)
Textbook of Pediatric Gastroenterology。
类似样品可以从其它物种中分离供评价。
设计IL-17RA特异性引物并用于以多种人文库为模板的TaqMan定量PCR。IL-17RA高表达于先天性免疫髓样细胞,包括树状突细胞和单核细胞。T细胞文库中也检测到表达。这些数据表明该受体在免疫细胞类型中表达,并可以受活化条件调节。
IL-17RA表
文库描述 | IL-17RA_H的CT |
DC,不包括单核细胞GM-CSF、IL-4,静息 | 16.97 |
U937前单核细胞系,活化 | 17.14 |
DC,不包括单核细胞GM-CSF、IL-4,静息 | 17.53 |
DC,70%CD1a+,不包括CD34+GM-CSF、TNFα,静息 | 18.17 |
单核细胞,LPS、gIFN、抗IL-10 | 18.27 |
DC,不包括单核细胞GM-CSF、IL-4,LPS活化4+16hr | 18.51 |
DC,不包括单核细胞GM-CSF、IL-4,单核因子活化4+16hr | 18.68 |
肾上皮癌细胞系CHA,活化 | 18.69 |
单核细胞,LPS,1hr | 18.72 |
单核细胞,LPS,6hr | 18.72 |
DC,70%CD1a+,不包括CD34+GM-CSF、TNFα,活化1hr | 18.91 |
DC,70%CD1a+,不包括CD34+GM-CSF、TNFα,活化6hr | 18.94 |
T细胞,TH1克隆HY06,活化 | 18.99 |
胎肺 | 19.15 |
T细胞,TH1克隆HY06,静息 | 19.18 |
T细胞,TH1克隆HY06,脱敏 | 19.23 |
单核细胞,LPS、gIFN、IL-10,4+16hr | 19.3 |
胚胎脾 | 19.51 |
胚胎睾丸 | 19.7 |
T细胞,TH0克隆Mot72,静息 | 19.71 |
T细胞,TH0克隆Mot72,静息 | 19.84 |
IL-17RA表(续)
DC,CD1a+CD86+,不包括CD34+GM-CSF、TNFα活化1+6hr | 19.94 |
外周血单个核细胞,活化 | 20.01 |
造血前体细胞系TF1,活化 | 20.07 |
肺成纤维细胞肉瘤细胞系MRC5,活化 | 20.18 |
脾细胞,活化 | 20.21 |
T细胞gd克隆,静息 | 20.27 |
胚胎卵巢 | 20.45 |
T细胞CD4+,TH2极化,活化 | 20.57 |
脾细胞,静息 | 20.6 |
胚胎子宫 | 20.62 |
DC 95%CD1a+,不包括CD34+GM-CSF、TNFα活化1+6hr | 20.94 |
上皮细胞,未刺激 | 20.96 |
外周血单个核细胞,静息 | 20.97 |
胚胎脂肪组织 | 21.13 |
B细胞系JY,活化 | 21.28 |
单核细胞,LPS、gIFN、IL-10 | 21.37 |
胎盘28周 | 21.38 |
NK20克隆合并,活化 | 21.55 |
两个正常人肺样品合并 | 21.63 |
正常人甲状腺 | 21.65 |
上皮细胞,IL-1b活化 | 21.72 |
正常人皮肤 | 21.84 |
T细胞,TH0克隆Mot72,脱敏 | 21.87 |
胚胎小肠 | 22.01 |
pME中的CD28-T细胞克隆 | 22.08 |
T细胞,TH2克隆HY935,活化 | 22.09 |
T细胞克隆,合并,静息 | 22.29 |
桥本甲状腺炎甲状腺样品 | 22.3 |
IL-17RA表(续)
NK20克隆合并,静息 | 22.4 |
B细胞EBV细胞系,静息 | 22.45 |
T细胞,TH2克隆HY935,静息 | 22.86 |
T细胞,TH0克隆Mot72,活化 | 23.3 |
单核细胞,LPS、gIFN、抗IL-10,4+16hr | 23.39 |
T细胞系Jurkat和Hut78,静息 | 23.4 |
T细胞,TH0克隆Mot72,活化 | 23.56 |
Pneumocystic Carnii肺炎肺样品 | 24.05 |
U937前单核细胞系,静息 | 25.01 |
类风湿性关节炎样品合并,人 | 25.85 |
三个重度吸烟者肺样品合并 | 26.1 |
DC 95%CD14+,不包括CD34+GM-CSF、TNFα活化1+6hr | 32.69 |
胎肾 | 33.7 |
胎肝 | 34.4 |
NK细胞毒克隆,静息 | 34.49 |
发炎的扁桃腺 | 35.02 |
正常野生型猴肺 | 35.45 |
胚胎胆囊 | 35.84 |
TR1 T细胞克隆 | 35.86 |
过敏性肺样品 | 36.39 |
牛皮癣患者皮肤样品 | 36.44 |
正常人结肠 | 37.34 |
胎脑 | 37.35 |
蛔虫激发的猴肺,4hr | 37.35 |
蛔虫激发的猴肺,24hr | 40 |
胎心 | 40 |
正常野生型猴结肠 | 40 |
溃疡性结肠炎人结肠样品 | 40 |
设计DCRS6_H特异性引物并用于以多种人文库为模板的TaqMan定量PCR。DCRS6_H表达于先天免疫髓样细胞,包括树状突细胞和单核细胞。T细胞文库中也检测到表达。这些数据表明该受体在免疫细胞类型中表达,并可以受活化条件调节。
DCRS6_H表
文库描述 | DCRS6_H的CT |
T细胞,TH0克隆Mot72,静息 | 15.54 |
T细胞,TH0克隆Mot72,静息 | 15.7 |
DC,不包括单核细胞GM-CSF、IL-4,静息 | 17.84 |
DC,不包括单核细胞GM-CSF、IL-4,静息 | 18.19 |
DC,不包括单核细胞GM-CSF、IL-4,LPS活化4+16hr | 18.3 |
DC,不包括单核细胞GM-CSF、IL-4,单核因子活化4+16hr | 18.3 |
T细胞,TH1克隆HY06,静息 | 18.43 |
NK细胞毒克隆,静息 | 18.53 |
T细胞克隆,合并,静息 | 18.8 |
T细胞,TH1克隆HY06,活化 | 19.03 |
T细胞,TH2克隆HY935,活化 | 19.1 |
TR1T细胞克隆 | 19.12 |
T细胞CD4+,TH2极化,活化 | 20.06 |
B细胞EBV细胞系,静息 | 20.3 |
T细胞,TH2克隆HY935,静息 | 20.48 |
肾上皮细胞癌细胞系CHA,活化 | 21.07 |
T细胞,TH1克隆HY06,脱敏 | 21.14 |
正常人结肠 | 21.29 |
NK20克隆合并,静息 | 21.49 |
T细胞gd克隆,静息 | 21.58 |
DCRS6_H表
胚胎胆囊 | 22.21 |
胎肾 | 22.79 |
胎肝 | 22.8 |
Pneumocystic Carnii肺炎肺样品 | 23.06 |
pME中的CD28-T细胞克隆 | 23.18 |
T细胞,TH0克隆Mot72,脱敏 | 23.2 |
胚胎卵巢 | 23.51 |
正常人甲状腺 | 24.03 |
胚胎小肠 | 24.13 |
胚胎睾丸 | 24.82 |
上皮细胞,IL-1b活化 | 26.08 |
三个重度吸烟者肺样品合并 | 26.49 |
胎盘28周 | 26.56 |
正常野生型猴肺 | 28.65 |
外周血单个核细胞,活化 | 33.39 |
蛔虫激发的猴肺,4hr | 36.59 |
胚胎脾 | 38.43 |
外周血单个核细胞,静息 | 40 |
T细胞,TH0克隆Mot72,活化 | 40 |
T细胞系Jurkat和Hut78,静息 | 40 |
脾细胞,静息 | 40 |
脾细胞,活化 | 40 |
B细胞系JY,活化 | 40 |
NK20克隆合并,活化 | 40 |
造血前体细胞系TF1,活化 | 40 |
U937前单核细胞系,静息 | 40 |
U937前单核细胞系,活化 | 40 |
单核细胞,LPS、gIFN、抗IL-10 | 40 |
单核细胞,LPS、gIFN、IL-10 | 40 |
单核细胞,LPS、gIFN、抗IL-10,4+16hr | 40 |
DCRS6_H表
单核细胞,LPS、gIFN、IL-10,4+16hr | 40 |
单核细胞,LPS,1hr | 40 |
单核细胞,LPS,6hr | 40 |
DC,70%CD1a+,不包括CD34+GM-CSF、TNFα,静息 | 40 |
DC,70%CD1a+,不包括CD34+GM-CSF、TNFα,活化1hr | 40 |
DC,70%CD1a+,不包括CD34+GM-CSF、TNFα,活化6hr | 40 |
DC,95%CD1a+,不包括CD34+GM-CSF、TNFα,活化1+6hr | 40 |
DC,95%CD14+,不包括CD34+GM-CSF、TNFα,活化1+6hr | 40 |
DC,CD1a+CD86+,不包括CD34+GM-CSF、TNFα,活化1+6hr | 40 |
上皮细胞,未刺激 | 40 |
肺成纤维细胞肉瘤系MRC5,活化 | 40 |
蛔虫激发的猴肺,24hr | 40 |
两个正常人肺样品合并 | 40 |
过敏性肺样品 | 40 |
正常野生型猴结肠 | 40 |
桥本甲状腺炎甲状腺样品 | 40 |
类风湿性关节炎样品合并,人 | 40 |
正常人皮肤 | 40 |
牛皮癣患者皮肤样品 | 40 |
发炎的扁桃腺 | 40 |
胎肺 | 40 |
胎心 | 40 |
胎脑 | 40 |
胚胎脂肪组织 | 40 |
胚胎子宫 | 40 |
T细胞,TH0克隆Mot72,活化 | 40 |
设计DCRS7_H特异性引物并用于以多种人文库为模板的TaqMan定量PCR。DCRS7_H表达于先天免疫髓样细胞,包括树状突细胞和单核细胞。胚胎细胞文库中也检测到表达。这些数据表明该受体在免疫细胞类型中表达,并可以受活化条件调节。
DCRS7_H表
文库描述 | DCRS7_H的CT |
胚胎子宫 | 19.05 |
混合DC | 19.34 |
胚胎小肠 | 19.46 |
胚胎卵巢 | 19.68 |
胚胎睾丸 | 19.75 |
胎肺 | 20.04 |
CHA | 20.24 |
正常甲状腺 | 20.32 |
DC/GM/IL-4 | 20.52 |
胚胎脾 | 20.86 |
正常肺 | 20.94 |
TF1 | 21 |
过敏性肺#19 | 21.02 |
牛皮癣皮肤 | 21.07 |
胎肝 | 21.15 |
MRC5 | 21.15 |
24hr.蛔虫肺 | 21.17 |
高剂量IL-4肺 | 21.23 |
CD1a+95% | 21.32 |
桥本甲状腺炎 | 21.35 |
克隆性结肠4003197A | 21.35 |
正常肺合并 | 21.36 |
70%DC静息 | 21.42 |
胎肾 | 21.58 |
成年胎盘 | 21.68 |
肺121897-1 | 21.8 |
DCRS7_H表
Pneumocystic Carnii肺炎肺20# | 21.81 |
A549未刺激 | 21.89 |
正常结肠#22 | 21.94 |
18hr.蛔虫肺 | 22.09 |
正常皮肤 | 22.1 |
克隆病结肠9609C144 | 22.13 |
胚胎脂肪组织 | 22.35 |
D6 | 22.39 |
DC静息,CD34-来源 | 22.45 |
DC,TNF/TGFb活化,CD34-来源 | 22.54 |
胎脑 | 22.9 |
DC CD40L活化,单核细胞来源 | 22.91 |
克隆病结肠403242A | 22.91 |
溃疡性结肠炎结肠#26 | 23 |
类风湿性关节炎滑膜合并 | 23.06 |
A549活化 | 23.06 |
Mono+IL-10 | 23.42 |
DC LPS | 23.49 |
Mot72活化 | 23.66 |
CD1a+CD86+ | 23.86 |
HY06静息 | 23.87 |
U937活化 | 23.97 |
发炎的扁桃腺 | 23.97 |
D1 | 24.06 |
M1 | 24.17 |
CD14+95% | 24.21 |
肺080698-2 | 24.28 |
DCRS7_H表
4hr蛔虫肺 | 24.37 |
Jurkat,活化pSPORT | 24.42 |
DC,静息,单核细胞来源 | 24.48 |
HY06活化 | 24.54 |
C+ | 24.64 |
脾细胞,静息 | 24.65 |
U937/CD004,静息 | 24.96 |
PBMC,静息 | 25.8 |
Mot72,静息 | 25.91 |
Mono+抗IL-10 | 26.14 |
NK合并 | 26.99 |
HY06,抗肽 | 27.34 |
肥大细胞,pME | 27.38 |
γδTc | 28.14 |
TC1080,CD28-,pMET7 | 31.05 |
PBMC,活化 | 31.89 |
NK,非细胞毒 | 32.3 |
RV-C30,TR1,pMET7 | 32.5 |
Bc | 33.72 |
C- | 33.8 |
脾细胞,活化 | 34.7 |
JY | 35.05 |
NK,细胞毒 | 36.44 |
NKL/IL-2 | 37.59 |
HY935,静息 | 37.6 |
NK合并,活化 | 38.15 |
Mot72,抗肽 | 38.87 |
胎心 | 40.92 |
B21,静息 | 42.05 |
Jurkat,静息,pSPORT | 42.8 |
DCRS7_H表
B21,活化 | 43.09 |
NKA6,pSPORT | 44.85 |
HY935,活化 | 45 |
M6 | 45 |
设计DCRS9_H特异性引物并用于以多种人文库为模板的TaqMan定量PCR。DCRS9_H表达于T细胞,胎肺和静息的单核细胞。这些数据表明该受体在免疫细胞类型中表达,并可以受活化条件调节。
DCRS9_H表
文库描述 | DCRS9_H的CT |
HY06,静息 | 22.35 |
胎肺 | 22.63 |
HY06,抗肽 | 22.72 |
HY06,活化 | 22.96 |
U937/CD004,静息 | 24.16 |
胚胎小肠 | 24.94 |
JY | 25.04 |
Mot72,静息 | 25.12 |
Jurkat,活化,pSPORT | 25.2 |
RV-C30,TR1,pMET7 | 26.51 |
胎肾 | 26.76 |
MRC5 | 27.2 |
牛皮癣皮肤 | 27.3 |
γδTc | 27.37 |
克隆病结肠,4003197A | 27.44 |
胚胎脾 | 27.72 |
正常肺 | 27.83 |
桥本甲状腺炎 | 28.03 |
B21,静息 | 28.32 |
DCRS9_H表
TF1 | 28.39 |
NK,细胞毒 | 28.44 |
TC1080,CD28-,pMET7 | 28.61 |
Pneumocystic Carnii肺炎肺#20 | 29.05 |
U937,活化 | 29.06 |
HY935,静息 | 29.09 |
CD1a+,95% | 29.13 |
B21,活化 | 29.2 |
Mot72,活化 | 29.21 |
胚胎睾丸 | 29.27 |
肺,080698-2 | 29.32 |
Jurkat,静息,pSPORT | 29.38 |
CD14+,95% | 29.38 |
正常甲状腺 | 29.53 |
Mot72,抗肽 | 29.65 |
脾细胞,静息 | 29.85 |
克隆病结肠,9609C144 | 30.28 |
肺,121897-1 | 30.37 |
24hr.蛔虫肺 | 30.59 |
高剂量IL-4肺 | 30.8 |
CD1a+,CD86+ | 31.42 |
正常皮肤 | 31.73 |
胚胎子宫 | 31.79 |
PBMC,活化 | 31.82 |
发炎的扁桃腺 | 31.98 |
胎脑 | 32.21 |
类风湿性关节炎滑膜合并 | 32.77 |
过敏性肺#19 | 33.18 |
18hr.蛔虫肺 | 33.42 |
DCRS9_H表
成年胎盘 | 33.43 |
正常肺合并 | 33.45 |
克隆病结肠,403242A | 33.52 |
NK合并 | 33.72 |
HY935,活化 | 33.75 |
DC/GM/IL-4 | 34.28 |
DC,静息,单核细胞来源 | 34.57 |
胚胎卵巢 | 35.06 |
胚胎脂肪组织 | 35.07 |
CHA | 35.2 |
PBMC,静息 | 35.95 |
Bc | 36.19 |
A549,未刺激 | 36.4 |
胎心 | 36.87 |
溃疡性结肠炎结肠#26 | 37.83 |
C- | 38.32 |
4hr.蛔虫肺 | 40.2 |
D6 | 40.62 |
C+ | 44.38 |
A549,活化 | 44.58 |
脾细胞,活化 | 45 |
NK合并,活化 | 45 |
NKA6,pSPORT | 45 |
NKL/IL-2 | 45 |
NK,非细胞毒 | 45 |
Mono+抗IL-10 | 45 |
Mono+IL-10 | 45 |
M1 | 45 |
M6 | 45 |
70%DC,静息 | 45 |
DCRS9_H表
V.物种对应物的克隆
D1 | 45 |
DC,LPS | 45 |
混合DC | 45 |
胎肝 | 45 |
肥大细胞,pME | 45 |
DC,CD40L,活化,单核细胞来源 | 45 |
DC,静息,CD34-来源 | 45 |
DC,TNF/TGFb活化,CD34-来源 | 45 |
正常结肠#22 | 45 |
可用多种策略获得其它物种的DCRS对应物,优选从其它灵长类或啮齿类。一种方法是用密切相关物种的DNA探针进行交叉杂交。加入进化相似的物种作为中间步骤可能会有用。另一种方法是用特异性PCR引物,它基于基因间相似性或区别的阻断的鉴定,例如,高保守或非保守的多肽或核苷酸序列区域。序列数据库检索可以鉴定物种对应物。VI.哺乳动物蛋白的生产
将一种适当的,例如GST融合构造物工程化以供表达,例如,在E.coli中。例如,构建小鼠IGIF pGEX质粒并转化入E.coli。将刚转化的细胞生长于,例如,含50μg/ml氨苄青霉素的LB培养基上,并用IPTG(Sigma,St.Louis,MO)诱导。诱导过夜后,收获细菌并分离含适当蛋白的菌体沉淀。匀浆沉淀,例如,在2升TE缓冲液中(50mMTris碱pHg.0,10mM EDTA和2mM pefabloc)。该物质通过微流体装置(Microfluidics,Newton,MA)3次。用Sorvall GS-3转子以13,000rpm离心1小时分离流体化的上清。所得上清液中包含细胞因子受体蛋白,过滤并通过用50mM Tris碱pH8.0平衡的谷胱甘肽Sepharose柱。合并包含DCRS8-GST融合蛋白的组份并切开,例如,用凝血酶(Enzyme Research Laboratories,Inc.,South Bend,IN)切开。合并切除液并通过用50mM Tris碱平衡的Q-SEPHAROSE柱。合并含DCRS8的组分并用冷蒸馏水稀释,以降低电导,并通过另一个新Q-SEPHAROSE柱,单独或连续过免疫亲和抗体柱。合并含DCRS8蛋白的组份,稀释,并保存于-70℃冰箱。
细胞因子蛋白的CD谱比较提示,该蛋白正确折叠。见Hazuda等(1969)
J.Biol.Chem.264:1689-1693。VII.制备特异性抗体
用该蛋白的重组形式腹膜内免疫Balb/c同系鼠,例如,用纯化的DCRS8或稳定转染的NIH-3T3细胞。在适当时间点用蛋白加强免疫动物,可以加或不加佐剂,以进一步刺激抗体生成。收集血清,或用收获的脾制备杂交瘤。
另外,用转化该基因或其片段的细胞免疫Balb/c小鼠,可以是内源或外源性细胞,或用分离的富集表达抗原的膜免疫。在适当时间收集血清,典型地在数次进一步给药后。可以使用多种基因治疗方法,例如,原位产生蛋白,以产生免疫应答。可以交叉吸附或免疫选择血清或抗体制备物以制备具有明确特异性和高亲和度的基本纯的抗体。
可以制造单克隆抗体。例如,脾细胞与适当的融合伴侣融合,用标准方法在生长培养基上选择杂交瘤。筛选杂交瘤上清确定是否存在结合DCRS8的抗体,例如通过ELISA或其它试验。也可选择或制备特异性识别DCRS8具体实施方案的抗体。
在另一种方法中,提呈合成肽或纯化抗体给免疫系统以产生单克隆或多克隆抗体。见,例如,Coligan编辑(1991)
Current Protocols in Immunology Wiley/Greene;和Harlow和Lane(1989)
Antibodies: A Laboratory Manual Cold Spring Harbor Press。在适当情况下,如上标记结合试剂,例如,标记荧光或其它,或者如在淘洗法中固定到基质上。也可导入核酸到动物细胞中来产生抗原,它可以引起免疫应答。见,例如,Wang等(1993)
Proc.Nat’l Acad.Sci.90:4156-4160;Barry等(1994)
BioTechniques 16:616-619;和Xiang等(1995)Immunity 2:129-135。VIII.融合蛋白制备
制造DCRS8或DCRS9的多种融合构造物。适当基因的一部分与表位标签融合,例如,FLAG标签,或与双杂系统构造物融合。见,例如,Fields和Song(1989)
Nature 340:245-246。
表位标签可在表达克隆方法中用抗FLAG抗体检测结合伴侣,例如,对应细胞因子受体的配体。双杂系统也可用于分离特异性结合受体亚基的蛋白。IX.结构活性关系
用标准方法和分析确定特定残基重要性的信息。进行标准突变分析,例如,通过在确定位置产生许多不同变体,例如,在以上鉴定的位置,并评估该变体的生物活性。这可以确定改变活性的位置,或集中注意于特定位置,以确定哪些残基的取代可以保留、阻断、或调节生物活性。
另外,天然变体分析可指出哪些位置允许天然突变。这可通过个体间或跨株系或物种的变体的群体分析来得到。分析选定个体的样品,例如,通过PCR分析和测序。这可以评估群体多态性。X.分离配体
与抗体非常相似,利用其结合特异性,细胞因子受体可用作特异性结合试剂,用于鉴定其结合伴侣。结合受体可以是受体亚基的异源二聚体;或可以涉及,例如DCRS8与另一种细胞因子受体亚基的复合体。如上标记结合试剂,例如,荧光标记或其它,或者固定到淘洗法中的基质上。
结合组合物用于筛选由细胞系制备的表达文库,它们表达结合伴侣,也即配体,优选与膜结合。标准染色方法用于检测或分选表面表达配体,或通过淘洗法筛选表面表达的转化细胞。通过多种染色或免疫荧光方法筛选细胞内表达。也见McMahan等(1991)
EMBO J.10:2821-2832。
例如,在第0天,用1ml粘连蛋白包被两格室permanox片子,10ng/ml PBS中,室温包被30分钟。用PBS漂洗一次,然后在1.5ml生长培养基中以每小格2-3×105细胞接种COS细胞。37℃保温过夜。
第1天,对于每个样品,准备0.5ml无血清DME溶液,其中含66μg/ml DEAE-葡聚糖、66μM氯喹、和4μg DNA。每一组准备一个阳性对照,例如,1和1/200稀释度的DCRS8-FLAG cDNA,和阴性对照。用无血清DME漂洗细胞,加DNA溶液并于37℃保温5小时。除去培养基并在2.5分钟内加0.5ml含10% DMSO的DME。除去并用DME洗一次。加1.5ml生长培养基并保温过夜。
第2天更换培养基。第3或4天,固定细胞并染色。用Hank’s缓冲盐溶液(HBSS)漂洗细胞两次,并在4%多聚甲醛(PFA)/葡萄糖中固定5分钟。用HBSS洗3次。除去所有液体后片子可以在-80℃保存。对每个小格,如下使用0.5ml培养液。加HBSS/皂角苷(0.1%)20分钟,其中含32μl/ml 1M NaN3。然后用HBSS/皂角苷洗涤细胞。加适当的DCRS8或DCRS8/抗体复合体到细胞中并保温30分钟。用HBSS/皂角苷洗细胞两次。必要时加一抗30分钟。加二抗,例如,1/200稀释度的Vector抗鼠抗体,并保温30分钟。准备ELISA溶液,例如Vector Elite ABC辣根过氧化物酶溶液,并预保温30分钟。例如,每2.5ml HBSS/皂角苷用1滴溶液A(亲和素)和1滴溶液B(生物素)。用HBSS/皂角苷洗细胞两次。加ABC HRP溶液并保温30分钟。用HBSS洗细胞两次,第2次两分钟,以闭合细胞。然后加Vector二氨基苯甲酸(DAB)5到10分钟。每5ml玻璃蒸馏水用2滴缓冲液加4滴DAB加2滴H2O2。仔细除去小格并在水中漂洗片子。空气干燥几分钟,然后加1滴Crystal Mount和盖玻片。85-90℃烤5分钟。
评估合并物和进一步亚克隆的正染,以分离负责结合的单个基因。
另外,受体试剂用于亲和纯化或分选表达假想配体的细胞。见,例如,Sambrook等或Ausubel等。
另一种策略是淘洗法筛选膜结合受体。如上构建受体cDNA。用适当的抗体固定,例如,识别DCRS8融合构造物上FLAG序列,或用一抗的抗体。选择和扩增的回归性循环导致富集适当克隆并最终分离表达受体的克隆。
噬菌体表达文库可用哺乳动物DCRS8筛选。适当标记技术,例如,抗FLAG抗体,可以特异性标记适当克隆。
我们测试了DCRS受体特异性结合IL-17家族细胞因子的能力。重组FLAG-hIL-17家族细胞因子用于有关Baf/3DCRS受体转染的表达重组IL-17R_H,DCRS6_H,DCRS7_H,DCRS8_H和DCRS9_H的结合试验,并用FACS分析。我们可以证明IL-17家族成员IL-74与表达DCRS6的Baf/3细胞特异性结合。在另外的试验中,我们表明IL-17特异性结合到IL-17R_H,DCRS7_H、DCRS8_H。进一步试验表明,IL-17结合到转染DCRS8_Hu的细胞上。这些试验表明,IL-17相关细胞因子受体的序列同源性给予IL-17细胞因子功能性结合能力。
所有引用的文献在此引作参考,每单个出版物或专利申请特别地和单独地表明其引作参考。
在不偏离其精神和范围的情况下可以作出许多修改和变体,这正如本领域技术人员所熟知。此处描述的具体实施方案只是以实施例的方式提供,并且本发明受所附权利要求书的限制,并包括这些权利要求的等价物;并且本发明不受此处以实施例方式提供的具体实施方案的限制。
序列表SEQ ID NO:1提供灵长类动物的DCRS6核苷酸序列。SEQ ID NO:2提供灵长类动物的DCRS6多肽序列。SEQ ID NO:3提供灵长类动物的DCRS6反向翻译。SEQ ID NO:4提供啮齿类动物的DCRS6核苷酸序列。SEQ ID NO:5提供啮齿类动物的DCRS6多肽序列。SEQ ID NO:6提供啮齿类动物的DCRS6反向翻译。SEQ ID NO:7提供灵长类动物的DCRS7核苷酸序列。SEQ ID NO:8提供灵长类动物的DCRS7多肽序列。SEQ ID NO:9提供灵长类动物的DCRS7反向翻译。SEQ ID NO:10提供啮齿类动物的DCRS7核苷酸序列。SEQ ID NO:11提供啮齿类动物的DCRS7多肽序列。SEQ ID NO:12提供啮齿类动物的DCRS7反向翻译。SEQ ID NO:13提供灵长类动物的DCRS8核苷酸序列。SEQ ID NO:14提供灵长类动物的DCRS8多肽序列。SEQ ID NO:15提供灵长类动物的DCRS8反向翻译。SEQ ID NO:16提供灵长类动物的DCRS9核苷酸序列。SEQ ID NO:17提供灵长类动物的DCRS9多肽序列。SEQ ID NO:18提供灵长类动物的DCRS9反向翻译。SEQ ID NO:19提供啮齿类动物的DCRS9核苷酸序列。SEQ ID NO:20提供啮齿类动物的DCRS9多肽序列。SEQ ID NO:21提供啮齿类动物的DCRS9反向翻译。SEQ ID NO:22提供灵长类动物的DCRS10核苷酸序列。SEQ ID NO:23提供灵长类动物的DCRS10多肽序列。SEQ ID NO:24提供灵长类动物的DCRS10反向翻译。SEQ ID NO:25提供啮齿类动物的DCRS10核苷酸序列。SEQ ID NO:26提供啮齿类动物的DCRS10多肽序列。SEQ ID NO:27提供啮齿类动物的DCRS10反向翻译。SEQ ID NO:28提供灵长类动物IL-17的受体多肽序列。SEQ ID NO:29提供啮齿类动物的IL-17受体多肽序列。SEQ ID NO:30提供蠕虫类动物的IL-17受体多肽序列。SEQ ID NO:31提供蠕虫类动物的DCRS6多肽序列。<110>先灵公司<120>哺乳动物受体蛋白;相关的试剂和方法<130>DX01170K PCT<140>PCT/US01/16767<141>2001-05-23<150>US60/206,862<151>2000-05-24<160>31<170>PatentIn Ver.2.0<210>1<211>1796<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>CDS<222>(4)..(1509)<220><221>mat_肽<222>(46)..(1509)<400>1gcg atg tcg ctc gtg ctg cta agc ctg gcc gcg ctg tgc agg agc gcc 48
Met Ser Leu Val Leu Leu Ser Leu Ala Ala Leu Cys Arg Ser Ala
-10 -5 -1 1gta ccc cga gag ccg acc gtt caa tgt ggc tct gaa act ggg cca tct 96Val Pro Arg Glu Pro Thr Val Gln Cys Gly Ser Glu Thr Gly Pro Ser
5 10 15cca gag tgg atg cta caa cat gat cta atc ccg gga gac ttg agg gac 144Pro Glu Trp Met Leu Gln His Asp Leu Ile Pro Gly Asp Leu Arg Asp
20 25 30ctc cga gta gaa cct gtt aca act agt gtt gca aca ggg gac tat tca 192Leu Arg Val Glu Pro Val Thr Thr Ser Val Ala Thr Gly Asp Tyr Ser
35 40 45att ttg atg aat gta agc tgg gta ctc cgg gca gat gcc agc atc cgc 240Ile Leu Met Asn Val Ser Trp Val Leu Arg Ala Asp Ala Ser Ile Arg50 55 60 65ttg ttg aag gcc acc aag att tgt gtg acg ggc aaa agc aac ttc cag 288Leu Leu Lys Ala Thr Lys Ile Cys Val Thr Gly Lys Ser Asn Phe Gln
70 75 80tcc tac agc tgt gtg agg tgc aat tac aca gag gcc ttc cag act cag 336Ser Tyr Ser Cys Val Arg Cys Asn Tyr Thr Glu Ala Phe Gln Thr Gln
85 90 95acc aga ccc tct ggt ggt aaa tgg aca ttt tcc tat atc ggc ttc cct 384Thr Arg Pro Ser Gly Gly Lys Trp Thr Phe Ser Tyr Ile Gly Phe Pro
100 105 110gta gag ctg aac aca gtc tat ttc att ggg gcc cat aat att cct aat 432Val Glu Leu Asn Thr Val Tyr Phe Ile Gly Ala His Asn Ile Pro Asn
115 120 125gca aat atg aat gaa gat ggc cct tcc atg tct gtg aat ttc acc tca 480Ala Asn Met Asn Glu Asp Gly Pro Ser Met Ser Val Asn Phe Thr Ser130 135 140 145cca ggc tgc cta gac cac ata atg aaa tat aaa aaa aag tgt gtc aag 528Pro Gly Cys Leu Asp His Ile Met Lys Tyr Lys Lys Lys Cys Val Lys
150 155 160gcc gga agc ctg tgg gat ccg aac atc act gct tgt aag aag aat gag 576Ala Gly Ser Leu Trp Asp Pro Asn Ile Thr Ala Cys Lys Lys Asn Glu
165 170 175gag aca gta gaa gtg aac ttc aca acc act ccc ctg gga aac aga tac 624Glu Thr Val Glu Val Asn Phe Thr Thr Thr Pro Leu Gly Asn Arg Tyr
180 185 190atg gct ctt atc caa cac agc act atc atc ggg ttt tct cag gtg ttt 672Met Ala Leu Ile Gln His Ser Thr Ile Ile Gly Phe Ser Gln Val Phe
195 200 205gag cca cac cag aag aaa caa acg cga gct tca gtg gtg att cca gtg 720Glu Pro His Gln Lys Lys Gln Thr Arg Ala Ser Val Val Ile Pro Val210 215 220 225act ggg gat agt gaa ggt gct acg gtg cag ctg act cca tat ttt cct 768Thr Gly Asp Ser Glu Gly Ala Thr Val Gln Leu Thr Pro Tyr Phe Pro
230 235 240act tgt ggc agc gac tgc atc cga cat aaa gga aca gtt gtg ctc tgc 816Thr Cys Gly Ser Asp Cys Ile Arg His Lys Gly Thr Val Val Leu Cys
245 250 255cca caa aca ggc gtc cct ttc cct ctg gat aac aac aaa agc aag ccg 864Pro Gln Thr Gly Val Pro Phe Pro Leu Asp Asn Asn Lys Ser Lys Pro
260 265 270gga ggc tgg ctg cct ctc ctc ctg ctg tct ctg ctg gtg gcc aca tgg 912Gly Gly Trp Leu Pro Leu Leu Leu Leu Ser Leu Leu Val Ala Thr Trp
275 280 285gtg ctg gtg gca ggg atc tat cta atg tgg agg cac gaa agg atc aag 960Val Leu Val Ala Gly Ile Tyr Leu Met Trp Arg His Glu Arg Ile Lys290 295 300 305aag act tcc ttt tct acc acc aca cta ctg ccc ccc att aag gtt ctt 1008Lys Thr Ser Phe Ser Thr Thr Thr Leu Leu Pro Pro Ile Lys Val Leu
310 315 320gtg gtt tac cca tct gaa ata tgt ttc cat cac aca att tgt tac ttc 1056Val Val Tyr Pro Ser Glu Ile Cys Phe His His Thr Ile Cys Tyr Phe
325 330 335act gaa ttt ctt caa aac cat tgc aga agt gag gtc atc ctt gaa aag 1104Thr Glu Phe Leu Gln Asn His Cys Arg Ser Glu Val Ile Leu Glu Lys
340 345 350tgg cag aaa aag aaa ata gca gag atg ggt cca gtg cag tgg ctt gcc 1152Trp Gln Lys Lys Lys Ile Ala Glu Met Gly Pro Val Gln Trp Leu Ala
355 360 365act caa aag aag gca gca gac aaa gtc gtc ttc ctt ctt tcc aat gac 1200Thr Gln Lys Lys Ala Ala Asp Lys Val Val Phe Leu Leu Ser Asn Asp370 375 380 385gtc aac agt gtg tgc gat ggt acc tgt ggc aag agc gag ggc agt ccc 1248Val Asn Ser Val Cys Asp Gly Thr Cys Gly Lys Ser Glu Gly Ser Pro
390 395 400agt gag aac tct caa gac ctc ttc ccc ctt gcc ttt aac ctt ttc tgc 1296Ser Glu Asn Ser Gln Asp Leu Phe Pro Leu Ala Phe Asn Leu Phe Cys
405 410 415agt gat cta aga agc cag att cat ctg cac aaa tac gtg gtg gtc tac 1344Ser Asp Leu Arg Ser Gln Ile His Leu His Lys Tyr Val Val Val Tyr
420 425 430ttt aga gag att gat aca aaa gac gat tac aat gct ctc agt gtc tgc 1392Phe Arg Glu Ile Asp Thr Lys Asp Asp Tyr Asn Ala Leu Ser Val Cys
435 440 445ccc aag tac cac ctc atg aag gat gcc act gct ttc tgt gca gaa ctt 1440Pro Lys Tyr His Leu Met Lys Asp Ala Thr Ala Phe Cys Ala Glu Leu450 455 460 465ctc cat gtc aag cag cag gtg tca gca gga aaa aga tca caa gcc tgc 1488Leu His Val Lys Gln Gln Val Ser Ala Gly Lys Arg Ser Gln Ala Cys
470 475 480cac gat ggc tgc tgc tcc ttg tagcccaccc atgagaagca agagacctta 1539His Asp Gly Cys Cys Ser Leu
485aaggcttcct atcccaccaa ttacagggaa aaaacgtgtg atgatcctga agcttactat 1599gcagcctaca aacagcctta gtaattaaaa cattttatac caataaaatt ttcaaatatt 1659gctaactaat gtagcattaa ctaacgattg gaaactacat ttacaacttc aaagctgttt 1719tatacataga aatcaattac agctttaatt gaaaactgta accattttga taatgcaaca 1779ataaagcatc ttcagcc 1796<210>2<211>502<212>PRT<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<400>2Met Ser Leu Val Leu Leu Ser Leu Ala Ala Leu Cys Arg Ser Ala Val
-10 -5 -1 1Pro Arg Glu Pro Thr Val Gln Cys Gly Ser Glu Thr Gly Pro Ser Pro
5 10 15Glu Trp Met Leu Gln His Asp Leu Ile Pro Gly Asp Leu Arg Asp Leu
20 25 30Arg Val Glu Pro Val Thr Thr Ser Val Ala Thr Gly Asp Tyr Ser Ile35 40 45 50Leu Met Asn Val Ser Trp Val Leu Arg Ala Asp Ala Ser Ile Arg Leu
55 60 65Leu Lys Ala Thr Lys Ile Cys Val Thr Gly Lys Ser Asn Phe Gln Ser
70 75 80Tyr Ser Cys Val Arg Cys Asn Tyr Thr Glu Ala Phe Gln Thr Gln Thr
85 90 95Arg Pro Ser Gly Gly Lys Trp Thr Phe Ser Tyr Ile Gly Phe Pro Val
100 105 110Glu Leu Asn Thr Val Tyr Phe Ile Gly Ala His Asn Ile Pro Asn Ala115 120 125 130Asn Met Asn Glu Asp Gly Pro Ser Met Ser Val Asn Phe Thr Ser Pro
135 140 145Gly Cys Leu Asp His Ile Met Lys Tyr Lys Lys Lys Cys Val Lys Ala
150 155 160Gly Ser Leu Trp Asp Pro Asn Ile Thr Ala Cys Lys Lys Asn Glu Glu
165 170 175Thr Val Glu Val Asn Phe Thr Thr Thr Pro Leu Gly Asn Arg Tyr Met
180 185 190Ala Leu Ile Gln His Ser Thr Ile Ile Gly Phe Ser Gln Val Phe Glu195 200 205 210Pro His Gln Lys Lys Gln Thr Arg Ala Ser Val Val Ile Pro Val Thr
215 220 225Gly Asp Ser Glu Gly Ala Thr Val Gln Leu Thr Pro Tyr Phe Pro Thr
230 235 240Cys Gly Ser Asp Cys Ile Arg His Lys Gly Thr Val Val Leu Cys Pro
245 250 255Gln Thr Gly Val Pro Phe Pro Leu Asp Asn Asn Lys Ser Lys Pro Gly
260 265 270Gly Trp Leu Pro Leu Leu Leu Leu Ser Leu Leu Val Ala Thr Trp Val275 280 285 290Leu Val Ala Gly Ile Tyr Leu Met Trp Arg His Glu Arg Ile Lys Lys
295 300 305Thr Ser Phe Ser Thr Thr Thr Leu Leu Pro Pro Ile Lys Val Leu Val
310 315 320Val Tyr Pro Ser Glu Ile Cys Phe His His Thr Ile Cys Tyr Phe Thr
325 330 335Glu Phe Leu Gln Asn His Cys Arg Ser Glu Val Ile Leu Glu Lys Trp
340 345 350Gln Lys Lys Lys Ile Ala Glu Met Gly Pro Val Gln Trp Leu Ala Thr355 360 365 370Gln Lys Lys Ala Ala Asp Lys Val Val Phe Leu Leu Ser Asn Asp Val
375 380 385Asn Ser Val Cys Asp Gly Thr Cys Gly Lys Ser Glu Gly Ser Pro Ser
390 395 400Glu Asn Ser Gln Asp Leu Phe Pro Leu Ala Phe Asn Leu Phe Cys Ser
405 410 415Asp Leu Arg Ser Gln Ile His Leu His Lys Tyr Val Val Val Tyr Phe
420 425 430Arg Glu Ile Asp Thr Lys Asp Asp Tyr Asn Ala Leu Ser Val Cys Pro435 440 445 450Lys Tyr His Leu Met Lys Asp Ala Thr Ala Phe Cys Ala Glu Leu Leu
455 460 465His Val Lys Gln Gln Val Ser Ala Gly Lys Arg Ser Gln Ala Cys His
470 475 480Asp Gly Cys Cys Ser Leu
485<210>3<211>1506<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>misc_特征<222>(6),(9),(12),(15),(18),(21),(24),(27),
(30),(33),(39),(42),(45),(48),(51),(54),
(60),(63),(66),(75),(78),(84),(87),(90),
(93),(96),(108),(120),(126),(129),(135),
(138),(144),(147),(150),(156),(159),(162),
(165),(168),(171),(174),(177),(180),(189),
(195),(204),(207),(213),(216),(219),(222),
(228),(231),(237),(240),(243),(249),(252),
(264),(267),(270),(276),(288),(294),(300),
(303),(315),(321),(330),(336),(339),(342),
(345),(348),(351),(360),(366),(375),(381),
(384),(390),(396),(399),(411),(414),(426),
(432),(450),(453),(456),(462),(465),(474),
(477),(480),(483),(489),(522),(528),(531),
(534),(537),(546),(555),(558),(579),(582),
(588),(597),(600),(603),(606),(609),(612),
(618),(627),(630),(642),(645),(654),(660),
(666),(675),(693),(696),(699),(702),(705),
(708),(714),(717),(720),(723),(729),(735),
(738),(741),(744),(750),(753),(756),(765),
(768),(774),(777),(789),(798),(801),(804),
(807),(810),(816),(822),(825),(828),(831),
(837),(840),(855),(861),(864),(867),(873),
(876),(879),(882),(885),(888),(891),(894),
(897),(900),(903),(906),(912),(915),(918),
(921),(924),(933),(942),(951),(963),(966),
(972),(975),(978),(981),(984),(987),(990),
(993),(1002),(1005),(1008),(1011),(1017),
(1020),(1041),(1056),(1065),(1080),(1083),
(1089),(1095),(1122),(1131),(1134),(1137),
(1146),(1149),(1152),(1164),(1167),(1176),
(1179),(1185),(1188),(1191),(1200),(1206),
(1209),(1218),(1221),(1227),(1233),(1239),
(1242),(1245),(1248),(1257),(1266),(1272),
(1275),(1278),(1287),(1296),(1302),(1305),
(1308),(1320),(1332),(1335),(1338),(1347),
(1359),(1377),(1380),(1383),(1386),(1392),
(1404),(1416),(1419),(1422),(1431),(1437),
(1440),(1446),(1458),(1461),(1464),(1467),
(1473),(1476),(1482),(1494),(1503),(1506)<223>n=任意核苷酸<400>3atgwsnytng tnytnytnws nytngcngcn ytntgymgnw sngcngtncc nmgngarccn 60acngtncart gyggnwsnga racnggnccn wsnccngart ggatgytnca rcaygayytn 120athccnggng ayytnmgnga yytnmgngtn garccngtna cnacnwsngt ngcnacnggn 180gaytaywsna thytnatgaa ygtnwsntgg gtnytnmgng cngaygcnws nathmgnytn 240ytnaargcna cnaarathtg ygtnacnggn aarwsnaayt tycarwsnta ywsntgygtn 300mgntgyaayt ayacngargc nttycaracn caracnmgnc cnwsnggngg naartggacn 360ttywsntaya thggnttycc ngtngarytn aayacngtnt ayttyathgg ngcncayaay 420athccnaayg cnaayatgaa ygargayggn ccnwsnatgw sngtnaaytt yacnwsnccn 480ggntgyytng aycayathat gaartayaar aaraartgyg tnaargcngg nwsnytntgg 540gayccnaaya thacngcntg yaaraaraay gargaracng tngargtnaa yttyacnacn 600acnccnytng gnaaymgnta yatggcnytn athcarcayw snacnathat hggnttywsn 660cargtnttyg arccncayca raaraarcar acnmgngcnw sngtngtnat hccngtnacn 720ggngaywsng arggngcnac ngtncarytn acnccntayt tyccnacntg yggnwsngay 780tgyathmgnc ayaarggnac ngtngtnytn tgyccncara cnggngtncc nttyccnytn 840gayaayaaya arwsnaarcc nggnggntgg ytnccnytny tnytnytnws nytnytngtn 900gcnacntggg tnytngtngc nggnathtay ytnatgtggm gncaygarmg nathaaraar 960acnwsnttyw snacnacnac nytnytnccn ccnathaarg tnytngtngt ntayccnwsn 1020garathtgyt tycaycayac nathtgytay ttyacngart tyytncaraa ycaytgymgn 1080wsngargtna thytngaraa rtggcaraar aaraarathg cngaratggg nccngtncar 1140tggytngcna cncaraaraa rgcngcngay aargtngtnt tyytnytnws naaygaygtn 1200aaywsngtnt gygayggnac ntgyggnaar wsngarggnw snccnwsnga raaywsncar 1260gayytnttyc cnytngcntt yaayytntty tgywsngayy tnmgnwsnca rathcayytn 1320cayaartayg tngtngtnta yttymgngar athgayacna argaygayta yaaygcnytn 1380wsngtntgyc cnaartayca yytnatgaar gaygcnacng cnttytgygc ngarytnytn 1440caygtnaarc arcargtnws ngcnggnaar mgnwsncarg cntgycayga yggntgytgy 1500wsnytn 1506<210>4<211>637<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>CDS<222>(1)..(210)<400>4gat ttc agc agc cag acg cat ctg cac aaa tac ctg gag gtc tat ctt 48Asp Phe Ser Ser Gln Thr His Leu His Lys Tyr Leu Glu Val Tyr Leu1 5 10 15ggg gga gca gac ctc aaa ggc gac tat aat gcc ctg agt gtc tgc ccc 96Gly Gly Ala Asp Leu Lys Gly Asp Tyr Asn Ala Leu Ser Val Cys Pro
20 25 30caa tat cat ctc atg aag gac gcc aca gct ttc cac aca gaa ctt ctc 144Gln Tyr His Leu Met Lys Asp Ala Thr Ala Phe His Thr Glu Leu Leu
35 40 45aag gct acg cag agc atg tca gtg aag aaa cgc tca caa gcc tgc cat 192Lys Ala Thr Gln Ser Met Ser Val Lys Lys Arg Ser Gln Ala Cys His
50 55 60gat agc tgt tca ccc ttg tagtccaccc gggggaatag agactctgaa 240Asp Ser Cys Ser Pro Leu65 70gccttcctac tctcccttcc agtgacaaat gctgtgtgac gactctgaaa tgtgtgggag 300aggctgtgtg gaggtagtgc tatgtacaaa cttgctttaa aactggagtt tgcaaagtca 360acctgagcat acacgcctga ggctagtcat tggctggatt tatgaagaca acacagttac 420agacaataat gagtgggacc tacatttggg atatacccaa agctgggtaa tgattatcac 480tgagaaccac gcactctggc catgaggtaa tacggcactt ccctgtcagg ctgtctgtca 540ggttgggtct gtcttgcact gcccatgctc tatgctgcac gtagaccgtt ttgtaacatt 600ttaatctgtt aatgaataat ccgtttggga ggctctc 637<210>5<211>70<212>PRT<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<400>5Asp Phe Ser Ser Gln Thr His Leu His Lys Tyr Leu Glu Val Tyr Leu1 5 10 15Gly Gly Ala Asp Leu Lys Gly Asp Tyr Asn Ala Leu Ser Val Cys Pro
20 25 30Gln Tyr His Leu Met Lys Asp Ala Thr Ala Phe His Thr Glu Leu Leu
35 40 45Lys Ala Thr Gln Ser Met Ser Val Lys Lys Arg Ser Gln Ala Cys His
50 55 60Asp Ser Cys Ser Pro Leu65 70<210>6<211>210<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>misc_特征<222>(9),(12),(18),(24),(36),(42),(48),(51),
(54),(57),(63),(69),(81),(84),(87),(90),
(96),(108),(120),(123),(126),(135),(141),
(144),(150),(153),(159),(165),(168),(177),
(180),(186),(198),(204),(207),(210)<223>n=任意核苷酸<400>6gayttywsnw sncaracnca yytncayaar tayytngarg tntayytngg nggngcngay 60ytnaarggng aytayaaygc nytnwsngtn tgyccncart aycayytnat gaargaygcn 120acngcnttyc ayacngaryt nytnaargcn acncarwsna tgwsngtnaa raarmgnwsn 180cargcntgyc aygaywsntg ywsnccnytn 210<210>7<211>2308<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>CDS<222>(181)..(2289)<220><221>mat_肽<222>(241)..(2289)<220><221>misc_特征<222>(140),(2232)<223>n=任意核苷酸<220><221>misc_特征<222>(664)<223>Xaa=任意氨基酸<400>7gagtcaggac tcccaggaca gagagtgcac aaactaccca gcacagcccc ctccgccccc 60tctggaggct gaagagggat tccagcccct gccacccaca gacacgggct gactggggtg 120tctgcccccc ttgggggcan ccacagggcc tcaggcctgg gtgccacctg gcactagaag 180atg cct gtg ccc tgg ttc ttg ctg tcc ttg gca ctg ggc cga agc cag 228Met Pro Val Pro Trp Phe Leu Leu Ser Leu Ala Leu Gly Arg Ser Gln-20 -15 -10 -5tgg atc ctt tct ctg gag agg ctt gtg ggg cct cag gac gct acc cac 276Trp Ile Leu Ser Leu Glu Arg Leu Val Gly Pro Gln Asp Ala Thr His
-1 1 5 10tgc tct ccg ggc ctc tcc tgc cgc ctc tgg gac agt gac ata ctc tgc 324Cys Ser Pro Gly Leu Ser Cys Arg Leu Trp Asp Ser Asp Ile Leu Cys
15 20 25ctg cct ggg gac atc gtg cct gct ccg ggc ccc gtg ctg gcg cct acg 372Leu Pro Gly Asp Ile Val Pro Ala Pro Gly Pro Val Leu Ala Pro Thr
30 35 40cac ctg cag aca gag ctg gtg ctg agg tgc cag aag gag acc gac tgt 420His Leu Gln Thr Glu Leu Val Leu Arg Cys Gln Lys Glu Thr Asp Cys45 50 55 60gac ctc tgt ctg cgt gtg gct gtc cac ttg gcc gtg cat ggg cac tgg 468Asp Leu Cys Leu Arg Val Ala Val His Leu Ala Val His Gly His Trp
65 70 75gaa gag cct gaa gat gag gaa aag ttt gga gga gca gct gac tta ggg 516Glu Glu Pro Glu Asp Glu Glu Lys Phe Gly Gly Ala Ala Asp Leu Gly
80 85 90gtg gag gag cct agg aat gcc tct ctc cag gcc caa gtc gtg ctc tcc 564Val Glu Glu Pro Arg Asn Ala Ser Leu Gln Ala Gln Val Val Leu Ser
95 100 105ttc cag gcc tac cct act gcc cgc tgc gtc ctg ctg gag gtg caa gtg 612Phe Gln Ala Tyr Pro Thr Ala Arg Cys Val Leu Leu Glu Val Gln Val
110 115 120cct gct gcc ctt gtg cag ttt ggt cag tct gtg ggc tct gtg gta tat 660Pro Ala Ala Leu Val Gln Phe Gly Gln Ser Val Gly Ser Val Val Tyr125 130 135 140gac tgc ttc gag gct gcc cta ggg agt gag gta cga atc tgg tcc tat 708Asp Cys Phe Glu Ala Ala Leu Gly Ser Glu Val Arg Ile Trp Ser Tyr
145 150 155act cag ccc agg tac gag aag gaa ctc aac cac aca cag cag ctg cct 756Thr Gln Pro Arg Tyr Glu Lys Glu Leu Asn His Thr Gln Gln Leu Pro
160 165 170gac tgc agg ggg ctc gaa gtc tgg aac agc atc ccg agc tgc tgg gcc 804Asp Cys Arg Gly Leu Glu Val Trp Asn Ser Ile Pro Ser Cys Trp Ala
175 180 185ctg ccc tgg ctc aac gtg tca gca gat ggt gac aac gtg cat ctg gtt 852Leu Pro Trp Leu Asn Val Ser Ala Asp Gly Asp Asn Val His Leu Val
190 195 200ctg aat gtc tct gag gag cag cac ttc ggc ctc tcc ctg tac tgg aat 900Leu Asn Val Ser Glu Glu Gln His Phe Gly Leu Ser Leu Tyr Trp Asn205 210 215 220cag gtc cag ggc ccc cca aaa ccc cgg tgg cac aaa aac ctg act gga 948Gln Val Gln Gly Pro Pro Lys Pro Arg Trp His Lys Asn Leu Thr Gly
225 230 235ccg cag atc att acc ttg aac cac aca gac ctg gtt ccc tgc ctc tgt 996Pro Gln Ile Ile Thr Leu Asn His Thr Asp Leu Val Pro Cys Leu Cys
240 245 250att cag gtg tgg cct ctg gaa cct gac tcc gtt agg acg aac atc tgc 1044Ile Gln Val Trp Pro Leu Glu Pro Asp Ser Val Arg Thr Asn Ile Cys
255 260 265ccc ttc agg gag gac ccc cgc gca cac cag aac ctc tgg caa gcc gcc 1092Pro Phe Arg Glu Asp Pro Arg Ala His Gln Asn Leu Trp Gln Ala Ala
270 275 280cga ctg cga ctg ctg acc ctg cag agc tgg ctg ctg gac gca ccg tgc 1140Arg Leu Arg Leu Leu Thr Leu Gln Ser Trp Leu Leu Asp Ala Pro Cys285 290 295 300tcg ctg ccc gca gaa gcg gca ctg tgc tgg cgg gct ccg ggt ggg gac 1188Ser Leu Pro Ala Glu Ala Ala Leu Cys Trp Arg Ala Pro Gly Gly Asp
305 310 315ccc tgc cag cca ctg gtc cca ccg ctt tcc tgg gag aat gtc act gtg 1236Pro Cys Gln Pro Leu Val Pro Pro Leu Ser Trp Glu Asn Val Thr Val
320 325 330gac gtg aac agc tcg gag aag ctg cag ctg cag gag tgc ttg tgg gct 1284Asp Val Asn Ser Ser Glu Lys Leu Gln Leu Gln Glu Cys Leu Trp Ala
335 340 345gac tcc ctg ggg cct ctc aaa gac gat gtg cta ctg ttg gag aca cga 1332Asp Ser Leu Gly Pro Leu Lys Asp Asp Val Leu Leu Leu Glu Thr Arg
350 355 360ggc ccc cag gac aac aga tcc ctc tgt gcc ttg gaa ccc agt ggc tgt 1380Gly Pro Gln Asp Asn Arg Ser Leu Cys Ala Leu Glu Pro Ser Gly Cys365 370 375 380act tca cta ccc agc aaa gcc tcc acg agg gca gct cgc ctt gga gag 1428Thr Ser Leu Pro Ser Lys Ala Ser Thr Arg Ala Ala Arg Leu Gly Glu
385 390 395tac tta cta caa gac ctg cag tca ggc cag tgt ctg cag cta tgg gac 1476Tyr Leu Leu Gln Asp Leu Gln Ser Gly Gln Cys Leu Gln Leu Trp Asp
400 405 410gat gac ttg gga gcg cta tgg gcc tgc ccc atg gac aaa tac atc cac 1524Asp Asp Leu Gly Ala Leu Trp Ala Cys Pro Met Asp Lys Tyr Ile His
415 420 425aag cgc tgg gcc ctc gtg tgg ctg gcc tgc cta ctc ttt gcc gct gcg 1572Lys Arg Trp Ala Leu Val Trp Leu Ala Cys Leu Leu Phe Ala Ala Ala
430 435 440ctt tcc ctc atc ctc ctt ctc aaa aag gat cac gcg aaa ggg tgg ctg 1620Leu Ser Leu Ile Leu Leu Leu Lys Lys Asp His Ala Lys Gly Trp Leu445 450 455 460agg ctc ttg aaa cag gac gtc cgc tcg ggg gcg gcc gcc agg ggc cgc 1668Arg Leu Leu Lys Gln Asp Val Arg Ser Gly Ala Ala Ala Arg Gly Arg
465 470 475gcg gct ctg ctc ctc tac tca gcc gat gac tcg ggt ttc gag cgc ctg 1716Ala Ala Leu Leu Leu Tyr Ser Ala Asp Asp Ser Gly Phe Glu Arg Leu
480 485 490gtg ggc gcc ctg gcg tcg gcc ctg tgc cag ctg ccg ctg cgc gtg gcc 1764Val Gly Ala Leu Ala Ser Ala Leu Cys Gln Leu Pro Leu Arg Val Ala
495 500 505gta gac ctg tgg agc cgt cgt gaa ctg agc gcg cag ggg ccc gtg gct 1812Val Asp Leu Trp Ser Arg Arg Glu Leu Ser Ala Gln Gly Pro Val Ala
510 515 520tgg ttt cac gcg cag cgg cgc cag acc ctg cag gag ggc ggc gtg gtg 1860Trp Phe His Ala Gln Arg Arg Gln Thr Leu Gln Glu Gly Gly Val Val525 530 535 540gtc ttg ctc ttc tct ccc ggt gcg gtg gcg ctg tgc agc gag tgg cta 1908Val Leu Leu Phe Ser Pro Gly Ala Val Ala Leu Cys Ser Glu Trp Leu
545 550 555cag gat ggg gtg tcc ggg ccc ggg gcg cac ggc ccg cac gac gcc ttc 1956Gln Asp Gly Val Ser Gly Pro Gly Ala His Gly Pro His Asp Ala Phe
560 565 570cgc gcc tcg ctc agc tgc gtg ctg ccc gac ttc ttg cag ggc cgg gcg 2004Arg Ala Ser Leu Ser Cys Val Leu Pro Asp Phe Leu Gln Gly Arg Ala
575 580 585ccc ggc agc tac gtg ggg gcc tgc ttc gac agg ctg ctc cac ccg gac 2052Pro Gly Ser Tyr Val Gly Ala Cys Phe Asp Arg Leu Leu His Pro Asp
590 595 600gcc gta ccc gcc ctt ttc cgc acc gtg ccc gtc ttc aca ctg ccc tcc 2100Ala Val Pro Ala Leu Phe Arg Thr Val Pro Val Phe Thr Leu Pro Ser605 610 615 620caa ctg cca gac ttc ctg ggg gcc ctg cag cag cct cgc gcc ccg cgt 2148Gln Leu Pro Asp Phe Leu Gly Ala Leu Gln Gln Pro Arg Ala Pro Arg
625 630 635tcc ggg cgg ctc caa gag aga gcg gag caa gtg tcc cgg gcc ctt cag 2196Ser Gly Arg Leu Gln Glu Arg Ala Glu Gln Val Ser Arg Ala Leu Gln
640 645 650cca gcc ctg gat agc tac ttc cat ccc ccg ggg acn tcc gcg ccg gga 2244Pro Ala Leu Asp Ser Tyr Phe His Pro Pro Gly Xaa Ser Ala Pro Gly
655 660 665cgc ggg gtg gga cca ggg gcg gga cct ggg gcg ggg gac ggg act 2289Arg Gly Val Gly Pro Gly Ala Gly Pro Gly Ala Gly Asp Gly Thr
670 675 680taaataaagg cagacgctg 2308<210>8<211>703<212>PRT<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>misc_特征<222>(664)<223>Xaa=任意氨基酸<400>8Met Pro Val Pro Trp Phe Leu Leu Ser Leu Ala Leu Gly Arg Ser Gln-20 -15 -10 -5Trp Ile Leu Ser Leu Glu Arg Leu Val Gly Pro Gln Asp Ala Thr His
-1 1 5 10Cys Ser Pro Gly Leu Ser Cys Arg Leu Trp Asp Ser Asp Ile Leu Cys
15 20 25Leu Pro Gly Asp Ile Val Pro Ala Pro Gly Pro Val Leu Ala Pro Thr
30 35 40His Leu Gln Thr Glu Leu Val Leu Arg Cys Gln Lys Glu Thr Asp Cys45 50 55 60Asp Leu Cys Leu Arg Val Ala Val His Leu Ala Val His Gly His Trp
65 70 75Glu Glu Pro Glu Asp Glu Glu Lys Phe Gly Gly Ala Ala Asp Leu Gly
80 85 90Val Glu Glu Pro Arg Asn Ala Ser Leu Gln Ala Gln Val Val Leu Ser
95 100 105Phe Gln Ala Tyr Pro Thr Ala Arg Cys Val Leu Leu Glu Val Gln Val
110 115 120Pro Ala Ala Leu Val Gln Phe Gly Gln Ser Val Gly Ser Val Val Tyr125 130 135 140Asp Cys Phe Glu Ala Ala Leu Gly Ser Glu Val Arg Ile Trp Ser Tyr
145 150 155Thr Gln Pro Arg Tyr Glu Lys Glu Leu Asn His Thr Gln Gln Leu Pro
160 165 170Asp Cys Arg Gly Leu Glu Val Trp Asn Ser Ile Pro Ser Cys Trp Ala
175 180 185Leu Pro Trp Leu Asn Val Ser Ala Asp Gly Asp Asn Val His Leu Val
190 195 200Leu Asn Val Ser Glu Glu Gln His Phe Gly Leu Ser Leu Tyr Trp Asn205 210 215 220Gln Val Gln Gly Pro Pro Lys Pro Arg Trp His Lys Asn Leu Thr Gly
225 230 235Pro Gln Ile Ile Thr Leu Asn His Thr Asp Leu Val Pro Cys Leu Cys
240 245 250Ile Gln Val Trp Pro Leu Glu Pro Asp Ser Val Arg Thr Asn Ile Cys
255 260 265Pro Phe Arg Glu Asp Pro Arg Ala His Gln Asn Leu Trp Gln Ala Ala
270 275 280Arg Leu Arg Leu Leu Thr Leu Gln Ser Trp Leu Leu Asp Ala Pro Cys285 290 295 300Ser Leu Pro Ala Glu Ala Ala Leu Cys Trp Arg Ala Pro Gly Gly Asp
305 310 315Pro Cys Gln Pro Leu Val Pro Pro Leu Ser Trp Glu Asn Val Thr Val
320 325 330Asp Val Asn Ser Ser Glu Lys Leu Gln Leu Gln Glu Cys Leu Trp Ala
335 340 345Asp Ser Leu Gly Pro Leu Lys Asp Asp Val Leu Leu Leu Glu Thr Arg
350 355 360Gly Pro Gln Asp Asn Arg Ser Leu Cys Ala Leu Glu Pro Ser Gly Cys365 370 375 380Thr Ser Leu Pro Ser Lys Ala Ser Thr Arg Ala Ala Arg Leu Gly Glu
385 390 395Tyr Leu Leu Gln Asp Leu Gln Ser Gly Gln Cys Leu Gln Leu Trp Asp
400 405 410Asp Asp Leu Gly Ala Leu Trp Ala Cys Pro Met Asp Lys Tyr Ile His
415 420 425Lys Arg Trp Ala Leu Val Trp Leu Ala Cys Leu Leu Phe Ala Ala Ala
430 435 440Leu Ser Leu Ile Leu Leu Leu Lys Lys Asp His Ala Lys Gly Trp Leu445 450 455 460Arg Leu Leu Lys Gln Asp Val Arg Ser Gly Ala Ala Ala Arg Gly Arg
465 470 475Ala Ala Leu Leu Leu Tyr Ser Ala Asp Asp Ser Gly Phe Glu Arg Leu
480 485 490Val Gly Ala Leu Ala Ser Ala Leu Cys Gln Leu Pro Leu Arg Val Ala
495 500 505Val Asp Leu Trp Ser Arg Arg Glu Leu Ser Ala Gln Gly Pro Val Ala
510 515 520Trp Phe His Ala Gln Arg Arg Gln Thr Leu Gln Glu Gly Gly Val Val525 530 535 540Val Leu Leu Phe Ser Pro Gly Ala Val Ala Leu Cys Ser Glu Trp Leu
545 550 555Gln Asp Gly Val Ser Gly Pro Gly Ala His Gly Pro His Asp Ala Phe
560 565 570Arg Ala Ser Leu Ser Cys Val Leu Pro Asp Phe Leu Gln Gly Arg Ala
575 580 585Pro Gly Ser Tyr Val Gly Ala Cys Phe Asp Arg Leu Leu His Pro Asp
590 595 600Ala Val Pro Ala Leu Phe Arg Thr Val Pro Val Phe Thr Leu Pro Ser605 610 615 620Gln Leu Pro Asp Phe Leu Gly Ala Leu Gln Gln Pro Arg Ala Pro Arg
625 630 635Ser Gly Arg Leu Gln Glu Arg Ala Glu Gln Val Ser Arg Ala Leu Gln
640 645 650Pro Ala Leu Asp Ser Tyr Phe His Pro Pro Gly Xaa Ser Ala Pro Gly
655 660 665Arg Gly Val Gly Pro Gly Ala Gly Pro Gly Ala Gly Asp Gly Thr
670 675 680<210>9<211>2109<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>misc_特征<222>(6),(9),(12),(21),(24),(27),(30),(33),
(36),(39),(42),(45),(57),(60),(63),(69),
(72),(75),(78),(81),(90),(93),(102),(105),
(108),(111),(114),(120),(123),(132),(141),
(147),(150),(153),(162),(165),(168),(171),
(174),(177),(180),(183),(186),(189),(192),
(198),(204),(210),(213),(216),(219),(234),
(246),(252),(255),(258),(261),(264),(270),
(273),(276),(282),(297),(318),(321),(324),
(327),(333),(336),(339),(348),(351),(357),
(360),(363),(369),(375),(378),(381),(384),
(393),(399),(402),(405),(408),(414),(417),
(420),(426),(432),(435),(438),(441),(444),
(447),(456),(462),(465) (468),(471),(474),
(477),(495),(498),(501),(504),(507),(513),
(516),(525),(531),(537),(540),(555),(564),
(573),(576),(585),(588),(591),(597),(606),
(612),(615),(624),(627),(630),(636),(642),
(645),(648),(654),(663),(669),(672),(675),
(681),(684),(702),(705),(708),(711),(726),
(732),(735),(738),(744),(747),(762),(765),
(768),(771),(783),(786),(795),(801),(804),
(807),(813),(825),(831),(834),(840),(846),
(849),(852),(855),(867),(873),(882),(885),
(888),(900),(909),(912),(915),(918),(921),
(924) (927),(930),(933),(939),(945),(948),
(954),(957),(963),(966),(969),(972),(978),
(981),(984),(993),(996),(999),(1002),(1005),
(1011),(1020),(1023),(1026),(1029),(1032),
(1035),(1038),(1050),(1053),(1056),(1062),
(1068),(1071),(1080),(1086),(1098),(1104),
(1110),(1113),(1116),(1119),(1122),(1134),
(1137),(1140),(1143),(1149),(1152),(1155),
(1158),(1170),(1173),(1176),(1182),(1185),
(1191),(1194),(1197),(1203),(1206),(1209),
(1212),(1215),(1221),(1224),(1227),(1230),
(1233),(1236),(1239),(1242),(1245),(1254),
(1257),(1266),(1272),(1275),(1284),(1290),
(1305),(1308),(1311),(1314),(1320),(1326),
(1350),(1356),(1359),(1362),(1368),(1371),
(1377),(1380),(1386),(1389),(1392),(1395),
(1398),(1401),(1407),(1410),(1413),(1428),
(1434),(1440),(1443),(1446),(1449),(1461),
(1464),(1467),(1470),(1473),(1476),(1479),
(1482),(1485),(1488),(1491),(1494),(1497),
(1500),(1503),(1509),(1512),(1521),(1524),
(1533),(1536),(1539),(1542),(1545),(1548),
(1551),(1554),(1557),(1560),(1569),(1572),
(1575),(1578),(1581),(1584),(1587),(1593),
(1599),(1602),(1605),(1611),(1614),(1617),
(1623),(1626),(1629),(1632),(1644),(1650),
(1653),(1659),(1662),(1671),(1674),(1677),
(1680),(1683),(1686),(1689),(1695),(1698),
(1701),(1704),(1707),(1710),(1713),(1719),
(1728),(1737),(1740),(1743),(1746),(1749),
(1752),(1755),(1761),(1764),(1773),(1779),
(1782),(1785),(1788),(1791),(1797),(1800),
(1803),(1812),(1818),(1821),(1824),(1827),
(1830),(1833),(1839),(1842),(1845),(1857),
(1860),(1863),(1869),(1875),(1878),(1881),
(1884),(1887),(1893),(1896),(1899),(1902),
(1905),(1911),(1914),(1917),(1920),(1926),
(1929),(1938),(1941),(1944),(1947),(1956),
(1959),(1962),(1965),(1968),(1971),(1974),
(1977),(1980),(1989),(1992),(2001),(2004),
(2007),(2010),(2013),(2019),(2022),(2025),
(2031),(2043),(2046),(2049),(2052),(2055),
(2058),(2061),(2064),(2067),(2070),(2078),
(2076),(2079),(2082),(2085),(2088),(2091),
(2094),(2097),(2100),(2106),(2109),<223>n=任意核苷酸<400>9atgccngtnc cntggttyyt nytnwsnytn gcnytnggnm gnwsncartg gathytnwsn 60ytngarmgny tngtnggncc ncargaygcn acncaytgyw snccnggnyt nwsntgymgn 120ytntgggayw sngayathyt ntgyytnccn ggngayathg tnccngcncc nggnccngtn 180ytngcnccna cncayytnca racngarytn gtnytnmgnt gycaraarga racngaytgy 240gayytntgyy tnmgngtngc ngtncayytn gcngtncayg gncaytggga rgarccngar 300gaygargara arttyggngg ngcngcngay ytnggngtng argarccnmg naaygcnwsn 360ytncargcnc argtngtnyt nwsnttycar gcntayccna cngcnmgntg ygtnytnytn 420gargtncarg tnccngcngc nytngtncar ttyggncarw sngtnggnws ngtngtntay 480gaytgyttyg argcngcnyt nggnwsngar gtnmgnatht ggwsntayac ncarccnmgn 540taygaraarg arytnaayca yacncarcar ytnccngayt gymgnggnyt ngargtntgg 600aaywsnathc cnwsntgytg ggcnytnccn tggytnaayg tnwsngcnga yggngayaay 660gtncayytng tnytnaaygt nwsngargar carcayttyg gnytnwsnyt ntaytggaay 720cargtncarg gnccnccnaa rccnmgntgg cayaaraayy tnacnggncc ncarathath 780acnytnaayc ayacngayyt ngtnccntgy ytntgyathc argtntggcc nytngarccn 840gaywsngtnm gnacnaayat htgyccntty mgngargayc cnmgngcnca ycaraayytn 900tggcargcng cnmgnytnmg nytnytnacn ytncarwsnt ggytnytnga ygcnccntgy 960wsnytnccng cngargcngc nytntgytgg mgngcnccng gnggngaycc ntgycarccn 1020ytngtnccnc cnytnwsntg ggaraaygtn acngtngayg tnaaywsnws ngaraarytn 1080carytncarg artgyytntg ggcngaywsn ytnggnccny tnaargayga ygtnytnytn 1140ytngaracnm gnggnccnca rgayaaymgn wsnytntgyg cnytngarcc nwsnggntgy 1200acnwsnytnc cnwsnaargc nwsnacnmgn gcngcnmgny tnggngarta yytnytncar 1260gayytncarw snggncartg yytncarytn tgggaygayg ayytnggngc nytntgggcn 1320tgyccnatgg ayaartayat hcayaarmgn tgggcnytng tntggytngc ntgyytnytn 1380ttygcngcng cnytnwsnyt nathytnytn ytnaaraarg aycaygcnaa rggntggytn 1440mgnytnytna arcargaygt nmgnwsnggn gcngcngcnm gnggnmgngc ngcnytnytn 1500ytntaywsng cngaygayws nggnttygar mgnytngtng gngcnytngc nwsngcnytn 1560tgycarytnc cnytnmgngt ngcngtngay ytntggwsnm gnmgngaryt nwsngcncar 1620ggnccngtng cntggttyca ygcncarmgn mgncaracny tncargargg nggngtngtn 1680gtnytnytnt tywsnccngg ngcngtngcn ytntgywsng artggytnca rgayggngtn 1740wsnggnccng gngcncaygg nccncaygay gcnttymgng cnwsnytnws ntgygtnytn 1800ccngayttyy tncarggnmg ngcnccnggn wsntaygtng gngcntgytt ygaymgnytn 1860ytncayccng aygcngtncc ngcnytntty mgnacngtnc cngtnttyac nytnccnwsn 1920carytnccng ayttyytngg ngcnytncar carccnmgng cnccnmgnws nggnmgnytn 1980cargarmgng cngarcargt nwsnmgngcn ytncarccng cnytngayws ntayttycay 2040ccnccnggna cnwsngcncc nggnmgnggn gtnggnccng gngcnggncc nggngcnggn 2100gayggnacn 2109<210>10<211>2314<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>CDS<222>(199)..(2292)<220><221>mat_肽<222>(259)..(2292)<400>10ccaaatcgaa agcacgggag ctgatactgg gcctggagtc caggctcact ggagtgggga 60agcatggctg gagaggaatt ctagcccttg ctctctccca gggacacggg gctgattgtc 120agcaggggcg aggggtctgc ccccccttgg gggggcagga cggggcctca ggcctgggtg 180ctgtccggca cctggaag atg cct gtg tcc tgg ttc ctg ctg tcc ttg gca 231
Met Pro Val Ser Trp Phe Leu Leu Ser Leu Ala
-20 -15 -10ctg ggc cga aac cct gtg gtc gtc tct ctg gag aga ctg atg gag cct 279Leu Gly Arg Asn Pro Val Val Val Ser Leu Glu Arg Leu Met Glu Pro
-5 -1 1 5cag gac act gca cgc tgc tct cta ggc ctc tcc tgc cac ctc tgg gat 327Gln Asp Thr Ala Arg Cys Ser Leu Gly Leu Ser Cys His Leu Trp Asp
10 15 20ggt gac gtg ctc tgc ctg cct gga agc ctc cag tct gcc cca ggc cct 375Gly Asp Val Leu Cys Leu Pro Gly Ser Leu Gln Ser Ala Pro Gly Pro
25 30 35gtg cta gtg cct acc cgc ctg cag acg gag ctg gtg ctg agg tgt cca 423Val Leu Val Pro Thr Arg Leu Gln Thr Glu Leu Val Leu Arg Cys Pro40 45 50 55cag aag aca gat tgc gcc ctc tgt gtc cgt gtg gtg gtc cac ttg gcc 471Gln Lys Thr Asp Cys Ala Leu Cys Val Arg Val Val Val His Leu Ala
60 65 70gtg cat ggg cac tgg gca gag cct gaa gaa gct gga aag tct gat tca 519Val His Gly His Trp Ala Glu Pro Glu Glu Ala Gly Lys Ser Asp Ser
75 80 85gaa ctc cag gag tct agg aac gcc tct ctc cag gcc cag gtg gtg ctc 567Glu Leu Gln Glu Ser Arg Asn Ala Ser Leu Gln Ala Gln Val Val Leu
90 95 100tcc ttc cag gcc tac ccc atc gcc cgc tgt gcc ctg ctg gag gtc cag 615Ser Phe Gln Ala Tyr Pro Ile Ala Arg Cys Ala Leu Leu Glu Val Gln
105 110 115gtg ccc gct gac ctg gtg cag cct ggt cag tcc gtg ggt tct gcg gta 663Val Pro Ala Asp Leu Val Gln Pro Gly Gln Ser Val Gly Ser Ala Val120 125 130 135ttt gac tgt ttc gag gct agt ctt ggg gct gag gta cag atc tgg tcc 711Phe Asp Cys Phe Glu Ala Ser Leu Gly Ala Glu Val Gln Ile Trp Ser
140 145 150tac acg aag ccc agg tac cag aaa gag ctc aac ctc aca cag cag ctg 759Tyr Thr Lys Pro Arg Tyr Gln Lys Glu Leu Asn Leu Thr Gln Gln Leu
155 160 165cct gac tgc agg ggt ctt gaa gtc cgg gac agc atc cag agc tgc tgg 807Pro Asp Cys Arg Gly Leu Glu Val Arg Asp Ser Ile Gln Ser Cys Trp
170 175 180gtc ctg ccc tgg ctc aat gtg tct aca gat ggt gac aat gtc ctt ctg 855Val Leu Pro Trp Leu Asn Val Ser Thr Asp Gly Asp Asn Val Leu Leu
185 190 195aca ctg gat gtc tct gag gag cag gac ttt agc ttc tta ctg tac ctg 903Thr Leu Asp Val Ser Glu Glu Gln Asp Phe Ser Phe Leu Leu Tyr Leu200 205 210 215cgt cca gtc ccg gat gct ctc aaa tcc ttg tgg tac aaa aac ctg act 951Arg Pro Val Pro Asp Ala Leu Lys Ser Leu Trp Tyr Lys Asn Leu Thr
220 225 230gga cct cag aac att act tta aac cac aca gac ctg gtt ccc tgc ctc 999Gly Pro Gln Asn Ile Thr Leu Asn His Thr Asp Leu Val Pro Cys Leu
235 240 245tgc att cag gtg tgg tcg cta gag cca gac tct gag agg gtc gaa ttc 1047Cys Ile Gln Val Trp Ser Leu Glu Pro Asp Ser Glu Arg Val Glu Phe
250 255 260tgc ccc ttc cgg gaa gat ccc ggt gca cac agg aac ctc tgg cac ata 1095Cys Pro Phe Arg Glu Asp Pro Gly Ala His Arg Asn Leu Trp His Ile
265 270 275gcc agg ctg cgg gta ctg tcc cca ggg gta tgg cag cta gat gcg cct 1143Ala Arg Leu Arg Val Leu Ser Pro Gly Val Trp Gln Leu Asp Ala Pro280 285 290 295tgc tgt ctg ccg ggc aag gta aca ctg tgc tgg cag gca cca gac cag 1191Cys Cys Leu Pro Gly Lys Val Thr Leu Cys Trp Gln Ala Pro Asp Gln
300 305 310agt ccc tgc cag cca ctt gtg cca cca gtg ccc cag aag aac gcc act 1239Ser Pro Cys Gln Pro Leu Val Pro Pro Val Pro Gln Lys Asn Ala Thr
315 320 325gtg aat gag cca caa gat ttc cag ttg gtg gca ggc cac ccc aac ctc 1287Val Asn Glu Pro Gln Asp Phe Gln Leu Val Ala Gly His Pro Asn Leu
330 335 340tgt gtc cag gtg agc acc tgg gag aag gtt cag ctg caa gcg tgc ttg 1335Cys Val Gln Val Ser Thr Trp Glu Lys Val Gln Leu Gln Ala Cys Leu
345 350 355tgg gct gac tcc ttg ggg ccc ttc aag gat gat atg ctg tta gtg gag 1383Trp Ala Asp Ser Leu Gly Pro Phe Lys Asp Asp Met Leu Leu Val Glu360 365 370 375atg aaa acc ggc ctc aac aac aca tca gtc tgt gcc ttg gaa ccc agt 1431Met Lys Thr Gly Leu Asn Asn Thr Ser Val Cys Ala Leu Glu Pro Ser
380 385 390ggc tgt aca cca ctg ccc agc atg gcc tcc acg aga gct gct cgc ctg 1479Gly Cys Thr Pro Leu Pro Ser Met Ala Ser Thr Arg Ala Ala Arg Leu
395 400 405gga gag gag ttg ctg caa gac ttc cga tca cac cag tgt atg cag ctg 1527Gly Glu Glu Leu Leu Gln Asp Phe Arg Ser His Gln Cys Met Gln Leu
410 415 420tgg aac gat gac aac atg gga tcg cta tgg gcc tgc ccc atg gac aag 1575Trp Asn Asp Asp Asn Met Gly Ser Leu Trp Ala Cys Pro Met Asp Lys
425 430 435tac atc cac agg cgc tgg gtc cta gta tgg ctg gcc tgc cta ctc ttg 1623Tyr Ile His Arg Arg Trp Val Leu Val Trp Leu Ala Cys Leu Leu Leu440 445 450 455gct gcg gcg ctt ttc ttc ttc ctc ctt cta aaa aag gac cgc agg aaa 1671Ala Ala Ala Leu Phe Phe Phe Leu Leu Leu Lys Lys Asp Arg Arg Lys
460 465 470gcg gcc cgt ggc tcc cgc acg gcc ttg ctc ctc cac tcc gcc gac gga 1719Ala Ala Arg Gly Ser Arg Thr Ala Leu Leu Leu His Ser Ala Asp Gly
475 480 485gcg ggc tac gag cgc ctg gtg gga gca ctg gcg tcc gcg ttg agc cag 1767Ala Gly Tyr Glu Arg Leu Val Gly Ala Leu Ala Ser Ala Leu Ser Gln
490 495 500atg cca ctg cgc gtg gcc gtg gac ctg tgg agc cgc cgc gag ctg agc 1815Met Pro Leu Arg Val Ala Val Asp Leu Trp Ser Arg Arg Glu Leu Ser
505 510 515gcg cac gga gcc cta gcc tgg ttc cac cac cag cga cgc cgt atc ctg 1863Ala His Gly Ala Leu Ala Trp Phe His His Gln Arg Arg Arg Ile Leu520 525 530 535cag gag ggt ggc gtg gta atc ctt ctc ttc tcg ccc gcg gcc gtg gcg 1911Gln Glu Gly Gly Val Val Ile Leu Leu Phe Ser Pro Ala Ala Val Ala
540 545 550cag tgt cag cag tgg ctg cag ctc cag aca gtg gag ccc ggg ccg cat 1959Gln Cys Gln Gln Trp Leu Gln Leu Gln Thr Val Glu Pro Gly Pro His
555 560 565gac gcc ctc gcc gcc tgg ctc agc tgc gtg cta ccc gat ttc ctg caa 2007Asp Ala Leu Ala Ala Trp Leu Ser Cys Val Leu Pro Asp Phe Leu Gln
570 575 580ggc cgg gcg acc ggc cgc tac gtc ggg gtc tac ttc gac ggg ctg ctg 2055Gly Arg Ala Thr Gly Arg Tyr Val Gly Val Tyr Phe Asp Gly Leu Leu
585 590 595cac cca gac tct gtg ccc tcc ccg ttc cgc gtc gcc ccg ctc ttc tcc 2103His Pro Asp Ser Val Pro Ser Pro Phe Arg Val Ala Pro Leu Phe Ser600 605 610 615ctg ccc tcg cag ctg ccg gct ttc ctg gat gca ctg cag gga ggc tgc 2151Leu Pro Ser Gln Leu Pro Ala Phe Leu Asp Ala Leu Gln Gly Gly Cys
620 625 630tcc act tcc gcg ggg cga ccc gcg gac cgg gtg gaa cga gtg acc cag 2199Ser Thr Ser Ala Gly Arg Pro Ala Asp Arg Val Glu Arg Val Thr Gln
635 640 645gcg ctg cgg tcc gcc ctg gac agc tgt act tct agc tcg gaa gcc cca 2247Ala Leu Arg Ser Ala Leu Asp Ser Cys Thr Ser Ser Ser Glu Ala Pro
650 655 660ggc tgc tgc gag gaa tgg gac ctg gga ccc tgc act aca cta gaa 2292Gly Cys Cys Glu Glu Trp Asp Leu Gly Pro Cys Thr Thr Leu Glu
665 670 675taaaagccga tacagtattc ct 2314<210>11<211>698<212>PRT<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<400>11Met Pro Val Ser Trp Phe Leu Leu Ser Leu Ala Leu Gly Arg Asn Pro-20 -15 -10 -5Val Val Val Ser Leu Glu Arg Leu Met Glu Pro Gln Asp Thr Ala Arg
-1 1 5 10Cys Ser Leu Gly Leu Ser Cys His Leu Trp Asp Gly Asp Val Leu Cys
15 20 25Leu Pro Gly Ser Leu Gln Ser Ala Pro Gly Pro Val Leu Val Pro Thr
30 35 40Arg Leu Gln Thr Glu Leu Val Leu Arg Cys Pro Gln Lys Thr Asp Cys45 50 55 60Ala Leu Cys Val Arg Val Val Val His Leu Ala Val His Gly His Trp
65 70 75Ala Glu Pro Glu Glu Ala Gly Lys Ser Asp Ser Glu Leu Gln Glu Ser
80 85 90Arg Asn Ala Ser Leu Gln Ala Gln Val Val Leu Ser Phe Gln Ala Tyr
95 100 105Pro Ile Ala Arg Cys Ala Leu Leu Glu Val Gln Val Pro Ala Asp Leu
110 115 120Val Gln Pro Gly Gln Ser Val Gly Ser Ala Val Phe Asp Cys Phe Glu125 130 135 140Ala Ser Leu Gly Ala Glu Val Gln Ile Trp Ser Tyr Thr Lys Pro Arg
145 150 155Tyr Gln Lys Glu Leu Asn Leu Thr Gln Gln Leu Pro Asp Cys Arg Gly
160 165 170Leu Glu Val Arg Asp Ser Ile Gln Ser Cys Trp Val Leu Pro Trp Leu
175 180 185Asn Val Ser Thr Asp Gly Asp Asn Val Leu Leu Thr Leu Asp Val Ser
190 195 200Glu Glu Gln Asp Phe Ser Phe Leu Leu Tyr Leu Arg Pro Val Pro Asp205 210 215 220Ala Leu Lys Ser Leu Trp Tyr Lys Asn Leu Thr Gly Pro Gln Asn Ile
225 230 235Thr Leu Asn His Thr Asp Leu Val Pro Cys Leu Cys Ile Gln Val Trp
240 245 250Ser Leu Glu Pro Asp Ser Glu Arg Val Glu Phe Cys Pro Phe Arg Glu
255 260 265Asp Pro Gly Ala His Arg Asn Leu Trp His Ile Ala Arg Leu Arg Val
270 275 280Leu Ser Pro Gly Val Trp Gln Leu Asp Ala Pro Cys Cys Leu Pro Gly285 290 295 300Lys Val Thr Leu Cys Trp Gln Ala Pro Asp Gln Ser Pro Cys Gln Pro
305 310 315Leu Val Pro Pro Val Pro Gln Lys Asn Ala Thr Val Asn Glu Pro Gln
320 325 330Asp Phe Gln Leu Val Ala Gly His Pro Asn Leu Cys Val Gln Val Ser
335 340 345Thr Trp Glu Lys Val Gln Leu Gln Ala Cys Leu Trp Ala Asp Ser Leu
350 355 360Gly Pro Phe Lys Asp Asp Met Leu Leu Val Glu Met Lys Thr Gly Leu365 370 375 380Asn Asn Thr Ser Val Cys Ala Leu Glu Pro Ser Gly Cys Thr Pro Leu
385 390 395Pro Ser Met Ala Ser Thr Arg Ala Ala Arg Leu Gly Glu Glu Leu Leu
400 405 410Gln Asp Phe Arg Ser His Gln Cys Met Gln Leu Trp Asn Asp Asp Asn
415 420 425Met Gly Ser Leu Trp Ala Cys Pro Met Asp Lys Tyr Ile His Arg Arg
430 435 440Trp Val Leu Val Trp Leu Ala Cys Leu Leu Leu Ala Ala Ala Leu Phe445 450 455 460Phe Phe Leu Leu Leu Lys Lys Asp Arg Arg Lys Ala Ala Arg Gly Ser
465 470 475Arg Thr Ala Leu Leu Leu His Ser Ala Asp Gly Ala Gly Tyr Glu Arg
480 485 490Leu Val Gly Ala Leu Ala Ser Ala Leu Ser Gln Met Pro Leu Arg Val
495 500 505Ala Val Asp Leu Trp Ser Arg Arg Glu Leu Ser Ala His Gly Ala Leu
510 515 520Ala Trp Phe His His Gln Arg Arg Arg Ile Leu Gln Glu Gly Gly Val525 530 535 540Val Ile Leu Leu Phe Ser Pro Ala Ala Val Ala Gln Cys Gln Gln Trp
545 550 555Leu Gln Leu Gln Thr Val Glu Pro Gly Pro His Asp Ala Leu Ala Ala
560 565 570Trp Leu Ser Cys Val Leu Pro Asp Phe Leu Gln Gly Arg Ala Thr Gly
575 580 585Arg Tyr Val Gly Val Tyr Phe Asp Gly Leu Leu His Pro Asp Ser Val
590 595 600Pro Ser Pro Phe Arg Val Ala Pro Leu Phe Ser Leu Pro Ser Gln Leu605 610 615 620Pro Ala Phe Leu Asp Ala Leu Gln Gly Gly Cys Ser Thr Ser Ala Gly
625 630 635Arg Pro Ala Asp Arg Val Glu Arg Val Thr Gln Ala Leu Arg Ser Ala
640 645 650Leu Asp Ser Cys Thr Ser Ser Ser Glu Ala Pro Gly Cys Cys Glu Glu
655 660 665Trp Asp Leu Gly Pro Cys Thr Thr Leu Glu
670 675<210>12<211>2094<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>misc_特征<222>(6),(9),(12),(21),(24),(27),(30),(33),
(36),(39),(42),(48),(51),(54),(57),(60),
(63),(69),(72),(81),(90),(93),(96),(102),
(105),(108),(111),(114),(123),(132),(138),
(141),(147),(150),(153),(156),(159),(165),
(168),(171),(174),(177),(180),(183),(186),
(189),(192),(195),(198),(204),(210),(213),
(216),(219),(225),(234),(243),(246),(252),
(255),(258),(261),(264),(270),(273),(276),
(282),(291),(297),(306),(309),(315),(321),
(327),(336),(339),(345),(348),(351),(357),
(363),(366),(369),(372),(381),(387),(393),
(396),(402),(405),(408),(414),(420),(423),
(426),(432),(435),(441),(444),(450),(453),
(456),(459),(462),(465),(483),(486),(489),
(492),(495),(501),(513),(519),(525),(528),
(543),(549),(552),(561),(564),(573),(576),
(579),(585),(588),(594),(603),(612),(615),
(618),(624),(630),(633),(636),(642),(651),
(654),(657),(660),(663),(669),(672),(690),
(696),(699),(705),(708),(711),(714),(717),
(723),(726),(732),(735),(750),(753),(756),
(759),(771),(774),(783),(789),(792),(795),
(801),(813),(819),(822),(828),(834),(840),
(843),(855),(861),(870),(873),(876),(882),
(888),(900),(903),(906),(909),(912),(915),
(918),(921),(924),(927),(936),(942),(945),
(954),(957),(960),(966),(969),(972),(984),
(987),(996),(999),(1008),(1011),(1014),
(1017),(1020),(1023),(1026),(1038),(1041),
(1044),(1053),(1068),(1071),(1074),(1077),
(1083),(1089),(1095),(1101),(1104),(1107),
(1119),(1125),(1131),(1137),(1143),(1149),
(1152),(1155),(1158),(1176),(1179),(1182),
(1194),(1197),(1200),(1209),(1212),(1215),
(1221),(1224),(1230),(1233),(1236),(1242),
(1245),(1248),(1251),(1254),(1260),(1263),
(1266),(1269),(1272),(1275),(1278),(1281),
(1284),(1293),(1296),(1308),(1311),(1329),
(1350),(1353),(1356),(1362),(1368),(1389),
(1392),(1398),(1401),(1404),(1410),(1413),
(1419),(1422),(1425),(1428),(1431),(1434),
(1437),(1449),(1452),(1455),(1467),(1470),
(1476),(1479),(1482),(1485),(1488),(1491),
(1494),(1497),(1500),(1503),(1506),(1512),
(1515),(1521),(1524),(1527),(1536),(1539),
(1542),(1545),(1548),(1551),(1554),(1557),
(1560),(1563),(1566),(1575),(1578),(1581),
(1584),(1587),(1590),(1596),(1602),(1605),
(1608),(1614),(1617),(1620),(1626),(1629),
(1632),(1635),(1653),(1656),(1659),(1665),
(1674),(1677),(1680),(1683),(1689),(1692),
(1698),(1701),(1704),(1707),(1710),(1713),
(1731),(1737),(1743),(1746),(1752),(1755),
(1758),(1767),(1770),(1773),(1776),(1782),
(1785),(1791),(1794),(1797),(1806),(1812),
(1815),(1818),(1821),(1824),(1827),(1833),
(1836),(1839),(1851),(1854),(1857),(1863),
(1869),(1872),(1875),(1878),(1881),(1887),
(1890),(1893),(1896),(1899),(1905),(1908),
(1911),(1914),(1920),(1923),(1926),(1932),
(1938),(1941),(1947),(1950),(1956),(1959),
(1962),(1965),(1968),(1971),(1974),(1977),
(1983),(1986),(1992),(1995),(1998),(2004),
(2007),(2010),(2013),(2016),(2019),(2025),
(2031),(2034),(2037),(2040),(2046),(2049),
(2052),(2073),(2076),(2079),(2085),(2088),
(2091)<223>n=任意核苷酸<400>12atgccngtnw sntggttyyt nytnwsnytn gcnytnggnm gnaayccngt ngtngtnwsn 60ytngarmgny tnatggarcc ncargayacn gcnmgntgyw snytnggnyt nwsntgycay 120ytntgggayg gngaygtnyt ntgyytnccn ggnwsnytnc arwsngcncc nggnccngtn 180ytngtnccna cnmgnytnca racngarytn gtnytnmgnt gyccncaraa racngaytgy 240gcnytntgyg tnmgngtngt ngtncayytn gcngtncayg gncaytgggc ngarccngar 300gargcnggna arwsngayws ngarytncar garwsnmgna aygcnwsnyt ncargcncar 360gtngtnytnw snttycargc ntayccnath gcnmgntgyg cnytnytnga rgtncargtn 420ccngcngayy tngtncarcc nggncarwsn gtnggnwsng cngtnttyga ytgyttygar 480gcnwsnytng gngcngargt ncarathtgg wsntayacna arccnmgnta ycaraargar 540ytnaayytna cncarcaryt nccngaytgy mgnggnytng argtnmgnga ywsnathcar 600wsntgytggg tnytnccntg gytnaaygtn wsnacngayg gngayaaygt nytnytnacn 660ytngaygtnw sngargarca rgayttywsn ttyytnytnt ayytnmgncc ngtnccngay 720gcnytnaarw snytntggta yaaraayytn acnggnccnc araayathac nytnaaycay 780acngayytng tnccntgyyt ntgyathcar gtntggwsny tngarccnga ywsngarmgn 840gtngarttyt gyccnttymg ngargayccn ggngcncaym gnaayytntg gcayathgcn 900mgnytnmgng tnytnwsncc nggngtntgg carytngayg cnccntgytg yytnccnggn 960aargtnacny tntgytggca rgcnccngay carwsnccnt gycarccnyt ngtnccnccn 1020gtnccncara araaygcnac ngtnaaygar ccncargayt tycarytngt ngcnggncay 1080ccnaayytnt gygtncargt nwsnacntgg garaargtnc arytncargc ntgyytntgg 1140gcngaywsny tnggnccntt yaargaygay atgytnytng tngaratgaa racnggnytn 1200aayaayacnw sngtntgygc nytngarccn wsnggntgya cnccnytncc nwsnatggcn 1260wsnacnmgng cngcnmgnyt nggngargar ytnytncarg ayttymgnws ncaycartgy 1320atgcarytnt ggaaygayga yaayatgggn wsnytntggg cntgyccnat ggayaartay 1380athcaymgnm gntgggtnyt ngtntggytn gcntgyytny tnytngcngc ngcnytntty 1440ttyttyytny tnytnaaraa rgaymgnmgn aargcngcnm gnggnwsnmg nacngcnytn 1500ytnytncayw sngcngaygg ngcnggntay garmgnytng tnggngcnyt ngcnwsngcn 1560ytnwsncara tgccnytnmg ngtngcngtn gayytntggw snmgnmgnga rytnwsngcn 1620cayggngcny tngcntggtt ycaycaycar mgnmgnmgna thytncarga rggnggngtn 1680gtnathytny tnttywsncc ngcngcngtn gcncartgyc arcartggyt ncarytncar 1740acngtngarc cnggnccnca ygaygcnytn gcngcntggy tnwsntgygt nytnccngay 1800ttyytncarg gnmgngcnac nggnmgntay gtnggngtnt ayttygaygg nytnytncay 1860ccngaywsng tnccnwsncc nttymgngtn gcnccnytnt tywsnytncc nwsncarytn 1920ccngcnttyy tngaygcnyt ncarggnggn tgywsnacnw sngcnggnmg nccngcngay 1980mgngtngarm gngtnacnca rgcnytnmgn wsngcnytng aywsntgyac nwsnwsnwsn 2040gargcnccng gntgytgyga rgartgggay ytnggnccnt gyacnacnyt ngar 2094<210>13<211>2786<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>CDS<222>(70)..(2283)<220><221>mat_肽<222>(118)..(2283)<220><221>misc_特征<222>(8),(144),(170),(194),(442),(475),(519)<223>n=任意核苷酸<220><221>misc_特征<222>(9),(18),(26),(109),(120),(134)<223>Xaa=任意氨基酸<400>13cccacgcntc cgggccagca gcgggcggcc ggggcgcaga gaacggcctg gctgggcgag 60cgcacggcc atg gcc ccg tgg ctg cag ctc tgc tcc gtc ttc ttt acg gtc 111
Met Ala Pro Trp Leu Gln Leu Cys Ser Val Phe Phe Thr Val
-15 -10 -5aac gcc tgc ctc aac ggc tcg cag ctg gct gtn gcc gct ggc ggg tcc 159Asn Ala Cys Leu Asn Gly Ser Gln Leu Ala Xaa Ala Ala Gly Gly Ser
-1 1 5 10ggc cgc gcg cng ggc gcc gac acc tgt agc tgg ang gga gtg ggg cca 207Gly Arg Ala Xaa Gly Ala Asp Thr Cys Ser Trp Xaa Gly Val Gly Pro15 20 25 30gcc agc aga aac agt ggg ctg tac aac atc acc ttc aaa tat gac aat 255Ala Ser Arg Asn Ser Gly Leu Tyr Asn Ile Thr Phe Lys Tyr Asp Asn
35 40 45tgt acc acc tac ttg aat cca gtg ggg aag cat gtg att gct gac gcc 303Cys Thr Thr Tyr Leu Asn Pro Val Gly Lys His Val Ile Ala Asp Ala
50 55 60cag aat atc acc atc agc cag tat gct tgc cat gac caa gtg gca gtc 351Gln Asn Ile Thr Ile Ser Gln Tyr Ala Cys His Asp Gln Val Ala Val
65 70 75acc att ctt tgg tcc cca ggg gcc ctc ggc atc gaa ttc ctg aaa gga 399Thr Ile Leu Trp Ser Pro Gly Ala Leu Gly Ile Glu Phe Leu Lys Gly
80 85 90ttt cgg gta ata ctg gag gag ctg aag tcg gag gga aga cag ngc caa 447Phe Arg Val Ile Leu Glu Glu Leu Lys Ser Glu Gly Arg Gln Xaa Gln95 100 105 110caa ctg att cta aag gat ccg aag cag ntc aac agt agc ttc aaa aga 495Gln Leu Ile Leu Lys Asp Pro Lys Gln Xaa Asn Ser Ser Phe Lys Arg
115 120 125act gga atg gaa tct caa cct ttn ctg aat atg aaa ttt gaa acg gat 543Thr Gly Met Glu Ser Gln Pro Xaa Leu Asn Met Lys Phe Glu Thr Asp
130 135 140tat ttc gta agg ttg tcc ttt tcc ttc att aaa aac gaa agc aat tac 591Tyr Phe Val Arg Leu Ser Phe Ser Phe Ile Lys Asn Glu Ser Asn Tyr
145 150 155cac cct ttc ttc ttt aga acc cga gcc tgt gac ctg ttg tta cag ccg 639His Pro Phe Phe Phe Arg Thr Arg Ala Cys Asp Leu Leu Leu Gln Pro
160 165 170gac aat cta gct tgt aaa ccc ttc tgg aag cct cgg aac ctg aac atc 687Asp Asn Leu Ala Cys Lys Pro Phe Trp Lys Pro Arg Asn Leu Asn Ile175 180 185 190agc cag cat ggc tcg gac atg cag gtg tcc ttc gac cac gca ccg cac 735Ser Gln His Gly Ser Asp Met Gln Val Ser Phe Asp His Ala Pro His
195 200 205aac ttc ggc ttc cgt ttc ttc tat ctt cac tac aag ctc aag cac gaa 783Asn Phe Gly Phe Arg Phe Phe Tyr Leu His Tyr Lys Leu Lys His Glu
210 215 220gga cct ttc aag cga aag acc tgt aag cag gag caa act aca gag atg 831Gly Pro Phe Lys Arg Lys Thr Cys Lys Gln Glu Gln Thr Thr Glu Met
225 230 235acc agc tgc ctc ctt caa aat gtt tct cca ggg gat tat ata att gag 879Thr Ser Cys Leu Leu Gln Asn Val Ser Pro Gly Asp Tyr Ile Ile Glu
240 245 250ctg gtg gat gac act aac aca aca aga aaa gtg atg cat tat gcc tta 927Leu Val Asp Asp Thr Asn Thr Thr Arg Lys Val Met His Tyr Ala Leu255 260 265 270aag cca gtg cac tcc ccg tgg gcc ggg ccc atc aga gcc gtg gcc atc 975Lys Pro Val His Ser Pro Trp Ala Gly Pro Ile Arg Ala Val Ala Ile
275 280 285aca gtg cca ctg gta gtc ata tcg gca ttc gcg acg ctc ttc act gtg 1023Thr Val Pro Leu Val Val Ile Ser Ala Phe Ala Thr Leu Phe Thr Val
290 295 300atg tgc cgc aag aag caa caa gaa aat ata tat tca cat tta gat gaa 1071Met Cys Arg Lys Lys Gln Gln Glu Asn Ile Tyr Ser His Leu Asp Glu
305 310 315gag agc tct gag tct tcc aca tac act gca gca ctc cca aga gag agg 1119Glu Ser Ser Glu Ser Ser Thr Tyr Thr Ala Ala Leu Pro Arg Glu Arg
320 325 330ctc cgg ccg cgg ccg aag gtc ttt ctc tgc tat tcc agt aaa gat ggc 1167Leu Arg Pro Arg Pro Lys Val Phe Leu Cys Tyr Ser Ser Lys Asp Gly335 340 345 350cag aat cac atg aat gtc gtc cag tgt ttc gcc tac ttc ctc cag gac 1215Gln Asn His Met Asn Val Val Gln Cys Phe Ala Tyr Phe Leu Gln Asp
355 360 365ttc tgt ggc tgt gag gtg gct ctg gac ctg tgg gaa gac ttc agc ctc 1263Phe Cys Gly Cys Glu Val Ala Leu Asp Leu Trp Glu Asp Phe Ser Leu
370 375 380tgt aga gaa ggg cag aga gaa tgg gtc atc cag aag atc cac gag tcc 1311Cys Arg Glu Gly Gln Arg Glu Trp Val Ile Gln Lys Ile His Glu Ser
385 390 395cag ttc atc att gtg gtt tgt tcc aaa ggt atg aag tac ttt gtg gac 1359Gln Phe Ile Ile Val Val Cys Ser Lys Gly Met Lys Tyr Phe Val Asp
400 405 410aag aag aac tac aaa cac aaa gga ggt ggc cga ggc tcg ggg aaa gga 1407Lys Lys Asn Tyr Lys His Lys Gly Gly Gly Arg Gly Ser Gly Lys Gly415 420 425 430gag ctc ttc ctg gtg gcg gtg tca gcc att gcc gaa aag ctc cgc cag 1455Glu Leu Phe Leu Val Ala Val Ser Ala Ile Ala Glu Lys Leu Arg Gln
435 440 445gcc aag cag agt tcg tcc gcg gcg ctc agc aag ttt atc gcc gtc tac 1503Ala Lys Gln Ser Ser Ser Ala Ala Leu Ser Lys Phe Ile Ala Val Tyr
450 455 460ttt gat tat tcc tgc gag gga gac gtc ccc ggt atc cta gac ctg agt 1551Phe Asp Tyr Ser Cys Glu Gly Asp Val Pro Gly Ile Leu Asp Leu Ser
465 470 475acc aag tac aga ctc atg gac aat ctt cct cag ctc tgt tcc cac ctg 1599Thr Lys Tyr Arg Leu Met Asp Asn Leu Pro Gln Leu Cys Ser His Leu
480 485 490cac tcc cga gac cac ggc ctc cag gag ccg ggg cag cac acg cga cag 1647His Ser Arg Asp His Gly Leu Gln Glu Pro Gly Gln His Thr Arg Gln495 500 505 510ggc agc aga agg aac tac ttc cgg agc aag tca ggc cgg tcc cta tac 1695Gly Ser Arg Arg Asn Tyr Phe Arg Ser Lys Ser Gly Arg Ser Leu Tyr
515 520 525gtc gcc att tgc aac atg cac cag ttt att gac gag gag ccc gac tgg 1743Val Ala Ile Cys Asn Met His Gln Phe Ile Asp Glu Glu Pro Asp Trp
530 535 540ttc gaa aag cag ttc gtt ccc ttc cat cct cct cca ctg cgc tac cgg 1791Phe Glu Lys Gln Phe Val Pro Phe His Pro Pro Pro Leu Arg Tyr Arg
545 550 555gag cca gtc ttg gag aaa ttt gat tcg ggc ttg gtt tta aat gat gtc 1839Glu Pro Val Leu Glu Lys Phe Asp Ser Gly Leu Val Leu Asn Asp Val
560 565 570atg tgc aaa cca ggg cct gag agt gac ttc tgc cta aag gta gag gcg 1887Met Cys Lys Pro Gly Pro Glu Ser Asp Phe Cys Leu Lys Val Glu Ala575 580 585 590gct gtt ctt ggg gca acc gga cca gcc gac tcc cag cac gag agt cag 1935Ala Val Leu Gly Ala Thr Gly Pro Ala Asp Ser Gln His Glu Ser Gln
595 600 605cat ggg ggc ctg gac caa gac ggg gag gcc cgg cct gcc ctt gac ggt 1983His Gly Gly Leu Asp Gln Asp Gly Glu Ala Arg Pro Ala Leu Asp Gly
610 615 620agc gcc gcc ctg caa ccc ctg ctg cac acg gtg aaa gcc ggc agc ccc 2031Ser Ala Ala Leu Gln Pro Leu Leu His Thr Val Lys Ala Gly Ser Pro
625 630 635tcg gac atg ccg cgg gac tca ggc atc tat gac tcg tct gtg ccc tca 2079Ser Asp Met Pro Arg Asp Ser Gly Ile Tyr Asp Ser Ser Val Pro Ser
640 645 650tcc gag ctg tct ctg cca ctg atg gaa gga ctc tcg acg gac cag aca 2127Ser Glu Leu Ser Leu Pro Leu Met Glu Gly Leu Ser Thr Asp Gln Thr655 660 665 670gaa acg tct tcc ctg acg gag agc gtg tcc tcc tct tca ggc ctg ggt 2175Glu Thr Ser Ser Leu Thr Glu Ser Val Ser Ser Ser Ser Gly Leu Gly
675 680 685gag gag gaa cct cct gcc ctt cct tcc aag ctc ctc tct tct ggg tca 2223Glu Glu Glu Pro Pro Ala Leu Pro Ser Lys Leu Leu Ser Ser Gly Ser
690 695 700tgc aaa gca gat ctt ggt tgc cgc agc tac act gat gaa ctc cac gcg 2271Cys Lys Ala Asp Leu Gly Cys Arg Ser Tyr Thr Asp Glu Leu His Ala
705 710 715gtc gcc cct ttg taacaaaacg aaagagtcta agcattgcca ctttagctgc 2323Val Ala Pro Leu
720tgcctccctc tgattcccca gctcatctcc ctggttgcat ggcccacttg gagctgaggt 2383ctcatacaag gatatttgga gtgaaatgct ggccagtact tgttctccct tgccccaacc 2443ctttaccgga tatcttgaca aactctccaa ttttctaaaa tgatatggag ctctgaaagg 2503catgtccata aggtctgaca acagcttgcc aaatttggtt agtccttgga tcagagcctg 2563ttgtgggagg tagggaggaa atatgtaaag aaaaacagga agatacctgc actaatcatt 2623cagacttcat tgagctctgc aaactttgcc tgtttgctat tggctacctt gatttgaaat 2683gctttgtgaa aaaaggcact tttaacatca tagccacaga aatcaagtgc cagtctatct 2743ggaatccatg ttgtattgca gataatgttc tcatttattt ttg 2786<210>14<211>738<212>PRT<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>misc_特征<222>(9),(18),(26),(109),(120),(134)<223>Xaa=任意氨基酸<400>14Met Ala Pro Trp Leu Gln Leu Cys Ser Val Phe Phe Thr Val Asn Ala
-15 -10 -5 -1Cys Leu Asn Gly Ser Gln Leu Ala Xaa Ala Ala Gly Gly Ser Gly Arg1 5 10 15Ala Xaa Gly Ala Asp Thr Cys Ser Trp Xaa Gly Val Gly Pro Ala Ser
20 25 30Arg Asn Ser Gly Leu Tyr Asn Ile Thr Phe Lys Tyr Asp Asn Cys Thr
35 40 45Thr Tyr Leu Asn Pro Val Gly Lys His Val Ile Ala Asp Ala Gln Asn
50 55 60Ile Thr Ile Ser Gln Tyr Ala Cys His Asp Gln Val Ala Val Thr Ile65 70 75 80Leu Trp Ser Pro Gly Ala Leu Gly Ile Glu Phe Leu Lys Gly Phe Arg
85 90 95Val Ile Leu Glu Glu Leu Lys Ser Glu Gly Arg Gln Xaa Gln Gln Leu
100 105 110Ile Leu Lys Asp Pro Lys Gln Xaa Asn Ser Ser Phe Lys Arg Thr Gly
115 120 125Met Glu Ser Gln Pro Xaa Leu Asn Met Lys Phe Glu Thr Asp Tyr Phe
130 135 140Val Arg Leu Ser Phe Ser Phe Ile Lys Asn Glu Ser Asn Tyr His Pro145 150 155 160Phe Phe Phe Arg Thr Arg Ala Cys Asp Leu Leu Leu Gln Pro Asp Asn
165 170 175Leu Ala Cys Lys Pro Phe Trp Lys Pro Arg Asn Leu Asn Ile Ser Gln
180 185 190His Gly Ser Asp Met Gln Val Ser Phe Asp His Ala Pro His Asn Phe
195 200 205Gly Phe Arg Phe Phe Tyr Leu His Tyr Lys Leu Lys His Glu Gly Pro
210 215 220Phe Lys Arg Lys Thr Cys Lys Gln Glu Gln Thr Thr Glu Met Thr Ser225 230 235 240Cys Leu Leu Gln Asn Val Ser Pro Gly Asp Tyr Ile Ile Glu Leu Val
245 250 255Asp Asp Thr Asn Thr Thr Arg Lys Val Met His Tyr Ala Leu Lys Pro
260 265 270Val His Ser Pro Trp Ala Gly Pro Ile Arg Ala Val Ala Ile Thr Val
275 280 285Pro Leu Val Val Ile Ser Ala Phe Ala Thr Leu Phe Thr Val Met Cys
290 295 300Arg Lys Lys Gln Gln Glu Asn Ile Tyr Ser His Leu Asp Glu Glu Ser305 310 315 320Ser Glu Ser Ser Thr Tyr Thr Ala Ala Leu Pro Arg Glu Arg Leu Arg
325 330 335Pro Arg Pro Lys Val Phe Leu Cys Tyr Ser Ser Lys Asp Gly Gln Asn
340 345 350His Met Asn Val Val Gln Cys Phe Ala Tyr Phe Leu Gln Asp Phe Cys
355 360 365Gly Cys Glu Val Ala Leu Asp Leu Trp Glu Asp Phe Ser Leu Cys Arg
370 375 380Glu Gly Gln Arg Glu Trp Val Ile Gln Lys Ile His Glu Ser Gln Phe385 390 395 400Ile Ile Val Val Cys Ser Lys Gly Met Lys Tyr Phe Val Asp Lys Lys
405 410 415Asn Tyr Lys His Lys Gly Gly Gly Arg Gly Ser Gly Lys Gly Glu Leu
420 425 430Phe Leu Val Ala Val Ser Ala Ile Ala Glu Lys Leu Arg Gln Ala Lys
435 440 445Gln Ser Ser Ser Ala Ala Leu Ser Lys Phe Ile Ala Val Tyr Phe Asp
450 455 460Tyr Ser Cys Glu Gly Asp Val Pro Gly Ile Leu Asp Leu Ser Thr Lys465 470 475 480Tyr Arg Leu Met Asp Asn Leu Pro Gln Leu Cys Ser His Leu His Ser
485 490 495Arg Asp His Gly Leu Gln Glu Pro Gly Gln His Thr Arg Gln Gly Ser
500 505 510Arg Arg Asn Tyr Phe Arg Ser Lys Ser Gly Arg Ser Leu Tyr Val Ala
515 520 525Ile Cys Asn Met His Gln Phe Ile Asp Glu Glu Pro Asp Trp Phe Glu
530 535 540Lys Gln Phe Val Pro Phe His Pro Pro Pro Leu Arg Tyr Arg Glu Pro545 550 555 560Val Leu Glu Lys Phe Asp Ser Gly Leu Val Leu Asn Asp Val Met Cys
565 570 575Lys Pro Gly Pro Glu Ser Asp Phe Cys Leu Lys Val Glu Ala Ala Val
580 585 590Leu Gly Ala Thr Gly Pro Ala Asp Ser Gln His Glu Ser Gln His Gly
595 600 605Gly Leu Asp Gln Asp Gly Glu Ala Arg Pro Ala Leu Asp Gly Ser Ala
610 615 620Ala Leu Gln Pro Leu Leu His Thr Val Lys Ala Gly Ser Pro Ser Asp625 630 635 640Met Pro Arg Asp Ser Gly Ile Tyr Asp Ser Ser Val Pro Ser Ser Glu
645 650 655Leu Ser Leu Pro Leu Met Glu Gly Leu Ser Thr Asp Gln Thr Glu Thr
660 665 670Ser Ser Leu Thr Glu Ser Val Ser Ser Ser Ser Gly Leu Gly Glu Glu
675 680 685Glu Pro Pro Ala Leu Pro Ser Lys Leu Leu Ser Ser Gly Ser Cys Lys
690 695 700Ala Asp Leu Gly Cys Arg Ser Tyr Thr Asp Glu Leu His Ala Val Ala705 710 715 720Pro Leu<210>15<211>2214<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>misc_特征<222>(6),(9),(15),(21),(27),(30),(39),(42),
(48),(54),(60),(63),(69),(72),(75),(78),
(81),(84),(87),(90),(93),(96),(99),(100),
(101),(102),(105),(108),(114),(120),(124),
(125),(126),(129),(132),(135),(138),(141),
(144),(147),(153),(156),(159),(171),(192),
(195),(201),(207),(210),(213),(222),(228),
(234),(246),(252),(261),(276),(279),(282),
(285),(291),(297),(300),(303),(306),(309),
(312),(324),(330),(336),(339),(345),(354),
(360),(366),(369),(373),(374),(375),(384),
(390),(399),(406),(407),(408),(414),(417),
(426),(429),(432),(441),(447),(448),(449),
(450),(453),(471),(483),(486),(489),(492),
(498),(516),(528),(540),(543),(546),(549),
(558),(561),(564),(570),(579),(582),(591),
(603),(606),(612),(621),(630),(633),(645),
(648),(660),(663),(675),(681),(693),(705),
(717),(720),(729),(735),(753),(756),(765),
(768),(774),(777),(786),(789),(792),(795),
(813),(816),(825),(831),(834),(837),(843),
(855),(858),(864),(867),(873),(876),(882),
(885),(888),(894),(897),(900),(903),(909),
(912),(915),(918),(921),(924),(930),(933),
(939),(942),(945),(951),(954),(963),(990),
(996),(1008),(1011),(1017),(1020),(1023),
(1029),(1032),(1035),(1038),(1041),(1044),
(1050),(1053),(1056),(1059),(1062),(1065),
(1071),(1077),(1086),(1089),(1098),(1116),
(1119),(1131),(1140),(1155),(1164),(1167),
(1170),(1176),(1191),(1194),(1200),(1206),
(1212),(1221),(1242),(1257),(1260),(1266),
(1272),(1287),(1314),(1317),(1320),(1323),
(1326),(1329),(1332),(1338),(1344),(1350),
(1353),(1356),(1359),(1362),(1365),(1371),
(1380),(1383),(1389),(1398),(1401),(1404),
(1407),(1410),(1413),(1416),(1428),(1431),
(1446),(1455),(1461),(1464),(1467),(1473),
(1479),(1482),(1485),(1494),(1497),(1509),
(1512),(1518),(1524),(1530),(1536),(1539),
(1548),(1551),(1560),(1563),(1572),(1575),
(1581),(1584),(1587),(1590),(1602),(1605),
(1611),(1614),(1617),(1620),(1623),(1629),
(1632),(1668),(1692),(1695),(1704),(1707),
(1710),(1713),(1716),(1722),(1728),(1731),
(1734),(1749),(1752),(1755),(1758),(1761),
(1770),(1782),(1785),(1788),(1794),(1806),
(1812),(1818),(1821),(1824),(1827),(1830),
(1833),(1836),(1839),(1842),(1845),(1851),
(1863),(1872),(1875),(1878),(1890),(1896),
(1899),(1902),(1905),(1908),(1914),(1917),
(1920),(1923),(1926),(1932),(1935),(1938),
(1944),(1947),(1953),(1956),(1959),(1962),
(1965),(1974),(1977),(1983),(1986),(1998),
(2001),(2004),(2007),(2010),(2013),(2019),
(2022),(2025),(2028),(2031),(2040),(2043),
(2046),(2049),(2058),(2064),(2067),(2070),
(2073),(2076),(2082),(2085),(2088),(2091),
(2094),(2097),(2100),(2103),(2106),(2118),
(2121),(2124),(2127),(2130),(2133),(2139),
(2142),(2145),(2148),(2151),(2154),(2163),
(2169),(2172),(2178),(2181),(2187),(2196),
(2202),(2205),(2208),(2211),(2214)<223>n=任意核苷酸<400>15atggcnccnt ggytncaryt ntgywsngtn ttyttyacng tnaaygcntg yytnaayggn 60wsncarytng cngtngcngc nggnggnwsn ggnmgngcnn nnggngcnga yacntgywsn 120tggnnnggng tnggnccngc nwsnmgnaay wsnggnytnt ayaayathac nttyaartay 180gayaaytgya cnacntayyt naayccngtn ggnaarcayg tnathgcnga ygcncaraay 240athacnathw sncartaygc ntgycaygay cargtngcng tnacnathyt ntggwsnccn 300ggngcnytng gnathgartt yytnaarggn ttymgngtna thytngarga rytnaarwsn 360garggnmgnc arnnncarca rytnathytn aargayccna arcarnnnaa ywsnwsntty 420aarmgnacng gnatggarws ncarccnnnn ytnaayatga arttygarac ngaytaytty 480gtnmgnytnw snttywsntt yathaaraay garwsnaayt aycayccntt yttyttymgn 540acnmgngcnt gygayytnyt nytncarccn gayaayytng cntgyaarcc nttytggaar 600ccnmgnaayy tnaayathws ncarcayggn wsngayatgc argtnwsntt ygaycaygcn 660ccncayaayt tyggnttymg nttyttytay ytncaytaya arytnaarca ygarggnccn 720ttyaarmgna aracntgyaa rcargarcar acnacngara tgacnwsntg yytnytncar 780aaygtnwsnc cnggngayta yathathgar ytngtngayg ayacnaayac nacnmgnaar 840gtnatgcayt aygcnytnaa rccngtncay wsnccntggg cnggnccnat hmgngcngtn 900gcnathacng tnccnytngt ngtnathwsn gcnttygcna cnytnttyac ngtnatgtgy 960mgnaaraarc arcargaraa yathtaywsn cayytngayg argarwsnws ngarwsnwsn 1020acntayacng cngcnytncc nmgngarmgn ytnmgnccnm gnccnaargt nttyytntgy 1080taywsnwsna argayggnca raaycayatg aaygtngtnc artgyttygc ntayttyytn 1140cargayttyt gyggntgyga rgtngcnytn gayytntggg argayttyws nytntgymgn 1200garggncarm gngartgggt nathcaraar athcaygarw sncarttyat hathgtngtn 1260tgywsnaarg gnatgaarta yttygtngay aaraaraayt ayaarcayaa rggnggnggn 1320mgnggnwsng gnaarggnga rytnttyytn gtngcngtnw sngcnathgc ngaraarytn 1380mgncargcna arcarwsnws nwsngcngcn ytnwsnaart tyathgcngt ntayttygay 1440taywsntgyg arggngaygt nccnggnath ytngayytnw snacnaarta ymgnytnatg 1500gayaayytnc cncarytntg ywsncayytn caywsnmgng aycayggnyt ncargarccn 1560ggncarcaya cnmgncargg nwsnmgnmgn aaytayttym gnwsnaarws nggnmgnwsn 1620ytntaygtng cnathtgyaa yatgcaycar ttyathgayg argarccnga ytggttygar 1680aarcarttyg tnccnttyca yccnccnccn ytnmgntaym gngarccngt nytngaraar 1740ttygaywsng gnytngtnyt naaygaygtn atgtgyaarc cnggnccnga rwsngaytty 1800tgyytnaarg tngargcngc ngtnytnggn gcnacnggnc cngcngayws ncarcaygar 1860wsncarcayg gnggnytnga ycargayggn gargcnmgnc cngcnytnga yggnwsngcn 1920gcnytncarc cnytnytnca yacngtnaar gcnggnwsnc cnwsngayat gccnmgngay 1980wsnggnatht aygaywsnws ngtnccnwsn wsngarytnw snytnccnyt natggarggn 2040ytnwsnacng aycaracnga racnwsnwsn ytnacngarw sngtnwsnws nwsnwsnggn 2100ytnggngarg argarccncc ngcnytnccn wsnaarytny tnwsnwsngg nwsntgyaar 2160gcngayytng gntgymgnws ntayacngay garytncayg cngtngcncc nytn 2214<210>16<211>2012<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>CDS<222>(1)..(1971)<220><221>mat_肽<222>(70)..(1971)<400>16atg ggg agc tcc aga ctg gca gcc ctg ctc ctg cct ctc ctc ctc ata 48Met Gly Ser Ser Arg Leu Ala Ala Leu Leu Leu Pro Leu Leu Leu Ile
-20 -15 -10gtc atc gac ctc tct gac tct gct ggg att ggc ttt cgc cac ctg ccc 96Val Ile Asp Leu Ser Asp Ser Ala Gly Ile Gly Phe Arg His Leu Pro
-5 -1 1 5cac tgg aac acc cgc tgt cct ctg gcc tcc cac acg gaa gtt ctg cct 144His Trp Asn Thr Arg Cys Pro Leu Ala Ser His Thr Glu Val Leu Pro10 15 20 25ata tcc ctt gcc gca cct ggt ggg ccc tct tct cca caa agc ctt ggt 192Ile Ser Leu Ala Ala Pro Gly Gly Pro Ser Ser Pro Gln Ser Leu Gly
30 35 40gtg tgc gag tct ggc act gtt ccc gct gtt tgt gcc agc atc tgc tgt 240Val Cys Glu Ser Gly Thr Val Pro Ala Val Cys Ala Ser Ile Cys Cys
45 50 55cag gtg gct cag gtc ttc aac ggg gcc tct tcc acc tcc tgg tgc aga 288Gln Val Ala Gln Val Phe Asn Gly Ala Ser Ser Thr Ser Trp Cys Arg
60 65 70aat cca aaa agt ctt cca cat tca agt tct ata gga gac aca aga tgc 336Asn Pro Lys Ser Leu Pro His Ser Ser Ser Ile Gly Asp Thr Arg Cys
75 80 85cag cac ctg ctc aga gga agc tgc tgc ctc gtc gtc acc tgt ctg aga 384Gln His Leu Leu Arg Gly Ser Cys Cys Leu Val Val Thr Cys Leu Arg90 95 100 105aga gcc atc aca ttt cca tcc cct ccc cag aca tct ccc aca agg gac 432Arg Ala Ile Thr Phe Pro Ser Pro Pro Gln Thr Ser Pro Thr Arg Asp
110 115 120ttc gct cta aaa gga ccc aac ctt cgg atc cag aga cat ggg aaa gtc 480Phe Ala Leu Lys Gly Pro Asn Leu Arg Ile Gln Arg His Gly Lys Val
125 130 135ttc cca gat tgg act cac aaa ggc atg gag gtg ggc act ggg tac aac 528Phe Pro Asp Trp Thr His Lys Gly Met Glu Val Gly Thr Gly Tyr Asn
140 145 150agg aga tgg gtt cag ctg agt ggt gga ccc gag ttc tcc ttt gat ttg 576Arg Arg Trp Val Gln Leu Ser Gly Gly Pro Glu Phe Ser Phe Asp Leu
155 160 165ctg cct gag gcc cgg gct att cgg gtg acc ata tct tca ggc cct gag 624Leu Pro Glu Ala Arg Ala Ile Arg Val Thr Ile Ser Ser Gly Pro Glu170 175 180 185gtc agc gtg cgt ctt tgt cac cag tgg gca ctg gag tgt gaa gag ctg 672Val Ser Val Arg Leu Cys His Gln Trp Ala Leu Glu Cys Glu Glu Leu
190 195 200agc agt ccc tat gat gtc cag aaa att gtg tct ggg ggc cac act gta 720Ser Ser Pro Tyr Asp Val Gln Lys Ile Val Ser Gly Gly His Thr Val
205 210 215gag ctg cct tat gaa ttc ctt ctg ccc tgt ctg tgc ata gag gca tcc 768Glu Leu Pro Tyr Glu Phe Leu Leu Pro Cys Leu Cys Ile Glu Ala Ser
220 225 230tac ctg caa gag gac act gtg agg cgc aaa aaa tgt ccc ttc cag agc 816Tyr Leu Gln Glu Asp Thr Val Arg Arg Lys Lys Cys Pro Phe Gln Ser
235 240 245tgg cca gaa gcc tat ggc tcg gac ttc tgg aag tca gtg cac ttc act 864Trp Pro Glu Ala Tyr Gly Ser Asp Phe Trp Lys Ser Val His Phe Thr250 255 260 265gac tac agc cag cac act cag atg gtc atg gcc ctg aca ctc cgc tgc 912Asp Tyr Ser Gln His Thr Gln Met Val Met Ala Leu Thr Leu Arg Cys
270 275 280cca ctg aag ctg gaa gct gcc ctc tgc cag agg cac gac tgg cat acc 960Pro Leu Lys Leu Glu Ala Ala Leu Cys Gln Arg His Asp Trp His Thr
285 290 295ctt tgc aaa gac ctc ccg aat gcc acg gct cga gag tca gat ggg tgg 1008Leu Cys Lys Asp Leu Pro Asn Ala Thr Ala Arg Glu Ser Asp Gly Trp
300 305 310tat gtt ttg gag aag gtg gac ctg cac ccc cag ctc tgc ttc aag gta 1056Tyr Val Leu Glu Lys Val Asp Leu His Pro Gln Leu Cys Phe Lys Val
315 320 325caa cca tgg ttc tct ttt gga aac agc agc cat gtt gaa tgc ccc cac 1104Gln Pro Trp Phe Ser Phe Gly Asn Ser Ser His ValGlu Cys Pro His330 335 340 345cag act ggg tct ctc aca tcc tgg aat gta agc atg gat acc caa gcc 1152Gln Thr Gly Ser Leu Thr Ser Trp Asn Val Ser Met Asp Thr Gln Ala
350 355 360cag cag ctg att ctt cacttc tcc tca aga atg cat gcc acc ttc agt 1200Gln Gln Leu Ile Leu His Phe Ser Ser Arg Met His Ala Thr Phe Ser
365 370 375gct gcc tgg agc ctc cca ggc ttg ggg cag gac act ttg gtg ccc ccc 1248Ala Ala Trp Ser Leu Pro Gly Leu Gly Gln Asp Thr Leu Val Pro Pro
380 385 390gtg tac act gtc agc cag gtg tgg cgg tca gat gtc cag ttt gcc tgg 1296Val Tyr Thr Val Ser Gln Val Trp Arg Ser Asp Val Gln Phe Ala Trp
395 400 405aag cac ctc ttg tgt cca gat gtc tct tac aga cac ctg ggg ctc ttg 1344Lys His Leu Leu Cys Pro Asp Val Ser Tyr Arg His Leu Gly Leu Leu410 415 420 425atc ctg gca ctg ctg gcc ctc ctc acc cta ctg ggt gtt gtt ctg gcc 1392Ile Leu Ala Leu Leu Ala Leu Leu Thr Leu Leu Gly Val Val Leu Ala
430 435 440ctc acc tgc cgg cgc cca cag tca ggc ccg ggc cca gcg cgg cca gtg 1440Leu Thr Cys Arg Arg Pro Gln Ser Gly Pro Gly Pro Ala Arg Pro Val
445 450 455ctc ctc ctg cac gcg gcg gac tcg gag gcg cag cgg cgc ctg gtg gga 1488Leu Leu Leu His Ala Ala Asp Ser Glu Ala Gln Arg Arg Leu Val Gly
460 465 470gcg ctg gct gaa ctg cta cgg gca gcg ctg ggc ggc ggg cgc gac gtg 1536Ala Leu Ala Glu Leu Leu Arg Ala Ala Leu Gly Gly Gly Arg Asp Val
475 480 485atc gtg gac ctg tgg gag ggg agg cac gtg gcg cgc gtg ggc ccg ctg 1584Ile Val Asp Leu Trp Glu Gly Arg His Val Ala Arg Val Gly Pro Leu490 495 500 505ccg tgg ctc tgg gcg gcg cgg acg cgc gta gcg cgg gag cag ggc act 1632Pro Trp Leu Trp Ala Ala Arg Thr Arg Val Ala Arg Glu Gln Gly Thr
510 515 520gtg ctg ctg ctg tgg agc ggc gcc gac ctt cgc ccg gtc agc ggc ccc 1680Val Leu Leu Leu Trp Ser Gly Ala Asp Leu Arg Pro Val Ser Gly Pro
525 530 535gac ccc cgc gcc gcg ccc ctg ctc gcc ctg ctc cac gct gcc ccg cgc 1728Asp Pro Arg Ala Ala Pro Leu Leu Ala Leu Leu His Ala Ala Pro Arg
540 545 550ccg ctg ctg ctg ctc gct tac ttc agt cgc ctc tgc gcc aag ggc gac 1776Pro Leu Leu Leu Leu Ala Tyr Phe Ser Arg Leu Cys Ala Lys Gly Asp
555 560 565atc ccc ccg ccg ctg cgc gcc ctg ccg cgc tac cgc ctg ctg cgc gac 1824Ile Pro Pro Pro Leu Arg Ala Leu Pro Arg Tyr Arg Leu Leu Arg Asp570 575 580 585ctg ccg cgt ctg ctg cgg gcg ctg gac gcg cgg cct ttc gca gag gcc 1872Leu Pro Arg Leu Leu Arg Ala Leu Asp Ala Arg Pro Phe Ala Glu Ala
590 595 600acc agc tgg ggc cgc ctt ggg gcg cgg cag cgc agg cag agc cgc cta 1920Thr Ser Trp Gly Arg Leu Gly Ala Arg Gln Arg Arg Gln Ser Arg Leu
605 610 615gag ctg tgc agc cgg ctc gaa cga gag gcc gcc cga ctt gca gac cta 1968Glu Leu Cys Ser Arg Leu Glu Arg Glu Ala Ala Arg Leu Ala Asp Leu
620 625 630ggt tgagcagagc tccaccgcag tcccgggtgt ctgcggccgc t 2012Gly<210>17<211>657<212>PRT<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<400>17Met Gly Ser Ser Arg Leu Ala Ala Leu Leu Leu Pro Leu Leu Leu Ile
-20 -15 -10Val Ile Asp Leu Ser Asp Ser Ala Gly Ile Gly Phe Arg His Leu Pro
-5 -1 1 5His Trp Asn Thr Arg Cys Pro Leu Ala Ser His Thr Glu Val Leu Pro10 15 20 25Ile Ser Leu Ala Ala Pro Gly Gly Pro Ser Ser Pro Gln Ser Leu Gly
30 35 40Val Cys Glu Ser Gly Thr Val Pro Ala Val Cys Ala Ser Ile Cys Cys
45 50 55Gln Val Ala Gln Val Phe Asn Gly Ala Ser Ser Thr Ser Trp Cys Arg
60 65 70Asn Pro Lys Ser Leu Pro His Ser Ser Ser Ile Gly Asp Thr Arg Cys
75 80 85Gln His Leu Leu Arg Gly Ser Cys Cys Leu Val Val Thr Cys Leu Arg90 95 100 105Arg Ala Ile Thr Phe Pro Ser Pro Pro Gln Thr Ser Pro Thr Arg Asp
110 115 120Phe Ala Leu Lys Gly Pro Asn Leu Arg Ile Gln Arg His Gly Lys Val
125 130 135Phe Pro Asp Trp Thr His Lys Gly Met Glu Val Gly Thr Gly Tyr Asn
140 145 150Arg Arg Trp Val Gln Leu Ser Gly Gly Pro Glu Phe Ser Phe Asp Leu
155 160 165Leu Pro Glu Ala Arg Ala Ile Arg Val Thr Ile Ser Ser Gly Pro Glu170 175 180 185Val Ser Val Arg Leu Cys His Gln Trp Ala Leu Glu Cys Glu Glu Leu
190 195 200Ser Ser Pro Tyr Asp Val Gln Lys Ile Val Ser Gly Gly His Thr Val
205 210 215Glu Leu Pro Tyr Glu Phe Leu Leu Pro Cys Leu Cys Ile Glu Ala Ser
220 225 230Tyr Leu Gln Glu Asp Thr Val Arg Arg Lys Lys Cys Pro Phe Gln Ser
235 240 245Trp Pro Glu Ala Tyr Gly Ser Asp Phe Trp Lys Ser Val His Phe Thr250 255 260 265Asp Tyr Ser Gln His Thr Gln Met Val Met Ala Leu Thr Leu Arg Cys
270 275 280Pro Leu Lys Leu Glu Ala Ala Leu Cys Gln Arg His Asp Trp His Thr
285 290 295Leu Cys Lys Asp Leu Pro Asn Ala Thr Ala Arg Glu Ser Asp Gly Trp
300 305 310Tyr Val Leu Glu Lys Val Asp Leu His Pro Gln Leu Cys Phe Lys Val
315 320 325Gln Pro Trp Phe Ser Phe Gly Asn Ser Ser His Val Glu Cys Pro His330 335 340 345Gln Thr Gly Ser Leu Thr Ser Trp Asn Val Ser Met Asp Thr Gln Ala
350 355 360Gln Gln Leu Ile Leu His Phe Ser Ser Arg Met His Ala Thr Phe Ser
365 370 375Ala Ala Trp Ser Leu Pro Gly Leu Gly Gln Asp Thr Leu Val Pro Pro
380 385 390Val Tyr Thr Val Ser Gln Val Trp Arg Ser Asp Val Gln Phe Ala Trp
395 400 405Lys His Leu Leu Cys Pro Asp Val Ser Tyr Arg His Leu Gly Leu Leu410 415 420 425Ile Leu Ala Leu Leu Ala Leu Leu Thr Leu Leu Gly Val Val Leu Ala
430 435 440Leu Thr Cys Arg Arg Pro Gln Ser Gly Pro Gly Pro Ala Arg Pro Val
445 450 455Leu Leu Leu His Ala Ala Asp Ser Glu Ala Gln Arg Arg Leu Val Gly
460 465 470Ala Leu Ala Glu Leu Leu Arg Ala Ala Leu Gly Gly Gly Arg Asp Val
475 480 485Ile Val Asp Leu Trp Glu Gly Arg His Val Ala Arg Val Gly Pro Leu490 495 500 505Pro Trp Leu Trp Ala Ala Arg Thr Arg Val Ala Arg Glu Gln Gly Thr
510 515 520Val Leu Leu Leu Trp Ser Gly Ala Asp Leu Arg Pro Val Ser Gly Pro
525 530 535Asp Pro Arg Ala Ala Pro Leu Leu Ala Leu Leu His Ala Ala Pro Arg
540 545 550Pro Leu Leu Leu Leu Ala Tyr Phe Ser Arg Leu Cys Ala Lys Gly Asp
555 560 565Ile Pro Pro Pro Leu Arg Ala Leu Pro Arg Tyr Arg Leu Leu Arg Asp570 575 580 585Leu Pro Arg Leu Leu Arg Ala Leu Asp Ala Arg Pro Phe Ala Glu Ala
590 595 600Thr Ser Trp Gly Arg Leu Gly Ala Arg Gln Arg Arg Gln Ser Arg Leu
605 610 615Glu Leu Cys Ser Arg Leu Glu Arg Glu Ala Ala Arg Leu Ala Asp Leu
620 625 630Gly<210>18<211>1971<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>misc_特征<222>(6),(9),(12),(15),(18),(21),(24),(27),
(30),(33),(36),(39),(42),(45),(51),(60),
(63),(69),(72),(75),(81),(87),(93),(96),
(108),(111),(117),(120),(123),(126),(132),
(138),(141),(144),(150),(153),(156),(159),
(162),(165),(168),(171),(174),(177),(180),
(186),(189),(192),(195),(204),(207),(210),
(213),(216),(219),(222),(228),(231),(246),
(249),(255),(264),(267),(270),(273),(276),
(279),(288),(294),(300),(303),(306),(312),
(315),(318),(324),(330),(333),(345),(348),
(351),(354),(357),(366),(369),(372),(375),
(381),(384),(387),(390),(396),(402),(405),
(408),(411),(417),(420),(423),(426),(429),
(438),(441),(447),(450),(456),(459),(468),
(474),(480),(486),(495),(504),(513),(516),
(519),(522),(531),(534),(540),(546),(549),
(552),(555),(558),(567),(576),(579),(582),
(588),(591),(594),(600),(603),(606),(612),
(615),(618),(621),(627),(630),(633),(636),
(639),(654),(657),(672),(675),(678),(681),
(690),(702),(705),(708),(711),(717),(720),
(726),(729),(741),(744),(747),(753),(765),
(768),(774),(786),(789),(792),(795),(807),
(816),(822),(828),(834),(837),(852),(855),
(864),(873),(882),(891),(897),(900),(903),
(906),(909),(915),(918),(924),(930),(933),
(936),(945),(960),(963),(975),(978),(984),
(987),(990),(993),(999),(1005),(1014),
(1017),(1026),(1032),(1038),(1044),(1056),
(1062),(1071),(1077),(1083),(1086),(1092),
(1101),(1110),(1113),(1116),(1119),(1122),
(1125),(1134),(1137),(1146),(1152),(1161),
(1167),(1176),(1179),(1182),(1191),(1194),
(1200),(1203),(1206),(1212),(1215),(1218),
(1221),(1224),(1227),(1236),(1239),(1242),
(1245),(1248),(1251),(1257),(1260),(1263),
(1269),(1275),(1278),(1284),(1293),(1305),
(1308),(1314),(1320),(1323),(1329),(1335),
(1338),(1341),(1344),(1350),(1353),(1356),
(1359),(1362),(1365),(1368),(1371),(1374),
(1377),(1380),(1383),(1386),(1389),(1392),
(1395),(1398),(1404),(1407),(1410),(1416),
(1419),(1422),(1425),(1428),(1431),(1434),
(1437),(1440),(1443),(1446),(1449),(1455),
(1458),(1464),(1470),(1476),(1479),(1482),
(1485),(1488),(1491),(1494),(1497),(1503),
(1506),(1509),(1512),(1515),(1518),(1521),
(1524),(1527),(1530),(1536),(1542),(1548),
(1557),(1560),(1566),(1569),(1572),(1575),
(1578),(1581),(1584),(1587),(1593),(1599),
(1602),(1605),(1608),(1611),(1614),(1617),
(1620),(1629),(1632),(1635),(1638),(1641),
(1644),(1650),(1653),(1656),(1662),(1665),
(1668),(1671),(1674),(1677),(1680),(1686),
(1689),(1692),(1695),(1698),(1701),(1704),
(1707),(1710),(1713),(1719),(1722),(1725),
(1728),(1731),(1734),(1737),(1740),(1743),
(1746),(1755),(1758),(1761),(1767),(1773),
(1782),(1785),(1788),(1791),(1794),(1797),
(1800),(1803),(1806),(1812),(1815),(1818),
(1821),(1827),(1830),(1833),(1836),(1839),
(1842),(1845),(1848),(1854),(1857),(1860),
(1866),(1872),(1875),(1878),(1884),(1887),
(1890),(1893),(1896),(1899),(1905),(1908),
(1914),(1917),(1920),(1926),(1932),(1935),
(1938),(1944),(1950),(1953),(1956), (1959),
(1962),(1968),(1971)<223>n=任意核苷酸<400>18atgggnwsnw snmgnytngc ngcnytnytn ytnccnytny tnytnathgt nathgayytn 60wsngaywsng cnggnathgg nttymgncay ytnccncayt ggaayacnmg ntgyccnytn 120gcnwsncaya cngargtnyt nccnathwsn ytngcngcnc cnggnggncc nwsnwsnccn 180carwsnytng gngtntgyga rwsnggnacn gtnccngcng tntgygcnws nathtgytgy 240cargtngcnc argtnttyaa yggngcnwsn wsnacnwsnt ggtgymgnaa yccnaarwsn 300ytnccncayw snwsnwsnat hggngayacn mgntgycarc ayytnytnmg nggnwsntgy 360tgyytngtng tnacntgyyt nmgnmgngcn athacnttyc cnwsnccncc ncaracnwsn 420ccnacnmgng ayttygcnyt naarggnccn aayytnmgna thcarmgnca yggnaargtn 480ttyccngayt ggacncayaa rggnatggar gtnggnacng gntayaaymg nmgntgggtn 540carytnwsng gnggnccnga rttywsntty gayytnytnc cngargcnmg ngcnathmgn 600gtnacnathw snwsnggncc ngargtnwsn gtnmgnytnt gycaycartg ggcnytngar 660tgygargary tnwsnwsncc ntaygaygtn caraarathg tnwsnggngg ncayacngtn 720garytnccnt aygarttyyt nytnccntgy ytntgyathg argcnwsnta yytncargar 780gayacngtnm gnmgnaaraa rtgyccntty carwsntggc cngargcnta yggnwsngay 840ttytggaarw sngtncaytt yacngaytay wsncarcaya cncaratggt natggcnytn 900acnytnmgnt gyccnytnaa rytngargcn gcnytntgyc armgncayga ytggcayacn 960ytntgyaarg ayytnccnaa ygcnacngcn mgngarwsng ayggntggta ygtnytngar 1020aargtngayy tncayccnca rytntgytty aargtncarc cntggttyws nttyggnaay 1080wsnwsncayg tngartgycc ncaycaracn ggnwsnytna cnwsntggaa ygtnwsnatg 1140gayacncarg cncarcaryt nathytncay ttywsnwsnm gnatgcaygc nacnttywsn 1200gcngcntggw snytnccngg nytnggncar gayacnytng tnccnccngt ntayacngtn 1260wsncargtnt ggmgnwsnga ygtncartty gcntggaarc ayytnytntg yccngaygtn 1320wsntaymgnc ayytnggnyt nytnathytn gcnytnytng cnytnytnac nytnytnggn 1380gtngtnytng cnytnacntg ymgnmgnccn carwsnggnc cnggnccngc nmgnccngtn 1440ytnytnytnc aygcngcnga ywsngargcn carmgnmgny tngtnggngc nytngcngar 1500ytnytnmgng cngcnytngg nggnggnmgn gaygtnathg tngayytntg ggarggnmgn 1560caygtngcnm gngtnggncc nytnccntgg ytntgggcng cnmgnacnmg ngtngcnmgn 1620garcarggna cngtnytnyt nytntggwsn ggngcngayy tnmgnccngt nwsnggnccn 1680gayccnmgng cngcnccnyt nytngcnytn ytncaygcng cnccnmgncc nytnytnytn 1740ytngcntayt tywsnmgnyt ntgygcnaar ggngayathc cnccnccnyt nmgngcnytn 1800ccnmgntaym gnytnytnmg ngayytnccn mgnytnytnm gngcnytnga ygcnmgnccn 1860ttygcngarg cnacnwsntg gggnmgnytn ggngcnmgnc armgnmgnca rwsnmgnytn 1920garytntgyw snmgnytnga rmgngargcn gcnmgnytng cngayytngg n 1971<210>19<211>808<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>CDS<222>(78)..(806)<220><221>mat_肽<222>(147)..(806)<400>19cagctccggg ccaggccctg ctgccctctt gcagacagga aagacatggt ctctgcgccc 60tgatcctaca gaagctc atg ggg agc ccc aga ctg gca gcc ttg ctc ctg 110
Met Gly Ser Pro Arg Leu Ala Ala Leu Leu Leu
-20 -15tct ctc ccg cta ctg ctc atc ggc ctc gct gtg tct gct cgg gtt gcc 158Ser Leu Pro Leu Leu Leu Ile Gly Leu Ala Val Ser Ala Arg Val Ala
-10 -5 -1 1tgc ccc tgc ctg cgg agt tgg acc agc cac tgt ctc ctg gcc tac cgt 206Cys Pro Cys Leu Arg Ser Trp Thr Ser His Cys Leu Leu Ala Tyr Arg5 10 15 20gtg gat aaa cgt ttt gct ggc ctt cag tgg ggc tgg ttc cct ctc ttg 254Val Asp Lys Arg Phe Ala Gly Leu Gln Trp Gly Trp Phe Pro Leu Leu
25 30 35gtg agg aaa tct aaa agt cct cct aaa ttt gaa gac tat tgg agg cac 302Val Arg Lys Ser Lys Ser Pro Pro Lys Phe Glu Asp Tyr Trp Arg His
40 45 50agg aca cca gca tcc ttc cag agg aag ctg cta ggc agc cct tcc ctg 350Arg Thr Pro Ala Ser Phe Gln Arg Lys Leu Leu Gly Ser Pro Ser Leu
55 60 65tct gag gaa agc cat cga att tcc atc ccc tcc tca gcc atc tcc cac 398Ser Glu Glu Ser His Arg Ile Ser Ile Pro Ser Ser Ala Ile Ser His
70 75 80aga ggc caa cgc acc aaa agg gcc cag cct tca gct gca gaa gga aga 446Arg Gly Gln Arg Thr Lys Arg Ala Gln Pro Ser Ala Ala Glu Gly Arg85 90 95 100gaa cat ctc cct gaa gca ggg tca caa aag tgt gga gga cct gaa ttc 494Glu His Leu Pro Glu Ala Gly Ser Gln Lys Cys Gly Gly Pro Glu Phe
105 110 115tcc ttt gat ttg ctg ccc gag gtg cag gct gtt cgg gtg act att cct 542Ser Phe Asp Leu Leu Pro Glu Val Gln Ala Val Arg Val Thr Ile Pro
120 125 130gca ggc ccc aag gca cgt gtg cgc ctt tgt tat cag tgg gca ctg gaa 590Ala Gly Pro Lys Ala Arg Val Arg Leu Cys Tyr Gln Trp Ala Leu Glu
135 140 145tgt gaa gac ttg agt agc cct ttt gat acc cag aaa att gtg tct gga 638Cys Glu Asp Leu Ser Ser Pro Phe Asp Thr Gln Lys Ile Val Ser Gly
150 155 160ggg cac act gta gac ctg cct tat gaa ttc ctt ctg ccc tgc atg tgc 686Gly His Thr Val Asp Leu Pro Tyr Glu Phe Leu Leu Pro Cys Met Cys165 170 175 180ata gag gcc tcc tac ctg caa gag gac act gtg agg cgc aaa agt gtc 734Ile Glu Ala Ser Tyr Leu Gln Glu Asp Thr Val Arg Arg Lys Ser Val
185 190 195cct tcc aga gct ggc ctg aag ctt atg gct cag act tct ggc agt caa 782Pro Ser Arg Ala Gly Leu Lys Leu Met Ala Gln Thr Ser Gly Ser Gln
200 205 210tac gct tca ctg act aca gcc agc ac 808Tyr Ala Ser Leu Thr Thr Ala Ser
215 220<210>20<211>243<212>PRT<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<400>20Met Gly Ser Pro Arg Leu Ala Ala Leu Leu Leu Ser Leu Pro Leu Leu
-20 -15 -10Leu Ile Gly Leu Ala Val Ser Ala Arg Val Ala Cys Pro Cys Leu Arg
-5 -1 1 5Ser Trp Thr Ser His Cys Leu Leu Ala Tyr Arg Val Asp Lys Arg Phe10 15 20 25Ala Gly Leu Gln Trp Gly Trp Phe Pro Leu Leu Val Arg Lys Ser Lys
30 35 40Ser Pro Pro Lys Phe Glu Asp Tyr Trp Arg His Arg Thr Pro Ala Ser
45 50 55Phe Gln Arg Lys Leu Leu Gly Ser Pro Ser Leu Ser Glu Glu Ser His
60 65 70Arg Ile Ser Ile Pro Ser Ser Ala Ile Ser His Arg Gly Gln Arg Thr
75 80 85Lys Arg Ala Gln Pro Ser Ala Ala Glu Gly Arg Glu His Leu Pro Glu90 95 100 105Ala Gly Ser Gln Lys Cys Gly Gly Pro Glu Phe Ser Phe Asp Leu Leu
110 115 120Pro Glu Val Gln Ala Val Arg Val Thr Ile Pro Ala Gly Pro Lys Ala
125 130 135Arg Val Arg Leu Cys Tyr Gln Trp Ala Leu Glu Cys Glu Asp Leu Ser
140 145 150Ser Pro Phe Asp Thr Gln Lys Ile Val Ser Gly Gly His Thr Val Asp
155 160 165Leu Pro Tyr Glu Phe Leu Leu Pro Cys Met Cys Ile Glu Ala Ser Tyr170 175 180 185Leu Gln Glu Asp Thr Val Arg Arg Lys Ser Val Pro Ser Arg Ala Gly
190 195 200Leu Lys Leu Met Ala Gln Thr Ser Gly Ser Gln Tyr Ala Ser Leu Thr
205 210 215Thr Ala Ser
220<210>21<211>729<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>misc_特征<222>(6),(9),(12),(15),(18),(21),(24),(27),
(30),(33),(36),(39),(42),(45),(48),(51),
(57),(60),(63),(66),(69),(72),(75),(78),
(81),(87),(93),(96),(99),(105),(108),(117),
(120),(123),(129),(132),(141),(147),(150),
(153),(162),(171),(174),(177),(180),(183),
(189),(195),(198),(201),(222),(228),(231),
(234),(237),(240),(249),(255),(258),(261),
(264),(267),(270),(273),(276),(285),(291),
(297),(303),(306),(309),(312),(318),(324),
(327),(333),(336),(342),(345),(351),(354),
(357),(360),(366),(369),(378),(381),(387),
(390),(393),(405),(408),(411),(420),(429),
(432),(435),(441),(447),(450),(453),(456),
(459),(465),(468),(471),(474),(480),(483),
(486),(489),(492),(507),(510),(525),(528),
(531),(534),(543),(555),(558),(561),(564),
(570),(573),(579),(582),(594),(597),(600),
(618),(621),(627),(639),(642),(645),(648),
(654),(657),(660),(663),(666),(669),(672),
(675),(681),(687),(693),(696),(699),(702),
(711),(714),(717),(720),(723),(726),(729)<223>n=任意核苷酸<400>21atgggnwsnc cnmgnytngc ngcnytnytn ytnwsnytnc cnytnytnyt nathggnytn 60gcngtnwsng cnmgngtngc ntgyccntgy ytnmgnwsnt ggacnwsnca ytgyytnytn 120gcntaymgng tngayaarmg nttygcnggn ytncartggg gntggttycc nytnytngtn 180mgnaarwsna arwsnccncc naarttygar gaytaytggm gncaymgnac nccngcnwsn 240ttycarmgna arytnytngg nwsnccnwsn ytnwsngarg arwsncaymg nathwsnath 300ccnwsnwsng cnathwsnca ymgnggncar mgnacnaarm gngcncarcc nwsngcngcn 360garggnmgng arcayytncc ngargcnggn wsncaraart gyggnggncc ngarttywsn 420ttygayytny tnccngargt ncargcngtn mgngtnacna thccngcngg nccnaargcn 480mgngtnmgny tntgytayca rtgggcnytn gartgygarg ayytnwsnws nccnttygay 540acncaraara thgtnwsngg nggncayacn gtngayytnc cntaygartt yytnytnccn 600tgyatgtgya thgargcnws ntayytncar gargayacng tnmgnmgnaa rwsngtnccn 660wsnmgngcng gnytnaaryt natggcncar acnwsnggnw sncartaygc nwsnytnacn 720acngcnwsn 729<210>22<211>2377<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>CDS<222>(180)..(1874)<400>22ttttgagcag aggcttccta ggctccgtag aaatttgcat acagcttcca cttcctgctt 60cagagcctgt tcttctactt acctgggccc ggagaaggtg gagggagacg agaagccgcc 120gagagccgac taccctccgg gcccagtctg tctgtccgtg gtggatctaa gaaactaga 179atg aac cga agc att cct gtg gag gtt gat gaa tca gaa cca tac cca 227Met Asn Arg Ser Ile Pro Val Glu Val Asp Glu Ser Glu Pro Tyr Pro1 5 10 15agt cag ttg ctg aaa cca atc cca gaa tat tcc ccg gaa gag gaa tca 275Ser Gln Leu Leu Lys Pro Ile Pro Glu Tyr Ser Pro Glu Glu Glu Ser
20 25 30gaa cca cct gct cca aat ata agg aac atg gca ccc aac agc ttg tct 323Glu Pro Pro Ala Pro Asn Ile Arg Asn Met Ala Pro Asn Ser Leu Ser
35 40 45gca ccc aca atg ctt cac aat tcc tcc gga gac ttt tct caa gct cac 371Ala Pro Thr Met Leu His Asn Ser Ser Gly Asp Phe Ser Gln Ala His
50 55 60tca acc ctg aaa ctt gca aat cac cag cgg cct gta tcc cgg cag gtc 419Ser Thr Leu Lys Leu Ala Asn His Gln Arg Pro Val Ser Arg Gln Val65 70 75 80acc tgc ctg cgc act caa gtt ctg gag gac agt gaa gac agt ttc tgc 467Thr Cys Leu Arg Thr Gln Val Leu Glu Asp Ser Glu Asp Ser Phe Cys
85 90 95agg aga cac cca ggc ctg ggc aaa gct ttc cct tct ggg tgc tct gca 515Arg Arg His Pro Gly Leu Gly Lys Ala Phe Pro Ser Gly Cys Ser Ala
100 105 110gtc agc gag cct gcg tct gag tct gtg gtt gga gcc ctc cct gca gag 563Val Ser Glu Pro Ala Ser Glu Ser Val Val Gly Ala Leu Pro Ala Glu
115 120 125cat cag ttt tca ttt atg gaa aaa cgt aat caa tgg ctg gta tct cag 611His Gln Phe Ser Phe Met Glu Lys Arg Asn Gln Trp Leu Val Ser Gln
130 135 140ctt tca gcg gct tct cct gac act ggc cat gac tca gac aaa tca gac 659Leu Ser Ala Ala Ser Pro Asp Thr Gly His Asp Ser Asp Lys Ser Asp145 150 155 160caa agt tta cct aat gcc tca gca gac tcc ttg ggc ggt agc cag gag 707Gln Ser Leu Pro Asn Ala Ser Ala Asp Ser Leu Gly Gly Ser Gln Glu
165 170 175atg gtg caa cgg ccc cag cct cac agg aac cga gca ggc ctg gat ctg 755Met Val Gln Arg Pro Gln Pro His Arg Asn Arg Ala Gly Leu Asp Leu
180 185 190cca acc ata gac acg gga tat gat tcc cag ccc cag gat gtc ctg ggc 803Pro Thr Ile Asp Thr Gly Tyr Asp Ser Gln Pro Gln Asp Val Leu Gly
195 200 205atc agg cag ctg gaa agg ccc ctg ccc ctc acc tcc gtg tgt tac ccc 851Ile Arg Gln Leu Glu Arg Pro Leu Pro Leu Thr Ser Val Cys Tyr Pro
210 215 220cag gac ctc ccc aga cct ctc agg tcc agg gag ttc cct cag ttt gaa 899Gln Asp Leu Pro Arg Pro Leu Arg Ser Arg Glu Phe Pro Gln Phe Glu225 230 235 240cct cag agg tat cca gca tgt gca cag atg ctg cct ccc aat ctt tcc 947Pro Gln Arg Tyr Pro Ala Cys Ala Gln Met Leu Pro Pro Asn Leu Ser
245 250 255cca cat gct cca tgg aac tat cat tac cat tgt cct gga agt ccc gat 995Pro His Ala Pro Trp Asn Tyr His Tyr His Cys Pro Gly Ser Pro Asp
260 265 270cac cag gtg cca tat ggc cat gac tac cct cga gca gcc tac cag caa 1043His Gln Val Pro Tyr Gly His Asp Tyr Pro Arg Ala Ala Tyr Gln Gln
275 280 285gtg atc cag ccg gct ctg cct ggg cag ccc ctg cct gga gcc agt gtg 1091Val Ile Gln Pro Ala Leu Pro Gly Gln Pro Leu Pro Gly Ala Ser Val
290 295 300aga ggc ctg cac cct gtg cag aag gtt atc ctg aat tat ccc agc ccc 1139Arg Gly Leu His Pro Val Gln Lys Val Ile Leu Asn Tyr Pro Ser Pro305 310 315 320tgg gac caa gaa gag agg ccc gca cag aga gac tgc tcc ttt ccg ggg 1187Trp Asp Gln Glu Glu Arg Pro Ala Gln Arg Asp Cys Ser Phe Pro Gly
325 330 335ctt cca agg cac cag gac cag cca cat cac cag cca cct aat aga gct 1235Leu Pro Arg His Gln Asp Gln Pro His His Gln Pro Pro Asn Arg Ala
340 345 350ggt gct cct ggg gag tcc ttg gag tgc cct gca gag ctg aga cca cag 1283Gly Ala Pro Gly Glu Ser Leu Glu Cys Pro Ala Glu Leu Arg Pro Gln
355 360 365gtt ccc cag cct ccg tcc cca gct gct gtg cct aga ccc cct agc aac 1331Val Pro Gln Pro Pro Ser Pro Ala Ala Val Pro Arg Pro Pro Ser Asn
370 375 380cct cca gcc aga gga act cta aaa aca agc aat ttg cca gaa gaa ttg 1379Pro Pro Ala Arg Gly Thr Leu Lys Thr Ser Asn Leu Pro Glu Glu Leu385 390 395 400cgg aaa gtc ttt atc act tat tcg atg gac aca gct atg gag gtg gtg 1427Arg Lys Val Phe Ile Thr Tyr Ser Met Asp Thr Ala Met Glu Val Val
405 410 415aaa ttc gtg aac ttt ttg ttg gta aat ggc ttc caa act gca att gac 1475Lys Phe Val Asn Phe Leu Leu Val Asn Gly Phe Gln Thr Ala Ile Asp
420 425 430ata ttt gag gat aga atc cga ggc att gat atc att aaa tgg atg gag 1523Ile Phe Glu Asp Arg Ile Arg Gly Ile Asp Ile Ile Lys Trp Met Glu
435 440 445cgc tac ctt agg gat aag acc gtg atg ata atc gta gca atc agc ccc 1571Arg Tyr Leu Arg Asp Lys Thr Val Met Ile Ile Val Ala Ile Ser Pro
450 455 460aaa tac aaa cag gac gtg gaa ggc gct gag tcg cag ctg gac gag gat 1619Lys Tyr Lys Gln Asp Val Glu Gly Ala Glu Ser Gln Leu Asp Glu Asp465 470 475 480gag cat ggc tta cat act aag tac att cat cga atg atg cag att gag 1667Glu His Gly Leu His Thr Lys Tyr Ile His Arg Met Met Gln Ile Glu
485 490 495ttc ata aaa caa gga agc atg aat ttc aga ttc atc cct gtg ctc ttc 1715Phe Ile Lys Gln Gly Ser Met Asn Phe Arg Phe Ile Pro Val Leu Phe
500 505 510cca aat gct aag aag gag cat gtg ccc acc tgg ctt cag aac act cat 1763Pro Asn Ala Lys Lys Glu His Val Pro Thr Trp Leu Gln Asn Thr His
515 520 525gtc tac agc tgg ccc aag aat aaa aaa aac atc ctg ctg cgg ctg ctg 1811Val Tyr Ser Trp Pro Lys Asn Lys Lys Asn Ile Leu Leu Arg Leu Leu
530 535 540aga gag gaa gag tat gtg gct cct cca cgg ggg cct ctg ccc acc ctt 1859Arg Glu Glu Glu Tyr Val Ala Pro Pro Arg Gly Pro Leu Pro Thr Leu545 550 555 560cag gtg gtt ccc ttg tgacaccgtt catccccaga tcactgaggc caggccatgt 1914Gln Val Val Pro Leu
565ttggggcctt gttctgacag cattctggct gaggctggtc ggtagcactc ctggctggtt 1974tttttctgtt cctccccgag aggccctctg gcccccagga aacctgttgt gcagagctct 2034tccccggaga cctccacaca ccctggcttt gaagtggagt ctgtgactgc tctgcattct 2094ctgcttttaa aaaaaccatt gcaggtgcca gtgtcccata tgttcctcct gacagtttga 2154tgtgtccatt ctgggcctct cagtgcttag caagtagata atgtaaggga tgtggcagca 2214aatggaaatg actacaaaca ctctcctatc aatcacttca ggctactttt atgagttagc 2274cagatgcttg tgtatcctca gaccaaactg attcatgtac aaataataaa atgtttactc 2334ttttgtaaaa aaaaaaaaaa aaaaaaaaag aaaaaaaaaa aaa 2377<210>23<211>565<212>PRT<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<400>23Met Asn Arg Ser Ile Pro Val Glu Val Asp Glu Ser Glu Pro Tyr Pro1 5 10 15Ser Gln Leu Leu Lys Pro Ile Pro Glu Tyr Ser Pro Glu Glu Glu Ser
20 25 30Glu Pro Pro Ala Pro Asn Ile Arg Asn Met Ala Pro Asn Ser Leu Ser
35 40 45Ala Pro Thr Met Leu His Asn Ser Ser Gly Asp Phe Ser Gln Ala His
50 55 60Ser Thr Leu Lys Leu Ala Asn His Gln Arg Pro Val Ser Arg Gln Val65 70 75 80Thr Cys Leu Arg Thr Gln Val Leu Glu Asp Ser Glu Asp Ser Phe Cys
85 90 95Arg Arg His Pro Gly Leu Gly Lys Ala Phe Pro Ser Gly Cys Ser Ala
100 105 110Val Ser Glu Pro Ala Ser Glu Ser Val Val Gly Ala Leu Pro Ala Glu
115 120 125His Gln Phe Ser Phe Met Glu Lys Arg Asn Gln Trp Leu Val Ser Gln
130 135 140Leu Ser Ala Ala Ser Pro Asp Thr Gly His Asp Ser Asp Lys Ser Asp145 150 155 160Gln Ser Leu Pro Asn Ala Ser Ala Asp Ser Leu Gly Gly Ser Gln Glu
165 170 175Met Val Gln Arg Pro Gln Pro His Arg Asn Arg Ala Gly Leu Asp Leu
180 185 190Pro Thr Ile Asp Thr Gly Tyr Asp Ser Gln Pro Gln Asp Val Leu Gly
195 200 205Ile Arg Gln Leu Glu Arg Pro Leu Pro Leu Thr Ser Val Cys Tyr Pro
210 215 220Gln Asp Leu Pro Arg Pro Leu Arg Ser Arg Glu Phe Pro Gln Phe Glu225 230 235 240Pro Gln Arg Tyr Pro Ala Cys Ala Gln Met Leu Pro Pro Asn Leu Ser
245 250 255Pro His Ala Pro Trp Asn Tyr His Tyr His Cys Pro Gly Ser Pro Asp
260 265 270His Gln Val Pro Tyr Gly His Asp Tyr Pro Arg Ala Ala Tyr Gln Gln
275 280 285Val Ile Gln Pro Ala Leu Pro Gly Gln Pro Leu Pro Gly Ala Ser Val
290 295 300Arg Gly Leu His Pro Val Gln Lys Val Ile Leu Asn Tyr Pro Ser Pro305 310 315 320Trp Asp Gln Glu Glu Arg Pro Ala Gln Arg Asp Cys Ser Phe Pro Gly
325 330 335Leu Pro Arg His Gln Asp Gln Pro His His Gln Pro Pro Asn Arg Ala
340 345 350Gly Ala Pro Gly Glu Ser Leu Glu Cys Pro Ala Glu Leu Arg Pro Gln
355 360 365Val Pro Gln Pro Pro Ser Pro Ala Ala Val Pro Arg Pro Pro Ser Asn
370 375 380Pro Pro Ala Arg Gly Thr Leu Lys Thr Ser Asn Leu Pro Glu Glu Leu385 390 395 400Arg Lys Val Phe Ile Thr Tyr Ser Met Asp Thr Ala Met Glu Val Val
405 410 415Lys Phe Val Asn Phe Leu Leu Val Asn Gly Phe Gln Thr Ala Ile Asp
420 425 430Ile Phe Glu Asp Arg Ile Arg Gly Ile Asp Ile Ile Lys Trp Met Glu
435 440 445Arg Tyr Leu Arg Asp Lys Thr Val Met Ile Ile Val Ala Ile Ser Pro
450 455 460Lys Tyr Lys Gln Asp Val Glu Gly Ala Glu Ser Gln Leu Asp Glu Asp465 470 475 480Glu His Gly Leu His Thr Lys Tyr Ile His Arg Met Met Gln Ile Glu
485 490 495Phe Ile Lys Gln Gly Ser Met Asn Phe Arg Phe Ile Pro Val Leu Phe
500 505 510Pro Asn Ala Lys Lys Glu His Val Pro Thr Trp Leu Gln Asn Thr His
515 520 525Val Tyr Ser Trp Pro Lys Asn Lys Lys Asn Ile Leu Leu Arg Leu Leu
530 535 540Arg Glu Glu Glu Tyr Val Ala Pro Pro Arg Gly Pro Leu Pro Thr Leu545 550 555 560Gln Val Val Pro Leu
565<210>24<211>1695<212>DNA<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<220><221>misc_特征<222>(9),(12),(18),(21),(27),(36),(42),(48),
(51),(57),(60),(66),(72),(81),(84),(96),
(102),(105),(108),(111),(120),(129),(132),
(138),(141),(144),(147),(150),(153),(159),
(168),(171),(174),(183),(189),(195),(198),
(201),(207),(210),(222),(225),(228),(231),
(234),(240),(243),(249),(252),(255),(261),
(264),(273),(282),(291),(294),(300),(303),
(306),(309),(315),(321),(324),(327),(333),
(336),(339),(342),(348),(351),(354),(360),
(363),(366),(369),(372),(375),(378),(381),
(396),(411),(423),(426),(429),(435),(438),
(441),(444),(447),(450),(456),(459),(468),
(477),(486),(489),(492),(498),(501),(504),
(510),(513),(516),(519),(522),(534),(540),
(543),(549),(555),(561),(564),(567),(570),
(576),(579),(582),(591),(594),(603),(609),
(618),(621),(624),(630),(636),(642),(645),
(648),(651),(654),(657),(660),(663),(672),
(681),(684),(687),(690),(693),(696),(699),
(702),(711),(723),(729),(735),(738),(744),
(753),(756),(759),(765),(768),(771),(777),
(780),(804),(807),(810),(813),(825),(828),
(834),(846),(849),(852),(855),(867),(876),
(879),(882),(885),(888),(894),(897),(900),
(903),(906),(909),(912),(915),(918),(921),
(927),(930),(939),(945),(954),(957),(960),
(978),(981),(984),(990),(999),(1005),(1008),
(1011),(1014),(1017),(1032),(1044),(1047),
(1053),(1056),(1059),(1062),(1065),(1068),
(1074),(1077),(1086),(1089),(1095),(1098),
(1101),(1107),(1110),(1116),(1119),(1122),
(1125),(1128),(1131),(1134),(1137),(1140),
(1143),(1146),(1149),(1155),(1158),(1161),
(1164),(1167),(1170),(1173),(1179),(1182),
(1188),(1191),(1200),(1203),(1209),(1218),
(1224),(1233),(1236),(1245),(1248),(1257),
(1266),(1269),(1272),(1278),(1287),(1290),
(1311),(1317),(1320),(1347),(1353),(1356),
(1365),(1368),(1380),(1383),(1389),(1392),
(1410),(1416),(1419),(1425),(1431),(1449),
(1452),(1458),(1473),(1503),(1506),(1518),
(1527),(1530),(1533),(1539),(1545),(1560),
(1563),(1566),(1572),(1581),(1587),(1593),
(1599),(1620),(1623),(1626),(1629),(1632),
(1635),(1650),(1653),(1656),(1659),(1662),
(1665),(1668),(1671),(1674),(1677),(1680),
(1686),(1689),(1692),(1695)<223>n=任意核苷酸<400>24atgaaymgnw snathccngt ngargtngay garwsngarc cntayccnws ncarytnytn 60aarccnathc cngartayws nccngargar garwsngarc cnccngcncc naayathmgn 120aayatggcnc cnaaywsnyt nwsngcnccn acnatgytnc ayaaywsnws nggngaytty 180wsncargcnc aywsnacnyt naarytngcn aaycaycarm gnccngtnws nmgncargtn 240acntgyytnm gnacncargt nytngargay wsngargayw snttytgymg nmgncayccn 300ggnytnggna argcnttycc nwsnggntgy wsngcngtnw sngarccngc nwsngarwsn 360gtngtnggng cnytnccngc ngarcaycar ttywsnttya tggaraarmg naaycartgg 420ytngtnwsnc arytnwsngc ngcnwsnccn gayacnggnc aygaywsnga yaarwsngay 480carwsnytnc cnaaygcnws ngcngaywsn ytnggnggnw sncargarat ggtncarmgn 540ccncarccnc aymgnaaymg ngcnggnytn gayytnccna cnathgayac nggntaygay 600wsncarccnc argaygtnyt nggnathmgn carytngarm gnccnytncc nytnacnwsn 660gtntgytayc cncargayyt nccnmgnccn ytnmgnwsnm gngarttycc ncarttygar 720ccncarmgnt ayccngcntg ygcncaratg ytnccnccna ayytnwsncc ncaygcnccn 780tggaaytayc aytaycaytg yccnggnwsn ccngaycayc argtnccnta yggncaygay 840tayccnmgng cngcntayca rcargtnath carccngcny tnccnggnca rccnytnccn 900ggngcnwsng tnmgnggnyt ncayccngtn caraargtna thytnaayta yccnwsnccn 960tgggaycarg argarmgncc ngcncarmgn gaytgywsnt tyccnggnyt nccnmgncay 1020cargaycarc cncaycayca rccnccnaay mgngcnggng cnccnggnga rwsnytngar 1080tgyccngcng arytnmgncc ncargtnccn carccnccnw snccngcngc ngtnccnmgn 1140ccnccnwsna ayccnccngc nmgnggnacn ytnaaracnw snaayytncc ngargarytn 1200mgnaargtnt tyathacnta ywsnatggay acngcnatgg argtngtnaa rttygtnaay 1260ttyytnytng tnaayggntt ycaracngcn athgayatht tygargaymg nathmgnggn 1320athgayatha thaartggat ggarmgntay ytnmgngaya aracngtnat gathathgtn 1380gcnathwsnc cnaartayaa rcargaygtn garggngcng arwsncaryt ngaygargay 1440garcayggny tncayacnaa rtayathcay mgnatgatgc arathgartt yathaarcar 1500ggnwsnatga ayttymgntt yathccngtn ytnttyccna aygcnaaraa rgarcaygtn 1560ccnacntggy tncaraayac ncaygtntay wsntggccna araayaaraa raayathytn 1620ytnmgnytny tnmgngarga rgartaygtn gcnccnccnm gnggnccnyt nccnacnytn 1680cargtngtnc cnytn 1695<210>25<211>1323<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>CDS<222>(1)..(1026)<400>25cag gac ctc cct ggg cct ctg agg tcc agg gaa ttg cca cct cag ttt 48Gln Asp Leu Pro Gly Pro Leu Arg Ser Arg Glu Leu Pro Pro Gln Phe1 5 10 15gaa ctt gag agg tat cca atg aac gcc cag ctg ctg ccg ccc cat cct 96Glu Leu Glu Arg Tyr Pro Met Asn Ala Gln Leu Leu Pro Pro His Pro
20 25 30tcc cca cag gcc cca tgg aac tgt cag tac tac tgc ccc gga ggg ccc 144Ser Pro Gln Ala Pro Trp Asn Cys Gln Tyr Tyr Cys Pro Gly Gly Pro
35 40 45tac cac cac cag gtg cca cac ggc cat ggc tac cct cca gca gca gcc 192Tyr His His Gln Val Pro His Gly His Gly Tyr Pro Pro Ala Ala Ala
50 55 60tac cag caa gta ctc cag cct gct ctg cct ggg cag gtc ctt cct ggg 240Tyr Gln Gln Val Leu Gln Pro Ala Leu Pro Gly Gln Val Leu Pro Gly65 70 75 80gca agg gca aga ggc cca cgc cct gtg cag aag gtc atc ctg aat gac 288Ala Arg Ala Arg Gly Pro Arg Pro Val Gln Lys Val Ile Leu Asn Asp
85 90 95tcc agc ccc caa gac caa gaa gag aga cct gca cag aga gac ttc tct 336Ser Ser Pro Gln Asp Gln Glu Glu Arg Pro Ala Gln Arg Asp Phe Ser
100 105 110ttc ccg agg ctc ccg agg gac cag ctc tac cgc cca cca tct aat gga 384Phe Pro Arg Leu Pro Arg Asp Gln Leu Tyr Arg Pro Pro Ser Asn Gly
115 120 125gtg gaa gcc cct gag gag tcc ttg gac ctt cct gca gag ctg aga cca 432Val Glu Ala Pro Glu Glu Ser Leu Asp Leu Pro Ala Glu Leu Arg Pro
130 135 140cat ggt ccc cag gct cca tcc cta gct gcc gtg cct aga ccc cct agc 480His Gly Pro Gln Ala Pro Ser Leu Ala Ala Val Pro Arg Pro Pro Ser145 150 155 160aac ccc tta gcc cga gga act cta aga acc agc aat ttg cca gaa gaa 528Asn Pro Leu Ala Arg Gly Thr Leu Arg Thr Ser Asn Leu Pro Glu Glu
165 170 175tta cgg aaa gtc ttt atc act tat tct atg gac aca gcc atg gag gtg 576Leu Arg Lys Val Phe Ile Thr Tyr Ser Met Asp Thr Ala Met Glu Val
180 185 190gtg aaa ttt gtg aac ttt ctg ttg gtg aac ggc ttc caa act gcg att 624Val Lys Phe Val Asn Phe Leu Leu Val Asn Gly Phe Gln Thr Ala Ile
195 200 205gac ata ttt gag gat aga atc cgg ggt att gat atc att aaa tgg atg 672Asp Ile Phe Glu Asp Arg Ile Arg Gly Ile Asp Ile Ile Lys Trp Met
210 215 220gag cgc tat ctt cga gat aag aca gtg atg ata atc gta gca atc agc 720Glu Arg Tyr Leu Arg Asp Lys Thr Val Met Ile Ile Val Ala Ile Ser225 230 235 240ccc aaa tac aaa cag gat gtg gaa ggc gct gag tcg cag ctg gac gag 768Pro Lys Tyr Lys Gln Asp Val Glu Gly Ala Glu Ser Gln Leu Asp Glu
245 250 255gac gag cat ggc tta cat act aag tac att cat cgg atg atg cag att 816Asp Glu His Gly Leu His Thr Lys Tyr Ile His Arg Met Met Gln Ile
260 265 270gag ttc ata agt cag gga agc atg aac ttc aga ttc atc cct gtg ctc 864Glu Phe Ile Set Gln Gly Ser Met Asn Phe Arg Phe Ile Pro Val Leu
275 280 285ttc cca aat gcc aag aag gag cat gtg ccg acc tgg ctt cag aac act 912Phe Pro Asn Ala Lys Lys Glu His Val Pro Thr Trp Leu Gln Asn Thr
290 295 300cat gtt tac agc tgg ccc aag aat aag aaa aac atc ctg ctg cgg ctg 960His Val Tyr Ser Trp Pro Lys Asn Lys Lys Asn Ile Leu Leu Arg Leu305 310 315 320ctc agg gag gaa gag tat gtg gct cct ccc cga ggc cct ctg ccc acc 1008Leu Arg Glu Glu Glu Tyr Val Ala Pro Pro Arg Gly Pro Leu Pro Thr
325 330 335ctt cag gtg gta ccc ttg tgacgatggc cactccagct cagtgccagc 1056Leu Gln Val Val Pro Leu
340ctgttctcac agcattcttc tagcggagct ggctggtggc acccaggccc tggaacacct 1116cttctacaga gtcctctgtc tcctgagtct gagttgtcct cgctgggctt ccagagcttc 1176agtgcctgga tgctgcaggt gacagaaaca aacatctatg accacaaaaa ctctcatcac 1236ttcagctact tttatgagtc ggtcagatgc tctgtgtcct tagaccagtc taaatcatgc 1296tcaaataata aaatgattat tctttgt 1323<210>26<211>342<212>PRT<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<400>26Gln Asp Leu Pro Gly Pro Leu Arg Ser Arg Glu Leu Pro Pro Gln Phe1 5 10 15Glu Leu Glu Arg Tyr Pro Met Asn Ala Gln Leu Leu Pro Pro His Pro
20 25 30Ser Pro Gln Ala Pro Trp Asn Cys Gln Tyr Tyr Cys Pro Gly Gly Pro
35 40 45Tyr His His Gln Val Pro His Gly His Gly Tyr Pro Pro Ala Ala Ala
50 55 60Tyr Gln Gln Val Leu Gln Pro Ala Leu Pro Gly Gln Val Leu Pro Gly65 70 75 80Ala Arg Ala Arg Gly Pro Arg Pro Val Gln Lys Val Ile Leu Asn Asp
85 90 95Ser Ser Pro Gln Asp Gln Glu Glu Arg Pro Ala Gln Arg Asp Phe Ser
100 105 110Phe Pro Arg Leu Pro Arg Asp Gln Leu Tyr Arg Pro Pro Ser Asn Gly
115 120 125Val Glu Ala Pro Glu Glu Ser Leu Asp Leu Pro Ala Glu Leu Arg Pro
130 135 140His Gly Pro Gln Ala Pro Ser Leu Ala Ala Val Pro Arg Pro Pro Ser145 150 155 160Asn Pro Leu Ala Arg Gly Thr Leu Arg Thr Ser Asn Leu Pro Glu Glu
165 170 175Leu Arg Lys Val Phe Ile Thr Tyr Ser Met Asp Thr Ala Met Glu Val
180 185 190Val Lys Phe Val Asn Phe Leu Leu Val Asn Gly Phe Gln Thr Ala Ile
195 200 205Asp Ile Phe Glu Asp Arg Ile Arg Gly Ile Asp Ile Ile Lys Trp Met
210 215 220Glu Arg Tyr Leu Arg Asp Lys Thr Val Met Ile Ile Val Ala Ile Ser225 230 235 240Pro Lys Tyr Lys Gln Asp Val Glu Gly Ala Glu Ser Gln Leu Asp Glu
245 250 255Asp Glu His Gly Leu His Thr Lys Tyr Ile His Arg Met Met Gln Ile
260 265 270Glu Phe Ile Ser Gln Gly Ser Met Asn Phe Arg Phe Ile Pro Val Leu
275 280 285Phe Pro Asn Ala Lys Lys Glu His Val Pro Thr Trp Leu Gln Asn Thr
290 295 300His Val Tyr Ser Trp Pro Lys Asn Lys Lys Asn Ile Leu Leu Arg Leu305 310 315 320Leu Arg Glu Glu Glu Tyr Val Ala Pro Pro Arg Gly Pro Leu Pro Thr
325 330 335Leu Gln Val Val Pro Leu
340<210>27<211>1026<212>DNA<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<220><221>misc_特征<222>(9),(12),(15),(18),(21),(24),(27),(30),
(36),(39),(42),(54),(60),(66),(75),(81),
(84),(87),(90),(96),(99),(102),(108),(111),
(135),(138),(141),(144),(159),(162),(168),
(174),(180),(183),(186),(189),(192),(204),
(207),(213),(216),(219),(222),(225),(231),
(234),(237),(240),(243),(246),(249),(252),
(255),(258),(261),(264),(267),(276),(282),
(291),(294),(297),(315),(318),(321),(327),
(336),(342),(345),(348),(351),(354),(363),
(369),(372),(375),(378),(384),(387),(393),
(396),(405),(408),(414),(417),(420),(426),
(429),(432),(438),(441),(447),(450),(453),
(456),(459),(462),(465),(468),(471),(474),
(477),(480),(486),(489),(492),(495),(498),
(501),(504),(507),(510),(513),(519),(522),
(531),(534),(540),(549),(555),(564),(567),
(576),(579),(588),(597),(600),(603),(609),
(618),(621),(642),(648),(651),(678),(684),
(687),(696),(699),(711),(714),(720),(723),
(741),(747),(750),(756),(762),(780),(783),
(789),(804),(828),(834),(837),(849),(858),
(861),(864),(870),(876),(891),(894),(897),
(903),(912),(918),(924),(930),(951),(954),
(957),(960),(963),(966),(981),(984),(987),
(990),(993),(996),(999),(1002),(1005),
(1008),(1011),(1017),(1020),(1023),(1026)<223>n=任意核苷酸<400>27cargayytnc cnggnccnyt nmgnwsnmgn garytnccnc cncarttyga rytngarmgn 60tayccnatga aygcncaryt nytnccnccn cayccnwsnc cncargcncc ntggaaytgy 120cartaytayt gyccnggngg nccntaycay caycargtnc cncayggnca yggntayccn 180ccngcngcng cntaycarca rgtnytncar ccngcnytnc cnggncargt nytnccnggn 240gcnmgngcnm gnggnccnmg nccngtncar aargtnathy tnaaygayws nwsnccncar 300gaycargarg armgnccngc ncarmgngay ttywsnttyc cnmgnytncc nmgngaycar 360ytntaymgnc cnccnwsnaa yggngtngar gcnccngarg arwsnytnga yytnccngcn 420garytnmgnc cncayggncc ncargcnccn wsnytngcng cngtnccnmg nccnccnwsn 480aayccnytng cnmgnggnac nytnmgnacn wsnaayytnc cngargaryt nmgnaargtn 540ttyathacnt aywsnatgga yacngcnatg gargtngtna arttygtnaa yttyytnytn 600gtnaayggnt tycaracngc nathgayath ttygargaym gnathmgngg nathgayath 660athaartgga tggarmgnta yytnmgngay aaracngtna tgathathgt ngcnathwsn 720ccnaartaya arcargaygt ngarggngcn garwsncary tngaygarga ygarcayggn 780ytncayacna artayathca ymgnatgatg carathgart tyathwsnca rggnwsnatg 840aayttymgnt tyathccngt nytnttyccn aaygcnaara argarcaygt nccnacntgg 900ytncaraaya cncaygtnta ywsntggccn aaraayaara araayathyt nytnmgnytn 960ytnmgngarg argartaygt ngcnccnccn mgnggnccny tnccnacnyt ncargtngtn 1020ccnytn 1026<210>28<211>207<212>PRT<213>未知<220><223>未知生物的说明:灵长类动物;推测为
人(Homo sapiens)<400>28Arg Lys Val Trp Ile Ile Tyr Ser Ala Asp His Pro Leu Tyr Val Asp1 5 10 15Val Val Leu Lys Phe Ala Gln Phe Leu Leu Thr Ala Cys Gly Thr Glu
20 25 30Val Ala Leu Asp Leu Leu Glu Glu Gln Ala Ile Ser Glu Ala Gly Val
35 40 45Met Thr Trp Val Gly Arg Gln Lys Gln Glu Met Val Glu Ser Asn Ser
50 55 60Lys Ile Ile Val Leu Cys Ser Arg Gly Thr Arg Ala Lys Trp Gln Ala65 70 75 80Leu Leu Gly Arg Gly Ala Pro Val Arg Leu Arg Cys Asp His Gly Lys
85 90 95Pro Val Gly Asp Leu Phe Thr Ala Ala Met Asn Met Ile Leu Pro Asp
100 105 110Phe Lys Arg Pro Ala Cys Phe Gly Thr Tyr Val Val Cys Tyr Phe Ser
115 120 125Glu Val Ser Cys Asp Gly Asp Val Pro Asp Leu Phe Gly Ala Ala Pro
130 135 140Arg Tyr Pro Leu Met Asp Arg Phe Glu Glu Val Tyr Phe Arg Ile Gln145 150 155 160Asp Leu Glu Met Phe Gln Pro Gly Arg Met His Arg Val Gly Glu Leu
165 170 175Ser Gly Asp Asn Tyr Leu Arg Ser Pro Gly Gly Arg Gln Leu Arg Ala
180 185 190Ala Leu Asp Arg Phe Arg Asp Trp Gln Val Arg Cys Pro Asp Trp
195 200 205<210>29<211>208<212>PRT<213>未知<220><223>未知生物的说明:啮齿类动物;推测为
小鼠(Mus musculus)<400>29Arg Lys Val Trp Ile Val Tyr Ser Ala Asp His Pro Leu Tyr Val Glu1 5 10 15Val Val Leu Lys Phe Ala Gln Phe Leu Ile Thr Ala Cys Gly Thr Glu
20 25 30Val Ala Leu Asp Leu Leu Glu Glu Gln Val Ile Ser Glu Val Gly Val
35 40 45Met Thr Trp Val Ser Arg Gln Lys Gln Glu Met Val Glu Ser Asn Ser
50 55 60Lys Ile Ile Ile Leu Cys Ser Arg Gly Thr Gln Ala Lys Trp Lys Ala65 70 75 80Ile Leu Gly Trp Ala Glu Pro Ala Val Gln Leu Arg Cys Asp His Trp
85 90 95Lys Pro Ala Gly Asp Leu Phe Thr Ala Ala Met Asn Met Ile Leu Pro
100 105 110Asp Phe Lys Arg Pro Ala Cys Phe Gly Thr Tyr Val Val Cys Tyr Phe
115 120 125Ser Gly Ile Cys Ser Glu Arg Asp Val Pro Asp Leu Phe Asn Ile Thr
130 135 140Ser Arg Tyr Pro Leu Met Asp Arg Phe Glu Glu Val Tyr Phe Arg Ile145 150 155 160Gln Asp Leu Glu Met Phe Glu Pro Gly Arg Met His His Val Arg Glu
165 170 175Leu Thr Gly Asp Asn Tyr Leu Gln Ser Pro Ser Gly Arg Gln Leu Lys
180 185 190Glu Ala Val Leu Arg Phe Gln Glu Trp Gln Thr Gln Cys Pro Asp Trp
195 200 205<210>30<211>190<212>PRT<213>未知<220><223>未知生物的说明:蠕虫类动物;推测为
Caenorabditis elegans<400>30Val Lys Val Met Ile Val Tyr Ala Asp Asp Asn Asp Leu His Thr Asp1 5 10 15Cys Val Lys Lys Leu Val Glu Asn Leu Arg Asn Cys Ala Ser Cys Asp
20 25 30Pro Val Phe Asp Leu Glu Lys Leu Ile Thr Ala Glu Ile Val Pro Ser
35 40 45Arg Trp Leu Val Asp Gln Ile Ser Ser Leu Lys Lys Phe Ile Ile Val
50 55 60Val Ser Asp Cys Ala Glu Lys Ile Leu Asp Thr Glu Ala Ser Glu Thr65 70 75 80His Gln Leu Val Gln Ala Arg Pro Phe Ala Asp Leu Phe Gly Pro Ala
85 90 95Met Glu Met Ile Ile Arg Asp Ala Thr His Asn Phe Pro Glu Ala Arg
100 105 110Lys Lys Tyr Ala Val Val Arg Phe Asn Tyr Ser Pro His Val Pro Pro
115 120 125Asn Leu Ala Ile Leu Asn Leu Pro Thr Phe Ile Pro Glu Gln Phe Ala
130 135 140Gln Leu Thr Ala Phe Leu His Asn Val Glu His Thr Glu Arg Ala Asn145 150 155 160Val Thr Gln Asn Ile Ser Glu Ala Gln Ile His Glu Trp Asn Leu Cys
165 170 175Ala Ser Arg Met Met Ser Phe Phe Val Arg Asn Pro Asn Trp
180 185 190<210>31<211>178<212>PRT<213>未知<220><223>未知生物的说明:蠕虫类动物;推测为
Caenorabditis elegans<400>31Phe Lys Val Met Leu Val Cys Pro Glu Val Ser Gly Arg Asp Glu Asp1 5 10 15Phe Met Met Arg Ile Ala Asp Ala Leu Lys Lys Ser Asn Asn Lys Val
20 25 30Val Cys Asp Arg Trp Phe Glu Asp Ser Lys Asn Ala Glu Glu Asn Met
35 40 45Leu His Trp Val Tyr Glu Gln Thr Lys Ile Ala Glu Lys Ile Ile Val
50 55 60Phe His Ser Ala Tyr Tyr His Pro Arg Cys Gly Ile Tyr Asp Val Ile65 70 75 80Asn Asn Phe Phe Pro Cys Thr Asp Pro Arg Leu Ala His Ile Ala Leu
85 90 95Thr Pro Glu Ala Gln Arg Set Val Pro Lys Glu Val Glu Tyr Val Leu
100 105 110Pro Arg Asp Gln Lys Leu Leu Glu Asp Ala Phe Asp Ile Thr Ile Ala
115 120 125Asp Pro Leu Val Ile Asp Ile Pro Ile Glu Asp Val Ala Ile Pro Glu
130 135 140Asn Val Pro Ile His His Glu Set Cys Asp Ser Ile Asp Ser Arg Asn145 150 155 160Asn Set Lys Thr His Set Thr Asp Ser Gly Val Ser Ser Leu Ser Ser
165 170 175Asn Ser
Claims (20)
1.一种物质组合物,选自:
a)基本纯的或重组的多肽,含有至少三个不同的非重叠片段,每段至少四个氨基酸与SEQ ID NO:14的片段一致;
b)基本纯的或重组的多肽,含有至少两个不同的非重叠片段,每段至少五个氨基酸与SEQ ID NO:14的片段一致;
c)天然序列DCRS8,含有成熟的SEQ ID NO:14;
d)融合多肽,含有DCRS8序列;
e)基本纯的或重组的多肽,含有至少三个不同的非重叠片段,每段至少四个氨基酸与SEQ ID NO:17或20的片段一致;
f)基本纯的或重组的多肽,含有至少两个不同的非重叠片段,每段至少五个氨基酸与SEQ ID NO:17或20的片段一致;
g)天然序列DCRS9,含有成熟的SEQ ID NO:17或20;或
h)融合多肽,含有DCRS9序列。
2.权利要求1的基本纯的或分离的抗原性多肽,其中所述一致性的不同非重叠片段包括:
a)至少八个氨基酸之一;
b)至少四个氨基酸之一和至少五个氨基酸中的另一个;
c)至少三个片段,每段至少四个、五个和六个氨基酸;或
d)至少十二个氨基酸之一。
3.权利要求1的物质组合物,其中所述:
a)多肽:
i.)包含表3或4的成熟序列;
ii.)是DCRS8或DCRS9的未糖基化形式;
iii.)来自灵长类,如人;
iv.)含有SEQ ID NO:14或17的至少十七个氨基酸;
v.)表现SEQ ID NO:14或17的至少七个氨基酸的至少四个非重叠片段;
vi.)是DCRS8或DCRS9的天然等位基因变体;
vii.)长度至少约30个氨基酸;
viii.)表现至少两个非重叠表位,它对灵长类DCRS8或DCRS9有特异性;
ix.)被糖基化;
x.)天然糖基化时分子量至少30kD;
xi.)是合成多肽;
xii.)连接到固相基质上;
xiii.)与另一个化学部分偶联;
xiv.)与天然序列是5倍或更少替换;或
xv.)是天然序列的缺失或插入变体。
4.一种组合物,其中含有:
a)基本纯的DCRS8或DCRS9和另一种细胞因子受体家族成员;
b)权利要求1的无菌的DCRS8或DCRS9多肽;
c)权利要求1的所述DCRS8或DCRS9多肽和载体,其中所述载体是:
i.)水性化合物,包括水、盐水、和/或缓冲液;和/或
ii.)配制成供口腔、直肠、鼻腔、外用、或胃肠道外给药。
5.权利要求1的融合多肽,含有:
a)表3或4的成熟蛋白序列;
b)检测或纯化标签,包括FLAG、His6、或Ig序列;或
c)另一种细胞因子受体蛋白的序列。
6.含有权利要求1多肽的试剂盒,并且:
a)含有所述蛋白或多肽的隔室;或
b)所述试剂盒中试剂使用或后处理的说明书。
7.一种结合化合物,含有来自抗体的抗原结合位点,它特异性结合权利要求1的天然DCRS8或DCRS9多肽,其中:
a)所述结合化合物在容器中;
b)所述DCRS8或DCRS9多肽来自人;
c)所述结合化合物是Fv、Fab、或Fab2片段;
d)所述结合化合物与另一种化学部分偶联;或
e)所述抗体:
i.)由抗表3或4的成熟多肽的肽序列产生;
ii.)由抗成熟DCRS8或DCRS9产生;
iii.)由抗纯化的人DCRS8或DCRS9产生;
iv.)经免疫选择;
v.)是多克隆抗体;
vi.)结合变性的DCRS8或DCRS9;
vii.)表现对抗原的Kd至少30μM;
viii.)连接到固相基质上,包括珠子或塑料膜;
ix.)是无菌组合物形式;或
x.)被可检测地标记,包括放射性标记或荧光标记。
8.含有权利要求7所述结合化合物的试剂盒,并且:
a)含有所述结合化合物的隔室;或
b)所述试剂盒中试剂使用或后处理的说明书。
9.一种制造抗原:抗体复合体的方法,含有:在适当条件下将灵长类DCRS8或DCRS9多肽与权利要求7的抗体接触,由此可以形成所述复合体。
10.权利要求9的方法,其中:
a)所述复合体从其它细胞因子受体纯化;
b)所述复合体从其它抗体中纯化;
c)所述接触是与含干扰素的样品接触;
d)所述接触允许定量检测所述抗原;
e)所述接触是与含所述抗体的样品接触;或
f)所述接触允许定量检测所述抗体。
11.一种组合物,含有
a)权利要求7的无菌结合化合物,或
b)权利要求7的所述结合化合物和载体,其中所述载体是:
i.)水性化合物,包括水、盐水、和/或缓冲液;和/或
ii.)配制成供口腔、直肠、鼻腔、外用、或胃肠道外给药。
12.一种编码权利要求1所述多肽的分离或重组核酸,其中所述:
a)DCRS8或DCRS9来自人;或
b)所述核酸:
i.)编码表3或4的抗原性肽序列;
ii.)编码表3或4的多种抗原性肽序列;
iii.)与编码所述片段的天然cDNA表现出至少十三个核苷酸的一致性;
iv.)是表达载体;
v.)进一步含有复制起点;
vi.)来自天然来源;
vii.)含有可检测的标记;
viii.)含有合成核苷酸序列;
ix.)小于6kb,优选小于3kb;
x.)来自灵长类;
xi.)含有天然全长的编码序列;
xii.)是编码所述DCRS8或DCRS9的基因的杂交探针;或
xiii.)是PCR引物,PCR产物,或突变引物。
13.含有权利要求12所述重组核酸的细胞或组织。
14.权利要求13的细胞,其中所述细胞是:
a)原核细胞;
b)真核细胞;
c)细菌细胞;
d)酵母细胞;
e)昆虫细胞;
f)哺乳动物细胞;
g)小鼠细胞;
h)灵长类细胞;或
i)人细胞。
15.含有权利要求12所述核酸的试剂盒,并且:
a)含有所述核酸的隔室;
b)进一步含有灵长类DCRS8或DCRS9多肽的隔室;或
c)所述试剂盒中试剂使用或后处理的说明书。
16.一种核酸,其中:
a)在30℃30分钟和小于2M盐的洗涤条件下,与SEQ ID NO:13或16的编码部分杂交;或
b)与灵长类DCRS8或DCRS9表现出一段至少约30个核苷酸的一致性。
17.权利要求16的核酸,其中:
a)所述洗涤条件是45℃和/或500mM盐;或
b)所述一段至少55个核苷酸。
18.权利要求16的核酸,其中:
a)所述洗涤条件是55℃和/或150mM盐;或
b)所述一段至少75个核苷酸。
19.一种调节细胞或组织培养细胞生理或发育的方法,其中包括将所述细胞与哺乳动物DCRS8或DCRS9的激动剂或拮抗剂接触。
20.权利要求19的方法,其中所述细胞用编码所述DCRS8或DCRS9以及另一种细胞因子受体亚基的核酸转化。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20686200P | 2000-05-24 | 2000-05-24 | |
US60/206,862 | 2000-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1444652A true CN1444652A (zh) | 2003-09-24 |
Family
ID=22768279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01813327A Pending CN1444652A (zh) | 2000-05-24 | 2001-05-23 | 哺乳动物受体蛋白;相关试剂和方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20030092881A1 (zh) |
EP (1) | EP1303604A2 (zh) |
JP (1) | JP2003534013A (zh) |
CN (1) | CN1444652A (zh) |
AU (1) | AU2001274920A1 (zh) |
CA (1) | CA2410083A1 (zh) |
MX (1) | MXPA02011617A (zh) |
WO (1) | WO2001090358A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106794194A (zh) * | 2014-06-30 | 2017-05-31 | 中央研究院 | 用于癌症治疗的介白素‑17受体b(il‑17rb)及其配体il‑17b之拮抗剂 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1076703B2 (en) | 1998-05-15 | 2010-12-15 | Genentech, Inc. | Therapeutic uses of il-17 homologous polypeptides |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
EP1897945B1 (en) * | 1999-12-23 | 2012-01-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US7094566B2 (en) | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
AR028256A1 (es) * | 2000-03-16 | 2003-04-30 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
US20040197306A1 (en) * | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002004519A2 (en) * | 2000-07-06 | 2002-01-17 | Zymogenetics, Inc. | Murine cytokine receptor |
EP1529843A3 (en) * | 2000-08-11 | 2005-06-08 | Eli Lilly & Company | Novel secreted proteins and their uses |
WO2002038764A2 (en) * | 2000-11-10 | 2002-05-16 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
EP2383278A1 (en) * | 2002-07-08 | 2011-11-02 | Genentech, Inc. | Method to determine B cell mediated diseases |
CA2497661A1 (en) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the diagnosis of immune related diseases using pro71061 |
PL1641822T3 (pl) | 2003-07-08 | 2013-10-31 | Genentech Inc | Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne |
MXPA06014465A (es) | 2004-06-10 | 2007-05-16 | Zymogenetics Inc | Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion. |
WO2006044840A2 (en) * | 2004-10-18 | 2006-04-27 | Zymogenetics, Inc. | Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation |
US20060147945A1 (en) * | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
DE602006016965D1 (de) * | 2005-09-28 | 2010-10-28 | Zymogenetics Inc | Il-17a- und il-17f-antagonisten und verwendungsverfahren |
US20070249533A1 (en) | 2005-09-28 | 2007-10-25 | Levin Steven D | Il-17a and il-17f antagonists and methods of using the same |
ATE467640T1 (de) * | 2006-02-10 | 2010-05-15 | Zymogenetics Inc | Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen |
WO2008118930A1 (en) | 2007-03-26 | 2008-10-02 | Zymogenetics, Inc. | Soluble il-17ra/rc fusion proteins and related methods |
NZ600584A (en) | 2008-05-05 | 2014-05-30 | Novimmune Sa | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof |
SG175276A1 (en) | 2009-05-05 | 2011-11-28 | Novimmune Sa | Anti-il-17f antibodies and methods of use thereof |
US9611295B2 (en) * | 2011-10-27 | 2017-04-04 | The Cleveland Clinic Foundation | Treatment of IL-17 mediated disease by blocking SEFIR-SEFIR interactions |
AU2014216515A1 (en) * | 2013-02-15 | 2015-10-08 | Thomas Jefferson University | Kit for tumor imaging |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4373495B2 (ja) * | 1995-03-23 | 2009-11-25 | イミュネックス・コーポレーション | Il−17受容体 |
US6635443B1 (en) * | 1997-09-17 | 2003-10-21 | Human Genome Sciences, Inc. | Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein |
CN1158386C (zh) * | 1998-04-29 | 2004-07-21 | 吉尼西斯研究及发展有限公司 | 从皮肤细胞中分离的多核苷酸及其使用方法 |
US6150502A (en) * | 1998-04-29 | 2000-11-21 | Genesis Research & Development Corporation Limited | Polypeptides expressed in skin cells |
ATE519847T1 (de) * | 1999-12-23 | 2011-08-15 | Genentech Inc | Il-17-homologe polypeptide und ihre therapeutische verwendung |
AR028256A1 (es) * | 2000-03-16 | 2003-04-30 | Amgen Inc | Moleculas similares a receptores il-17 y usos de las mismas |
US20040197306A1 (en) * | 2000-05-24 | 2004-10-07 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
-
2001
- 2001-05-23 EP EP01941579A patent/EP1303604A2/en not_active Withdrawn
- 2001-05-23 US US09/863,818 patent/US20030092881A1/en not_active Abandoned
- 2001-05-23 WO PCT/US2001/016767 patent/WO2001090358A2/en active Application Filing
- 2001-05-23 CN CN01813327A patent/CN1444652A/zh active Pending
- 2001-05-23 MX MXPA02011617A patent/MXPA02011617A/es not_active Application Discontinuation
- 2001-05-23 AU AU2001274920A patent/AU2001274920A1/en not_active Abandoned
- 2001-05-23 JP JP2001587152A patent/JP2003534013A/ja active Pending
- 2001-05-23 CA CA002410083A patent/CA2410083A1/en not_active Abandoned
-
2004
- 2004-08-23 US US10/924,667 patent/US20050009145A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106794194A (zh) * | 2014-06-30 | 2017-05-31 | 中央研究院 | 用于癌症治疗的介白素‑17受体b(il‑17rb)及其配体il‑17b之拮抗剂 |
Also Published As
Publication number | Publication date |
---|---|
WO2001090358A2 (en) | 2001-11-29 |
MXPA02011617A (es) | 2003-03-10 |
US20030092881A1 (en) | 2003-05-15 |
AU2001274920A1 (en) | 2001-12-03 |
EP1303604A2 (en) | 2003-04-23 |
JP2003534013A (ja) | 2003-11-18 |
WO2001090358A3 (en) | 2003-01-23 |
CA2410083A1 (en) | 2001-11-29 |
US20050009145A1 (en) | 2005-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1444652A (zh) | 哺乳动物受体蛋白;相关试剂和方法 | |
CN1225555C (zh) | 人Toll样受体蛋白、相关试剂和方法 | |
CN1452633A (zh) | 哺乳动物基因、相关试剂及方法 | |
CN1575337A (zh) | 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法 | |
CN1173033C (zh) | Tnf/ngf超家族受体和可溶性寡聚tnf/ngf超家族受体的调节剂 | |
CN1310945C (zh) | 人g蛋白偶联受体的内源形式和非内源形式 | |
CN1906297A (zh) | Il-23及其受体、相关试剂和方法 | |
CN1184315C (zh) | 包含死亡结构域的受体-5 | |
CN1222539C (zh) | 人受体蛋白;相关的试剂和方法 | |
CN1094446A (zh) | Eck受体配体 | |
CN1211255A (zh) | Ob受体及诊断和治疗体重疾病的方法 | |
CN1759123A (zh) | Il-23激动剂及拮抗剂的用途;相关试剂 | |
CN1271387A (zh) | 哺乳动物细胞因子∶白介素-b30和相关试剂 | |
CN1493597A (zh) | 分离树突状细胞膜蛋白基因 | |
CN1357042A (zh) | 白介素-17相关哺乳动物细胞因子、编码其的多核苷酸、应用 | |
CN1867352A (zh) | 趋化因子变体的治疗性应用 | |
CN1445236A (zh) | 促进毛发生长的寡肽 | |
CN1372594A (zh) | Ox2受体的同系物 | |
CN1245533A (zh) | 哺乳动物趋化因子 | |
CN1323716C (zh) | Sarp-1在治疗和/或预防硬皮病中的应用 | |
CN101039956A (zh) | 细胞表面糖蛋白 | |
CN1886155A (zh) | 分离的哺乳动物膜蛋白基因和相关试剂 | |
CN1118571C (zh) | 具有血小板生成素活性的蛋白质 | |
CN1780853A (zh) | 分泌性蛋白质家族 | |
CN1812803A (zh) | 人类肥大细胞表达的膜蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |